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Chapter 1
General Introduction:
Specificity, Diversity and Regulation in TGF-ß Superfamily 
Signaling
Ester Piek, Carl-Henrik Heldin, and Peter ten Dijke
Ludwig Institute for Cancer Research, Uppsala, Sweden
FASEB Journal, in press
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Transforming growth factor-^ (TGF-P) superfamily members are multifunctional cell-cell 
signaling proteins that play pivotal roles in tissue homeostasis and development of multicellular 
animals. They mediate their pleiotropic effects from membrane to nucleus through distinct 
combinations of type I and type II serine/threonine kinase receptors and their downstream effectors 
known as Smad proteins. Certain Smads, termed receptor-regulated Smads, become phosphorylated 
by activated type I receptors and form heteromeric complexes with a common mediator Smad4, 
which translocate into the nucleus to control gene transcription. In addition to these signal 
transducing Smads, anti-Smads have been identified that inhibit the activation of receptor-regulated 
Smads. In contrast to the still growing TGF-P superfamily, with over 25 members, relatively few 
type I and type II receptors as well as Smads have been identified to date. In this review we will 
focus on recent insights into the molecular mechanisms by which signaling specificity between 
different TGF-P superfamily members is achieved and regulated, and how a single family member 
can elicit a broad scala of biological responses.
THE TGF-P SUPERFAMILY AND BINDING PROTEINS
TGF-fi superfamily: multiple factors with pleiotropic functions
The TGF-P superfamily is composed of a large number of multifunctional cytokines including 
TGF-^s, activins, inhibins, anti-mullerian hormone (AMH), bone morphogenetic proteins (BMPs) 
and growth and differentiation factors (GDFs). The highly similar TGF-P isoforms TGF-^1, TGF- 
P2 and TGF-^3 potently inhibit cellular proliferation of many cell types, including those from 
epithelial origin. Some mesenchymal cells, however, are stimulated in their growth by TGF-p. In 
addition, TGF-^s strongly induce extracellular matrix synthesis, integrin expression and modulate 
immune responses (reviewed in Roberts and Sporn, 1990, Letterio and Roberts, 1998). BMPs are 
potent inducers of bone and cartilage formation and, in addition, play important developmental roles 
in induction of ventral mesoderm, differentiation of neural tissue and organogenesis (reviewed in 
Kingsley, 1994; Hogan, 1996). Activins, named after their initial identification as activators of 
follicle stimulating hormone (FSH) secretion from pituitary glands, are also known to promote 
erythropoiesis, mediate dorsal mesoderm induction and contribute to survival of nerve cells 
(reviewed in Mathews, 1994). All growth factors belonging to the TGF-P superfamily play 
important roles in embryonic patterning and tissue homeostasis. Their inappropriate functioning has 
been implicated in several pathological situations, like fibrosis, rheumatoid arthritis and 
carcinogenesis.
Distinct in vivo expression patterns o f TGF-fi isoforms
TGF-^1, TGF-^2 and TGF-^3 are highly redundant in their biological activities in vitro. 
However, they differ in their in vivo expression patterns (reviewed in Roberts and Sporn, 1992), 
which explains largely the unique isoform-specific phenotypes displayed by the TGF-P knockout 
mice. TGF-P1-deficient mice are devoid of obvious developmental abnormalities, but undergo early 
postnatal death due to excessive infiltration of inflammatory lymphocytes and macrophages into
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several organs (Shull et al., 1992; Kulkarni et al., 1993; Diebold et al., 1995). It is thought that 
maternally supplied TGF-^1, in combination with redundant expression of TGF-P isoforms, 
contributes to normal development of the embryos. TGF-^1-null mice born from TGF-P1-deficient 
mothers display abnormal cardiac development (Letterio et al., 1994). TGF-^2 knockout mice show 
multiple developmental malformations of tissues and organs, leading to perinatal death (Sanford et 
al., 1997). TGF-^3-null mice die shortly after birth, displaying delayed pulmonary development and 
defective palate development (Kaartinen et al., 1995; Proetzel et al., 1995).
Analysis of the genes encoding for the three TGF-^s revealed that each isoform is controlled by 
differentially regulated promoters (reviewed in Roberts et al., 1991). The existence of different 
genes, encoding functionally similar proteins, yet controlled by differentially regulated promoters, 
might provide an important mechanism to ensure tissue-specific and spatio-temporal expression 
patterns of the different TGF-P isoforms, thereby resulting in proper embryonic development and 
tissue homeostasis.
In addition, posttranscriptional control mechanisms contribute to regulation of the production of 
TGF-P. TGF-^1, TGF-^2 and TGF-^3 have long GC-rich 5’-untranslated regions, and 
intramolecular duplex loops located in close proximity to the transcriptional start site negatively 
modulate TGF-P expression, possibly by binding cell type-specific cytoplasmic molecules (Kim et 
al., 1992).
Control o f TGF-fi bioactivity 
Several members of the TGF-P superfamily are synthesized as large inactive precursor molecules 
that are proteolytically processed in the Golgi apparatus by the convertase family of endoproteases, 
of which furin is a member. Furin cleaves the precursor into TGF-P and an N-terminally located 
latency-associated protein LAP (reviewed in Munger et al., 1997, and references therein; Cui et al., 
1998). LAP remains non-covalently linked to TGF-P, yielding small latent TGF-P complexes that 
are significantly more stable compared to bioactive TGF-p. Within the Golgi, LAP covalently 
interacts with latent TGF-^-binding proteins (LTBPs) to form large latent complexes (reviewed in 
Munger et al., 1997, and references therein). Four different LTBP homologs, LTBPs 1-4, have been 
characterized, including several alternative splice variants (reviewed in Taipale and Keski-Oja, 
1997; Saharinen et al., 1998). LTBPs function to enhance secretion and stability of the TGF-^-LAP 
complex, ensure correct folding of TGF-P, and target the latent TGF-P complex to the extracellular 
matrix of certain cells and tissues for storage, or to the cell surface where activation takes place 
(reviewed in Munger et al., 1997; Taipale and Keski-Oja, 1997, and references therein). LTBP-1, -2 
and -4 contain RGD sequences which are integrin binding sites (Saharinen et al., 1998; Munger et 
al., 1998). It has been shown that large latent TGF-P complexes directly interact with integrin a v/p1 
at the cell surface (Munger et al., 1998), which possibly enables TGF-P to activate integrin 
signaling. Activation and release of TGF-P at the cell surface is physically controlled by proteases, 
like plasmin or cathepsin that cleave LAP, and by binding of LAP to mannose-6-phosphate 
receptors (Munger et al., 1997; Taipale and Keski-Oja, 1997, and references therein). Lipoprotein 
Lp(a) inhibits activation of plasminogen to plasmin and thereby negatively affects activation of 
TGF-P (reviewed in Angles-Cano, 1997, and references therein). Other mechanisms that have been
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implicated in activation of latent TGF-P are deglycosylation of LAP (Miyazono and Heldin, 1989), 
exposure to reactive oxygen species (Barcellos-Hoff and Dix, 1996) or acidic cellular 
microenvironments (Jullien et al., 1989). In addition, an important activator of TGF-P in vivo 
appears thrombospondin-1, which induces a conformational change of LAP and thereby activates 
TGF-P (Fig. 1) (Crawford et al., 1998).
Figure 1 Activation of latent TGF-P. TGF-P is synthesized as large latent complexes. In platelets the 
TGF-P latent complex consists of mature TGF-P which is noncovalently associated with a 
disulphide-bonded complex of a dimer of the N-terminal propeptide of the TGF-P precursor (also 
termed latency associated peptide, LAP) and a third component termed latent TGF-P binding 
protein (LTBP). Active TGF-P (capable of receptor binding) can be released from the latent 
complex by specific proteases, like plasmin. This process is likely to occur at the plasma membrane. 
Lipoprotein Lp(a) is structurally related to plasminogen, the precursor of plasmin. Lp(a) can inhibit 
plasmin generation, and inhibit activation of latent TGF-P. An alternative mechanism for activation 
of latent TGF-P is through thrombospondin, which appears to induce a conformational change in 
LAP.
Signaling diversity by generation o f heterodimeric ligands
After proteolytic cleavage of the mature C-terminal parts, biologically active TGF-P1, P2 or P3 
homodimers are generated. Homodimers are most abundant, but TGF-P1.2 (Cheifetz et al., 1987; 
Ogawa et al., 1992) and TGF-P 2.3 (Ogawa et al., 1992) heterodimers have been identified in vivo. 
For activin, four different P chains have been identified, PA, PB, PC and PE (reviewed in 
Massague, 1998, and references therein), of which PA and PB are known to form homo- as well as 
heterodimers. Whether heterodimers can also be formed with the PC and PE chains, and whether 
these different isoforms exert different biological activities is not clear. Inhibins, which are 
heterodimers of inhibin a-chains and activin P-chains, are functional antagonists of activin 
signaling (reviewed in Mathews, 1994). In the case of BMPs, BMP2/7 and BMP4/7 heterodimers 
are much more potent in induction of ventral mesoderm (Nishimatsu and Thomsen, 1998), as well 
as in bone-induction (Israel et al., 1996), compared to their respective homodimers. The co­
expression of individual BMPs in several tissues suggests that heterodimer formation might occur in 
vivo, and heterodimers of BMP2 and BMP-7 have been isolated from bovine bone (Sampath et al., 
1990). The mechanism underlying potentiated signaling by heterodimers compared to homodimers 
has not been investigated, but might be due to formation of receptor complexes consisting of, for
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example, two different type II and two different type I receptors, which may activate downstream 
signaling in a more potent manner.
TGF-fi superfamily binding proteins
After production of bioactive TGF-P superfamily members, several extracellular proteins can 
bind and modify their activity (Table 1). The extracellular matrix proteoglycans decorin and 
biglycan have been described to inhibit TGF-P activity (Yamaguchi et al., 1990). Transgenic mice 
lacking biglycan expression show dramatically decreased bone mass, suggesting an important role 
for biglycan in the constitution of bone, possibly by its function as source for storage of TGF-P 
superfamily members (Xu et al., 1998).
The serum protein a2-macroglobulin associates with circulating TGF-P superfamily members, 
and via its interaction with the a2-macroglobulin receptor, takes care of clearance of the growth 
factors from serum (LaMarre et al., 1991; Mather, 1996). Fibronectin can bind TGF-P and promote 
its bioactivity, possibly by changing it from a latent to a bioactive conformation (Fava and McClure, 
1987), and collagen IV may function to store bioactive TGF-P in the extracellular matrix (Paralkar 
et al., 1991).
Factors that are known to play important roles during embryonic development are follistatin, 
noggin, chordin, and short gastrulation (Sog), the Drosophila homologue of chordin (François and 
Bier, 1995). These proteins are secreted by the Spemann organizer and compete with BMPs to exert 
opposing effects on developmental fates of mesoderm and ectoderm (reviewed in Thomsen, 1997, 
and references therein). Mice deficient in noggin expression display excessive cartilage formation 
and failure of joint specification during skeletogenesis (Brunet et al., 1998). The TGF-P superfamily 
member Xnr3 has been reported to interfere with BMP signaling in the Xenopus Spemann organizer 
via an intracellular antagonistic mechanism that prevents BMP synthesis (reviewed in Thomsen,
1997).
Recently, cerberus, DAN, and gremlin have been identified as antagonists of BMP signaling 
during early embryogenesis (Hsu et al., 1998). Cerberus can also counteract signaling by activin and 
nodal. These proteins, like noggin and chordin, have been shown to directly interact with the growth 
factors, thereby preventing interaction of the ligands with their signaling receptors (reviewed in 
Thomsen, 1997; Hsu et al., 1998). Follistatin counteracts activin signaling by a similar mechanism 
(reviewed in Mather, 1996), whereas the mechanism by which follistatin interferes with BMP 
signaling is unclear; BMP-follistatin complexes were found to interact normally with BMP 
receptors (Iemura et al., 1998).
Interaction of chordin or Sog with BMPs is controlled by metalloproteases of the astacin family, 
to which tolloid, the Drosophila homologue of BMP1, Xenopus xolloid and zebrafish Ztld belong, 
and which are able to proteolytically cleave chordin and Sog, thereby liberating bioactive BMPs 
(Blader et al., 1997; reviewed in Mullins, 1998).
An extensive number of membrane-bound or transmembrane TGF-P binding proteins are known 
to interfere with TGF-P action. The type I and type II serine/threonine kinase receptors, which will 
be discussed in detail below, are directly involved in TGF-P signal transduction. TGF-P receptor
Table 1 TGF-p superfamily binding proteins
TGF-p superfamily binding 
protein
interacting ligands molecular characteristics functional properties reference
decorin TGF-ps extracellular, proteoglycan storage in extracellular matrix, 
inhibitor of TGF-p activity
Yamaguchi et al, 1990
biglycan TGF-ps extracellular, proteoglycan storage in extracellular matrix, 
inhibitor of TGF-p activity
Yamaguchi et al, 1990; Xu et 
al, 1998
60 kDa protein TGF-ps extracellular, matrix-associated inhibitor of ligand-receptor 
interaction
Piek et al, 1997
a2-macroglobulin TGF-ps, activins serum component clearance factor Mather, 1996
follistatin activins, BMPs extracellular, heparan-sulphate 
proteoglycan binding protein
inhibitor of ligand-receptor 
interaction
Mather, 1996
noggin BMPs extracellular, soluble inhibitor of ligand-receptor 
interaction
Thomsen, 1997
chordin BMPs extracellular, soluble inhibitor of ligand-receptor 
interaction
Thomsen, 1997
cerberus BMPs, activins extracellular, soluble inhibitor of ligand-receptor 
interaction
Hsu et al, 1998
Dan BMPs extracellular, soluble inhibitor of ligand-receptor 
interaction
Hsu et al, 1998
gremlin BMPs extracellular, soluble inhibitor of ligand-receptor 
interaction
Hsu et al., 1998
TpR-III TGF-ps transmembrane, proteoglycan accessory receptor, ligand 
presentation
Sankar et al, 1995; Lopez- 
Casillas eta l, 1993, 1994
endoglin TGF-P 1, TGF-p3, activins, 
BMPs
transmembrane, proteoglycan unknown, signal modulator? Cheifetz et al, 1992; Lastres et 
al, 1996; Barbara e ta l, 1999
Xnr3 BMPs intracellular, nodal-related inhibitor of ligand synthesis Thomsen, 1997
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type III (TPR-III), also known as betaglycan, and endoglin are transmembrane proteins which share 
high sequence homology in their short cytoplasmic tails rich in serine residues (Lopez-Casillas, 
1991; Cheifetz et al., 1992). Betaglycan has several high affinity binding sites for TGF-P1, TGF-P2 
and TGF-P3 (Kaname and Ruoslahti, 1996), and facilitates binding of TGF-P to their type II 
receptors (Fig. 2), a property which is especially of importance for TGF-P2 that has low intrinsic 
affinity for TPR-II (Lopez-Casillas et al., 1993; Sankar et al., 1995). In contrast, soluble betaglycan 
acts as an antagonist of TGF-P bioactivity by preventing the interaction of TGF-P with the signaling 
receptors (Lopez-Casillas et al., 1991, 1994).
The role of endoglin in modulation of TGF-P signaling appears to be different from betaglycan. 
In contrast to betaglycan, endoglin can interact with TGF-P1, TGF-P3, activin A, BMP-2 and BMP- 
7, and requires appropriate type I or type II receptors for efficient ligand binding (Lastres et al., 
1996; Barbara et al., 1999). Ectopic expression of endoglin in monocytes results in a selective 
abrogation of TGF-P 1-induced growth inhibition and fibronectin synthesis (Lastres et al., 1996). 
Furthermore, mutations in endoglin or ALK-1, a putative TGF-P type I receptor in endothelial cells, 
form the basis for the vascular disorder hereditary haemorrhagic telangiectasia type 1 (McAllister et 
al., 1994; Johnson et al., 1996), suggesting that endoglin and ALK-1 act in a common signal 
transduction pathway.
In many vascular endothelial cells and hematopoietic progenitor cells, TGF-P 1 and TGF-P3 are 
equipotent in mediating signaling, but TGF-P2 has weaker biological effects (Cheifetz et al., 1992; 
Ohta et al., 1987). This difference in potency between different TGF-P isoforms can be accounted 
for by the lack of betaglycan in these cells. In other cell types differential activities of TGF-P 
isoforms have been observed, but their modes of action have not been correlated to receptor binding 
properties (Flanders et al., 1991; Shah et al., 1995). Several cell membrane-associated TGF-P 
binding proteins, including certain glycosyl-phosphatidylinositol (GPI)-anchored proteins (Cheifetz 
and Massague, 1991; MacKay and Danielpour, 1991), have been identified which are endowed with 
specific affinity for certain TGF-P isoforms, but their role in TGF-P signaling is not clear. 
Furthermore, a 60 kDa TGF-P binding protein has been characterized (Butzow et al., 1993; Piek et 
al., 1997) which exhibits TGF-P1 binding specificity and interferes with binding of TGF-P to the 
signaling receptors (Piek et al., 1997).
SIGNALING VIA TGF-P SUPERFAMILY RECEPTORS
TGF-P superfamily members induce formation o f heteromeric complexes o f type I  and type II  
receptors
Type I and type II serine/threonine kinase receptors are directly involved in signaling by TGF-P 
superfamily members (Fig. 2). TGF-P1, TGF-P3 and activins initially bind to their corresponding 
type II receptors, after which the type I receptors are recruited into the signaling complex. TGF-P2 
directly interacts with a complex of TPR-I and TPR-II (Rodriguez et al., 1995). BMPs have low 
affinity for type II or type I receptors individually, and high affinity binding requires formation of a 
heteromeric type I/type II receptor complex (ten Dijke et al., 1994b; Rosenzweig et al., 1995). At
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present, only few type I and type II receptors for the TGF-P superfamily are known. However, 
depending on the ligand, multiple heterotetrameric complexes consisting of two type I and two type 
II receptor-homodimers are possible (Yamashita et al., 1994b). In view of the existence of 
heterodimeric ligands, it is conceivable that two different type I and two different type II receptors 
constitute the receptor complex, thereby creating combinatorial signaling.
TGF-P
R-Smad
Figure 2 Mechanism of TGF-P receptor activation. Schematic illustration of the current model for 
TGF-P receptor activation. TGF-P 1 initially binds the accessory TGF-P type III receptor (TPR-III), 
which presents the ligand to TGF-P type II receptor (TPR-II). Subsequently, TGF-P bound to TPR- 
II, recruits TGF-P type I receptor (TPR-I) into the complex thereby forming a heteromeric complex 
of two TPR-IIs and two TPR-Is. The constitutively active TPR-II kinase phosphorylates TPR-I, 
which propagates the signal downstream through phosphorylation of particular R-Smads, i.e. Smad2 
and Smad3. Recruitment of Smad2 and Smad3 to TGF-P receptor complex is achieved through 
Smad anchor for activation (SARA). SARA is membrane associated, and capable of binding both 
R-Smad and the TGF-P receptor complex.
TGF-Ps form heteromeric complexes between TPR-II and TPR-I (Attisano et al., 1993; Franzen 
et al., 1993b), activins signal via a combination of ActR-II or ActR-IIB, and ActR-IB (Attisano et 
al., 1992, 1993). Activins have also been shown to interact with ActR-I (Attisano et al., 1993; ten 
Dijke et al., 1994a), although this receptor appears to play a minor role in activin signaling. BMPs 
interact with ActR-II, ActR-IIB or BMPR-II, in combination with ActR-I, BMPR-IA or BMPR-IB 
(ten Dijke et al., 1994b; Rosenzweig et al., 1995; Yamashita et al., 1995b). For AMH only a type II 
receptor has been identified (di Clemente et al., 1994). A potential AMH type I receptor is ActR-I, 
which is co-expressed with AMHR-II in the Mullerian duct and which can mediate AMH-specific 
repression of FSH-induced aromatase activity (Visser et al., 1998). TGF-P can bind and signal 
through ALK-1 in endothelial cells, and has therefore been implicated as an endothelial-specific 
TGF-P type I receptor (T. Imamura, P. ten Dijke and K. Miyazono, personal communication). 
Disruption of ALK-1 expression results in defects in angiogenesis or vasculogenesis and embryonic 
lethality at midgestation (E. Li, personal communication). Activin receptor-like kinase 7 (ALK7) is 
an orphan receptor (Ryden et al., 1996). Recently, a novel type I receptor, designated zALK8, was 
cloned and shown to be widely expressed throughout early zebrafish development (Yelick et al.,
General introduction 15
1998). Mammalian homologues of zALK8, as well as of zebrafish TARAM-A which is a type I 
receptor involved in induction of anterior dorsal mesoderm (Renucci et al., 1996), have not yet been 
identified. The ligands for these receptors have not been elucidated.
Activation and regulation o f serine/threonine kinase type I  and type II receptors
Type I receptor kinases become activated upon phosphorylation by the constitutively active type 
II receptor kinase (Fig. 2). Thus, type I receptors act downstream of type II receptors (Wrana et al., 
1994). Consistent with this finding, type I receptors were found to determine the specificity of the 
intracellular signals induced by different TGF-P superfamily members, while the L45 region in type 
I receptors was found to be important in determining the specificity of type I receptors (Feng and 
Derynck, 1997; Chen et al., 1998b; Persson et al., 1998).
The phosphorylation status of TPR-II has been shown to influence TGF-P signaling. TPR-II is a 
constitutively active kinase that requires phosphorylation of Ser213, located outside the kinase 
domain, to mediate its autocatalytic effect. Ligand-dependent autophosphorylation of TPR-II on 
either Ser409 or Ser416 differentially contributes to regulation of its activity, leading to stimulation 
or inhibition of TGF-P signaling, respectively (Luo and Lodish, 1997).
Differential kinetics in biosynthesis, ligand-induced internalization and down-regulation of type I 
versus type II receptors have been contributed to differential modulation of TGF-P signaling (Koli 
and Arteaga, 1997; Wells et al., 1997; Anders et al., 1997, 1998). The half-life and processing of 
TPR-II in the endoplasmic reticulum is considerably shorter than that of TPR-I (Koli and Arteaga, 
1997; Wells et al., 1997; Anders et al., 1998). Furthermore, homo- and heteromeric receptor 
complexes have distinct endocytotic fates (Anders et al., 1997). Rapid modulation of TPR-II 
expression levels as well as ligand-bound TPR-I/TPRII complexes may be important for fine-tuning 
signaling by TGF-P.
Diversity in receptor availability might be provided by the existence of alternative receptor 
transcripts, as identified for ActR-IA (Shoji et al., 1998), ActR-IB (Xu et al., 1994), ActR-IIB 
(Attisano et al., 1993), AMHR-II (di Clemente et al., 1994), and TPR-II (Suzuki et al., 1994). In the 
case of ActR-IIB, differential affinity of activin for the alternatively spliced gene products has been 
observed. In addition, differences in the cytoplasmic domains offer possibilities for differential 
modes of signaling (Attisano et al., 1993).
Several growth factors are known to bind to the same type II receptor, for example activins and 
BMPs which share ActR-II and ActR-IIB (Yamashita et al., 1995b; Piek et al., 1999a). This enables 
signaling by several growth factors with access to a limited scala of available receptor types, while 
on the other hand it can lead to competition of different ligands for the same type II receptors, 
thereby fine-tuning signaling via type I receptors. This is for example the case between activin and 
inhibin, in which inhibin is known to counteract many of activin functions by competing for binding 
to the activin type II receptor (Lebrun and Vale, 1997). A similar mechanism has been suggested to 
underlie the inhibitory action of zebrafish antivin, most closely related to mouse lefty, on activin 
signaling (Thisse and Thisse, 1999), and appears to contribute to the functional antagonism 
observed between activin and OP-1 in Tera-2 embryonal carcinoma cells (Piek et al., 1999a).
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Whether different ligands might also compete for binding to common type I receptors is not clear at 
present.
Cytoplasmic TGF-P receptor interacting proteins distinct from Smads
A number of cytoplasmic proteins are now known to interact with the kinase domain of type I 
and type II receptors, thereby manipulating or mediating their signaling capacities (Table 2). TRIP-
I, a protein that contains five WD domains, is known to bind and become phosphorylated by TPR-
II. The interaction requires a functional TPR-II kinase (Chen et al., 1995). Overexpression of TRIP- 
1 attenuates TGF-P-induced PAI-1 transcriptional response, but not TGF-P-induced cyclin A 
response (Choy and Derynck, 1998). The WD domain-containing protein STRAP can associate with 
TPR-I and TPR-II. STRAP and the inhibitory Smad7 synergistically block TGF-P-mediated 
transcriptional activation (Datta et al., 1998). Another WD-40 repeat protein Ba, a subunit of 
protein phosphatase 2a, has been reported to interact with and become phosphorylated by TPR-I. 
B a potentiates the antiproliferative effect mediated by TGF-P (Griswold-Prenner et al., 1998). TPR- 
I-associated protein-1 (TRAP-1) interacts specifically with the activated TPR-I. However, its 
functional role in TGF-P signaling is unclear (Charng et al., 1998).
The immunophilin FKBP12 interacts with type I serine/threonine kinase receptors (Wang et al., 
1996c) through an FK506-like Leu-Pro motif preceding the kinase domain (Chen et al., 1997c). 
FKBP-12 inhibits the phosphorylation of the type I receptors by the type II receptors, possibly by 
sterical hindrance, and may function to prevent leaky signaling in the basal cell state (Chen et al., 
1997c). FKBP12 dissociates from TPR-I following ligand-induced phosphorylation of TPR-I by 
TPR-II (Wang et al., 1996c; Chen et al., 1997c).
Farnesyltransferase a  (FTa) has also been shown to interact with and become phosphorylated by 
activin and TGF-P type I receptors (Wang et al., 1996b). However, farnesyl transferase activity was 
shown to be dispensable for TGF-P signaling.
Type I receptors as determinants o f downstream signal propagation
Activation of type I receptors by type II receptors occurs by phosphorylation of serine and 
threonine residues in the GS domain, a 30 amino acids region preceding the kinase domain of type I 
receptors which is characterized by repeats of glycine and serine residues (Wrana et al., 1994). 
Specificity of signal propagation to Smad molecules, the main downstream components in 
serine/threonine kinase receptor signaling, is determined by type I receptors (reviewed in Heldin et 
al., 1997; Massague, 1998). More specifically, a region flanking P-strands 4 and 5 in the kinase 
domain, designated L45 loop, confers a high degree of specificity in Smad-interaction with the type
I receptors (Feng and Derynck, 1997; Chen et al., 1998b; Persson et al., 1998). The L45 loop is 
highly conserved among type I receptors with comparable signaling specificity, but significantly 
differs between BMP and TGF-P or activin type I receptors (Chen et al., 1998b; Persson et al., 
1998). Swapping the L45 loop between TPR-I and BMPR-IB followed by ligand-stimulation was 
shown to result in exchange of Smad1 versus Smad2 recognition specificity, accompanied by a 
switch in transcriptional responses (Chen et al., 1998b; Persson et al., 1998). However, 
constitutively active variants of these receptor chimeras do not completely substitute for their
Table 2 TGF-p superfamily receptor-interacting proteins
receptor-interacting protein interacting receptor type molecular characteristics functional properties reference
FKBP12 type I receptors immunophilin inhibitor of TpR-I kinase Wang etal, 1996c
FToc TGF-p type I receptor famesyl transferase unknown Wang et ah, 1996b
TRIP-1 TGF-p type II receptor WD-40 repeat protein signal modulator Choy and Derynck, 1998
STRAP TGF-p type I, II receptors WD-40 repeat protein inhibitor of transcriptional 
responses
Dattaeia/., 1998
TRAP-1 TGF-p type I receptor without motif inhibitor of TGF-p signaling Chamg et ah, 1998
Ba TGF-P type I receptor, activin 
type I receptor
WD-40 repeat protein, 
phosphatase 2A-subunit
enhancer of growth inhibition Griswold-Prenner et al.f 1998
apolipoprotein J TGF-p type I, II receptors nuclear protein or secreted 
glycoprotein
role in TGF-P receptor signaling 
and/or processing
Reddy etah, 1996
SARA TGF-P receptor complex FYVE-containing protein Smad subcellular localizer Tsukazaki et ah, 1998
Smad type I receptors transcription factor signal transducer Heldin etah, 1997
BRAM-1 BMP type IA receptor El A-associated protein unknown Kurozumi et ah, 1998
XIAP BMP type IA receptor inhibitor of apoptosis protein adaptor protein for TABI, 
inhibitor of apoptosis
Yamaguchi et ah, 1999
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constitutively active wild type counterparts (Chen et al., 1998b; Persson et al., 1998), indicating that 
the L45 loops can not be the only determinants of signaling specificity. Furthermore, BMPR-IA and 
BMPR-IB have identical L45 loops, which are completely divergent from that of ActR-I. However, 
all three type I receptors are able to phosphorylate Smad1, Smad5 and Smad8 upon their activation 
(Chen et al., 1998b; Macias-Silva et al., 1998; Persson et al., 1998). Many differential effects 
between the two BMP type I receptors have been described (Kawakami et al., 1996; Zou et al., 
1997; Chen et al., 1998a), while differential effects by members of the BMP subfamily have been 
observed that appear to be dose-dependent or cell-type-specific (Wang et al., 1993; Asahina et al.,
1996). CDMP-1 and CDMP-2, which both interact with BMPR-IB and BMPR-II, induce 
chondrogenesis versus osteogenesis (Nishitoh et al., 1996; Erlacher et al., 1998). Thus, in addition 
to a role for the L45 loop, additional mechanisms must contribute to specify downstream signaling 
following activation of type I receptors.
It has been shown that the cytoplasmic juxtamembrane region of TPR-I is involved in specifying 
signal transduction, since mutations of certain serine or threonine residues within this region 
selectively impair TGF-P mediated growth inhibition, but do not affect TGF-P-induced PAI-1 or 
fibronectin synthesis (Saitoh et al., 1996). However, in vivo phosphorylation of these sites by TPR-
II has not yet been reported. Mutation of Ser165, located N-terminal of the GS domain, results in 
potentiation of TGF-P-mediated growth inhibition and extracellular matrix induction, but 
diminishes TGF-P-induced apoptosis (Souchelnytskyi et al., 1996). Thus, additional residues in 
TPR-I appear to modulate distinct pathways triggered by TGF-P.
In certain cell systems it has been observed that the expression level of type I receptors correlates 
with extracellular matrix production and gene transcription, while the expression level of type II 
receptors correlates to the growth inhibitory response, suggesting participation of type I and type II 
receptors in different signaling pathways (Laiho et al., 1991; Geiser et al., 1992; Chen et al., 1993; 
Ebner et al., 1993; Centrella et al., 1995). However, the observations made are all compatible with 
an alternative interpretation i.e. that all signals are initiated by activation of the type I receptor and 
that different activation thresholds of the signaling pathways leading to growth inhibition versus 
gene transcription underly the apparent differential modes of signaling by type I and type II 
receptors.
INTRACELLULAR SIGNALING BY TGF-P SUPERFAM ILY MEMBERS
Receptor-activated Smads and common-mediator Smads as mediators o f TGF-P signal transduction
Genetic studies in Drosophila and C. elegans have led to the identification of a conserved family 
of intracellular signal transducers for TGF-P superfamily members. The founding member, mothers 
against dpp (Mad) (Raftery et al., 1995; Sekelsky et al., 1995) was isolated from a genetic screen 
for enhancers of a weak Dpp maternal phenotype. Subsequently, three Mad-homologues, called 
sma-2, sma-3 and sma-4, were picked up in C. elegans by searching for genes whose mutations 
caused the same small body size phenotype as observed for mutant Daf4, a type II serine/threonine 
kinase receptor (Savage et al., 1996). At present, eight different Sma- and Mad-related proteins have
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been identified in mammals, and termed Smads (Fig. 3A). They can be subdivided into three 
distinct subclasses: receptor-activated Smads (R-Smads), common mediator Smads (Co-Smads) and 
inhibitory Smads (anti-Smads). R-Smads and Co-Smads are homologous in their N- and C- 
terminals, called the MH1 and MH2 domains, respectively. These domains are connected by a 
proline-rich linker region. R-Smads contain an SSXS phosphorylation motif in their very C-termini.
Smad1, Smad5 and Smad8 are involved in BMP signaling and become phosphorylated by ActR- 
I, BMPR-IA or BMPR-IB (Thomsen, 1996; Chen et al., 1997b; Macias-Silva et al., 1998; Tamaki et 
al., 1998). Smad2 and Smad3 are mediators of TGF-P and activin signaling and interact with and 
become phosphorylated by TPR-I or ActR-IB (Eppert et al., 1996; Macias-Silva et al., 1996; Zhang 
et al., 1996; Nakao et al., 1997b). Consistent with these findings, injection of BMP-Smads into 
Xenopus animal caps results in ventralization of mesoderm (Baker and Harland, 1996; Graff et al., 
1996; Thomsen, 1996; Chen et al., 1997b; Macias-Silva et al., 1998) and ectopic expression of 
Smad2 in Xenopus embryos, induces dorsal mesoderm and secondary axis formation analogous to 
activin/Vg-1-like responses (Baker and Harland, 1996; Graff et al., 1996). Smad2-null mice lack 
anterior-posterior specification and fail to develop mesoderm (Nomura and Li, 1998; Waldrip et al., 
1998). The phenotype of Smad2 knockouts is strikingly similar to Nodal knockouts, and suggests 
that they cooperate in regulation of gastrulation (Nomura and Li, 1998). Mutant mice lacking 
Smad3 expression have been reported to be viable and fertile but develop colon carcinomas four to 
six months after birth (Zhu et al., 1998) or exhibit limb malformations (Datto et al., 1999). Smad3 
null cell lines showed strongly impaired TGF-P responsiveness and indicated an important role for 
Smad3 in TGF-P-mediated inhibition of cellular proliferation (Datto et al., 1999). The Smad3 
knockout phenotype observed by Zhu and coworkers (1998) classifies Smad3 as a tumor-suppressor 
gene, although Smad3 mutations have not yet been detected in tumorigenesis (Riggins et al., 1997).
TGF-P-mediated phosphorylation of Smad1 has been observed in breast tumor cells, but the 
receptor by which this phosphorylation is mediated has not been determined (Liu et al., 1998). 
Smad5 phosphorylation in response to TGF-P was detected in CD34+ cells (Bruno et al., 1998). 
ALK-1 has been shown to bind TGF-P and to phosphorylate and activate BMP-Smads (Macias- 
Silva et al., 1998; T. Imamura, P. ten Dijke, and K. Miyazono, personal communication), and thus 
could possibly mediate TGF-P-induced Smad phosphorylation in these cells.
At present, three Co-Smads have been characterized, i.e. mammalian Smad4/DPC4 (deleted in 
colon carcinoma; Hahn et al., 1996), C. elegans Sma-4 (Savage et al., 1996), and Drosophila 
Medea (Das et al., 1998). Co-Smads play a critical role in signaling by TGF-P superfamily 
members, illustrated by the absence of TGF-P signaling and R-Smad-functioning in Smad4- 
deficient tumor cell lines, as well as by the synergistic action of Smad4 with R-Smads in 
transcriptional activation of target genes and induction of mesoderm (Lagna et al., 1996; de Winter 
et al., 1997; Liu et al., 1997a; Nakao et al., 1997b; Zhang et al., 1997). The importance of Smad4
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Figure 3 The Smad family of intracellular signal transducers for TGF-P superfamily proteins. (A) A 
phylogenetic analysis of mammalian Smad proteins. (B) The Mad Homology (MH)1 and MH2 
domains have affinity for each other; type I receptor-mediated phosphorylation at the C-terminus 
may induce a conformation change thereby relieving the autoinhibitory effect of MH1 on MH2 and 
vice versa. (C) Schematic structure of R-Smad and its functional domains. Direct DNA binding is 
mediated through the MH1 domain, whereas MH2 has transcriptional activation activity. The sites 
of phosphorylation by type I receptors at the extreme carboxy-terminus and by ERK in linker region 
are indicated.
functioning is furthermore shown by its tumor-suppressor activity; mutation or deletion of Smad4 is 
often associated with tumorigenesis (Hahn et al., 1996; Schutte et al., 1996; Shi et al., 1997; Le Dai 
et al., 1998; Zhou et al., 1998b). Tumor cell lines expressing endogenous Smad4-mutants 
universally failed to transcriptionally activate transfected luciferase reporters containing Smad
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binding elements (Le Dai et al., 1998). Mice lacking expression of Smad4 show a BMP knockout 
phenotype, characterized by growth retardation and gastrulation defects (Sirard et al., 1998). 
However, the abnormalities in mesoderm development of Smad4-null mice could be overcome by 
the presence of wild-type extraembryonic tissue, indicating that Smad4 is not critical for early 
gastrulation (Sirard et al., 1998). Although several explanations are possible, one reasonable 
argument is that a yet unidentified Co-Smad is involved in mediating early embryonic 
differentiation induced by members of the TGF-P superfamily. At later stages of development, 
Smad4 is important for anterior specifications (Sirard et al., 1998).
Additional indications for the possible existence of novel Co-Smads comes from studies in 
Drosophila where Medea, in contrast to Mad, is dispensable for oogenesis (Wisotzkey et al., 1998). 
An explanation for the fact that Mad knockouts have a more severe phenotype than Medea 
knockouts might be that Mad is able to signal certain responses independent of Medea. 
Furthermore, mutations in Medea efficiently block signaling by Saxophone (Sax), but fail to fully 
suppress the phenotype of Thick Veins (Tkv), both of which are Dpp type I receptors (Das et al., 
1998). Although Medea might be abundantly present to allow Tkv signaling even when 
hypomorphic alleles are expressed, the inability to fully abrogate Tkv signaling might also reside in 
the fact that another, yet unidentified, Co-Smad is involved in Tkv signaling, or that Tkv can signal 
independent of Medea. Interestingly, in addition to the Xsmad4 ortholog, a Smad4/Medea-like 
protein, was recently identified in Xenopus (LeSueur and Graff, 1999; C. Hill, personal 
communication).
Mechanisms controlling Smad-activation
R-Smads circulate as monomers in the cytoplasm (Kawabata et al., 1998) and, following ligand- 
induced type I receptor activation, specifically interact with the L45 loop in the kinase domain of 
type I receptors (Chen et al., 1998b; Persson et al., 1998). Recruitment of R-Smads to the TGF-P 
receptors is established by the action of SARA, a FYVE zinc finger domain containing protein, that 
interacts with both TGF-P receptors and Smad2 or Smad3 (Fig. 2) (Tsukazaki et al., 1998; ten Dijke 
and Heldin, 1999). The highly conserved L3 loop of R-Smads, which protrudes from the MH2 core 
domain as observed in the Smad4-MH2 crystal structure (Shi et al., 1997), is involved in specifying 
type I receptor interactions (Lo et al., 1998). This loop varies between the different R-Smads in only 
two amino acids, and exchanging these residues between Smad1 and Smad2 switches their 
specificity in receptor-recognition (Chen et al., 1998b; Lo et al., 1998).
Following type I receptor interaction, R-Smads become activated by phosphorylation of their C- 
terminal SS(M/V)S motifs (Fig. 3B) (Macias-Silva et al., 1996; Abdollah et al., 1997; 
Souchelnytskyi et al., 1997; Kretzschmar et al., 1997b), domains which are dispensable for 
receptor-association (Lo et al., 1998). Phosphorylation of R-Smads triggers their homomerization, 
as well as heteromerization with Co-Smads (Liu et al., 1997a; Kretzschmar et al., 1997b), or can 
lead to the formation of R-Smad heteromers (Baker and Harland, 1996; Kawabata et al., 1998) 
independent of Smad4 availability (Kawabata et al., 1998). This leads to the speculation that 
homomeric R-Smads, heteromeric R-Smads, and R-Smad/Co-Smad complexes might control 
different biological responses.
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In contrast to R-Smads, Co-Smads do not contain the C-terminal phosphorylation motif SSXS, 
and do not get phosphorylated by activated type I receptor (Macias-Silva et al., 1996; Zhang et al.,
1996). Although the L3 loop of Co-Smads shares high amino acid homology with the L3 loop of R- 
Smads, Co-Smads do not interact with type I receptors (Zhang et al., 1996), but instead, their L3 
loop is important for heteromerization with phosphorylated R-Smads (Shi et al., 1997). Analysis of 
Smad-deletion mutants (Wu et al., 1997; Zhang et al., 1997) together with the crystal structure of 
the Smad4-MH2 domain (Shi et al., 1997) have indicated that the MH2 domains of R-Smads and 
Co-Smads are involved in formation of homo-and heteromeric trimers. Following association of R- 
Smads with Co-Smads, the heteromeric complexes are translocated into the nucleus (Fig. 5).
Domains controlling nuclear translocation
Whereas ligand-induced nuclear translocation of R-Smads is not dependent on expression of Co- 
Smads (Liu et al., 1997a; Wisotzkey et al., 1998), Co-Smads require association with activated R- 
Smads in order to enter the nucleus (Souchelnytskyi et al., 1997; Das et al., 1998; Wisotzkey et al., 
1998). A C-terminal truncation of Smad4, corresponding to a mutation of Smad4 found in 
pancreatic tumors (Hahn et al., 1996) and identified in an inactive form of Mad in Drosophila 
(Sekelsky et al., 1995), dominant-negatively interferes with nuclear transport of all R- and Co- 
Smads (Zhang et al., 1997). In contrast, a comparable mutation in R-Smads does not affect their 
nuclear localization (Zhang et al., 1997). This indicates that the C-terminal part of Co-Smads is 
required for nuclear trafficking (Zhang et al., 1997), while phosphorylation of R-Smads, though 
required for their functionality, is not obligatory for nuclear transport. How these mutant Co-Smads 
interfere with the nuclear transport function of R-Smads needs to be further studied. Removal of the 
N-terminus and linker region of R-Smads results in strong, ligand-independent, nuclear localization 
(Baker and Harland, 1996; Zhang et al., 1997), whereas an additional C-terminal truncation of the 
remaining MH2 domain results in cytoplasmic accumulation at the nuclear membrane (Zhang et al.,
1997). Presumably, ligand-induced heteromerization results in a conformational change of the Smad 
molecules, thereby exposing nuclear translocation signals residing in the linker region of R-Smads 
or the MH2 domain of R- and Co-Smads. Whether the cytoplasmic residence of R-Smads and Co- 
Smads in the absence of ligand is merely due to autoinhibition of the MH2 effector domain by 
association with the MH1 domain (Hata et al., 1997), or whether a cytoplasmic tether exists that 
anchors R- and Co-Smads in the cytoplasm in the absence of ligand, is not clear (Zhang et al.,
1997).
R-Smads and Co-Smads as sequence-specific transcriptional activators
Once in the nucleus, R-Smads and Co-Smads are involved in transcriptional regulation of target 
genes (Fig. 3C) (reviewed in Derynck et al., 1998), and the MH1 and MH2 domains differentially 
contribute to this property. Direct binding of Smads to DNA was first shown by the interaction of 
the Drosophila Mad-MH1 domain with specific sequences in the promoter of the Dpp-target gene 
vestigial (Kim et al., 1997). A prerequisite for the interaction of Mad, Smad3, but not Smad4, with 
DNA is the dissociation of the MH2 domain from the MH1 domain, which is achieved by ligand-
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induced phosphorylation of the SSXS motif in R-Smads (Kim et al., 1997; Liu et al., 1997b). Thus, 
the MH2 domain can exert an autoinhibitory action on the MH1 DNA binding domain.
In several promoters of genes induced by TGF-P signaling, like JunB and PAI-1 (Yingling et al., 
1997; Dennler et al., 1998; Jonk et al., 1998), unique elements have been identified with which 
Smad3 and Smad4 physically interact. The sequences of the Smad-binding elements (SBEs) in these 
promoters are highly related, and indicate an AGAC-containing motif as binding site for Smad3 and 
Smad4. This sequence was also picked up in a random screening for Smad-interacting DNA 
sequences (Zawel et al., 1998), and mutation of these SBEs in the PAI-1 promoter impairs TGF-P 
responsiveness (Dennler et al., 1998).
Crystallization of the Smad3 MH1 domain bound to an optimal Smad binding sequence, revealed 
that the so called P-hairpin loop, protruding from the MH1 core domain, interacts with DNA (Shi et 
al., 1998). The P-hairpin loop is highly conserved among R-Smads and Co-Smads. However, 
Smad2 contains an extra exon preceding this region, encoding 30 amino acids, which might 
interfere with the correct conformation of the P-hairpin loop; in contrast to Smad3 and Smad4, 
Smad2 has not yet been shown to interact with DNA. Removal of exon 3 in Smad2 enables its 
efficient binding to DNA (Yagi et al., 1999, J.-M Gauthier, personal communication).
In several TGF-P target genes, multiple copies of SBEs can be identified, often located in close 
proximity to sites for other transcription factors (Yingling et al., 1997; Dennler et al., 1998; Labbe 
et al., 1998; Zhang et al., 1998; Zhou et al., 1998a). Smads have been shown to mediate 
transcriptional activation by interaction with other regulatory promoter units, like the TPA- 
responsive elements (TREs)/AP-1 sites in the 3 TP-Lux promoter, which actually overlap in 
sequence with SBEs (Yingling et al., 1997; Zhang et al., 1998). Smads cooperate with the 
transcription factor TFE3 in the regulation of the PAI-1 gene (Hua et al., 1998). The 
p21/WAF1/Cip1 and p15/INK4B gene promoters lack SBEs, but TGF-P transcriptionally regulates 
these genes via the Sp1 site (Datto et al., 1995; Li et al., 1995; Moustakas and Kardassis, 1998). It 
has been suggested that the interaction of Smads with additional transcription factors (Fig. 4), like 
AP-1 (Zhang et al., 1998; Liberati et al., 1999; Wong et al., 1999), forkhead activin signal 
transducers (FAST; Labbe et al., 1998; Zhou et al., 1998a; Liu et al., 1999) or Sp1 (Datto et al., 
1995; Moustakas and Kardassis, 1998), confers additional DNA-binding specificity to the Smad- 
containing transcriptional complex (see below).
R-Smads and Co-Smads as transcriptional (co-)activators
Studies with Xenopus explants, in which injection of the Smad2-MH2 domain fully induced 
dorsalization of mesoderm and secondary axis formation analogous to activin signaling (Baker and 
Harland, 1996), suggested an effector function for MH2 domains. Furthermore, transcriptional 
activation properties of R- and Co-Smads were shown by fusion constructs of Smad1-MH2 or 
Smad4-MH2 domains with Gal4-DNA binding domains (Liu et al., 1996). Heteromerization of Co- 
Smads with R-Smads is obligatory for their transcriptional activation properties (Liu et al., 1997a; 
Wu et al., 1997; Feng et al., 1998).
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of Smads
transcription factors
co-activators CBP/p300 MSG1
Figure 4 Smad interacting proteins. Overview of the interacting proteins for Smad3 and Smad4. All 
proteins that interact with Smad3 also interact with Smad2, except for c-Jun, c-Fos and Evi-1. The 
interaction of T^R-I with Smad2 or Smad3 occurs through the L3 loop in the MH2 domain, and 
association of FAST-1 with Smad2 or Smad3 is determined by an exposed a-helix 2 in MH2 
domain. SAD, Smad activation domain.
Several domains in Smad4 have now been identified to contribute to its indispensable role in 
signaling by members of the TGF-P superfamily. As mentioned above, the MH1 domain enables the 
interaction of R-Smad/Co-Smad complexes with DNA, which is of particular importance for 
Smad2-Smad4 heteromeric complexes (Liu et al., 1997a), since Smad2 is not endowed with DNA 
binding capacities. The MH1 domain autosuppresses the MH2 effector domain (Hata et al., 1997), 
and heteromerization of Co-Smads with phosphorylated R-Smads has been suggested to release the 
inhibitory association (Wrana and Pawson, 1997). Studies in which chimeras between Smad1 and 
Smad4 were tested, revealed that the proline-rich linker region of Smad4 contains a domain that is 
important for its transcriptional activity mediated by the MH2 domain (de Caestecker et al., 1997). 
This Smad activation domain (SAD) functionally interacts with the transcription coactivator MSG1 
(de Caestecker et al., 1997; Shioda et al., 1998). MSG1 strongly enhances Smad4 transcriptional 
activity, provided that Smad4 is present in a heteromeric complex with R-Smads (Shioda et al., 
1998). Smad heteromerization possibly introduces a configuration which allows transactivators to 
associate and thereby endow Smad4 with transcriptional potencies (Shioda et al., 1998).
Smads interact with transcription factors
The first evidence that Smads interact and cooperate with transcription factors comes from the 
observed interaction between Smad2, Smad4 and Xenopus FAST-1 (XFAST-1), making a complex 
that interacts with the activin responsive element (ARE) in the Xenopus Mix2 promoter (Fig. 4, 5) 
(Chen et al., 1996, 1997a; Liu et al., 1997a). Human FAST-1 and mouse FAST-2 (mFAST-2) have 
been identified as well, but share little sequence homology with XFAST-1 (Labbe et al., 1998; Zhou 
et al., 1998a; Liu et al., 1999). Whereas FAST-1 efficiently interacts with DNA but lacks
General introduction 25
transcriptional activation properties, Smad2 and Smad4 contribute in providing additional DNA 
interactions as well as essential transcriptional activation properties (Chen et al., 1996, 1997a; Liu 
et al., 1997a, 1999; Zhou et al., 1998a). Phosphorylation of the Smad2 SSMS motif is required for 
interaction of a-helix 2, exposed from the MH2-trimer structure, with FAST-1 (Chen et al., 1996, 
1997a; Zhou et al., 1998a).
Smad2 and Smad3, in cooperation with mFast-2, exert opposing effects in transcriptional 
activation of the ARE element in the goosecoid promoter (Labbe et al., 1998). Whereas 
Smad2/Smad4/mFAST-2 complexes drive transcriptional activation of the goosecoid reporter, 
Smad3/Smad4/mF AST-2 suppresses promoter activation, presumably because Smad3 and Smad4 
share the same DNA binding site (Labbe et al., 1998). This suggests that the relative expression 
levels of Smad2 and Smad3 in a cell might determine the outcome of certain biological responses 
induced by TGF-p.
Additional evidence for differential roles of Smad2 and Smad3 comes from observations in 
human keratinocytes, where TGF-P stimulates Smad2 and Smad3 to comparable extents, while 
activin, as observed in enhanced phosphorylation, Smad4 heteromerization, and nuclear 
translocation, specifically activates Smad3 compared to Smad2 (Shimizu et al., 1998). In human 
lung epithelial cells, Smad3 more potently induces apoptosis compared to Smad2 (Yanagisawa et 
al., 1998).
Cooperation o f Smads with the AP-1 complex
Characterization of Smad binding sites in the 3TP-Lux reporter revealed that Smads can mediate 
transcription via 12-O-tetradecanoyl-13-acetate (TPA)-responsive elements (TREs; Baker and 
Harland, 1996; Lagna et al., 1996; Zhang et al., 1996; Yingling et al., 1997), to which the 
transcription factor AP-1, a dimer of c-Jun and c-Fos, binds. These AP-1 binding sites overlap in 
sequence with consensus Smad binding sites (Yingling et al., 1997). Using a reporter system (TRE- 
luc) in which luciferase expression is controlled by four tandem AP-1 sites derived from the 
collagenase promoter, it was shown that Smad3 and Smad4 synergistically activate the TRE-luc 
reporter following TGF-^-induced interaction of Smad3 with the AP-1 sites (Zhang et al., 1998). 
TGF-^-induced reporter activity was further enhanced in the presence of c-Jun-c-Fos heterodimers 
(Fig. 4) (Zhang et al., 1998). Following TGF-^-induced Smad activation, Smad3 and Smad4 can 
interact with JunB, c-Jun and JunD, as well as with c-Fos (Zhang et al., 1998; Liberati et al., 1999). 
By footprint analysis and electromobility shift assays, it was shown that c-Jun and Smad3 can bind 
simultaneously to overlapping sequences in the TRE (Zhang et al., 1998). Crystallographic analysis 
of the Smad3 MH1 domain bound to DNA indicated that a conformational change of the N- 
terminus of c-Fos would allow the multimeric Smad-AP-1 complex to interact with a single AP-1 
site (Shi et al., 1998). This cross-talk might be an important level of coordination between Smads 
and MAPK/JNK signaling.
Interaction with the coactivatorsp300/CBP
Insight in how Smads mediate their transcriptional activating function was recently unravelled by 
the interaction of R-Smads with the co-activators p300 and CREB binding protein (Fig. 4) (CBP;
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Feng et al., 1998; Janknecht et al., 1998; Nishihara et al., 1998; Shen et al., 1998; Topper et al.,
1998). These co-activators contribute to transcriptional activation by loosening the chromatin 
structure, or by increasing the affinity of certain transcription factors for DNA, through their 
intrinsic (or associated) acetyltransferase activity. In addition, they act as bridging factor between 
transcription factors and the basal transcription machinery (Janknecht et al., 1998, and references 
therein). In view of the indispensability of Smad4 for transcriptional activation of the Smad- 
p300/CBP complex, Smad4 might function as co-activator as well (Feng et al., 1998). The 
interaction between the MH2 domain of R-Smads and CBP/p300 is triggered by ligand-induced 
phosphorylation of the C-terminal SSXS motif (Feng et al., 1998; Janknecht et al., 1998; Topper et 
al., 1998). Most likely, phosphorylation induces a conformational change in the R-Smad molecule 
which then results in exposure of the CBP/p300 binding site; deletion of the N-terminus and part of 
the C-terminus, leaving the CBP binding site intact, enhances the affinity of Smad3 for CBP/p300 
(Janknecht et al., 1998). The C-terminal region of CBP is required for Smad-interaction (Feng et al., 
1998; Janknecht et al., 1998; Topper et al., 1998), and can associate with other transcription factors 
like the adenoviral oncoprotein E1A. E1A is known to interfere with TGF-^-mediated signaling 
(Abraham et al., 1992; Datto et al., 1997), and is shown to abrogate Smad-mediated transcriptional 
activation (Feng et al., 1998; Janknecht et al., 1998; Topper et al., 1998), most likely by its direct 
competition with Smads for binding to CBP/p300 (Abraham et al., 1992; Datto et al., 1997).
Negative regulation o f Smad function
Activin and BMPs have been shown to compete which each other in Xenopus mesoderm 
development, due to limiting amounts of Smad4 (Candia et al., 1997). In view of the limited 
amounts of CBP/p300 in the cell (Janknecht et al., 1998), and the observed competition between 
different signal transduction pathways at the level of co-activator availability (Horvai et al., 1997), 
competition between members of the TGF-P superfamily as observed in embryogenesis can also be 
expected to occur at the level of CBP/p300.
Interaction of the first zinc-finger domain of the nuclear protein Evi-1 with the MH2 domain of 
Smad3 interferes with binding of Smad3 to DNA (Fig. 4), thereby repressing transcriptional activity 
of Smad3 as well as growth inhibition (Kurokawa et al., 1998). Evi-1 shows a spatial and temporal 
expression pattern during mouse embryogenesis, suggesting that it could play a regulatory role 
during development (Perkins et al., 1991).
Inhibitory Smads
Mammalian Smad6, Smad7 and Drosophila Dad have been characterized as inhibitors of TGF-P 
signal transduction (Fig. 5) (Hayashi et al., 1997; Imamura et al., 1997; Nakao et al., 1997a; 
Tsuneizumi et al., 1997; Inoue et al., 1998). Whereas their N-terminal domains are highly diverse 
and share only weak similarity to other Smads, they are homologous to the R- and Co-Smads in 
their MH2 domains. However, anti-Smads lack the C-terminal SSXS phosphorylation motif, which 
may enable them to stably associate with type I receptors and to interfere with receptor binding and 
activation of R-Smads. Phosphorylation of the type I receptors by the type II receptors is essential 
for anti-Smad association (Hayashi et al., 1997; Nakao et al., 1997a; Souchelnytskyi et al., 1998),
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Figure 5 TGF-P superfamily signaling through signal transducing Smad and inhibitory Smad 
proteins. Following type I receptor activation R-Smads become phosphorylated and form 
homomeric complexes with each other, and assemble into heteromeric complexes with Co-Smad, 
Smad4. Trimers are shown, but hexamers have not been excluded. The stoichiometry between the 
components is unclear. The heteromeric complexes translocate into the nucleus, where they 
regulate, in combination with other transcription factors, transcription of target genes. Smad2, 
Smad4 and FAST-1 are components of an activin-responsive factor that interacts directly in an 
activin-dependent manner with an activin response element of the Mix.2 promoter. Inhibitory Smads 
act opposite from R-Smads by competing with them for interaction with activated type I receptors or 
by directly competing with R-Smads for heteromeric complex formation with Co-Smad. Smad7 
appears to be a general inhibitor of TGF-P superfamily signaling, whereas Smad6 preferentially 
inhibits BMP-induced responses.
and the MH2 domain of anti-Smads suffices in exhibiting the inhibitory effect (Hayashi et al., 1997; 
Nakao et al., 1997a; Hata et al., 1998a; Souchelnytskyi et al., 1998), as manifested by inhibition of 
R-Smad phosphorylation, abolition of Co-Smad heteromerization and their nuclear translocation, as
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well as abrogation of growth factor-induced transcriptional responses and growth inhibition 
(Hayashi et al., 1997; Imamura et al., 1997; Nakao et al., 1997a; Afrakhte et al., 1998; Hata et al., 
1998a; Inoue et al., 1998; Itoh et al., 1998; Souchelnytskyi et al., 1998). It has been reported that 
Smad6 can exert its inhibitory effect via an alternative mode, which involves BMP-induced 
association of Smad6 with phosphorylated Smad1, thereby competing with activated Smad1 for 
heteromerization with Smad4 (Hata et al., 1998a) (Fig. 5).
The expression of the inhibitory Smads is quickly induced upon stimulation by TGF-P 
superfamily members, and thereby provides an auto-inhibitory mechanism in TGF-P signaling 
(Nakao et al., 1997a; Tsuneizumi et al., 1997; Afrakhte et al., 1998; Takase et al., 1998). The 
human Smad7 promoter contains SBE consensus sites, which, when fused to a luciferase gene, 
induces luciferase activity following TGF-P stimulation (G. Brodin and R. Heuchel, personal 
communication). Thus, following receptor activation, R- and Co-Smads might be directly involved 
in transcriptional regulation of the Smad7 gene.
The MH1 domain of anti-Smads might play a role in specification of their inhibitory actions; 
Xenopus and mouse Smad7, which share 96% identity in their C-terminal domain, but only 51% in 
the N-terminal region, exert differential effects in inhibition of TGF-P and activin signaling 
(Souchelnytskyi et al., 1998). Mouse Smad7 inhibits T^R-I-induced phosphorylation of Smad2 and 
Smad3 (Hayashi et al., 1997; Nakao et al., 1997a; Souchelnytskyi et al., 1998), BMPR-IA and 
BMPR-IB-mediated phosphorylation of Smad1 and Smad5, and ActR-I mediated phosphorylation 
of Smad1 (Souchelnytskyi et al., 1998), and therefore appears to be a common inhibitor of R-Smad 
activation. Whereas Smad6 has been implicated in inhibition of TGF-P signaling (Hayashi et al., 
1997; Topper et al., 1997), it appears to play a more pronounced role in inhibition of BMP-signaling 
(Fig. 5) (Imamura et al., 1997; Afrakhte et al., 1998; Hata et al., 1998a; Nakayama et al., 1998b; 
Takase et al., 1998). The anti-Smad inhibitory mechanism in TGF-P superfamily signaling is 
evolutionarily well conserved; it has recently been shown that Dad, which is a Dpp-inducible anti- 
Smad in Drosophila (Tsuneizumi et al., 1997), interacts with Tkv and thereby prevents binding and 
phosphorylation of Mad by Tkv (Inoue et al., 1998).
The in vivo relevance of Smad6, Smad7 and Dad is shown in several systems. Smad6 and Smad7 
were initially identified as genes induced by shear stress in vascular endothelial cells (Topper et al.,
1997). Smad7 interferes with inhibition of activin-mediated growth arrest and apoptosis in B-cells 
(Ishisaki et al., 1998a). Smad6, Smad7 and Dad antagonize BMP and activin-mediated mesoderm 
development in Xenopus explants and have neural-inducing potencies, presumably by inhibiting 
BMP-4 action (Nakao et al., 1997a; Tsuneizumi et al., 1997; Hata et al., 1998a; Nakayama et al., 
1998a, 1998b).
Alternative functions for Smad6 and Smad7 may exist as well. In Xenopus, XSmad6 was found 
to be partially or completely restricted to the nuclei in most cells (Nakayama et al., 1998a). In 
mammalian cells, Smad7 has been located in the nucleus in the absence of ligand, but rapidly 
accumulated in the cytoplasm following TGF-P stimulation (Itoh et al., 1998). In accordance to its 
importance for inhibition of R-Smad signaling, the anti-Smad C-terminal tail also harbors domains 
required for transport across the nuclear membrane (Itoh et al., 1998). Whereas nuclear localization 
of inhibitory Smads might be required to allow phosphorylation of R-Smads following receptor-
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activation, it is not clear whether anti-Smads can also function in transcriptional regulation. 
Differential compartmentalization of the inhibitory Smads, in combination with induction of their 
expression following signaling by TGF-P superfamily members, and the fact that anti-Smads can 
selectively eliminate particular R-Smad pathways, provides a tightly controlled cell-autonomous 
regulatory mechanism.
Intracellular TGF-fi signaling pathways distinct from Smad-pathways
The mitogen-activated protein kinase kinase kinase TAK1 (TGF-P activated kinase 1) has been 
shown to be phosphorylated and thereby activated upon TGF-P or BMP-4 stimulation (Yamaguchi 
et al., 1995), and can mediate transcriptional activation of a luciferase reporter driven by a TGF-^- 
inducible element of the PAI-1 promoter containing three AP-1 sites. This effect is strongly 
enhanced by the TAK1-activator TAB1 (Shibuya et al., 1996). The in vivo relevance of the 
cooperative functioning of TAK1 and TAB1 was demonstrated in Xenopus mesoderm development, 
in which TAK1 and TAB1 promoted ventral mesoderm induction and perturbed neural 
differentiation, thereby substituting BMP signaling (Shibuya et al., 1998). The human X- 
chromosome-linked inhibitor of apoptosis protein (XIAP) can interact with both BMP receptors as 
well as with TAB1, and enhances ventralization of Xenopus embryos in a TAB1-TAK1-dependent 
manner (Yamaguchi et al., 1999).
Using the transmembrane and cytoplasmic domain of BMPR-IA as bait in yeast two hybrid 
screens, BRAM1 (BMP receptor-associated molecule) was identified. The C-terminal region of 
BRAM1 is responsible for specific interaction with BMPR-IA, and does not associate with the 
kinase domain of T^R-I (Kurozumi et al., 1998). Furthermore, this region in BRAM1 is also 
responsible for interaction with TAB1 (Kurozumi et al., 1998). Expression of GST-coupled BMPR- 
IA, HA-tagged BRAM1 and myc-tagged TAB1 in COS7 cells showed that the three proteins form a 
ternary complex. BRAM1 might function as an adaptor protein for positioning TAB1 in close 
proximity of BMPR-IA kinase domain (Kurozumi et al., 1998). The role of BRAM1 in activation of 
the TAB1/TAK1 signaling cascade, as well as its possible effect on Smad-receptor interaction and 
Smad-activation is not clear at present.
A downstream phosphorylation target in the MAPK cascade triggered by TAK1 is mitogen- 
activated protein kinase kinase 4 (MKK4)/stress-activated protein kinase/extracellular signal­
regulated kinase SEK1 (Yamaguchi et al., 1995; Shirakabe et al., 1997), which is involved in the 
stress-activated protein kinase (SAPK)/c-Jun NH2-terminal kinase (JNK) pathway, finally leading 
to activation of c-Jun. In view of the fact that JNK activity induced by hematopoietic progenitor 
kinase-1 (HPK-1) can be perturbed by expression of a kinase inactive form of TAK1, there are 
indications that TGF-P might exert JNK activation via the HPK1-TAK1-SAPK/JNK route (Wang et 
al., 1997). The small Rho-like GTPases, Rho, Rac, and cdc42, which signal via the SAPK/JNK 
pathway, have also been shown to be important for certain aspects of TGF-P signaling (Mucsi et al., 
1996; Atfi et al., 1997b).
The SAPK/JNK pathway has been shown to affect TGF-P signaling via the Smad-pathway, since 
overexpression of dominant negative members of the SAPK/JNK pathway prevent both TGF-^- and 
Smad4-mediated transcriptional activation of the 3TP-Lux reporter (Atfi et al., 1997a). The
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interface of SAPK/JNK- and Smad-signaling might be at the level of interaction between c-Jun and 
Smad3, since they have been shown to associate following TGF-P stimulation and synergize in 
activation of the 3TP-Lux reporter by cooperative binding to the AP-1 sites (Shi et al., 1998; Zhang 
et al., 1998).
Other levels of interaction between MAPK pathways and Smad signaling have been shown to 
occur in the linker region that connects the MH1 DNA-binding domain with the MH2 
transcriptional domain of receptor-activated Smads. Several ERK recognition sites (PXSP, or PXTP 
motifs) (Fig. 3B) and JNK motifs (XXSP) are located in the linker region of R-Smads. 
Phosphorylation of these sites in Smad1 by EGF or HGF has been shown to circumvent nuclear 
translocation of Smad1, and indicates a role for ERK signaling in the modulation of TGF-P 
signaling (Kretzschmar et al., 1997a). On the other hand, EGF and HGF have been shown to 
mediate signaling via Smad2, activated by kinases downstream of MEK1 (de Caestecker et al.,
1998). Furthermore, deletion of the C-terminal phosphorylation motif SS(V/M)S abrogates HGF- 
induced Smad1 or Smad2 phosphorylation, their nuclear translocation, as well as HGF-induced gene 
transcription of 3TP-Lux, indicating that these residues are important for Smad functioning in both 
TGF-P and HGF or EGF signaling (de Caestecker et al., 1998). The discrepancy with the data 
obtained by Kretzschmar et al. (1997a) might be due to the different cell lines that were used to 
address the involvement of tyrosine kinase signaling in Smad-phosphorylation, presumably by 
differential MAPK pathways that lead to the observed Smad-phosphorylations.
Analogously, differences in cellular context might underlie the apparently contradicting reports 
on the role of Ras/MAPK signaling in TGF-P signaling in different tumor cell systems. 
Phosphorylation of the ERK-sites in the linker region of Smad3 by activated Ras, MEK1 or in v- 
HA-Ras-transformed mouse mammary epithelial EpH4 cells, inhibits TGF-^-mediated 
transcriptional responses, Smad nuclear translocation as well as growth inhibition (J. Massagué, 
personal communication). To the contrary, in IEC1.4 cells, TGF-P rapidly induces Ras/MEK 
signaling, and this signal transduction pathway cooperates in TGF-P mediated Smad-signaling, 
presumably by phosphorylation of Smad1 on the four ERK-sites in the linker region (Yue et al.,
1999).
CONCLUSIONS AND PERSPECTIVES
Recent genetic and biochemical studies in B - d k f  'mr, C qirnog fkW dm otr  and mammals have 
now firmly established the TGF-^/Smad pathway as a pivotal means for intracellular signaling of 
TGF-P superfamily members (reviewed in Massagué, 1998; Nishimatsu and Thomsen, 1998). Upon 
ligand-induced heteromeric complex formation of distinct type I and type II receptors, particular R- 
Smads transiently interact with and become phosphorylated by the activated type I receptor kinase. 
Subsequently, R-Smads assemble with Co-Smads into heteromeric complexes that translocate into 
the nucleus, where they regulate, in combination with other transcription factors, the transcription of 
target genes.
General introduction 31
One TGF-P superfamily member can couple with multiple type I receptors and multiple Smads, 
each mediating a distinct set of responses (reviewed in Massague, 1998; Nishimatsu and Thomsen,
1998). Thus, the receptor and Smad expression profile in the target cell is an important factor that 
decides which particular cellular responses are induced by a TGF-P superfamily member. In 
addition, the repertoir of transcription factors that are present in the cell with which the Smads can 
interact is a critical determinant. Although multimerized Smad binding element is sufficient to drive 
TGF-P-induced transcription (reviewed in Derynck ds k+1998), emerging promoter analyses of 
TGF-P superfamily target genes indicate that transcriptional regulation is achieved by cooperation 
of Smads with other transcription factors. Complex formation of Smads with these transcription 
factors may occur independent of DNA binding or require DNA binding for additional selectivity 
(reviewed in Derynck ds k+1998).
The TGF-P/Smad pathway has been implicated in many responses, including growth inhibition, 
differentiation and many transcriptional responses. An important issue that needs to be addressed is 
the requirement of particular Smads in these responses. In addition, it will be important to explore 
the possibility that Smad-independent signaling also occurs. Interestingly, recent observations point 
to the existence of intracellular pathways different from the established Smad pathways. For 
example, the TAB1-TAK1 pathway was found to be directly linked with the BMP receptor complex 
through XIAP (Yamaguchi ds k+1999). Further studies are needed to determine the functional 
importance of this pathway and to examine whether it is functionally linked to the Smad pathways.
An important task for the future is to determine the genetic programs that are triggered upon 
challenging different cell types with different TGF-P family members. This will become feasable by 
applying the newly developed functional genomics and proteomics technology and thereby 
determine the time- and dose-dependent effects of TGF-P family members on the expression of 
thousands of genes/proteins simultaneously. In addition, the changes in expression patterns upon 
ectopic expression of constitutively active or dominant negative versions of signaling components 
or upon ligand stimulation in cells deficient in such components can be measured. The target 
genes/proteins identified will need experimental follow up to evaluate their importance in various 
biological responses. Moreover, the involvement of different type I receptors and Smad molecules 
in various TGF-P family members-induced responses can be elucidated using this methodology.
The multifunctional character of TGF-P superfamily members implicates a need for tight control 
of their activities. Indeed, both positive and negative (feedback) regulatory mechanisms have been 
observed at nearly every step in the TGF-P superfamily signaling cascade; from the release of 
biologically active ligand to the Smad-mediated transcriptional effects. Cross-talk of the TGF- 
P/Smad pathway with other pathways will be a theme of many future studies, d f -  how other 
signaling inputs affect the activity, expression, stability or subcellular localization of TGF-P 
superfamily receptors and Smads. In addition, the pleiotropic action of TGF-P superfamily 
members has driven the evolvement of multiple closely related TGF-P superfamily members with 
different expression and activation patterns. The mammalian TGF-P superfamily will likely 
continue to grow until the complete human sequence has been elucidated in the beginning of the 
next century.
Much of our insight into signaling mechanisms has come from the genetically accessable model 
organisms, Cqirnogfk' and B - d k f 'n r  (reviewed in Massague, 1998; Nishimatsu and Thomsen,
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1998). In CqirnogHi, dpp signals through two type I receptors, saxophone and thick veins, and their 
downstream effector Mad. Recently an activin/TGF-P signal transduction pathway was identified in 
Cqirnogfk (Brummel ds k + 999 ; Das ds k+ 999). Activation of the activin type I receptor, Atr-I, 
stimulates dSmad2-dependent pathways. The type II receptor punt and Medea are shared 
components between the Dpp and activin/TGF-P pathway. B - d k f 'n r  research obtained a boost by 
the recent completion of its entire genome sequence (reviewed in Ruvkun and Hobert, 1998). This 
vertebrate has four TGF-P-like ligands, including DAF-7 and DBL-1, one type II receptor, hd- 
DAF-4, and two type I receptors, hd- DAF-1 and SMA-6. Thus, DAF-4 is required for both 
pathways and type I receptors determine signaling specificity (Krishna ds k+1998); DAF-1 is 
important in dauer larva formation and SMA-6 for body size determination and male tail 
development. Six Smad proteins are present in the B - d k f  nr genome; Sma-2, Sma-3 and Sma-4 
have been implicated in the DAF-7/DAF-1 pathway and Smad-mediators DAF-8, DAF-14 and 
DAF-3 in DBL-1/SMA-6-induced signaling responses. Cqirnogfk' and B - d k f 'n r  will continue to 
be extremely important to elucidate the molecular mechanisms that underly TGF-P superfamily 
signaling.
In mammals the physiological significance of interactions between ligand and receptor, between 
receptors and Smads and between Smads and Smad interacting proteins, and the importance of the 
signaling pathways in which they act, need to be validated through comparison of the phenotypes of 
mice deficient in a particular TGF-P superfamily member, receptor, Smad or target gene. In those 
cases in which a null mutation leads to an early embryonal lethal phenotype, conditional knock-out 
approaches will be required to study the role of this component in late development or adult tissues. 
In addition, transgenic approaches in mice with dominant negative or constitutively active forms of 
TGF-P superfamily signal transducers under inducible or tissue specific promoters will provide 
important information regarding issues of signaling specificity and diversity in different cellular 
contexts.
The improved understanding by which TGF-P superfamily members elicit and regulate different 
responses will be essential in the design of new therapeutic approaches for various diseases caused 
by deregulated activity of TGF-P family members. For example, antagonists of TGF-P could be 
applied in various types of fibrosis that are due to TGF-P overactivity, and agonists of TGF-P in 
diseases in which enhanced activity is beneficial, such as wound healing or immunosuppression. In 
most cases it will be advantageous not to inhibit or activate all activities of TGF-P superfamily 
members. By understanding the molecular mechanisms that underly specificity, diversity and 
regulation in TGF-P superfamily signaling, it will be possible to screen for pharmacological 
compounds that inhibit or mimic only defined activities of TGF-P superfamily members.
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SCOPE OF THE THESIS
The TGF-P superfamily of cytokines consists of over 30 members (Fig. 6). Not only are different 
members able to elicit distinct responses within one cell type but, moreover, a single factor can 
evoke a wide variety of biological effects on different cell types. However, relatively few 
serine/threonine kinase type I and type II receptors, through which TGF-P family members elicit 
their biological effects, have been identified. In addition, the recently identified family of Smad 
proteins, cytoplasmic signal transducing molecules acting downstream of serine/threonine kinase 
receptors, is still small compared to the extensive TGF-P family. Moreover, knockout phenotypes 
between TGF-P family members are all distinct. It is therefore puzzling how specificity in signaling 
by individual members is achieved. The goal of the studies described in this thesis is to gain insight 
into the molecular mechanisms that contribute to diversity in signaling by TGF-P family members.
We started out to search for putative novel serine/threonine kinase type I receptors and TGF-P 
binding proteins, since these molecules are expected to be directly involved in transduction and 
modulation of TGF-P signaling. In chapter 2 we describe the characterization of a 60 kDa TGF-P 
binding protein identified by affinity-labeling and cross-linking studies using radiolabeled TGF-P. 
This protein prevents binding of TGF-P to the signaling receptors and, in its cell membrane-bound 
configuration, has preferential affinity for the TGF-^1 isoform. In chapter 3 we present a Southern 
blot hybridization strategy to analyze mixtures of equally sized serine/threonine kinase type I 
receptor fragments, generated by the polymerase chain reaction (PCR) using degenerate primers 
based on conserved amino acid stretches in the type I receptor kinase domain. Indications for a 
putative novel receptor are found in fetal kidney tissue.
To further address the mechanisms contributing to specificity in TGF-P growth factor signaling, 
we made use of distinct cell types which show defined responses upon stimulation by TGF-P or 
other members of the superfamily, reflecting particular physiological, developmental or tumorigenic 
processes in which TGF-P family members are involved.
In the human embryonal carcinoma cell line Tera 2 Clone 13 (T2Cl13), which resembles early 
embryonic cells, we observe a functional antagonism between activin A and osteogenic protein-1 
(OP-1)/bone morphogenetic protein-7 (BMP-7) (chapter 4), a phenomenon which is of crucial 
importance during early embryonic development to assure proper mesoderm formation. Both 
cytokines share and, as a consequence, compete for binding to the activin type II receptor, while in 
addition, competition is observed downstream of the type I receptors that mediate signaling for 
activin A and OP-1.
One of the most studied but little understood biological activities mediated by TGF-P is its 
biphasic action in carcinogenesis; it acts as a tumor suppressor in benign stages of tumorigenesis, 
inhibiting cellular proliferation of, mainly, epithelial cell types, and exerts a tumor promoting role at 
more malignant stages of tumorigenesis by stimulating tumor stroma formation and its immuno­
suppressive effects. In chapter 5 we investigate different aspects of TGF-P1 signaling in six glioma 
cell lines whose growth is differentially affected by TGF-P1. These studies indicate that the diverse 
biological responses induced by TGF-P1 are controlled by a complex involvement of multiple 
factors, in combination with different activation thresholds.
34 Chapter 1
Figure 6 Overview of the TGF-P superfamily. The superfamily comprises distinct factors that are 
arranged in subfamilies of related isoforms. AMH: anti-Mullerian hormone; BMP: bone 
morphogenetic protein; CDMP; cartilage-derived morphogenetic protein; DPP; decapentaplegic 
protein; GDF: growth and differentiation factor; MIS: Mullerian inhibiting substance; OP-1: 
osteogenic protein; Ost’n: osteogenin; TGF-P: transforming growth factor-P; Vg: vegetal; Vgr: Vg- 
related.
Epithelial-mesenchymal transitions are important and beneficial for cell movement during 
embryonic development, but promote metastasis and thereby aggravate tumorigenesis. The 
epithelial breast tumor cell line NMuMG has been described to undergo mesenchymal 
transdifferentiation following exposure to TGF-p. In chapter 6 we investigate whether other 
members of the TGF-P family are endowed with transdifferentiating potencies as observed for TGF- 
p. In addition, molecular aspects contributing to potent TGF-P 1 signaling versus weak activin A and 
OP-1 signaling in NMuMG cells are examined. Our results suggest the involvement of receptor 
expression levels as a mechanism to control signaling.
Comparison of activin A and TGF-P 1 signaling in thyroid follicle cells further indicate 
regulation of signaling at the level of receptor expression. In addition, these data suggest a negative 
regulatory role for TGF-P 1 and activin A in thyroid follicle cell proliferation and function (chapter
7).
Members of the BMP subfamily play pivotal roles in the development of bone and cartilage. In 
chapter 8 we compare three different BMP-family members, cartilage-derived morphogenetic
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protein-1 (CDMP-1), CDMP-2 and OP-1 in induction of chondrogenesis and osteogenesis, both in 
vivo and in vitro. The three ligands are found to exert differential effects in bone development, 
which can be correlated to their differential receptor affinities.
TGF-P plays an important role in the immune system and during wound healing, where, among 
other functions, it acts as chemoattractant for several hematopoietic cell types. In chapter 9 we 
study the effect of TGF-P family members on chemotaxis of human mast cells, and compare their 
activities with inhibition of cell growth and binding to TGF-P type I and type II receptors. 
Examination of the downstream signal transduction components possibly involved suggests a role 
for Smads as well as for tyrosine kinases in TGF-P-mediated chemotaxis of mast cells (chapter 10).
In conclusion, deeper insight is achieved into the variety and complexity of biological effects 
mediated by diverse TGF-P family members. Moreover, this work presents evidence for multiple 
mechanisms by which specificity and diversity in signaling by TGF-P family members is achieved.

Chapter 2
Characterization of a 60 kDa Cell Surface-Associated TGF-ß 
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ABSTRACT
We have characterized a 60 kDa transforming growth factor-^ (TGF-P) binding protein that was 
originally identified on LNCaP adenocarcinoma prostate cells by affinity cross-linking of cell 
surface proteins using 125I-TGF-^1. Binding of 125I-TGF-^1 to the 60 kDa protein was competed by
an excess of unlabeled TGF-^1, but not by TGF-^2, TGF-^3, activin or osteogenic protein-1 (OP-
1251), also termed bone morphogenetic protein-7 (BMP-7). In addition, no binding of I-TGF-^2 and
125I-TGF-^3 to the 60 kDa binding protein on LNCaP cells could be demonstrated using affinity 
labeling techniques. The 60 kDa TGF-P binding protein showed no immunoreactivity with 
antibodies against the known type I and type II receptors for members of the TGF-P superfamily. 
Treatment of LNCaP cells with 0.25 M NaCl, 1 ^g/ml heparin or 10% glycerol caused a release of 
the 60 kDa protein from the cell surface. In addition, we found that the previously described TGF-P 
type IV receptor on GH3 cells, which does not form a heteromeric complex with TGF-P receptors, 
could be released from the cell surface by these same treatments. This suggests that the 60 kDa 
protein and the similarly sized TGF-P type IV receptor are related proteins. The eluted 60 kDa 
LNCaP protein was shown to interfere with the binding of TGF-P to the TGF-P receptors. Thus, the 
cell surface-associated 60 kDa TGF-P binding protein may play a role in regulating TGF-P binding 
to TGF-P receptors.
INTRODUCTION
Transforming growth factor-^ (TGF-P) was originally described as a growth stimulator for 
normal rat kidney cells in soft agar in the presence of transforming growth factor-a (Anzano et al.,
1983). However, many other biological activities have subsequently been ascribed to this factor, 
which is the prototype of a large family of structurally related factors (reviewed in Massagué, 1990; 
Roberts and Sporn, 1990). Although the three highly similar mammalian TGF-P isoforms, TGF-^1, 
TGF-^2 and TGF-^3, mainly exert overlapping biological activities like inhibition of cell growth, 
modulation of the immune response and deposition of extracellular matrix proteins, some isoform- 
specific activities have been described. TGF-^1, in contrast to TGF-^3, induces scar formation after 
wounding (Shah et al., 1995). TGF-^1 and TGF-^3 are more potent than TGF-^2 in inhibiting 
proliferation of hematopoietic progenitor cells and endothelial cells (Cheifetz et al., 1990). Other 
factors belonging to the TGF-P superfamily are activins and inhibins, bone morphogenetic proteins 
(BMPs) and the growth and differentiation factors (GDFs).
TGF-P family members mediate their biological activities by binding to cell surface receptors. 
The TGF-P type I (T^R-I; 53 kDa) and type II receptors (T^R-II; 75 kDa) are transmembrane 
serine/threonine kinase receptors, which are directly involved in signal transduction (reviewed in 
ten Dijke et al., 1994b; Wrana et al., 1994; Attisano et al., 1996). After binding of TGF-^1 to T^R- 
II, T^R-I is recruited into the complex and becomes phosphorylated by T^R-II on serine and 
threonine residues in the GS-box. T^R-I is directly responsible for downstream signal transduction 
that leads to a phosphorylation and heteromerization of particular Smads which subsequently are
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shuttled to the nucleus where, in complex with other proteins, they affect the transcription of 
specific genes (reviewed in Massague, 1996).
Betaglycan (200-400 kDa), also referred to as TGF-P type III receptor (TPR-III) (Lopez-Casillas 
et al., 1991; Wang et al., 1991), and endoglin (180 kDa; Cheifetz et al., 1988) are structurally 
related transmembrane proteins with very short intracellular tails. They probably function in 
presenting TGF-P to TPR-II, rather than in a direct participation in signal transduction. Whereas 
TPR-III binds all three TGF-P isoforms with equal affinity, endoglin binds TGF-P2 only weakly 
which may explain differences in biological potencies of the three TGF-P isoforms in endothelial 
cell growth inhibition. In rat pituitary GH3 cells, binding of TGF-P to complexes of 70-74 kDa have 
been detected and referred to as the TGF-P type IV receptor (TPR-IV; Cheifetz et al., 1988; 
Yamashita et al., 1995a). A TGF-P type V (400 kDa) receptor has been purified from bovine liver 
(O’Grady et al., 1991).
In addition, there are many other cell surface or extracellular matrix-associated binding proteins 
for TGF-P, which might influence signal transduction indirectly by presenting ligand to the 
signaling receptors or by inhibiting receptor binding. TGF-P isoform-specific binding proteins have 
been identified as well (Mac Kay et al., 1990; Mac Kay and Danielpour, 1991). Several glycosyl- 
phosphatidyl-inositol (GPI) anchored cell surface proteins have been described that bind TGF-Ps in 
an isoform-specific manner (Cheifetz and Massague, 1991; Dumont et al., 1995). Butzow et al. 
(1993) have reported the characterization of a 60 kDa TGF-P binding protein that associates with 
heparan sulfate proteoglycans on the cell surface of HepG2 cells, and which can be released by 10 
^g/ml heparin or 0.25 M NaCl. Human a2-HS glycoprotein and its bovine counterpart fetuin, a 
major component of fetal serum, have also been shown to bind several members of the TGF-P 
superfamily (Demetriou et al., 1996). Other soluble proteins that bind TGF-P are a2-macroglobulin 
(O’Connor-McCourt and Wakefield, 1987), collagen type IV (Paralkar et al., 1991), fibronectin 
(Fava and McClure, 1987), decorin and biglycan (Yamaguchi et al., 1990), as well as 
thrombospondin (Murphy-Ullrich et al., 1992).
Loss of TGF-P signaling, either by absence of the signaling receptors or by lack of downstream 
signaling components, has been implicated in several types of cancer (Filmus and Kerbel, 1993; 
Schutte et al., 1996). The androgen-dependent prostate adenocarcinoma cell-line LNCaP lacks 
expression of TPR-I due to a genetic alteration in the gene for this receptor (Kim et al., 1996a). 
Under normal in vitro culture conditions LNCaP cells are insensitive to TGF-P (Wilding et al., 
1989). The growth of the cells can be stimulated or inhibited by androgens like dihydrotestosterone 
(DHT; Schuurmans et al., 1988; Sonnenschein et al., 1989; Lee et al., 1995). Conflicting reports 
have been published about the responsiveness of LNCaP cells to TGF-P in the presence of 
proliferation-modulating factors like DHT (Carruba et al., 1994; Kim et al., 1996b, 1996c), EGF 
and TGF-a (Schuurmans et al., 1991; Janssen et al., 1995), or retinoic acid (Fong et al., 1993).
In a search for novel receptors for TGF-P we performed affinity cross-linking of cell surface 
proteins on different cell types. A 60 kDa TGF-P binding protein distinct from the known 
serine/threonine kinase receptors was identified on LNCaP cells. When associated to the 
extracellular matrix of LNCaP cells, this 60 kDa protein bound only the TGF-P 1 isoform. In 
addition the protein interferes with binding of TGF-P to TGF-P receptors on mink lung epithelial
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Mv1Lu cells. Our data suggest that the presently characterized 60 kDa protein may regulate TGF-P 
binding to its signaling receptors.
MATERIALS AND METHODS
Cell culture
LNCaP and PC3 human prostate cancer cells, GH3 rat pituitary tumor cells and Mv1Lu cells (CCL64), were 
obtained from the American Type Culture Collection (Rockville, MD). LNCaP cells were routinely cultured in RPMI 
1640 medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 50 ^g/ml streptomycin. PC3 cells 
and Mv1Lu cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 
100 units/ml penicillin and 50 ^g/ml streptomycin. GH3 cells were grown in DMEM supplemented with 10% horse 
serum, 5% fetal bovine serum, 100 units/ml penicillin and 50 ^g/ml streptomycin. The cells were grown in 5% CO2 
atmosphere at 37°C.
Antibodies
Antisera against activin receptor-like kinase (ALK)-1, activin receptor (ActR) type I, ActR-IB, BMP receptor 
(BMPR) type IA, BMPR-IB, TPR-I, TPR-II and endoglin were raised against synthetic peptides corresponding to the 
intracellular juxtamembrane parts of the type I receptors, the C-terminal tail of TPR-II and the intracellular part of 
endoglin, as described previously (Franzen et al., 1993b; ten Dijke et al., 1994b; Yamashita et al., 1994a). A 
monoclonal antibody against TPR-II extracellular domain was obtained from H. Ohashi at Kirin Brewery Co., Tokyo, 
Japan. Antiserum to the intracellular part of TPR-III was prepared against the synthetic peptide 
GETARRQQVPTSPPASENSS and obtained from K. Miyazono, Cancer Institute, Tokyo, Japan. Antiserum against the 
GS-domain of TPR-I was prepared against the synthetic peptide DLIYDMTTSGSGSG. The peptides were synthesized 
with an Applied Biosystems 430A peptide synthesizer using t-butoxycarbonyl chemistry and were purified by reverse­
phase high performance liquid chromatography. The peptides were coupled to keyhole limpet hemocyanin (Calbiochem- 
Behring) using glutaraldehyde, mixed with Freund’s adjuvant and used to immunize rabbits. Antisera against ActR-II 
and BMPR-II were raised against synthetic peptides as described previously (Ichijo et al., 1993; Rosenzweig et al., 
1995). Antiserum against bovine fetuin was obtained from K.M. Dziegielewska and antisera against a2HS-glycoprotein 
were obtained from K.M. Dziegielewska and W. Jahnen-Dechent.
Affinity cross-linking studies and immunoprecipitations
Human recombinant TGF-P 1 was obtained from H. Ohashi at Kirin Brewery Co., Tokyo, Japan, TGF-P2 from B. 
Pratt at Genzyme Corporation, Framingham, USA and TGF-P3 from N. Cerletti at CIBA-GEIGY A.G., Basel, 
Switzerland. Activin A was obtained from Y. Eto, Ajinomoto Co., Kawasaki, Japan and osteogenic protein-1 (OP-1), 
BMP-2 and murine growth and differentiation factor (GDF)-5 were obtained from T.K. Sampath, Creative 
Biomolecules Inc., Hopkinton, USA. The ligands were iodinated according to the chloramine-T method (Frolik et al., 
1984). Cells were incubated for 3 h on ice in binding buffer (phosphate-buffered saline (PBS) containing 0.9 mM CaCl2, 
0.49 mM MgCl2 and 0.1% bovine serum albumin) in the presence of 200 pM of iodinated ligand. For competition 
binding assays 400-fold excess of unlabeled ligand was added. After labeling of the cells they were washed three times 
in binding buffer followed by one wash with binding buffer free of bovine serum albumin. Cross-linking with 0.28 mM
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disuccinimidyl suberate (DSS) was done in the same buffer for 15 min on ice. The cross-linking was quenched with 
detachment buffer containing 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 10% glycerol, 0.3 mM phenylmethylsulfonyl 
fluoride (PMSF) or with PBS buffer containing 10 mM Tris-HCl pH 7.5 and 0.3 mM PMSF. The cells were scraped off 
the plates in detachment buffer and they were lysed after centrifugation in solubilization buffer (125 mM NaCl, 10 mM 
Tris-HCl pH 7.5, 1 mM EDTA, 1 mM PMSF, 1.5% trasylol and 1% Triton X-100) for 40 min on ice. In case of 
subsequent immunoprecipitations with anti-TGF-P receptor antibodies, the immunocomplexes were collected on 
protein-A sepharose beads (Immunosorb: EC Diagnostics AB, Uppsala, Sweden). The beads were centrifuged and 
washed three times with solubilization buffer, followed by one wash in distilled water. Immunocomplexes and 
solubilized cell extracts were mixed with SDS-sample buffer (80 mM Tris-HCl, pH 8.8, 0.01% bromphenol blue, 24% 
glycerol, 4% SDS, 10 mM dithiothreitol), boiled for 3 min and separated by SDS-gel electrophoresis using a 5-12.5% 
gradient polyacrylamide gel. For autoradiographic analysis gels were exposed to Hyperfilm MP (Amersham).
Dithiothreitol treatment
LNCaP cells and PC3 cells were treated with or without 1 mM dithiothreitol (DTT) in binding buffer without bovine
125serum albumin at 37°C for 8 min, and then affinity-labeled with 200 pM I-TGF-P followed by cross-linking with 
0.28 mM DSS. The cross-linked complexes were analyzed by SDS-gel electrophoresis and visualized using a Fuji-X 
BioImager.
Endoglycosidase F treatment
125LNCaP cells and PC3 cells were incubated with 200 pM I-TGF-P and cross-linked with 0.28 mM DSS. Cross­
linked complexes were incubated with 0.5 unit of endoglycosidase F (Boehringer Mannheim Biochemica) in a buffer 
containing 100 mM sodium phosphate (pH 6.1), 50 mM EDTA, 1% Triton X-100, 0.1% SDS, and 1% 2- 
mercaptoethanol at 37°C for 24 h. Samples were boiled in SDS sample buffer and analyzed by SDS-gel electrophoresis 
and visualized using a Fuji-X BioImager.
Northern blot analysis
Isolation of total RNA and Northern blotting was performed as previously described (Franzen et al., 1993a). The 
filters were hybridized and washed with a TPR-I specific cDNA probe, as previously described (Franzen et al., 1993b).
Mitogenic assays
For growth inhibition assays LNCaP cells were seeded in RPMI 1640 medium containing 10% fetal bovine serum 
and antibiotics at a density of 5.0x104 cells per well in 24-well tissue culture plates. The next day growth factors were
3
added at various concentrations. After treatment for 20 h cells were incubated with 0.1 ^Ci/ml [ H]thymidine 
(Amersham, UK) for an additional 2 h. Cells were fixed in ice-cold 5% trichloroacetic acid for 20 min, washed with
3
water and solubilized in 200 |j.l 0.1 M NaOH at room temperature. [ H]Thymidine incorporation was measured in a 
liquid scintillation P-counter using Ecoscint (National Diagnostics).
The effect of TGF-P on dihydrotestosterone (DHT)-mediated cellular proliferation of LNCaP cells was measured by 
[3H]thymidine incorporation assays. Cells were seeded at a density of 2.5x104 cells per well in 24-well tissue culture 
plates in phenol red-free RPMI 1640 medium containing 10% charcoal stripped fetal bovine serum and antibiotics. 
After two days culture medium was refreshed and cells were stimulated with various concentrations of DHT in the
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3 3  presence or absence of 400 pM TGF-P1. After 2 days [ H]thymidine was added for 2 h and [ H]thymidine
incorporation was measured as described above.
Extraction o f  the 60 kDa TGF- binding protein from the cell surface
LNCaP cells and GH3 cells which were grown to confluence in 25 cm2 flasks were affinity labeled with 200 pM
125I-TGF-P 1 followed by DSS cross-linking. Extraction of TGF-P binding proteins from the cell surface was performed 
by incubations twice for 15 min on ice in PBS buffer containing different concentrations of NaCl, heparin or glycerol. 
Cells were solubilized and prepared for SDS-gel electrophoresis as described above. The two washes were pooled and 
proteins were precipitated in 10% trichloroacetic acid for 30 min on ice, followed by 15 min centrifugation and an 
acetone wash. The samples were boiled in sample buffer and separated by SDS-gel electrophoresis followed by 
autoradiography.
Competition binding assay with the 60 kDa TGF-P binding protein
Confluent LNCaP cells (25x106 cells) in 175 cm2 flasks were washed twice in binding buffer in the absence of 
bovine serum albumin. Cells were scraped off the flasks in 10 ml of bovine serum albumin-free binding buffer, spun 
down for 5 min at 4°C and resuspended in 1 ml of PBS containing 10% glycerol. Extraction of the 60 kDa TGF-P 
binding protein was done for 30 min at 4°C. Thereafter, cells were spun down and the supernatant was centrifuged at
13,000 rpm for 30 min at 4°C. An affinity cross-linking assay was performed on 2.5x106 Mv1Lu cells in 6-well culture
125plate dishes using 20 pM I-TGF-P in 1 ml of PBS containing 10% glycerol and 0.1% bovine serum albumin in the 
presence or absence of 60 kDa TGF-P binding protein eluted from 25x106 LNCaP cells. Samples were analyzed by 
SDS-gel electrophoresis and autoradiography.
RESULTS
Identification o f a 60 kDa TGF-ft cell surface binding protein in LNCaP cells distinct from TGF-P 
receptors
125Binding of I-TGF-P 1 to LNCaP cells followed by cross-linking with DSS revealed complexes 
of approximately 70-74 kDa (Fig. 1). Subtracting the molecular mass of the cross-linked monomeric 
TGF-P1 results in the estimated size of approximately 60 kDa. Under non-reducing conditions only 
one TGF-P1 cross-linked complex of 67 kDa was observed (Fig. 1). Cross-linking studies using 
125I-TGF-P2 and 125I-TGF-P3 gave weaker bands, suggesting that the affinity of the 60 kDa protein 
for these TGF-P isoforms is much lower than the affinity for TGF-P 1 (Fig. 2A). The binding of 125I- 
TGF-P1 to the 60 kDa protein as well as to the TPR-III (see Fig. 3A for its identification) was fully 
competed with 400-fold excess of unlabeled TGF-P 1 (Fig. 2B), indicating specificity in binding. 
Compared to TGF-P1, a 400 fold-excess of TGF-P2 or TGF-P3 competed to a lesser extent with 
125I-TGF-P1 for binding to the 60 kDa protein, while the binding of 125I-TGF-P1 to TPR-III was 
clearly displaced. Activin and OP-1 also failed to compete for binding of 125I-TGF-P1 to the TGF-P 
binding proteins on LNCaP cells (data not shown). These results indicate that the 60 kDa protein on 
LNCaP cells displays TGF-P 1 isoform-specific binding.
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Figure 1 Identification of TGF-ß binding proteins on LNCaP prostate 
adenocarcinoma cells. 10x106 LNCaP cells were affinity-labeled with 200 pM 
I-TGF-ß1 followed by cross-linking with 0.28 mM DSS. Cell lysates were 
analyzed by SDS-gel electrophoresis under reducing (R) and non-reducing (NR) 
conditions, followed by autoradiography or Fuji-X BioImager analysis.
Figure 2 Analysis of ligand binding specificity of the 60 kDa TGF-ß binding protein on LNCaP cells. (Left) Cross­
linking of cell surface proteins on LNCaP cells with different TGF-ß isoforms. 10x106 LNCaP cells were incubated with
125 125 125
200 pM I-TGF-ß1, I-TGF-ß2 or I-TGF-ß3, followed by cross-linking with 0.28 mM DSS. Cell lysates were
125analyzed by SDS-gel electrophoresis, followed by Fuji-X BioImager analysis. (Right) Competition of I-TGF-ß1 
binding to LNCaP cell surface proteins by excess cold TGF-ß. 10x106 LNCaP cells were incubated with 100 pM 125I- 
TGF-ß1 in the absence or presence of 400 fold excess cold TGF-ß 1, TGF-ß2 or TGF-ß3. After cross-linking with 0.28 
mM DSS, cell lysates were analyzed by SDS-gel electrophoresis, followed by autoradiography.
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Immunoprécipitations with antisera raised against the intracellular domain of TPR-I, TPR-II,
125TPR-III and endoglin failed to bring down the 60 kDa I-TGF-P1 cross-linked protein complexes 
(Fig. 3A). TPR-III appeared to be expressed by LNCaP cells since its presence was confirmed by 
immunoprecipitation of the 125I-TGF-P1 cross-linked 200 kDa protein complexes using the TPR-III 
antiserum. To further explore the possibility that the 60 kDa TGF-P binding protein on LNCaP cells 
is related to the similarly sized TPR-I, the following experiments were performed. TPR-I is known 
to contain N-linked glycosylation which can be removed by treatment with endoglycosidase F. 
However, endoglycosidase F treatment of LNCaP cells did not alter the size of the TGF-P 1 binding 
complexes (Fig. 3B), indicating that the proteins do not contain N-linked carbohydrate chains. 
Binding of TGF-P to TPR-I can be abolished by dithiothreitol (DTT). However, when LNCaP cells 
were treated with DTT preceding affinity cross-linking studies, the 70-74 kDa protein complexes 
could still be detected (Fig. 3C). In PC-3 cells TPR-I was clearly affected by endoglycosidase F or 
DTT treatment. In addition, these experiments revealed that PC-3 cells also contain the 70-74 kDa 
protein complexes. Moreover, Northern blot analysis revealed that LNCaP cells lack expression of 
TPR-I in contrast to other cell lines examined (Fig. 3D). Taken together, these observations indicate 
that the 60 kDa LNCaP protein is distinct from TPR-I.
In order to examine whether the TGF-P binding components are related to other known
125serine/threonine kinase type I receptors we subjected the I-TGF-P1 affinity labeled cross-linked 
complexes from LNCaP cells to immunoprecipitation with specific antisera raised against the 
known type I receptors (activin receptor-like kinases (ALK)1-6; ten Dijke et al., 1994a) and with an 
antibody raised against the GS-domain. These antisera, as well as antisera against the extracellular 
domain of TPR-II, did not immunoprecipitate any of the TGF-P 1 protein complexes in LNCaP cells 
(Fig. 3E and data not shown).
Figure 3 Biochemical characterization of TGF-P cross­
linked protein complexes on LNCaP cells. (A) 
Immunoprecipitation of 125I-TGF-P1 cross-linked protein 
complexes from LNCaP cells with TGF-P receptor antisera. 
40x106 LNCaP cells were affinity labeled with 200 pM 
125I-TGF-P1 followed by cross-linking with 0.28 mM DSS. 
Aliquots of cell lysates were analyzed directly by SDS-gel 
electrophoresis, followed by Fuji-X BioImager analysis, or 
first subjected to immunoprecipitation (IP) using antisera 
against TP R-I, TPR-II, TPR-III and endoglin.
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125Figure 3 (B) Endoglycosidase F treatment of I-TGF-p1 affinity cross-linked protein complexes on LNCaP cells and
PC3 cells. 10x106 LNCaP cells and PC3 cells were affinity labeled with 200 pM 125I-TGF-pi, followed by DSS (0.28
mM) cross-linking. Cell lysates were treated with 0.5 unit of endoglycosidase F (Endo F) for 24h at 37°C and analyzed
by SDS-gel electrophoresis, followed by Fuji-X Bioimager analysis. (C) Dithiothreitol (DTT) treatment of LNCaP cells
and PC3 cells followed by 125I-TGF-pi affinity cross-linking. 10x106 LNCaP cells and PC3 cells were incubated with
or without 1 mM dithiothreitol (DTT) in binding buffer without bovine serum albumin for 8 min. at 37 C. Cells were
125subsequently incubated with 200 pM I-TGF-P1, followed by cross-linking with 0.28 mM DSS. Cell lysates were 
analyzed by SDS-gel electrophoresis followed by Fuji-X BioImager analysis. (D) Northern blot analysis of TpR-I 
expression in LNCaP cells. 10 |j.g Total RNA from human embryonic lung cells (HEL), PC-3 cells, a previously 
described PC-3 subline PC-3U (Franzen et al., 1993a), LNCaP cells, human lung carcinoma cells (A549) and human
breast adenocarcinoma cells (MCF-7) was subjected to Northern blot analysis using a TpR-I specific probe. (E)
125Immunoprecipitation of I-TGF-P1 cross-linked protein complexes from LNCaP cells with antisera against type I and 
type II receptors for members of the TGF-P superfamily. 70x106 LNCaP cells were affinity labeled with 200 pM 125I- 
TGF-P1 followed by cross-linking with 0.28 mM DSS. Aliquots of cell lysates were analyzed directly by SDS-gel 
electrophoresis, followed by autoradiography, or first subjected to immunoprecipitation (IP) using antisera against 
ALK1, ActR-I, BMPR-IA, ActR-IB, TpR-I, BMPR-IB and TpR-II.
LNCaP cells are TGF-p resistant, but respond to other TGF-p superfamily members
The growth modulating effects of different members of the TGF-p superfamily on LNCaP cells 
were tested by [ H]-thymidine incorporation assays. TGF-p 1 had no significant antimitogenic effect 
on LNCaP cells, while activin and GDF-5 clearly inhibited the growth of LNCaP cells to less than 
50% of control cells (Fig. 4A). The inhibition was even more pronounced upon addition of BMP-2 
or OP-1 (Fig. 4A). Kim et al. (1996c) have reported the abolishment of DHT-mediated cellular 
proliferation by TGF-p. Therefore, the potential effect of TGF-p on dihydrotestosterone (DHT)- 
stimulated LNCaP cells was investigated (Fig. 4B). While stimulation of LNCaP cells with 
increasing concentrations of DHT resulted in a typical bell-shaped growth curve (Schuurmans et al., 
1988; Sonnenschein et al., 1989; Lee et al., 1995) showing maximum stimulation of cell growth at 
10-10 M DHT, addition of TGF-pi did not affect this DHT-induced proliferation. Thus, although 
LNCaP cells do have the potency to react on several members of the TGF-p superfamily, they are 
non-responsive to TGF-p itself.
Cross-linking studies with radiolabeled ligands showed that in LNCaP cells activin A bound to 
the activin type IB receptor (ActR-1B) and the activin type II receptor (ActR-II) (Fig. 4C) while OP- 
1 bound to the BMP type 1B receptor (BMPR-I) and the BMP type II receptor (BMPR-II) and 
weakly to ActR-II (Fig. 4D). Apparently, activin A and OP-1 did not bind to the 60 kDa TGF-p 
binding protein.
The 60 kDa TGF-p binding protein is a cell surface-associated protein
In order to explore the basis for the cell membrane-association of the 60 kDa TGF-p binding 
protein, we investigated whether the 125I-TGF-p1 cross-linked protein complexes could be released 
by treatment of the cell cultures with NaCl (Fig. 5A). Elution of the protein complexes from the cell 
surface into the medium could clearly be detected after incubation in buffers containing 0.25 M or
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Figure 4 Analysis of responsiveness of LNCaP cells to members of the TGF-ß superfamily and identification of ligand 
binding to receptors. (A) Cellular proliferation of LNCaP cells in the presence of different members of the TGF-ß 
superfamily. LNCaP cells were seeded at a density of 50,000 cells/well in 24-well plates and stimulated for 20 h with 
800 pM activin A, 6.25 nM BMP-2, 6.25 nM GDF-5, 6.25 nM OP-1 and 800 pM TGF-ß 1. Inhibition of cellular
3
proliferation was measured by [ H]-thymidine incorporation and results are expressed in % of unstimulated control. 
Each column represents the mean of triplicate observations. The vertical bars denote standard deviations. (B) Cellular 
proliferation of LNCaP cells in the presence of different concentrations of DHT and/or TGF-ß 1. LNCaP cells were 
seeded at a density of 25,000 cells/well in 24-well plates. Cells were grown in the presence of different concentrations of 
DHT and/or 400 pM TGF-ß 1 for 4 days. [ H]-thymidine incorporation was measured and results are expressed in % of 
unstimulated control. Each column represents the mean of triplicate observations. The vertical bars denote standard
deviations. (C) Analysis of activin receptor expression in LNCaP cells. 30x106 LNCaP cells were incubated with 400
125pM I-activin A, followed by cross-linking with 0.28 mM DSS. Aliquots of cell lysates were analyzed directly by
SDS-gel electrophoresis, followed by autoradiography, or first subjected to immunoprecipitation (IP) using antisera
against activin receptors. (D) Analysis of OP-1 receptor expression in LNCaP cells. 60x106 LNCaP cells were incubated 
125with 250 pM I-OP-1, followed by cross-linking with 0.28 mM DSS. Aliquots of cell lysates were analyzed directly 
by SDS-gel electrophoresis, followed by Fuji-X BioImager analysis, or first subjected to immunoprecipitation (IP) using 
antisera against OP-1 receptors, followed by autoradiography.
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more of NaCl. Incubation of LNCaP cells in 1 pg/ml or more of heparin in PBS after affinity cross­
linking also resulted in a release of the TGF-P-bound complexes (Fig. 5B). Heparin is known to 
dissociate proteins that are attached to glycosaminoglycans. In addition, release of the TGF-P bound 
protein complexes could be achieved after incubation in 10% glycerol in PBS (Fig. 5C).
Figure 5 Determination of the elution characteristics of the 60 kDa TGF-p binding protein. LNCaP cells were grown 
to confluence in 25 cm2 flasks. Cell surface proteins on LNCaP cells were affinity-cross-linked with 200 pM 125I-TGF- 
p1, followed by two washes with different concentrations of (A) NaCl and (B) heparin or (C) glycerol in combination 
with heparin. The two washes from each flask were pooled and trichloroacetic acid precipitated. Cells were lysed and all 
samples were analyzed by SDS-gel electrophoresis, followed by autoradiography.
The 58-62 kDa TGF-p binding proteins on GH3 cells have similar properties to the 60 kDa TGF- 
¡51 binding protein from LNCaP cells
GH3 cells contain TGF-P binding proteins of similar size as the 60 kDa protein on LNCaP cells 
and which have been designated TGF-P type IV receptors. Therefore, we investigated whether the 
TGF-P binding protein on GH3 cells showed the same isoform-specificity and cell surface- 
associated characteristics as the LNCaP TGF-P binding protein. Regarding the isoform-specificity 
of the proteins on GH3 cells the 69 kDa cross-linked TGF-P type I receptor which had high affinity 
for all three TGF-P isoforms, partly overlapped with the complex containing the 60 kDa component 
(Fig. 6A) making firm conclusions difficult. The upper protein band in the 70-74 kDa region 
appears to be somewhat weaker when 125I-TGF-P2 or 125I-TGF-P3 were used in the cross-linking
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studies, which is in line with our observations for the 60 kDa TGF-P binding protein from LNCaP 
cells. Similar to our findings for the TGF-P 1 binding component in LNCaP cells, the 70-74 kDa 
complexes on GH3 cells were released upon treatment with 0.5 M NaCl, 10 ^g/ml heparin (Fig. 6B) 
or 10 % glycerol (data not shown), whereas TPR-I was not eluted from the cells under these 
conditions.
Figure 6 Characterization of the TGF-P binding proteins on GH3 cells. (A) Identification of TGF-P binding
characteristics of TpR-IV on GH3 cells. 10x10° GH3 cells were incubated with 200 pM 125I-TGF-p1, ^ JI-TGF-p 2 or
125I-TGF-P3 and cross-linked with 0.28 mM DSS. Aliquots of cell lysates were analyzed directly by SDS-gel 
electrophoresis, followed by Fuji-X BioImager analysis, or first subjected to immunoprecipitation (IP) using an
antiserum against TP R-I. (B) Sodium chloride and heparin dependent release of TGF-P cross-linked protein complexes
2 125on GH3 cells. GH3 cells were grown to confluency in 25 cm flasks and incubated with I-TGF-P 1 followed by cross­
linking with 0.28 mM DSS. Cells were washed twice with PBS (C), 0.5 M NaCl in PBS (N) or 10 ^g/ml heparin in PBS 
(H). The two washes were pooled and trichloroacetic acid precipitated. Cells were lysed and all samples were analyzed 
by SDS-gel electrophoresis, followed by autoradiography.
125t
The 60 kDa protein interferes with TGF-P receptor binding
The 60 kDa protein, extracted from LNCaP cells by a wash with 10% glycerol in PBS, was
125tested for its effect on I-TGF-P binding to the TGF-P receptors on MvlLu cells (Fig. 7). MvlLu 
cells do not contain the 60 kDa TGF-P binding protein, yet express high levels of TPR-I, TP R-II 
and TPR-III. It therefore seems to be a suitable model system to investigate the possible function of 
the 60 kDa TGF-P binding protein from LNCaP cells. In the presence of 60 kDa LNCaP-derived 
protein the binding of all three TGF-P isoforms to the TGF-P receptors was inhibited. After
125incubation of I-TGF-P 1 with the glycerol extract followed by cross-linking, only the 70-74 kDa 
protein complexes were detected (data not shown) indicating that the decrease in TGF-P binding to 
its receptors was mediated by the 60 kDa protein and not by other proteins present in the wash. 
These results suggest that in a soluble form the 60 kDa protein has affinity for all three TGF-P 
isoforms. Thus, the 60 kDa TGF-P binding protein can modulate the binding of TGF-P to its 
receptors implying that it might regulate TGF-P receptor-mediated signaling.
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125Figure 7 Functional characterization of the 60 kDa TGF-p binding protein. Affinity cross-linking of I-TGF-p to 
TGF-p receptors on Mv1Lu cells in the presence of LNCaP eluted 60 kDa TGF-p binding protein. The 60 kDa TGF-p
binding proteins were eluted from LNCaP cells with 10% glycerol in PBS. 2.5x106 Mv1Lu cells were incubated with 20
125 125 125pM I-TGF-P1, I-TGF-P 2 or I-TGF-^3 in binding buffer without glycerol or LNCaP eluted proteins, or in
binding buffer with 10% glycerol but in the absence of LNCaP eluted proteins or in binding buffer containing 10%
glycerol and cell surface-eluted proteins from 25x106 LNCaP cells, followed by cross-linking with 0.28 mM DSS. Cell
lysates were analyzed directly by SDS-gel electrophoresis, followed by autoradiography.
DISCUSSION
This study describes the characterization of a 60 kDa TGF-P binding protein that was originally 
identified on LNCaP cells by affinity cross-linking of cell surface proteins with 125I-TGF-p1. Our 
results show that the 60 kDa TGF-P binding protein is distinct from T^R-I, T^R-II and other known 
type I receptors for members of the TGF-P superfamily. Rather than being a transmembrane protein, 
the 60 kDa TGF-P binding protein is associated to the cell surface of LNCaP cells. It appears to be 
present on multiple cell types, including PC-3 cells and GH3 cells, and can regulate the access o f 
TGF-P to its receptors.
The cell surface-associated TGF-0 binding protein on LNCaP cells exists in multiple forms, 
observed as 70-74 kDa TGF-P bound protein complexes upon analysis by SDS-gel electrophoresis 
(Fig. 1). Since the 70-74 kDa protein complexes include 12 kDa subunits of monomeric cross­
linked TGF-P, the actual size of the binding protein is estimated to approximately 60 kDa. Under
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non-reducing conditions the multiple TGF-P bound protein complexes run slightly faster, as a 67 
kDa component (Fig. 1), suggesting that the 60 kDa TGF-P binding protein contains cysteine- 
bridges.
Whereas LNCaP cells do express TPR-III (Fig. 3A), they lack expression of TPR-I (Fig. 3A-3E) 
due to a genetic alteration in the gene encoding this receptor (Kim et al., 1996a), and the expression 
level of TPR-II is very low (Kim et al., 1996c). Transfection of TPR-I into LNCaP cells results in 
recovery of TGF-P responsiveness, showing that the TGF-P signaling pathway downstream of TPR- 
I is intact in LNCaP cells (Kim et al., 1996a). There are contradictory reports, however, on the 
responsiveness of LNCaP cells to TGF-P in the presence of proliferation-inducing factors like 
dihydrotestosterone (Schuurmans et al., 1988; Wilding et al., 1989; Kim et al., 1996b, 1996c). 
Although TGF-P has been described to suppress the mitogenic activity of 10-10 M DHT in LNCaP 
cells (Kim et al., 1996c), we observed no inhibition of the growth stimulatory effect of 10-10 M 
DHT on LNCaP cells by the addition of TGF-P. Cross-linking studies on 10-10 M DHT-stimulated 
LNCaP cells did not indicate an upregulation of expression of TGF-P receptors or TGF-P binding 
proteins compared to untreated cells (data not shown). Apparently, the 60 kDa TGF-P binding 
protein on LNCaP cells is not able to directly transduce growth modulating TGF-P activities.
The 60 kDa protein identified on LNCaP cells appeared to bind TGF-P 1 with higher affinity than 
TGF-P2 and TGF-P3. The affinity constant of the 60 kDa protein for TGF-P1 remains to be 
determined. Activin A and OP-1 did not bind to the 60 kDa protein. Isoform-specific TGF-P 
binding proteins have been described which are attached to the cell membrane via a glycosyl- 
phosphatidyl-inositol (GPI) anchor (Cheifetz and Massagué, 1991; Dumont et al., 1995). The 60 
kDa TGF-P binding protein from LNCaP cells is not GPI anchored as its release could not be 
induced by phosphatidyl-inositol-phospholipase C (data not shown). To our knowledge this is the 
first demonstration of a protein which binds TGF-P1 and TGF-P3 with different affinity. TGF-P1 
and TGF-P3 have very similar in vitro biological activities (Cheifetz et al., 1990). However, they 
differ in their activity with respect to scar formation (Shah et al., 1995).
Dissociation of the 70-74 kDa TGF-P cross-linked protein complexes from LNCaP cells by 
sodium chloride or heparin indicated that the 60 kDa TGF-P binding protein is associated to 
structures at the cell surface, perhaps to heparan sulfate proteoglycans. Heparin can compete for 
binding of proteins that are attached to heparan sulfate proteoglycans. The ability of the 60 kDa 
TGF-P binding protein from LNCaP cells to be eluted by salt or heparin is reminiscent of the 
characteristics of a previously described 60 kDa TGF-P binding protein localized in the 
extracellular matrix of HepG2 cells (Bützow et al., 1993). The affinity constant of the HepG2 60 
kDa protein for TGF-P is 1.6 nM, which is comparable to the affinity of TPR-III for TGF-P (1.9 
nM) described by Andres et al. (1989). It remains to be determined whether the 60 kDa TGF-P 
binding protein on HepG2 cells exerts TGF-P isoform-specificity as well.
The identity of the 60 kDa TGF-P binding protein is unknown. Certain components known to 
bind TGF-P, like a2-macroglobulin, fibronectin and decorin (O’Connor-McCourt and Wakefield, 
1987; Fava and McClure, 1987; Yamaguchi et al., 1992), can be excluded as candidates in view of 
their differences in size. Recently, bovine fetuin and its human counterpart a2-HS glycoprotein with 
molecular sizes of 60 kDa, have been described to bind several members of the TGF-P superfamily
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(Demetriou et al., 1996). However, the characteristics of the 60 kDa protein from LNCaP cells 
make it unlikely that it is fetuin or a2-HS glycoprotein. Whereas fetuin and a2-HS glycoprotein 
have highest affinity for BMPs and bind with weaker affinity to TGF-^s, the 60 kDa protein from 
LNCaP cells has highest affinity for TGF-P and no appreciable affinity for activin A or BMPs. 
Fetuin and a2-HS glycoprotein contain a number of N- and O-glycosylated chains (Dziegielewska
et al., 1990). However, endoglycosidase F treatment of the 60 kDa protein from LNCaP cells cross-
125linked with I-TGF-P did not result in faster migration on SDS-gel electrophoresis. Cross-linking 
of radiolabeled TGF-P to calf serum, in which fetuin is abundantly present (reviewed in Brown et 
al., 1992), or to commercial a2-HS glycoprotein, revealed TGF-^-bound protein complexes distinct
from the 70-74 kDa TGF-^ cross-linked complexes on LNCaP cells (data not shown). In addition,
125we were unable to immunoprecipitate cross-linked I-TGF-^1 complexes from LNCaP cells using 
antisera against a2-HS glycoprotein; moreover, these antisera did not recognize the eluted 60 kDa 
TGF-P binding protein using immunoblotting (data not shown). The 60 kDa TGF-P binding protein 
identified from HepG2 cells by Butzow et al. (1993) was shown to be produced by these cells, 
thereby excluding serum delivery.
The 60 kDa TGF-^ binding protein is possibly a follistatin-like protein. Follistatin is an activin 
binding protein that inhibits activin receptor binding. Like follistatin (Ueno et al., 1987; Inouye et 
al., 1992; Sugino et al., 1993), the 60 kDa TGF-^ binding protein inhibits signaling of TGF-^ 
superfamily members and it may associate to heparan sulfate proteoglycans on the cell surface.
The 70-74 kDa TGF-P binding protein complexes have been observed on several cell lines, like 
HEP-G2 cells, HEP-G3 cells, HT-12 cells (Butzow et al., 1993) and PC-3 cells (Fig. 3B, Fig. 3C). 
In rat pituitary GH3 cells TGF-P binding protein complexes with similar size as the 60 kDa binding 
protein on LNCaP cells have been identified (Cheifetz et al., 1988; Yamashita et al., 1995a), and 
referred to as TGF-P type IV receptor. We showed that T^R-IV can be eluted from the cell surface 
of GH3 cells by salt, heparin and glycerol in a way similar to what we observed for the 60 kDa 
protein on LNCaP cells. In addition, Yamashita et al. (1995a) previously showed that a treatment of 
GH3 cells with endoglycosidase F did not result in a shift in molecular weight of the 70-74 kDa 
TGF-P bound protein complexes in SDS-gel electrophoresis and transient DTT treatment did not 
abolish the binding of TGF-P, similar to the 60 kDa protein from LNCaP cells. Therefore, we 
conclude that T^R-IV is a cell-associated TGF-P binding protein which may be related to the 60 
kDa protein from LNCaP cells. We are currently investigating whether the T^R-IV on GH3 cells 
and the 60 kDa TGF-P binding protein on LNCaP cells exert the same biological activities.
In soluble form, the 60 kDa LNCaP protein was shown to impede the binding of TGF-P to the 
T^Rs, suggesting that it may inhibit TGF-P signaling. The effects of the 60 kDa component on 
TGF-^1-induced growth inhibition could not be tested directly due to the presence of growth 
promoting contaminants in the partially purified preparation of the 60 kDa component. Although 
affinity cross-linking of iodinated TGF-P to the glycerol-eluted LNCaP extract revealed that the 60 
kDa protein is the only TGF-P binding protein, the 60 kDa TGF-P binding protein is present at very 
low abundance (data not shown). Therefore, it seems to be inevitable that, in order to clarify the role 
of the 60 kDa TGF-P binding protein on modulation of TGF-P action, the 60 kDa TGF-P binding 
protein has to be purified. Interestingly, soluble 60 kDa TGF-P binding protein, in contrast to its cell
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surface-associated configuration, does have affinity for all three TGF-P isoforms. Discrepancies in 
TGF-P binding affinities of soluble and cell surface-associated 60 kDa protein are subject for 
further studies. When bound to the cell surface the 60 kDa TGF-P binding protein may also regulate 
binding to TpRs. The 60 kDa protein was not coimmunoprecipitated with TPR-I in GH3 cells (Fig. 
6A, Yamashita et al., 1995a), suggesting that it may not be involved in ligand presentation to the 
receptors. Thus, the 60 kDa TGF-P binding protein most likely sequesters ligand, and neutralizes 
TGF-P bioactivity. Alternatively, it may have a storage function for TGF-P at the cell surface and 
extracellular matrix, from which it can be released in active form, e.g. during wound repair. Thus, 
the 60 kDa cell surface-associated TGF-P binding protein identified on LNCaP cells might play an 
important role in modulating isoform-specific TGF-P activities.
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ABSTRACT
Members of the transforming growth factor (TGF)-P superfamily mediate their pleiotropic 
activities by signaling through type II and type I serine/threonine kinase receptors. In contrast to the 
large TGF-P superfamily, only 7 different mammalian type I receptors have been cloned to date. To 
identify putative novel TGF-P superfamily type I receptors, we performed polymerase chain 
reaction (PCR) amplification on cDNA derived from different cell lines and tissues, using 
degenerate oligonucleotide primers based upon highly conserved amino acid regions in the catalytic 
domain of serine/threonine kinases. Selection for type I serine/threonine kinase receptors was 
achieved by a final ‘nested’ PCR step, using degenerate primers based upon conserved blocks of 
amino acid residues SWFRETE and GTQGKPA. This resulted in the generation of a mixture of 
uniformly sized DNA fragments that could not be separated by standard agarose gel electrophoresis.
Here we describe a method called Southern blot (SB)-PCR technique, which enables the 
separation of PCR fragments of equal length. Hybridization of these PCR pools on Southern blots 
containing four lanes of mouse genomic DNA digested with different restriction enzymes, resulted 
in the generation of cell line- and tissue-specific Southern blot patterns in which each receptor is 
represented by its own unique fingerprint. The Southern blot-PCR technique can be widely applied 
for fast and simple analysis of the constitution of mixed pools of equally sized PCR fragments 
derived from multigene family members, and facilitates the detection of putative novel family 
members.
INTRODUCTION
Members belonging to multigene families are characterized by several highly conserved stretches 
of amino acid residues, especially in regions with high structural and functional importance, like the 
catalytic domain of protein kinases (Hanks et al., 1988; Hanks and Hunter, 1995; Henikoff et al., 
1997). Polymerase chain reaction (PCR)-amplification, using degenerate oligonucleotide primers 
based upon homologous domains, has successfully resulted in the identification of novel genes and 
gene families, for example the serine/threonine kinase type I receptors for members of the 
transforming growth factor (TGF)-P superfamily (ten Dijke et al., 1993; Franzen et al., 1993b).
Growth factors belonging to the TGF-P superfamily mediate a broad range of biological 
activities (reviewed in Roberts and Sporn, 1990; Kingsley et al., 1994) and signal through type I 
serine/threonine kinase receptors, which become activated following ligand-induced 
heteromerization with serine/threonine kinase type II receptors (Wrana et al., 1994). Although the 
TGF-P superfamily counts more than 30 members at present, only seven mammalian type I 
receptors have been identified, designated activin receptor-like kinase-1 (ALK-1), activin receptor 
type I (ActR-I), ActR-IB, bone morphogenetic protein receptor type IA (BMPR-IA), BMPR-IB, 
TGF-P receptor type I (TPR-I), and ALK-7. Whereas ALK-1 and ALK-7 are orphan receptors, 
ActR-I, BMPR-IA and BMPR-IB mediate signaling by BMPs, while activin and TGF-P signal 
through ActR-IB and TPR-I, respectively (Franzen et al., 1993b; ten Dijke et al., 1993, 1994b;
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Cárcamo et al., 1994; Lorentzon et al., 1996; Rydén et al., 1996; Macías-Silva et al., 1998). In view 
of the large number of TGF-P superfamily members and the broad range of biological activities that 
these pluripotent growth factors elicit, it is tempting to suggest that additional, yet unidentified, type 
I, as well as type II, serine/threonine kinase receptors exist.
A great disadvantage of the use of degenerate primers for amplification of multigene family 
members, like the TGF-P type I receptors, is that the PCR fragments generated from different 
members are often of equal size, which makes standard agarose or polyacrylamide separation 
impossible and demands elaborate molecular cloning and DNA sequence analysis. Thus, to simplify 
the identification of novel PCR-amplified serine/threonine kinase type I receptors, we have 
developed the here described Southern blot (SB)-PCR technique. The combination of PCR 
amplification and Southern blot analysis allows the separation of individual serine/threonine kinase 
type I receptors present in a mixture of equally sized PCR fragments, in which each receptor is 
characterized by its own unique Southern blot fingerprint. The technique can be applied for 
profiling the expression of RT-PCR amplified multigene family members in different tissues and 
cell lines, and allows the identification of putative novel family members.
MATERIALS AND METHODS
cDNA constructs
Plasmids containing complete cDNA sequences of human ALK-1, ActR-I, BMPR-IA, T0R-I, mouse BMPR-IB, and 
rat ALK-7, as well as a partial cDNA sequence of human ActR-IB were kindly provided by Dr. Peter ten Dijke (Ludwig 
Institute for Cancer Research, Uppsala, Sweden).
Cell lines
Mouse fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn 
calf serum, 100 units/ml penicillin and 50 |J.g/ml streptomycin. The human embryonal carcinoma cell line Tera 2 Clone 
13 (T2Cl13), was maintained in a-minimum essential medium (aMEM) lacking nucleosides and deoxynucleosides, 
supplemented with 10% foetal calf serum, 100 units/ml penicillin and 50 |J.g/ml streptomycin. Cells were cultured at 
37°C in a 7.5% CO2 containing atmosphere.
cDNA synthesis
With informed consent of the parents, biopsies from therapeutic and spontaneous abortions (11-24 wk gestation) 
were taken within 15 h after delivery.Total RNA from human embryonic kidney was isolated as described (Kalscheuer et 
al., 1993) and obtained from Dr. E.C.M. Mariman at the Dept of Human Genetics, (Nijmegen, the Netherlands). Poly- 
A+ RNA from rat articular cartilage tissue, isolated as described in Glansbeek et al., (1997), was obtained from H. 
Glansbeek at the Dept. of Rheumatology (Nijmegen, the Netherlands). T2Cl13 cells were grown to confluency. Cells 
were harvested and mRNA was isolated using the Micro-Fast Track kit (Invitrogen, San Diego, USA). Reverse 
transcription (RT) of 50 ng T2Cl13 or rat articular cartilage poly-A+ RNA was performed for 60 min at 39°C using 100 
units Superscript II reverse transcriptase (Gibco, Gaithersburg, MD, USA) in 1xRT-buffer consisting of 50 mM Tris- 
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol (DTT), 1 mM each dATP, dCTP, dGTP, dTTP
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(Pharmacia, Uppsala, Sweden), 7.5 units RNAguard (Pharmacia, Uppsala, Sweden) and 6.5 pmole of a degenerate 
oligonucleotide primer ('YMAPEVL 13-mer', 5'-AG(ACT)AC(CT)TC(ACGT)GG(AGT)G-3') corresponding to the 
conserved serine/threonine kinase sequence YMAPEVL in subdomain VIII. For human fetal kidney tissue, cDNA 
synthesis was performed on 125 ng total RNA using 500 ng oligo-dT12-18 primer (Pharmacia, Uppsala, Sweden). Water 
instead of mRNA was used as control for contamination.
PCR amplification o f  serine/threonine kinase type I  receptor fragments
PCR amplification was performed using degenerate oligonucleotide primers (Gene Assembler Plus; Pharmacia, 
Uppsala, Sweden) based on conserved sequences within the kinase domain of type I receptors. The sense primers (5'- 
GTGGCTGT(CG)AA (AG)(AG)T(AC)TT(CT)(CT)(CT)-3'; VAVKIF) and (5'-(CG)(CT)TGGTT(CT)(AC) 
G(ACG)GA(AG)AC(ACGT)GA(AG)-3'; SWFRETE) corresponded to the amino acid sequences VAVKIF in kinase 
subdomain II, and SWFRETE in subdomain III, respectively (Hanks et al., 1988; ten Dijke et al., 1994b). The antisense 
primers (5'GC(AGT)GG(CT)TT(CGT)CC(CT)TC(ACGT)GT(ACGT)CC-3'; GTQGKPA), (5'-AG(ACT) 
AC(CT)TC(ACGT)GG(AGT)GCC-3'; YMAPEVL 15-mer) and (5'-AG(ACT)AC(CT)TC(ACGT) 
GG(AGT)GCCAT(AG)TA-3'; YMAPEVL 20-mer) corresponded to the conserved motifs GTQGKPA and YMAPEVL 
in subdomains VIA and VIII, respectively. The PCR reaction mixture consisted of 20 mM Tris-HCl (pH 8.4), 50 mM 
KCl, 1.5 mM MgCl2, 1 mM each dATP, dCTP, dGTP, dTTP (Pharmacia, Uppsala, Sweden), 2 units Taq DNA 
polymerase (Gibco, Gaithersburg, MD, USA) and 0.5 |xM of each primer. The primer combination VAVKIF- 
YMAPEVL 15-mer was used in the first round of PCR. Cycling parameters included an initial denaturation step at 94°C 
for 2 min followed by 35 thermal cycles of 94°C for 1 min, 50°C for 1 min and 72°C for 2 min, ending with extension at 
72°C for 7 min. The annealing temperature in the second and third rounds of PCR, using the primers VAVKIF- 
YMAPEVL 20-mer and SWFRETE-GTQGKPA, respectively, was 55°C. PCR products of 262 bp were isolated by 
agarose gel electrophoresis and purified by the Qiaquick gel extraction kit (Qiagen, Chatsworth, CA).
Preparation o f Southern Blots
High molecular weight DNA was prepared from mouse fibroblasts. Cells were lysed in 1xTNE (10mM Tris pH7.5, 
100mM NaCl, 1mM EDTA) containing 1% SDS, followed by treatment with proteinase K at a final concentration of 
50|j.g/ml at 65°C. Genomic DNA was isolated by phenol-extraction and ethanol-precipitation, and restriction digested 
with EcoR-I (Boehringer Mannheim, Mannheim, Germany), Hind-III (Pharmacia, Uppsala, Sweden), Pst-I (Gibco, 
Gaithersburg, MD, USA) or Taq-I (New England Biolabs, Beverly, MA , USA). Southern blots were prepared from 1% 
agarose gels with 10 ^g digested genomic DNA per lane. DNA from the gels was transferred to Hybond-C nylon 
membranes (Amersham, Amersham, UK) and covalently linked by ultraviolet-mediated cross-linking.
Hybridizations
Purified serine/threonine kinase type I receptor PCR fragments, as well as cell line- or tissue-derived RT-PCR 
fragments, were labeled by random priming using the Multiprime DNA labeling system (Amersham, Amersham, UK). 
For Southern blot analysis of a complex pool of equally sized PCR fragments, individually labeled serine/threonine 
kinase type I receptor probes were combined in the hybridization solution. Hybridization was performed in 5xSSC 
(1xSSC=150 mM NaCl, 15 mM sodium citrate pH 7.0), 0.1% N-lauroylsarcosine, 0.5% SDS, 1% blocking reagent 
(Boehringer Mannheim, Mannheim, Germany) at 65°C overnight. The membranes were washed in 2xSSC / 0.5% SDS
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at 52°C for 30 min and exposed to Kodak X-OMAT / AR films (Eastman Kodak Co., Rochester, NY, USA). Under 
these conditions, no cross-hybridization was observed.
RESULTS
PCR amplification o f serine/threonine kinase receptors
Members of the serine/threonine kinase receptor family share high sequence homology in their 
catalytic domains (Fig. 1A). The amino acid sequences VAVKIF and YMAPEVL, which are highly 
conserved among all serine/threonine kinases, and the type I receptor specific domains SWFRETE- 
GTQGKPA, were chosen for the design of degenerate oligonucleotide PCR primers. A three-step 
PCR amplification using different sets of primers, VAVKIF-YMAPEVL 15-mer, VAVKIF- 
YMAPEVL 20-mer, and SWFRETE-GTQGKPA (Fig. 1A), was developed to increase specificity 
for type I receptors while scaling up the amount of DNA fragments in successive rounds of RT-PCR 
amplification. The rationale behind different primer sequences was to reduce the chance for 
selective amplification of particular family members, due to more favorite annealing conditions. The 
efficiency of these primer combinations in the amplification of type I serine/threonine kinase 
receptors was tested for all seven members of the serine/threonine kinase type I receptor family, 
ALK-1, ActR-I, ActR-IB, BMPR-IA, BMPR-IB, TPR-I, and ALK-7. In each PCR amplification, 10 
ng receptor plasmid construct was used as template DNA. As expected, the primers based upon the 
serine/threonine kinase-specific domains VAVKIF and YMAPEVL gave rise to 468 bp products, 
while the primer combination SWFRETE-GTQGKPA, based upon type I receptor-specific domains, 
resulted in 262 bp DNA fragments (Fig. 1B). The primer combination VAVKIF-YMAPEVL 15- 
mer was less favorite for ALK1 and excluded amplification of BMPR-IB, whereas VAVKIF- 
YMAPEVL 20-mer as well as SWFRETE-GTQGKPA gave fairly comparable yields of PCR- 
amplified fragments of the different type I receptors. Thus, amplification of serine/threonine kinase 
type I receptors using degenerate primers based on conserved sequences in the catalytic domain, 
resulted in the generation of equally sized PCR fragments that were unseparatable by agarose gel 
electrophoresis. These DNA fragments were subsequently subjected to the here described Southern 
blot-fingerprinting analysis.
Separation o f equally sized DNA fragments on Southern blots
For actual separation of equally sized receptor fragments, Southern blots containing four lanes of 
genomic DNA digested with EcoR-I, Pst-I, Hind-III, or Taq-I were constructed. Using the primer 
combination SWFRETE-GTQGKPA, individual 262 bp type I receptor probes were generated and 
hybridized on separate Southern blots, yielding receptor-specific fingerprints (Fig. 2A). For certain 
type I receptors, such as ActR-IB, two or more hybridizing bands could be observed per lane in the 
genomic digest. Under the hybridization conditions as described above, no cross-hybridization 
between the family members was observed. A mixture of six individually generated SWFRETE- 
GTQGKPA receptor species probes was hybridized on a single Southern blot, resulting in a 
complex pattern of multiple bands (Fig. 2B). Comparing this combined serine/threonine kinase type
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Figure 1 Amplification of serine/threonine kinase type I receptors using degenerate primers in PCR. A) Amino acid 
sequence alignment of the catalytic domain of serine/threonine kinase type I receptors. The location of the primers used 
for amplification of type I receptor fragments are indicated.
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Figure IB Separation of PCR-amplified type I serine/ 
threonine kinase receptor fragments by agarose gel 
electrophoresis. Plasmids containing eDNAs of ALK-1, 
ActR-I, BMPR-IA, ActR-IB, TpR-I and BMPR-IB were 
used as templates in PCR. Amplification using the primer 
combinations VAVKIF-YMAPEVL 15-mer, or VAVKIF- 
468 bp YMAPEVL 20-mer, resulted in 468 bp products, while the 
primers SWFRETE and GTQGKPA gave rise to 262 bp 
PCR fragments. 1) ALK-1, 2) ActR-I, 3) BMPR-IA, 4) 
ActR-IB, 5) TPR-I, 6) BMPR-IB, 7) ALK-7, C) control.
I receptor pattern with that of the individual receptor fingerprints enabled the analysis of the 
receptor-identity of the individual bands in the composite pattern (Fig. 2B). PCR amplification of an 
equimolar mixture of the six different type I receptor cDNA templates using the subsequent primer 
combinations VAVKIF-YMAPEVL 15-mer, VAVKIF-YMAPEVL 20-mer, and SWFRETE- 
GTQGKPA, followed by hybridization resulted in a Southern blot pattern in which BMPR-IB was 
missing, while ALK-1 was equally well detected as the other type I receptors (data not shown). 
Thus, in spite of reduced amplification of ALK-1 by the primer combination VAVKIF-YMAPEVL 
15-mer (Fig. 1B), the amplification levels were high enough to be detected by Southern blot 
analysis. The absence of BMPR-IB was expected in view of the lack of amplification by the 
VAVKIF-YMAPEVL 15-mer primer (Fig. 1B). Thus, Southern blot-hybridization of a complex 
pool of equally sized PCR fragments clearly results in the separation of the individual receptor 
species as represented by the multiple bands in the overall hybridization pattern.
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Figure 2 Southern blot analysis of PCR amplified type I 
serine/threonine kinase receptor fragments. Top panel; 
Hybridization of SWFRETE-GTQGKPA-primed PCR 
fragments of ALK-1, ActR-I, BMPR-IA, ActR-IB, TpR-I 
and BMPR-IB on Southern blots containing four lanes of 
differentially digested mouse genomic DNA. Left panel; 
Southern blot hybridization of a 262 bp mixture of six 
different serine/threonine kinase type I receptor PCR 
fragments. Comparison of the composite pattern with the 
individual receptor fingerprints results in the delineation of 
the respective receptor bands. E = EcoR-I, P = Pst-I, H = 
Hind-III, T = Taq-I.
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Analysis of serine/threonine kinase receptor expression in cell lines and tissues
To reveal whether the Southern blot-PCR method would be applicable for the analysis of 
serine/threonine kinase receptor expression in different cell lines or tissues, we performed RT-PCR 
on the embryonal carcinoma cell line T2Cl13, human embryonic kidney tissue, and rat articular 
cartilage tissue. To avoid analysis of unrelated fragments due to the use of degenerate primers under 
low stringency conditions in PCR, the amplified material was run out on an agarose gel and the 
bands containing DNA fragments of 262 bp, corresponding to SWFRETE-GTQGKPA-amplified 
type I serine/threonine kinase receptors, were excised (data not shown). Gel-extracted fragments 
were used as probes for Southern blot analysis. As shown in Fig. 3, Southern blot-PCR analysis of 
serine/threonine kinase type I receptor expression in the cell line and tissues resulted in the 
simultaneous detection of several family members, indicated by the multiple bands in the Southern 
blot profile. The cell line and tissues presented in Fig. 3 show unique overall Southern blot patterns, 
indicating source-specificity. Using the individual fingerprints of the six different type I receptors
Figure 3 Southern blot analysis of RT-PCR amplified serine/threonine kinase type I receptor fragments from cell lines 
and tissues. Poly-A+ RNA was used for the generation of cDNA, either using an oligo-dT12-18 primer (human embryonic 
kidney tissue), or a degenerate 13-mer primer based on the conserved YMAPEVL motif (T2Cl13, rat articular cartilage 
tissue). Three successive rounds of PCR were performed, using the primer combinations VAVKIF-YMAPEVL 15-mer, 
VAVKIF-YMAPEVL 20-mer, and SWFRETE-GTQGKPA. The 262 bp PCR fragments were isolated and hybridized 
on mouse genomic Southern blots. Comparison of the Southern blot patterns with known receptor fingerprints results in 
the analysis of the hybridizing bands. For rat articular cartilage and human embryonic kidney, novel bands compared to 
the individual receptor fingerprints (Fig. 2) can be identified (*). E = EcoR-I, P = Pst-I, H = Hind-III, T = Taq-I.
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(Fig. 2), the presence of ActR-I, ActR-IB, BMPR-IA and T^R-I could be detected in the T2Cl13 
profile. In the Southern blot pattern of rat articular cartilage, ALK-1, and to a lesser extent TpR-I, 
could be identified. An incomplete pattern was observed for ActR-I, most likely due to low amounts 
of its probe fragments. For human embryonal kidney tissue, ALK-1, ActR-I, ActR-IB, BMPR-IA 
and TpR-I were detected, together with novel bands in the EcoR-I, Pst-I and Hind-III lanes (Fig 3). 
Altogether, the Southern blot-PCR method allows the separation of a large number of 
simultaneously amplified RT-PCR fragments on a single Southern blot, and thereby enables the 
analysis of expression of multigene family members in different cell lines or tissues. Furthermore, it 
allows for the detection of putative novel multigene family members.
DISCUSSION
Amplification of multigene family members using degenerate primers often results in the 
generation of complex pools of equally sized PCR fragments. To circumvent laborious subcloning 
and DNA sequence analysis, we developed the Southern blot-PCR technique which allows the 
separation of a mixture of different serine/threonine kinase type I receptor fragments of equal length 
by hybridization on a single Southern blot, in which each receptor species is represented by its own 
unique fingerprint (Fig. 2A-H). The Southern blot-PCR technique can be applied for analysis of RT- 
PCR-amplified mixtures of multigene family members derived from cell lines and tissues, and 
offers the possibility to detect novel related genes. An overview of the technique is presented in Fig. 
4.
The profile of the Southern blot fingerprints is determined by the location of EcoR-I, Pst-I, Hind- 
III and Taq-I sites in the respective mouse receptor genes. According to the genomic organization of 
mouse ActR-I and BMPR-IA (Schmitt et al., 1995; Mishina et al., 1995), and human ActR-IB (Xu 
et al., 1994), ALK-1 and T^R-I (Vellucci and Reiss, 1997), serine/threonine kinase type I receptor 
genes contain several introns in the region encoding the catalytic domain. At least one intron can be 
found in the genomic sequence that corresponds to the SWFRETE-GTQGKPA-amplified cDNA 
sequence (Mishina et al., 1995; Schmitt et al., 1995; Velluci and Reiss, 1997). The presence of 
cognate restriction sites in this intron, or in the mouse exon sequences corresponding to the PCR- 
primed cDNA fragments, can result in the detection of multiple hybridizing bands per lane of 
genomic DNA, for example observed in the fingerprints of ActR-I, ActR-IB and TpR-I. According 
to the murine cDNA sequences of ALK-1, ActR-I, ActR-IB, BMPR-IA, BMPR-IB, and TpR-I, 
deposited in GenBank (Accession Nos. L48015, L15436, Z31663, Z23154, Z23143, D25540), Pst-I 
and Taq-I sites are present in the SWFRETE-GTQGKPA cDNA sequence of ALK-1, a Hind-III and 
Taq-I site are located in the corresponding sequence of T^R-I, and a Pst-I recognition site exists in 
ActR-IB, BMPR-IA and BMPR-IB. For ActR-I, which lacks any of these restriction sites in its 
SWFRETE-GTQGKPA mouse exon sequence, the multiple hybridizing bands in the ActR-I 
Southern blot profile are likely due to the presence of cognate restriction sites in the 5 kilobase 
intron (Schmitt et al., 1995). Because of lack of information on the genomic organization of mouse 
ActR-IB in the region that corresponds to the SWFRETE-GTQGKPA coding sequence, it is not
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possible to explain the multiplicity of bands identified in the ActR-IB Southern blot fingerprint. For 
human ActR-IB, several alternative splice variants have been described, arising downstream of the 
region that corresponds to the VAVKIF-YMAPEVL coding sequences (Xu et al., 1994). Since our 
PCR strategy selects for 262 bp SWFRETE-GTQGKPA-primed fragments, this does not allow the 
detection of alternative splice variants. At present it can not be excluded that the mouse genome 
contains a highly homologous, yet unidentified, serine/threonine kinase type I receptor gene with 
which the ActR-IB receptor probe cross-hybridizes. It should be noted that under the conditions 
here, no cross-hybridization among the known type I receptors was observed.
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Figure 4 The Southern blot-PCR technique. Overview of the sequential steps that lead to separation of equally sized 
RT-PCR fragments by Southern blot hybridization.
Although ALK-1 and BMPR-IA each contain a Pst-I site in the exon sequence of interest, no 
double bands are observed in the Pst-I Southern blot lanes of the individual receptor fingerprints 
(Fig. 2). For the BMPR-IA gene, a 6.4 kb intron is located 14 bp from the Pst-I restriction site. Most 
probably, the genomic fragment generated is very small, or the 14 bp coding sequence is too short to 
be recognized by the BMPR-IA probe. We speculate that the ‘novel’ 1500 bp Pst-1 band present in
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the Southern blot pattern of rat articular cartilage and human embryonic kidney, two tissues with 
high levels of ALK-1 (Fig. 3), represents the ALK-1 Pst-1 genomic fragment which is not 
detectable in the relatively weak ALK-1 fingerprint presented in Fig. 2.
Southern blot analysis of receptor fragments amplified from T2Cl13 cells revealed the expression 
of ActR-I, BMPR-IA, ActR-IB, and T^R-I (Fig. 2, Fig. 3). This was confirmed by RT-PCR using 
receptor-specific primers (Piek et al., data not shown), as well as by receptor affinity-binding studies 
using iodinated TGF-P superfamily members. These studies also revealed the expression of BMPR- 
IB in T2Cl13 cells. In view of the failure of the primer combination ‘VAVKIF’-’YMAPEVL 15- 
mer’ to amplify BMPR-IB (Fig. 1B), the absence of BMPR-IB in the T2Cl13 Southern blot 
fingerprint was expected. Adjustment of the degenerate primer sequences could be useful to 
optimize the range of family members detected. In contrast to T2Cl13 cells, in which ALK-1 
expression was below Southern blot-PCR detection levels, ALK-1 was detected in rat articular 
cartilage and human fetal kidney. We failed to detect expression of ALK-7, a recently identified 
member of the serine/threonine kinase type I receptor family, in T2Cl13 cells by Northern blot 
analysis (data not shown). However, ALK-7 displays a restricted expression pattern with high levels 
in brain and prostate, although its expression was also detected in certain developing organs 
(Lorentzon et al., 1996; Ryden et al., 1996). For human embryonic kidney tissue, novel bands were 
identified in the Southern blot profile, which could possibly represent ALK-7. As observed in Fig. 
1B, rat ALK-7 cDNA was recognized by the primers used in the PCR strategy. However, at present 
the identity of the novel bands present in the Southern blot profile of human embryonic kidney 
tissue is not clear. For a novel gene one would theoretically expect at least one band in each lane of 
genomic DNA. However, the absence of a novel band in the Taq-I lane could, for example, be due 
to its overlapping size with any of the known type I receptor bands, which is for example observed 
for BMPR-IA and T^R-I in the Taq-I lane. In theory, it should be possible to isolate hybridized PCR 
fragments, possibly encoding novel family members, by reamplification of full length probe DNA 
eluted from the filter pieces of interest. Alternatively, a library of the genomic fragments that 
correspond in size to the novel bands on the Southern blots can be constructed, followed by 
screening with the 262 bp RT-PCR mixture derived from human fetal kidney tissue.
Various techniques have been developed to facilitate the identification of novel multigene family 
members. Kraus and Aaronson (1991) have described a method in which exon-containing probes of 
known tyrosine kinases were hybridized to genomic Southern blots under reduced stringency 
conditions, resulting in the identification of novel protein tyrosine kinase genes. Boehm (1993) has 
developed a fingerprinting method in which equally sized RT-PCR species are distinguished by 
their restriction digestion profiles using frequently cutting enzymes. Some drawbacks of this method 
are the limiting number of restriction sites available in short RT-PCR fragments, in combination 
with the possibility of overlooking family members due to conservation of restriction sites. 
Robinson et al., (1996) described an improved RT-PCR approach which in combination with 
thymidine-track based sequencing analysis allowed the profiling of tyrosine kinase expression in 
prostate carcinoma, together with the identification of several novel tyrosine kinases out of 600 
clones screened. In addition, single stranded conformation polymorphism (SSCP) has been 
exploited as a method to separate equally sized PCR fragments generated from members of the
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TGF-P type I receptor family (Pieneman et al., manuscript in preparation). General disadvantages of 
SSCP-analysis are that each receptor is represented by only two bands. This increases the risk of 
overlapping fragments derived from different family members, and might require additional 
enzymatic digestions to achieve unique positions of each of the receptor fragments (Pieneman et al., 
manuscript in preparation). In Southern blot-PCR analysis, the likelyhood that different family 
members hybridize to genomic digests of identical size decreases for each restriction enzyme used, 
which virtually excludes the possibility of duplicate fingerprints and thereby reduces the risk of 
overlooking novel family members. Furthermore, the Southern blot-PCR method, which makes use 
of PCR-probes that are radioactively labeled to high specific activity, has the potency to detect low 
abundant fragments, up to the radioactive detection levels determined by the sensitivity of the 
autoradiographic film or the phosphor-imager. Recurrent detection of highly abundant fragments as 
encountered in analytical methods that are based on molecular cloning of multiple PCR-amplified 
family member species, is circumvented. Other advantages are that multiple fragments can be 
analyzed simultaneously by hybridization on a single Southern blot. When once a fingerprint for 
individual multigene family members is obtained one can analyze Southern blot profiles in all types 
of cell lines and tissues of interest (Fig.3), independent of the origin of the species. This in contrast 
to SSCP, which requires the availability and profiling of all orthologous multigene family members, 
corresponding to the species from which the cell line or tissue is derived. The Southern blot PCR 
technique is ideal for small multigene families which contain sufficient members to allow the design 
of family-specific degenerate primers, and whose concomitant hybridization on a single Southern 
blot results in a composite pattern that enables the identification of individual members. For large 
multigene families, such as the protein kinase superfamily with more than 400 members (Hanks et 
al., 1988; Hanks and Hunter, 1995; Henikoff et al., 1997), modulation of the primer sequences 
enables the selection of certain subfamilies within the extensive multigene family, thus controlling 
the complexity of the Southern blot profiles. In conclusion, the Southern blot-PCR method is an 
efficient and simple method for the analysis of PCR-pools of uniformly sized multigene family 
fragments, which greatly facilitates the detection of putative novel family members.
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ABSTRACT
Activin A and osteogenic protein-1 (OP-1) exerted antagonistic effects on each other’s responses 
on the human Tera-2 embryonal carcinoma cell line. OP-1 dose-dependently inhibited activin A- 
induced activation of p3TP-Lux transcriptional reporter, containing part of the human plasminogen 
activator inhibitor-1 (PAI-1) promoter, while activin A inhibited OP-1-mediated alkaline
phosphatase induction. Approximately equimolar concentrations of both growth factors resulted in
12550% inhibition of the respective biological responses. Affinity cross-linking studies using I-
125activin A or I-OP-1 followed by receptor-immunoprecipitations revealed that both ligands bound
to the activin type II receptor (ActR-II), but recruited different type I receptors. In addition, OP-1
125 125competed with binding of I-activin A, and activin A competed with binding of I-OP-1 to
ActR-II. Transient transfection studies showed that competition between activin A and OP-1 also
occurred at the type I receptor level; constitutively active (CA)-ActR-I inhibited CA-ActR-IB-
mediated p3TP-Lux reporter induction. There was no competition between activin A and OP-1 for
availability of Smad4, indicating that the concentration of this common signal transducer is not
limiting for generating the observed biological responses. Overexpression of ActR-II abolished the
inhibitory effect of OP-1 on activin A-induced p3TP-Lux activation and, surprisingly, led to OP-1-
induced transcriptional reporter activity. Whereas the exact mechanism of competition is unclear,
the role of ActR-II in the competition between activin A and OP-1 is discussed in light of the
observed interference in downstream signaling by CA-ActR-I and CA-ActR-IB.
INTRODUCTION
Activin and bone morphogenetic protein-7 (BMP-7), also referred to as osteogenic protein-1 
(OP-1), are both members of the transforming growth factor-^ (TGF-P) superfamily, which consists 
of a large number of growth factors involved in cellular proliferation, differentiation and embryonic 
development (reviewed in Roberts and Sporn, 1990; Mathews, 1994; Reddi, 1997). Activin was 
first identified in ovarian gonadal fluids as a protein that induces secretion of follicle stimulating 
hormone from pituitary cells (Ling et al., 1986; Vale et al., 1986), and has furthermore been 
implicated in erythropoiesis (Shiozaki et al., 1992), neurogenesis (Schubert et al., 1990; Hashimoto 
et al., 1992), and in development of the reproductive system (reviewed in Findlay, 1993). In 
addition, it plays an important role during early embryonic development, leading for example to 
induction of dorsal mesoderm in Xenopus laevis animal cap explants (Asashima et al., 1990; Smith 
et al., 1990; Thomsen et al., 1990; van den Eijnden-van Raaij et al., 1990). BMPs form the largest 
subfamily within the transforming growth factor (TGF)-P superfamily, including more than fifteen 
members at present (reviewed in Hogan, 1996). The first members that were isolated were 
characterized as inducers of bone and cartilage formation when injected ectopically in rats (Wozney 
et al., 1988). In addition to their pleiotropic effects on chondrocytes and osteoblasts, such as 
stimulation of proteoglycan synthesis or alkaline phosphatase activity (Vukicevic et al., 1989), 
BMPs also exert profound effects on many other cell types; they induce chemotaxis of monocytes
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(Cunningham et al., 1992), differentiate neural cells (Paralkar et al., 1992; Perides et al., 1994), and 
have a widespread action during embryonic development (reviewed in Hogan, 1996).
Members of the TGF-P superfamily exert their biological effects by formation of a heteromeric 
complex between type I and type II serine/threonine kinase receptors. In the case of TGF-P and 
activin signaling, the type II receptor initially binds ligand and subsequently recruits specific type I 
receptor(s) into the complex, whereas for BMPs both type I and type II receptors contribute to the 
generation of a stable ligand-receptor complex (Liu et al., 1995; Rosenzweig et al., 1995; ten Dijke 
et al., 1994c). After phosphorylation by type II receptors, type I receptors propagate the signal by 
activation of cytoplasmic signaling components. Two activin type II receptors, designated ActR-II 
and ActR-IIB, have been identified (Mathews and Vale, 1991; Attisano et al., 1992; Mathews et al., 
1992). Only one BMP type II receptor (BMPR-II) has been cloned (Liu et al., 1995; Rosenzweig et 
al., 1995), but certain BMPs, including OP-1 and BMP-2, can also bind to ActR-II and ActR-IIB 
(ten Dijke et al., 1994c; Yamashita et al., 1995b; Hoodless et al., 1996). Activin is able to recruit 
two type I receptors, designated ActR-I and ActR-IB (ten Dijke et al., 1994b), but propagates its 
signals mainly through ActR-IB. BMPs signal through BMPR-IA, BMPR-IB and ActR-I receptors 
(ten Dijke et al., 1994c; Liu et al., 1995; Rosenzweig et al., 1995; Macias-Silva et al., 1998).
Smads are key cytoplasmic molecules involved in TGF-P signaling. Whereas Smad2 and Smad3 
are mediators of TGF-P as well as activin signaling, Smad1, Smad5 and Smad8 are involved in 
BMP signaling (reviewed in Heldin et al., 1997; Massague, 1998). Upon interaction with activated 
type I receptors, ligand-restricted Smads are phosphorylated in a highly conserved SS(V/M)S motif 
in their very carboxy-terminal tail. Receptor-activated Smads associate with the common-mediator 
Smad4, and are subsequently translocated to the nucleus where the transcription of target genes is 
regulated (reviewed in Heldin et al., 1997; Massague, 1998). TGF-P superfamily signaling causes 
upregulation of expression of the inhibitory Smad6 and Smad7 (Nakao et al., 1997a; Afrakhte et al., 
1998; Takase et al., 1998), which exert their antagonistic actions on TGF-P superfamily signaling 
by competition with pathway-restricted Smads for binding to type I receptors, or by preventing 
heteromeric complex formation of pathway-restricted Smads with Smad4 (Hayashi et al., 1997; 
Imamura et al., 1997; Nakao et al., 1997a; Hata et al., 1998a; Souchelnytskyi et al., 1998).
Human embryonal carcinoma cells are the stem cells of non-seminomatous testicular germ cell 
tumors, which strongly resemble early embryonic cells in their pluripotent character (Andrews et al.,
1984). In view of the pivotal roles of members of the TGF-P superfamily during early embryonic 
development, we studied the effects of activin A and OP-1 on the human embryonal carcinoma cell 
line Tera-2 clone 13 (T2Cl13). Retinoic acid (RA) treatment of T2Cl13 cells results in 
differentiation into several cell types, including neuroectodermal cells (Andrews 1988; Thompson et 
al., 1984). ). Activin A induces expression of growth differentiation factor-3 (GDF-3) in T2Cl13 
cells (Caricasole et al., 1998). Andrews et al. (1994) have shown that OP-1 inhibits proliferation of 
the closely related cell line NTera2, and induces differentiation in a direction distinct from that 
when cells are treated with RA- or hexamethylene bisacetamide. Here we show that in T2Cl13 cells, 
activin A and OP-1 antagonize each other in activation of a p3TP-Lux transcriptional reporter which 
contains part of the plasminogen activator inhibitor-1 (PAI-1) promoter, and in induction of alkaline
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phosphatase activity, respectively. The possible mechanisms underlying the antagonism between 
activin A and OP-1 are discussed.
MATERIALS AND METHODS
Cell culture
Tera-2 clone 13 (T2Cl13) cells were cultured in a-minimal essential medium (a-MEM) lacking nucleosides and 
deoxynucleosides, supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 50 |J.g/ml 
streptomycin. Cells were grown in a 5% CO2 containing atmosphere at 37°C in tissue culture flasks coated with gelatin 
(Type A 300 Bloom; Sigma, St. Louis, MO).
Transient transfection
Activin A was provided by Y. Eto at Ajinomoto Company (Kawasaki, Japan), TGF-P1 was from N. Ferrara at 
Genentech (San Francisco, CA), heamagglutinin (HA)-tagged constitutively active (CA)-ActR-I as well as p3TP-Lux 
promoter-reporter construct containing three sets of tetradecanoyl phorbol acetate-responsive elements together with 
part of the human PAI-1 promoter was obtained from J. Massague (Memorial Sloan-Kettering Cancer Center, NY). CA- 
ActR-IB expression construct was from J.P. de Winter (Hubrecht Laboratory, Utrecht, The Netherlands), and ActR-II 
expression construct was obtained from L.S. Mathews and W.W. Vale (Salk Institute, San Diego, CA). Both constructs 
were found to express proteins of expected molecular weight. For calculation of molar concentrations of the ligands 
used in the assays, molecular masses of 25 kDa and 35 kDa were taken for activin A and OP-1, respectively (Yamashita 
et al., 1995b).
Cells were seeded at a density of 4.0x104 cells/cm2 in 6-well tissue culture plates. The next day, cells were 
transfected according to the calcium-phosphate precipitation method or by using FuGene-6 transfection reagent 
(Boehringer Mannheim, Indianapolis, IN). Expression plasmid for flag-tagged Smad4 has been described previously and 
was found to express flag-tagged Smad4 protein of expected molecular weight (Nakao et al., 1997b). After overnight 
incubation, cells were stimulated with all-trans retinoic acid (RA; Sigma, St. Louis, MO), activin A or OP-1 for 24 h. In 
the competition experiments, cells were stimulated with OP-1 followed by addition of activin A. Similar results were 
obtained when cells were preincubated with OP-1 followed by stimulation with activin A. Luciferase activity was 
measured using Luciferase Assay System (Promega Biotech Inc., Madison, WI). In all transfections the P-galactosidase 
expression plasmid pCH110 (Pharmacia, Uppsala, Sweden) served as an internal control to correct for transfection 
efficiency. P-Galactosidase activity was measured in 100 mM Na2HPO4/NaH2PO4 (pH 7.3), 1 mM MgCl2, 100 mM 2- 
mercapto-ethanol and 0.67 mg/ml o-nitrophenyl-galactopyranoside (Sigma, St. Louis, MO).
Alkaline phosphatase assay
Cells were seeded at a density of 4.0x104 cells/cm2 in 96-well tissue culture plates. The next day, culture medium 
was replaced and the various concentrations of activin A, OP-1 and RA were added as indicated. Activin A was added 
45 min prior to stimulation with OP-1. Alkaline phosphatase activity was measured 48 h after stimulation as described 
by van der Plas et al. (1994). Alkaline phosphatase activity was corrected for cell number as measured by neutral red 
staining (Lowik et al., 1993).
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Affinity cross-linking and immunoprecipitation
Activin A and OP-1 were iodinated according to the chloramine-T method (Frolik et al., 1984). T2Cl13 cells were 
grown to confluence in 80 cm2 tissue culture flasks. Affinity binding and cross-linking of 125I-activin A or 125I-OP-1 to 
binding proteins on T2Cl13 cells, followed by immunoprecipitation with receptor-specific antisera, was performed as 
previously described (Piek et al., 1997). Competitor ligands were added 5 min prior to addition of iodinated ligands. 
Pretreatment of cells with competitor ligand for 45 min, followed by addition of iodinated ligand showed the same 
ActR-II competition profile (data not shown).
Northern blot analysis
Confluent T2Cl13 cells were kept in a-MEM containing 0.5 % FBS 14 h prior to stimulation with 0.4 nM TGF-01,
1.0 nM activin, 2.9 nM OP-1, 0.5x10-5 M RA, or combinations of these, for 90 min at 37°C. RNA extraction and 
Northern blot analysis were performed as described previously (Nakao et al., 1997a). The cDNA probes used in the 
hybridizations were a 1.8 kb Eco RIXho I human Smad7 fragment, a 2 kb Eco RI fragment of the human Smad6 gene, 
and a 1.5 kb mouse junB  fragment. For GAPDH hybridizations the complete human GAPDH cDNA plasmid was 
labeled.
RESULTS
OP-1 antagonizes activin A-induced p3TP-Lux activity in T2Cl13 cells
The effect of activin A and OP-1 on T2Cl13 cells, transfected with the p3TP-Lux reporter 
construct that contains part of the human PAI-1 promoter was measured. As shown in Fig. 1A, 
p3TP-Lux activity was dose-dependently induced by activin A, while OP-1 had no effect. Treatment 
for 24 h with RA gave only a two-fold induction, but it acted synergistically with activin A on the 
induction of p3TP-Lux activity. The combination of RA and OP-1 did not activate the p3TP-Lux 
reporter. Figure 1B and Fig. 1C show that OP-1, in the absence or presence of RA, respectively, 
dose-dependently inhibited the activin A-induced p3TP-Lux activity, with 50% inhibition observed 
at approximately equimolar concentrations activin A and OP-1.
Activin A inhibits OP-1- induced alkaline phosphatase activity
Members of the BMP subfamily, including OP-1, are known to induce alkaline phosphatase activity 
in mesenchymal cells including chondroblasts and osteoblasts (Vukicevic et al., 1989). Furthermore 
it has been established that RA can induce alkaline phosphatase activity, due to increased 
transcriptional activation of the gene (Scheibe et al., 1991) or by stabilization of the mRNA 
transcripts (Zhou et al., 1994). The effect of activin A and OP-1 on induction of alkaline 
phosphatase activity in T2Cl13 cells was therefore examined. Activin A or OP-1 was not able to 
induce alkaline phosphatase activity (data not shown). However, in the presence of RA, OP-1, in 
contrast to activin A, potently induced alkaline phosphatase activity (Fig. 2A). Thus, whereas 
activin A specifically induced p3TP-Lux activity in T2Cl13 cells, an effect that was potentiated by 
the addition of RA, OP-1 in combination with RA resulted in an induction of alkaline phosphatase 
activity. Interestingly, treatment of cells with OP-1 and RA in the presence of activin A resulted in a
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Figure 1 Activation of the p3TP-Lux reporter in T2C113 cells. A) Effect of activin A, OP-1 and RA on induction of the 
p3TP-Lux reporter. Cells were transfected with 1 p3TP-Lux reporter construct using the calcium phosphate co­
precipitation method. After 24 h, activin A or OP-1 were added at indicated concentrations in the absence (white bars) 
or presence (black bars) of 0.5x10-5 M RA. Luciferase activity was measured after 24 h. Values are corrected for 
transfection efficiency as measured by co-transfected (3-galactosidase gene activity. B) Competition by OP-1 on activin 
A-induced p3TP-Lux activation in T2Cl13 cells. Cells were transfected with 1 ^g p3TP-Lux reporter and 24 h later cells 
were stimulated with increasing amounts of OP-1 in the absence (white bars) or presence (black bars) of 2 nM activin A. 
Luciferase activity was measured after 24 h. C) Competition by OP-1 on RA/activin A-induced p3TP-Lux activation in 
T2Cl13 cells. Transfection was performed as described above. Cells were stimulated with increasing amounts of OP-1 in 
the absence (white bars) or presence (black bars) of 2 nM activin A and 0.5x10-5 M RA. Data are representative of at 
least 2 individual experiments and each bar represents the mean of triplicate measurements.
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decreased OP-1-induced alkaline phosphatase activity (Fig. 2B), and 50% inhibition was achieved 
with approximately equimolar concentrations of activin A and OP-1. Thus, activin A and OP-1 
antagonize each other’s biological effects in T2Cl13 cells.
A
B
Figure 2 Activation of alkaline phosphatase activity in T2Cl13 cells. A) Effect of activin A and OP-1 on induction of 
alkaline phosphatase activity in the presence of 0.5x10-5 M RA. Cells were stimulated with activin A or OP-1 at 
indicated concentrations and after 48 h alkaline phosphatase activity was measured. Values are corrected for cell number 
as measured by neutral red staining. B) Competition by activin A with RA/OP-1-induced alkaline phosphatase activity in 
T2Cl13 cells. Cells were stimulated for 48 h with increasing amounts of activin A in the absence (white bars) or 
presence (black bars) of 2.9 nM OP-1 and 0.5x10-5M RA. All data are representative of at least 2 individual experiments 
and each bar represents the mean of four observations.
Activin A and OP-1 induce Smad6, Smad7, and JunB mRNA expression
The inhibitory Smad6 and Smad7, as well as the transcription factor junB, have all been shown to 
be early response genes in TGF-^-mediated signaling (Pertovaara et al., 1989; Laiho and Keski-Oja, 
1989; Nakao et al., 1997a; Afrakhte et al., 1998; Takase et al., 1998). In view of the fact that OP-1 
needed the addition of RA to be able to induce alkaline phosphatase activity, a late response, we 
wanted to examine whether involvement of RA was a general requirement for OP-1 signaling in 
T2Cl13 cells. Cells were stimulated for 90 min with activin A, OP-1 (both at concentrations that 
had shown to result in optimal induction of p3TP-Lux reporter activity and alkaline phosphatase 
activity, respectively) or RA, or combinations of these factors. Northern blot analysis showed that 
both activin A and OP-1 could activate mRNA expression of Smad6, Smad7, and junB, while
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simultaneous addition of the growth factors resulted in additive transcription of these early response 
genes. Activin A-induced junB mRNA expression was enhanced in the additional presence of RA. 
RA treatment, however, did not increase activin A or OP-1-mediated effects on Smad6 and Smad7 
mRNA levels. TGF-^ showed no significant effect on mRNA expression of these genes, most likely 
due to very low TGF-^ receptor expression levels in these cells (Weima et al., 1989). Thus, T2Cl13 
cells express all receptors and intracellular signaling components that enable activin A as well as 
OP-1 to signal directly. RA can potentiate early as well as late responses induced by activin A or 
OP-1 in T2Cl13 cells. In addition, the data show that activin A and OP-1 do not only compete each 
other’s effects, but can also induce the same transcriptional responses in T2Cl13 cells.
Figure 3 Northern blot analysis of mRNA-induction of 
the early responsive genes Smad6, Smad7, and junB  by 
TGF-p1, activin A, OP-1, and/or RA. T2Cl13 cells were 
kept for 14 h in medium containing 0.5 % FBS prior to 
stimulation for 90 min with 0.4 nM TGF-p1, 1.0 nM 
activin A, 2.9 nM OP-1, 0.5x10-5 M RA, or combinations 
of these. Total RNA was subjected to Northern blot 
analysis using Smad6, Smad7, and junB  specific probes.
Activin A and OP-1 compete for binding to ActR-II
In order to reveal by which receptors activin A and OP-1 signal in T2Cl13 cells, affinity cross­
linking of 125I-activin A and 125I-OP-1 to binding proteins on the cell surface of T2Cl13 cells was 
performed, followed by immunoprecipitations with activin or OP-1 type I and type II receptor-
125specific antisera, respectively. As shown in Fig. 4 A, I-activin A mainly bound to a combination
125of ActR-IB and ActR-II, while weaker interactions were observed with ActR-I and ActR-IIB. I- 
OP-1 had highest affinity for a combination of ActR-I and ActR-II (Fig. 4B), while complexes 
containing BMPR-IA and BMPR-IB were only weakly detectable. Thus, activin A and OP-1 shared 
the same type II receptor, but recruited different type I receptors. Signaling through these type I 
receptors apparently resulted in both overlapping as well as differential activities mediated by 
activin A and OP-1 (Fig. 1, Fig. 2, Fig 3).
The fact that activin A and OP-1 shared the same type II receptor, led us to investigate whether
competition for binding to ActR-II could be a mechanism that underlied the antagonism between
125activin A and OP-1. Affinity cross-linking of I-activin A to binding proteins on T2Cl13 cells in 
the presence of increasing amounts of OP-1, followed by immunoprecipitation with ActR-II
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Figure 4 Receptor-binding analysis of activin A and OP-1 in T2Cl13 cells. A) Identification of activin receptors in
125T2Cl13 cells. Cells were affinity labeled with 400 pM I-activin A followed by cross-linking with 0.28 mM 
disuccinimidyl suberate (DSS). Cell lysates were subjected to immunoprecipitations (IP) using antisera against activin
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receptor type I (ActR-I), ActR-IB, ActR-II and ActR-IIB. Immunoprecipitated complexes were analyzed by SDS-gel 
electrophoresis followed by autoradiographic analysis. Type I R and Type II R indicate type I and type II activin
receptors, respectively. B) Identification of receptors for OP-1 in T2Cl13 cells. Cells were affinity labeled with 715 pM
125I-OP-1 followed by cross-linking with 0.28 mM DSS. Cell lysates were subjected to immunoprecipitations (IP) using 
antisera against activin receptor type I (ActR-I), bone morphogenetic protein receptor (BMPR)-IA, BMPR-IB, ActR-II,
ActR-IIB, and BMPR-II. Immunoprecipitated complexes were analyzed by SDS-gel electrophoresis followed by Fuji-X
125BioImager analysis. Type II R indicates type II receptors. C) Competition of I-activin A binding to ActR-II by OP-1.
125T2Cl13 cells were incubated with 400 pM I-activin A in the absence or presence of excess cold activin A or OP-1. 
After cross-linking with 0.28 mM DSS, cell lysates were subjected to immunoprecipitation with ActR-II antiserum.
Immunoprecipitated complexes were subjected to SDS-gel electrophoresis, followed by autoradiographic
125analysis.’Molar Ratio’ indicates the relative ratio in molar concentrations between competitor and I-activin A. D)
125 125Competition of I-OP-1 binding to ActR-II by activin A. T2Cl13 cells were incubated with 143 pM I-OP-1 in the
absence or presence of excess cold OP-1 or activin A. After cross-linking with 0.28 mM DSS, cell lysates were
subjected to immunoprecipitation with ActR-II antiserum. Immunoprecipitated complexes were subjected to SDS-gel
electrophoresis, followed by autoradiographic analysis. ’Molar Ratio’ indicates the relative ratio in molar concentrations
125between competitor and I-OP-1.
125antiserum, revealed that OP-1 competed with I-activin A for binding to ActR-II (Fig. 4C).
125Analogously, activin A competed with binding of I-OP-1 to ActR-II (Fig. 4D). While activin A
125and OP-1 competed with approximately similar efficiency with I-OP-1 for binding to ActR-II
125(Fig. 4D), activin A was much more efficient than OP-1 in competing with the binding of I- 
activin A to ActR-II (Fig. 4C). OP-1 is known to have about three-fold lower binding affinity for
ActR-II than activin A (Yamashita et al., 1995b). An equimolar amount of activin A competed
125efficiently with I-activin A; it can not be excluded, however, that the affinities of iodinated
125versus unlabeled activin A differ, or that the amount of recovered I-activin A after iodination and 
column purification was overestimated. Together, these data show that activin A and OP-1 both can 
compete with the binding of their iodinated counterparts to ActR-II, suggesting a mechanism for the 
observed antagonism between activin A and OP-1.
ActR-I inhibits ActR-IB-induced p3TP-Lux reporter activity
Besides investigation of competition between activin A and OP-1 at the ActR-II level, we also 
explored the possibility of competition in downstream signaling between ActR-IB and ActR-I, the 
main type I receptors in T2Cl13 cells for activin A and OP-1, respectively. CA-ActR-IB, in contrast 
to CA-ActR-I, efficiently induced p3TP-Lux reporter activity, while CA-ActR-I strongly inhibited 
activin A- as well as CA-ActR-IB-induced p3TP-Lux activation (Fig. 5). The vectors encoding CA- 
ActR-I and CA-ActR-IB expressed receptor proteins with expected molecular weights and in vitro 
kinase activities upon their overexpression in COS cells (data not shown). OP-1 only mildly 
inhibited CA-ActR-IB-induced p3TP-Lux activation, possibly due to the strong p3TP-Lux induction 
levels by CA-ActR-IB which could not be overcome by OP-1-mediated activation of type I receptor 
signaling. Together, these data suggest an active role of type I receptors and downstream signaling 
in the antagonism between activin A and OP-1 in p3TP-Lux reporter activation.
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Figure 5 Analysis of competition between CA-ActR-I and CA-ActR-IB. T2C113 cells were transiently transfected with 
1 |J.g p3TP-Lux reporter in the absence or presence of 0.5 |J.g CA-ActR-I and/or 0.5 CA-ActR-IB cDNA, using 
FuGene-6 transfection reagent. After 24 h, cells were stimulated without (C) or with 1.0 nM activin A (A) or 5.7 nM 
OP-1 (O). Luciferase activity was measured after 24 h, and values are corrected for transfection efficiency measuring 
co-transfected p-galactosidase gene activity.
Overexpression of ActR-II abrogates the antagonism between activin A and OP-1
A mechanism that has been described to underly the antagonism between activin and BMPs in 
mesoderm formation during early embryonic development in Xenopus laevis entails competition 
between activin- and BMP-activated pathway-restricted Smads for heteromerization with Smad4 
(Candia et al., 1997). To study whether limitation in availability of Smad4 could explain the 
observed competition between activin A and OP-1 in T2Cl13, cells were transiently transfected with 
p3TP-Lux reporter in the absence or presence of Smad4-encoding plasmid. As shown in Fig. 6 A, 
overexpression of Smad4 could not overcome the competition by OP-1 on activin A-induced 
activation of p3TP-Lux reporter, suggesting that the endogenous Smad4 expression level in T2Cl13 
cells is not limiting and does not account for the observed competition between activin A and OP-1 
signaling. In agreement with this observation, the competition observed between CA-ActR-I and 
CA-ActR-IB in activation of p3TP-Lux reporter activity was also not due to limited amounts of 
Smad4 (Fig. 6B).
In contrast to the case for Smad4, overexpression of ActR-II abrogated OP-1-mediated inhibition 
of activin A-induced p3TP-Lux reporter activity (Fig. 6 A), which would suggest that the ActR-II 
expression levels in T2Cl13 cells are limiting for optimal activin A signaling in the presence of OP- 
1. However, since overexpression of ActR-II resulted in OP-1-induced p3TP-Lux activity (Fig.6A), 
this precludes us from assigning a definite role for ActR-II in functional antagonism by receptor 
binding competition. Simultaneous addition of activin A and OP-1 to T2Cl13 cells overexpressing 
both Smad4 and ActR-II, did not result in an additive upregulation of p3TP-Lux activity (Fig. 6A), 
suggesting that maximum induction levels of p3TP-Lux activation were already reached by the 
individually applied concentrations of activin A and OP-I.
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Figure 6 Functional analysis of the activin A and OP-1 competition mechanism in T2C113 cells. A) Analysis of 
involvement of Smad4 or ActR-II in the antagonism by OP-1 on activin-A-induced p3TP-Lux reporter activity. Cells 
were transiently transfected with 1 ^g p3TP-Lux reporter in the absence or presence of 0.5 ^g Smad4 or 0.5 ^g ActR-II 
cDNA using FuGene-6 transfection reagent. After 24 h, cells were stimulated without (C, white bars) or with 1.0 nM 
activin A (\\\ bars), 2.9 nM OP-1 (/// bars), or 1.0 nM activin A and 2.9 nM OP-1 (black bars). Luciferase activity was 
measured after 24 h and corrected for transfection efficiency measuring co-transfected ß-galactosidase gene activity. B) 
Analysis of involvement of competition for Smad4 in CA-ActR-I-mediated antagonism of CA-ActR-IB-induced p3TP- 
Lux activitation. T2Cl13 cells were transiently transfected with 1 ^g p3TP-Lux reporter in the absence (white bars) or 
presence (black bars) of 0.5 ^g Smad4 cDNA, co-expressed without or with 0.5 ^g of CA-ActR-I, 0.5 ^g CA-ActR-IB, 
or 0.5 ^g CA-ActR-I and 0.5 ^g CA-ActR-IB, using FuGene-6 transfection reagent. Equal amounts of cDNA were 
transfected per well, where necessary corrected with empty vector pcDNA. Luciferase activity was measured after 24 h 
as described in (A).
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DISCUSSION
Here, we describe signaling by activin A and OP-1 in undifferentiated T2Cl13 cells. We show 
that activin A and OP-1 antagonize each other with respect to induction of p3TP-Lux reporter 
activity and alkaline phosphatase activity. Affinity cross-linking studies indicate that both growth 
factors bind to ActR-II, while activin A predominantly recruits ActR-IB and OP-1 mainly recruits 
ActR-I into the signaling complex. Competition binding studies do suggest that activin A and OP-1 
antagonize each other’s biological effects by competition for binding to ActR-II, although the molar 
ratios of competitor relative to effector required to detect competition between activin A and OP-1 
are much higher in the ActR-II binding studies compared to the bioassays. Whereas these 
discrepancies might be inherent to the different practical set-ups in which the assays are performed, 
it might also indicate that competition for binding to ActR-II is not the only factor in the functional 
antagonism between activin A and OP-1.
In contrast to the ligand-specific bioassays in which we observed competition between activin A 
and OP-1, both growth factors were able to induce mRNA expression of Smad6, Smad7 and JunB. 
TGF-^1, activin A and OP-1 have been shown to be common inducers of Smad6 and Smad7 
mRNA expression in several cell lines (Afrakhte et al., 1998; Takase et al., 1998). Apparently, 
ActR-II expression levels are not limiting for the induction of these responses, since simultaneous 
addition of activin A and OP-1 resulted in approximately additive induction of gene expression. The 
Smad activation levels to induce Smad6, Smad7 and JunB gene transcription might be lower than 
required for induction of p3TP-Lux reporter or alkaline phosphatase, although the difference in 
time-scale between these early and late response makes it difficult to compare the assays.
Activation of the respective type I receptors through which activin A and OP-1 signal, is 
dependent on the expression levels of ActR-II in T2Cl13 cells. Thus, if activin type II receptors are 
limiting, simultaneous addition of activin A and OP-1 will result in their competition for 
heteromeric receptor complex formation, and as a consequence in reduced activation of Smad 
molecules specifically involved in activin A (i.e. Smad2, Smad3) or OP-1 (i.e. Smad1, Smad5, 
Smad8) signaling. Following overexpression of ActR-II, the type II receptor is no longer limiting for 
formation of diverse heteromeric complexes in the presence of activin A and OP-1. Therefore, 
either in the absence or in the presence of OP-1, activin A-induced activation of the p3TP-Lux 
reporter is expected to be further enhanced compared to cells that do not overexpress ActR-II (Fig. 
6A) to levels that depend on type I receptor expression levels, as well as on the availability of 
downstream signaling components. Remarkably, overexpression of ActR-II in T2Cl13 cells enables 
OP-1 to induce p3TP-Lux reporter activity to levels comparable to those observed for activin A. 
This effect is most likely mediated via activation of ActR-I, the main type I receptor to which OP-1 
binds in T2Cl13 (Fig. 4B), although potentiation of binding to BMPR-IA and/or BMPR-IB can not 
be excluded. Recently, it was shown that ActR-I specifically interacts with OP-1 and transduces 
signaling via activation of the BMP-Smads, Smad1 and Smad5 (Macias-Silva et al., 1998). In 
addition, it has been described that ActR-I, when co-expressed with ActR-II or ActR-IIB, can 
induce p3TP-Lux reporter activity upon stimulation with activin or OP-1 (Attisano et al., 1993; 
Yamashita et al., 1995b). Taken together, these findings make the observed abrogation of OP-1-
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mediated antagonism on activin A signaling following co-expression of ActR-II difficult to 
interpret.
Competition for binding to ActR-II has been described for inhibin which antagonizes activin 
signaling by preventing activin-mediated heteromeric complex formation of type I and type II 
receptors (Xu et al., 1995; Lebrun and Vale, 1997). In contrast to the mechanism described for 
inhibin, we observe that the antagonism between activin A and OP-1 also occurs at or downstream 
of the type I receptor level, since CA-ActR-I interferes with activation of p3TP-Lux reporter 
induced by CA-ActR-IB; the antagonism in downstream signaling between activin A and OP-1, as 
well as between CA-ActR-I and CA-ActR-IB, is not due to limited availability of Smad4. One can 
speculate that competition for another common signal transducing molecule underlies the type I 
receptor antagonism, or that a pathway-specific component serves to block the downstream signal of 
the competing pathway.
An important issue to address is how the antagonism between activin A and OP-1 is translated at 
the level of downstream signal propagation. We hypothesize that, in the case of limiting ActR-II 
availability, type I receptor activation will be reduced, resulting in reduced activation of downstream 
signaling components, for example Smads, that are specifically involved in activin A signaling and 
OP-1 signaling. On the other hand, if the functional antagonism between activin A and OP-1 is the 
consequence of competition between ActR-I and ActR-IB, one has to consider the possibility that 
certain signal transduction components activated by one (or both) signaling pathway(s) might 
specifically interfere with the other competing pathway. In this respect, it has been reported that 
Smad6, for example, inhibits phosphorylation of Smad2 as well as BMPR-IB-mediated activation of 
Smad1, but does not affect Smad3 phosphorylation or BMPR-IA-mediated Smad1 activation 
(Imamura et al., 1997). Furthermore, activin A and OP-1 induce Smad6 mRNA with different 
kinetics in epithelial cells; activin A causes a transient induction that peaks after 90 min, while OP-1 
causes sustained expression of Smad6 mRNA, lasting for more than 24 h (Afrakhte et al., 1998). 
Thus, induction of inhibitory signal transduction components, like Smad6 or Smad7, might result in 
selective inhibition of receptor-activated Smads or type I receptors (Whitman, 1998a), and could as 
such contribute to the observed functional antagonism between activin A and OP-1.
Members of the TGF-P superfamily exert diverse biological activities on both human and murine 
embryonal carcinoma cells (Schubert et al., 1990; Van den Eijnden-van Raaij et al., 1991; Andrews 
et al., 1994; Vidricaire et al., 1994; Caricasole et al., 1998), while their effects are often generated 
in synergism with RA (Momoi et al., 1992; Knezevic et al., 1995; Glozak and Rogers, 1996), which 
is an important differentiation factor of embryonic cells. RA is known to upregulate plasminogen 
activator inhibitor (PAI-1) in Tera-2 cells (Tienari et al., 1991). Activin A and RA exerted 
synergistic effects on induction of p3TP-Lux reporter activation (Fig. 1A), as well as on induction 
of PAI-1 mRNA and PAI-1 protein levels (data not shown). Furthermore, RA together with activin 
A or OP-1 synergistically induced jun B mRNA expression; activin-mediated induction of junB 
might be involved in growth inhibitory effects induced by activin (Hashimoto et al., 1993). In 
addition, we show that OP-1 potentiates the effect of RA on alkaline phosphatase induction in 
T2Cl13 cells. RA is known to stabilize as well as enhance transcription of, for example, alkaline 
phosphatase transcripts (Scheibe et al., 1991; Zhou et al., 1994). However, the molecular
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mechanism underlying the observed synergism between RA and activin A or OP-1 in T2Cl13 cells 
remains to be elucidated.
Although competition between activin A and OP-1 does not fully inhibit p3TP-Lux reporter 
activation and alkaline phosphatase activity (Fig. 1, Fig. 2), one can speculate that the level of 
competition achieved is sufficiently high to abrogate certain gene responses which are controlled by 
higher activation thresholds. Especially during embryonic development where members of the TGF- 
P superfamily are known to act as morphogens (reviewed in Whitman, 1998b) and competition 
between activin and OP-1 is important for proper development, delicate control of downstream 
activation levels will result in selective gene expression. The mechanism responsible for the 
antagonism between activin A and OP-1 in T2Cl13 cells is not fully understood, but may be partly 
explained by competition for binding to ActR-II and/or to competition downstream of ActR-I and 
ActR-IB.
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ABSTRACT
A panel of six human glioma cell lines was examined for TGF-^1 responsiveness. U-178 MG 
and U-251 MG AgCl1 were significantly inhibited by TGF-^1, while U-343 MGa 31L and U-343 
MGa 35L were potently stimulated to proliferate. TGF-^1 induced endogenous PAI-1 protein 
synthesis, Smad binding element/(CAGA)12-luciferase reporter activity, as well as mRNA 
expression of Smad6 and Smad7 in all gliomas. Interestingly, TGF-^1 differentially stimulated or 
inhibited the expression of TfiR-I and TfiR-II mRNA in the gliomas. Affinity cross-linking studies 
using 125I-TGF-^1 revealed that the gliomas expressed TGF-P type I (T^R-I) and type II (T^R-II) 
receptors, although binding to T^R-II in U-343 MGa 31L and U-251 MG AgCl1 was low to 
undetectable. Smad2 protein was abundantly present in U-178 MG, U-343 MG, and U-343 MGa 
35L, while Smad3 was readily detectable in U-178 MG, U-343 MG, U-343 MGa 35L and U-251 
MG AgCl1. In all gliomas, TGF-^1 induced phosphorylation of Smad2. The level to which TGF-^1 
could activate the pathway leading to induction of the (CAGA)12 luciferase reporter seemed to 
correlate to the expression levels of TGF-P receptors, Smad3 and Smad4 proteins. However, despite 
the plethora of data regarding TGF-^1 signaling in the different glioma cell lines, the mechanism 
underlying the differential growth effects mediated by TGF-^1 is still unclear. The results suggest 
that a complex balance between several components in the TGF-P signaling pathway controls 
glioma responsiveness to TGF-^1, and extend reports indicating that distinct signal transduction 
pathways are involved in growth inhibition and other cellular responses.
INTRODUCTION
Transforming growth factor (TGF)-P is the prototype of a large family of multifunctional 
proteins, including TGF-^s, bone morphogenetic proteins (BMPs), activins and inhibins. These 
growth factors exert a broad range of biological activities including inhibition or stimulation of cell 
growth, deposition of extracellular matrix proteins, immunosuppression and regulation of 
embryonic development (reviewed in Roberts and Sporn, 1990). Moreover, TGF-P is known to act 
as a tumor suppressor at early stages of carcinogenesis, while at later stages it promotes malignant 
outgrowth (Cui et al., 1996).
Members of the TGF-P superfamily mediate their activities by heteromeric complexes of type I 
and type II serine/threonine kinase receptors. TGF-P type II receptor (T^R-II) initially binds TGF-P, 
followed by recruitment and activation of the TGF-P type I receptor (T^R-I). T^R-I is the direct 
effector of downstream signal propagation. Mutations in T^R-I and T^R-II have been associated 
directly with tumorigenesis (reviewed in Heldin et al., 1997). TGF-P type III receptor (T^R-III, also 
called betaglycan), and possibly endoglin, functions in presenting TGF-P to T^R-IL
Smad proteins play a pivotal role in intracellular TGF-P signal transduction. Three different 
types of Smad proteins have been identified: receptor-activated Smads, common-mediator Smads 
and inhibitory Smads (reviewed in Heldin et al., 1997). The group of TGF-P receptor-activated 
Smads include Smad2 and Smad3, which are phosphorylated by T^R-I at a conserved Ser-Ser-X-
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Ser (SSXS) motif in their very carboxyterminal ends. This triggers heteromerization with the 
commonly used partner Smad4, also called DPC4 (deleted in pancreatic carcinoma locus 4). The 
heteromeric Smad complex is translocated into the nucleus where transcription of target genes is 
effected (reviewed in Heldin et al., 1997).
TGF-P has been shown to play important roles in glioma tumorigenesis. It can inhibit glioma cell 
growth simultaneously with stimulation of migration and invasiveness of glioma cells, most likely 
due to induction of extracellular matrix synthesis (Merzak et al., 1994). On the other hand, TGF-P 
is known to stimulate growth of hyperdiploid gliomas, presumably by its stimulation of autocrine 
PDGF secretion (reviewed in Jennings and Pietenpol, 1998). In addition, TGF-P stimulates 
progression of malignant glioma by its function as immunosuppressant and promoter of 
vascularization. Here, we describe several aspects of TGF-P 1 signaling in six human glioma cell 
lines, which exert differential growth effects upon TGF-P 1-stimulation.
MATERIALS AND METHODS
Cell culture
The human malignant glioma cell lines U-178 MG, U-343 MG, U-343 MGa 31L, U-343 MGa 35L, U-251 MG 
AgCl1 and U-1242 MG were routinely cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
5% fetal bovine serum (FBS), 5% newborn calf serum (NCS), 100 units/ml penicillin and 50 |J.g/ml streptomycin. Cells 
were grown in 5% CO2-containing atmosphere at 37°C. Gliomas seeded for the different experiments were grown in 
DMEM containing 5% serum.
Thymidine incorporation assays
Cells were seeded in 24-well plates at sparse, sub-confluent or high cell densities. The next day recombinant human
TGF-P 1, provided by Dr. N. Ferrara at Genentech (San Francisco, CA), was added at a concentration of 10 ng/ml and
3 3after 20 hr 1 ^Ci/ml [ H]thymidine (Amersham, Aylesbury, UK) was added for 4 hr. [ H]Thymidine incorporation was
measured as described previously (Piek et al., 1997). The experiments were performed at least twice, and for each cell
line a representative experiment showing the mean and standard deviation of triplicate observations is presented in
Figure 1. For statistical analysis we used an analysis of variance (ANOVA), followed by multiple comparison by
Fisher’s method.
Affinity cross-linking and immunoprecipitation
Glioma cells were grown in 80 cm2 tissue culture flasks to high density. The next day, affinity binding and cross­
linking of 125I-TGF-P1 to TGF-P binding proteins on the glioma cell lines, followed by immunoprecipitations with 
TGF-P receptor specific antisera, were performed as described (Piek et al., 1997). The affinity cross-linking studies 
were performed twice and representative results are shown (Fig. 2).
Northern blotting
Cells grown to high density were serum starved for 2 hr in DMEM containing 0.1% BSA, followed by stimulation 
with or without 5 ng/ml TGF-P 1 for 2 h. Total RNA was extracted using guanidinium thiocyanate in combination with
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centrifugation on a caesium chloride cushion. A total of 15 |j.g RNA was loaded per lane of a 0.8% formamide-agarose 
gel and RNA was blotted on Hybond C+ nylon membranes (Amersham, Aylesbury, UK). Probes specific for Smad6, 
Smad7 (described in Nakao et al., 1997a; Afrakhte et al., 1998), TfiR-II (0.8 kB EcoR1/BamH1 fragment), actin 
(Clontech, Palo Alto, CA), as well as TfiR-I plasmid, were labelled by the Rediprime labelling kit (Amersham, 
Aylesbury, UK) and separated from non-incorporated nucleotides by PD10 Nick columns (Pharmacia, Uppsala, 
Sweden). Hybridization was performed in ExpressHyb solution (Clontech, Palo Alto, CA) according to the 
manufacturer’s protocol. Blots were subjected to analysis by Fuji-X Bioimager (Tokyo, Japan), as well as exposed to 
Hyperfilm MP (Amersham). For each probe, two independent Northern blot experiments were performed, and a 
representative results are shown in Figure 3 and Figure 5.
Metabolic labeling and Smad immunoprecipitation
The glioma cell lines were grown to confluence. Cells were rinsed in PBS and medium was changed to methionine-
and cysteine-free MCDB 104 medium (SVA, Uppsala, Sweden) containing 0.1 % BSA and 1 ^Ci/ml
35 35[ S]methionine/[ S]cysteine. Cells were labeled for 4 hr. In those experiments where TGF-p1-induced 
phosphorylation of Smads was studied, cells were stimulated with 10 ng/ml TGF-P1 during the last hour of metabolic 
labeling. Medium was removed and cells were lysed in solubilization buffer (125 mM NaCl, 10 mM Tris-HCl pH 7.5, 1 
mM EDTA, 1 mM PMSF, 1.5% Trasylol, and 1% Triton X-100) for 40 min on ice. Cell lysates were pre-cleaned by 
incubation with protein-A Sepharose beads (Immunosorb; EC Diagnostics AB, Uppsala, Sweden) for 45 min at 4°C. 
After removal of the beads by centrifugation, cell extracts were subjected to immunoprecipitation with Smad-specific 
anti-sera. The anti-sera for Smad2, and Smad3 were raised as described by Nakao et al., (1997b). Anti-serum DQQ was 
used to detect Smad2, DHQ was specific for Smad3, and anti-serum PS2 raised against the phosphorylated synthetic 
peptide SS(P)MS(P) was used to detect phosphorylated Smad2. As control for specificity and to facilitate detection of 
the proteins of interest on the autoradiogram, immunoprecipitation with the Smad-specific anti-sera was carried out in 
the absence or the presence of the peptide to which each of the anti-sera was originally raised. Immunoprecipitation was 
performed for 3 hr at 4°C after which immunocomplexes were collected on protein-A Sepharose beads. The beads were 
centrifuged and washed 3 times in solubilization buffer, 3 times in RIPA buffer (150 mM NaCl, 0.1 % SDS, 0.5 % 
deoxycholate, 0.5 % Triton X-100, 50 mM Tris pH 8.0), 3 times in high salt buffer (20 mM Tris-HCl pH 7.5, 500 mM 
NaCl, 1% Triton, X-100) and once in water. Immunocomplexes were mixed with SDS-sample buffer, boiled for 3 min 
and separated by SDS-PAGE using an 8.5% polyacrylamide gel. Immunoprecipitated Smads were visualized by 
Amplify (Amersham) and exposure to Hyperfilm MP (Amersham). The experiments were performed twice and 
representative results are shown (Fig. 4).
Transient transfections
Cells were seeded at approximately 2x105 cells per well of a 6-well tissue culture plate. The next day, cells were 
transfected with the TGF-P-inducible (CAGA)12 luciferase reporter construct which encodes 12 repeats of the 
AGCCAGACA sequence, identified as Smad3/Smad4 binding element in the human PAI-1 promoter (Dennler et al., 
1998). Transfection was carried out using the calcium phosphate co-precipitation method. After 24 hr the culture 
medium was replaced and cells were stimulated with 10 ng/ml TGF-P1 for 24 hr. Cells were lysed with Reporter Lysis 
Buffer (Promega Biotech Inc., Madison, WI) followed by measurement of luciferase activity using the Luciferase Assay 
System (Promega, Madison, WI). In all transfections the P-galactosidase expression plasmid pCH110 (Pharmacia, 
Uppsala, Sweden) served as internal control to correct for transfection efficiency. P-galactosidase activity was measured
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in 100 mM Na2HPO4/NaH2PO4, 1 mM MgCl2, 100 mM 2-mercapto-ethanol and 0.67 mg/ml o-nitrophenyl- 
galactopyranoside. The experiments were performed five times; Figure 6 shows a representative experiment indicating 
the mean and standard deviation of triplicate values.
PAI-1 assay
Glioma cells were seeded in 6-well dishes at sparse, sub-confluent or high cell densities. The next day, TGF-P 1 was 
added and the PAI-1 assay was performed as described by Yamashita et al., (1995b). The experiments were performed 
twice, and representative data are shown (Fig. 7).
RESULTS
Differential effects o f TGF-fi1 on glioma cell growth
The effect of TGF-P1 on DNA synthesis of six glioma cell lines, seeded at different cell 
densities, was investigated (Fig. 1, Table I). Treatment of cells for 24 hr with 10 ng/ml TGF-P1 
resulted in significant inhibition of DNA synthesis of U-178 MG and U-251 MG AgCl1 cells. For 
U-178 MG maximum inhibition of up to 30% occurred at high cell densities, while for U-251 MG 
AgCl1 a comparable maximum inhibition was observed also at sub-confluent cell densities. 
Although the clonal sub-lines U-343 MG, U-343MGa 31L and U-343 MGa 35L are genetically 
closely related (Nister et al., 1987), the TGF-P 1-mediated growth effects were strikingly different. 
Whereas growth of U-343 MG cells was hardly affected by TGF-P1, U-343 MGa 31L and U-343 
MGa 35L were significantly stimulated, up to 160% at high cell densities. This stimulation of DNA 
synthesis was observed independent of cell densities with a maximum effect from 2 ng/ml (data not 
shown). After serum-starvation, the growth stimulatory responses mediated by TGF-P 1 were even 
more pronounced, reaching up to 600% for U-343 MGa 31L cells (data not shown). TGF-P 1 had no 
remarkable effect on the DNA synthesis of U-1242 MG cells. Thus, in a panel of six different 
glioma cell lines we observed two cell lines, U-178 MG and U-251 MG AgCl1, that were 
significantly inhibited by TGF-P1, two cell lines, U-343 MG and U-1242 MG, that were not 
significantly affected by TGF-P 1 treatment and two clonal relatives, U-343MGa 31L and U- 
343MGa 35L, that were potently stimulated by TGF-P1. This led us to investigate the molecular 
mechanisms underlying the differences in TGF-P 1-mediated growth modulation of these glioma cell 
types.
Expression o f TGF-P receptors in glioma cells
To investigate whether there was a correlation between relative TGF-P receptor levels and the 
differential growth effects mediated by TGF-P 1 on the glioma cell lines, we examined binding of 
125I-TGF-P1 to TGF-P type I, type II and type III receptors (TPR-I, TPR-II, TPR-III) as well as 
endoglin. This was done by affinity cross-linking studies in combination with immunoprecipitations 
using the respective TGF-P receptor-specific anti-sera. These studies give relative indications on the 
amounts of TPR-I and TPR-II that are present on the cell lines. As shown in Figure 2, both TPR-I 
and TPR-II were abundantly present on U-178 MG, U-343 MG, U-343 MGa 35L and U-1242 MG
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Figure 1 Effect of TGF-P 1 on DNA synthesis of six human glioma cell lines, U-178 MG, U-343 MG, U-343 MGa 
31L, U-343 MGa 35L, U-251 MG AgCll, and U-1242 MG. Sparse (S), sub-confluent (SC), or dense (D) cell cultures 
were stimulated without (white bars) or with (black bars) 10 ng/ml TGF-P 1 for 20 hr, followed by 4 hr [ H]thymidine 
incorporation. Data represent mean and standard deviations of triplicate observations. * p<0.01, ** p< 0.0005, *** p< 
0.0001.
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Figure 2 ( ^ )  Analysis of TGF-P1 receptor expression in human glioma cells. Cells were grown to high density and
125affinity labeled with 200 pM I-TGF-P1, followed by cross-linking with 0.28 mM disuccinimidyl suberate (DSS).
Aliquots of cell lysates were analyzed directly by SDS-gel electrophoresis followed by autoradiography, or were first
subjected to immunoprecipitation (IP) using anti-sera against TGF-P type I receptor (TPR-I; I), TPR-II (II), TPR-III
125(III) or endoglin (E). 70-74 kDa indicates I-TGF-P1 bound protein complexes of 70-74 kDa.
cells. For U-251 MG AgCl1 and U-343 MGa 31L, binding of 125I-TGF-P1 was mainly observed on 
TPR-I. Since binding of 125I-TGF-P1 to TPR-I requires formation of a heteromeric complex
between TPR-II and TPR-I, U-251 MG AgCl1 cells most likely express a TGF-P type II receptor;
125the reason for the inability to detect the receptor may be inefficient cross-linking of I-TGF-P 1 to 
TPR-II. 125I-TGF-P1-bound protein complexes, slightly larger in size than 125I-TGF-P1-cross-linked
TPR-I, were present in U-343 MGa 31L, U-343 MGa 35L, U-251 MG AgCl1 and U-1242 MG cells
125(Fig. 2; non-immunoprecipitated cell lysates). We have previously characterized 70-74 kDa I-
TGF-P1-bound protein complexes on LNCaP cells; these complexes consisted of a 60 kDa TGF-P1
125binding protein (Piek et al., 1997). Whether the I-TGF-P1 bound complexes observed on the 
glioma cells correspond to the 60 kDa protein is not clear at present.
TPR-III was abundantly present on U-343 MGa 35L cells, while also U-251 MG AgCl1, U-1242
MG and U-343 MG also showed readily detectable levels of TPR-III. In U-178 MG and especially
125U-343 MGa 31L cells, TPR-III was hardly detectable. Binding of I-TGF-P1 to endoglin could be 
observed clearly on U-178 MG, U-1242 MG, and to a lesser extent on U-343 MG cells. As 
observed for U-178 MG, U-343 MGa 35L and U-1242 MG cells, the TPR-III anti-serum, and to a 
lesser extent the endoglin anti-serum, co-immunoprecipitated TPR-I and TPR-II, indicating that 
TPR-III and endoglin form a complex with the signaling receptors. Table II presents an overview of 
the different TGF-P receptors and their relative expression levels on the six glioma cell lines. There 
was no clear correlation between 125I-TGF-P1-bound TPR-I and TPR-II levels, the ratio between 
TPR-I and TPR-II, or expression of TPR-III or endoglin, and the observed biological effects 
mediated by TGF-P 1 in the different glioma cell lines.
TPR-I and TPR-II mRNA expression is modulated by TGF-P1 in glioma cells
Northern blot analysis showed that TfiR-II expression could be detected in all cell lines, although 
its expression in U-251 MG AgCl1 was much lower than that in the other lines (Fig. 3). TfiR-I 
mRNA expression could be detected in all glioma cell lines (Fig. 3). However, the mRNA levels of 
TPR-I and TfiR-II were differentially modulated by TGF-P 1 in the different cell lines, and this was 
observed in two independent experiments. Stimulation with 5 ng/ml TGF-P 1 for 2 hr resulted in a 
1.5-fold and 3-fold increase of TfiR-I mRNA in U-1242 MG and U-178 MG cells, respectively (see 
also Table I). Expression of TfiR-I and TfiR-II in U-343 MG cells was reduced to 40% and 60%, 
respectively. In U-343 MGa 35L cells, expression of TfiR-I and TfiR-II was reduced to 25% and 
75%, respectively. TGF-P receptor expression in U-251 MG AgCl1 cells was reduced to 
approximately 60%. These data suggest that TGF-P 1-mediated autoregulation of TGF-P receptor 
expression could contribute to the diverse biological effects mediated by TGF-P 1 in the different
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glioma cell lines; this modulation did not, however, correlate with the differential growth response 
to TGF-P 1 in the glioma cells tested.
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Figure 3 Northern blot analysis of TfiR-I and TftR-II expression in glioma cells. Cells at high density were serum- 
starved for 2 hr, followed by stimulation without or with 5 ng/ml TGF-P1 for 2 hr. Total RNA (15 |ig) was subjected to 
Northern blot analysis using TftR-I, TftR-II and actin-specific probes.
Expression o f Smad2, Smad3 and Smad4 in glioma cells
TGF-P receptor-activated Smad2 and Smad3, as well as the common-mediator Smad4, have 
been reported to play key roles in TGF-P signaling (Nakao et al., 1997b). Smad protein expression 
in the different glioma cell lines was detected by metabolic labeling in combination with 
immunoprecipitation using Smad-specific anti-sera. As control for specificity, the respective anti­
sera were incubated with the peptides to which the anti-sera had been raised originally. Smad2 
protein expression was detectable in all of the cell lines examined (Fig. 4, Table II), with highest 
levels in U-178 MG, U-343 MG and U-343 MGa 35L. U-178 MG, U-343 MG and U-251 MG 
AgCll showed clearly detectable levels of Smad3. As shown in Figure 4, Smad3 protein could not 
readily be detected in U-343 MGa 31L cells, while in U-343 MGa 35L cells a background band 
overlapped in size with Smad3. All cell lines expressed Smad3 mRNA, but mRNA levels were low 
in U-178 MG and U-343 MGa 31L cells (data not shown). Smad4 protein was more difficult to 
detect, due either to low expression levels or to lower affinity of the anti-serum, but it could be 
identified at least in U-178 MG and U-343 MGa 35L (data not shown). All cell lines expressed 
mRNA for Smad4 (data not shown). Apparently, the relative expression levels of Smad proteins 
involved in TGF-P 1 signaling varied greatly among the different glioma cell lines, and these 
differences were apparent even in the three closely related sub-clones U-343 MG, U-343 MGa 31L 
and U-343 MGa 35L.
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Figure 4 Analysis of Smad protein expression and TGF-P 1-induced Smad2 phosphorylation in U-178 MG and U-343 
MGa 35L cells, including controls for specificity of PS2 anti-serum in the absence of exogenously added TGF-P 1, and
in U-343 MG, U-343 MGa 31L, U-251 MG AGCl1 and U-1242 MG cells. Cells were grown to confluence, followed by
35 35metabolic labeling with [ S]methionine/[ S]cysteine for 4 hr. During the last hour of labeling, cells were stimulated 
without or with 10 ng/ml TGF-P 1. Cell lysates were subjected to immunoprecipitation (IP) using Smad2-, Smad3- and 
phosphorylated Smad2 (PS2) specific anti-sera, in the absence or the presence of blocking peptides (BP) to which each 
of the antisera was raised. Immunoprecipitated complexes were analyzed by SDS-gel electrophoresis, followed by 
autoradiography. * Smad2, ** Smad3.
TGF-fi1-mediatedphosphorylation o f Smad2 in glioma cells
To study whether endogenously expressed Smad2 becomes phosphorylated upon TGF-P 1 
stimulation, metabolic labeling of the different glioma cell lines was performed in which 10 ng/ml 
TGF-P 1 was added during the last hour of labeling. Cell extracts were subjected to 
immunoprecipitation using an anti-serum, termed PS2, raised against the phosphorylated 
carboxyterminal SSMS motif in Smad2 (Fig. 4). PS2 anti-serum did not recognize Smad2 protein in 
the absence of endogenously produced or exogenously added TGF-P (Fig. 4; data not shown), 
whereas upon TGF-P 1 stimulation it clearly recognized phosphorylated Smad2 in all six glioma cell 
lines (Fig. 4, Table II). The detection was specific as shown by the peptide competition. The PS2 
anti-serum specifically detected phosphorylated Smad2; no protein with a size corresponding to 
Smad3 could be detected (Fig. 4); the perceptible reduction of the background band at the Smad3 
level in U-343 MGa 35L is due to lower protein amounts in that lane. These data suggest that 
Smad2 is actively involved in TGF-P signaling in all glioma cell lines examined.
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TGF-fil induces Smad6 and Smad7 mRNA expression in glioma cells
TGF-P 1 has been reported to strongly induce mRNA expression of the inhibitory Smads, Smad6 
and Smad7, which might provide a negative feedback mechanism in TGF-P signaling (Nakao et al., 
1997a; Afrakhte et al., 1998). Therefore, Smad6 and Smad7 mRNA expression in response to TGF- 
P1 stimulation was studied by Northern blot analysis. Total RNA was extracted from confluent cells 
that were stimulated for 2 hr with or without 5 ng/ml TGF-P 1. In all glioma cell lines, basal 
expression of Smad7 mRNA was observed. Upon TGF-P 1 stimulation, Smad6 and Smad7 mRNA 
levels were elevated in all cell lines (Fig. 5, Table I).
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Figure 5 Northern blot analysis of Smad6 and Smad7 expression in glioma cells. Cells at high density were serum- 
starved for 2 hr, followed by stimulation without or with 5 ng/ml TGF-P 1 for 2 hr. Total RNA (15 ^g) was subjected to 
Northern blot analysis using Smad6, Smad7 and actin-specific probes.
TGF-fil-induced transcriptional activation o f the (CAGA)12-luciferase reporter in glioma cells 
TGF-P 1-induced transcriptional activation was furthermore investigated by transient transfection 
of the different glioma cell lines with a (CAGA)12-luciferase reporter construct, which contains 
binding sites for Smad3 and Smad4 and is potently induced by TGF-P 1 (Dennler et al., 1998). For 
the glioma cell lines studied, the (CAGA)12-luciferase reporter was most efficiently induced by 
TGF-P1 in U-178 MG cells, which expresses high amounts of TGF-P receptors, Smad3 and Smad4, 
while in U-343 MGa 31L, in which we observed low expression levels of TPR-II and Smad3, only 
weak induction was observed (Fig,. 6, Table 1). Apparently, the level to which TGF-P 1 could 
activate the pathway leading to induction of the (CAGA)12 reporter varied among the different cell 
lines, and the induction levels appeared to correlate to the expression levels of TGF-P receptors and 
Smad3 and Smad4 proteins.
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Figure 6 Analysis of TGF-P1-induced transcriptional activation of the (CAGA)12-luciferase reporter in glioma cells. 
Cells were seeded at 2x105 cells per well of a 6-well tissue culture plate and transfected with 2 |ig (CAGA)12-luciferase 
reporter and 0.25 ^g P-galactosidase expression plasmid using the calcium phosphate co-precipitation method. After 24 
hr, cells were stimulated without (C) or with (T) 10 ng/ml TGF-P 1 for 24 hr. Luciferase values were corrected for 
transfection efficiency as measured by P-galactosidase activity, which varied greatly between the different cell lines; 
‘Relative transfection efficiency’ indicates average P-galactosidase values measured per cell line, expressed relatively to 
the transfection efficiency of U-343 MG cells, which showed highest P-galactosidase values. Luciferase values for 
control cells are set at ‘0.1’ and TGF-P1 -induced luciferase values are expressed as average (CAGA)12-luciferase 
reporter induction ± standard deviations of triplicate observations relative to controls.
TGF-fil-inducedPAI-1 synthesis in glioma cells
TGF-P1-mediated plasminogen activator inhibitor-1 (PAI-1) protein synthesis was evaluated in 
the different glioma cell lines. Cells were seeded at sparse, sub-confluent or high densities, and 
metabolically labeled in the presence of 10 ng/ml TGF-P1. As indicated in Figure 7, all cell lines 
showed TGF-P1-induced PAI-1 synthesis. Except for U-251 MG AgCl1 at higher cell densities, all 
cell lines expressed basal levels of PAI-1 protein, possibly due to endogenous synthesis of bioactive 
TGF-P1. It has been reported that many gliomas secrete TGF-P (Jennings et al., 1991; Jennings and 
Pietenpol, 1998). This could also explain the basal Smad7 mRNA levels (Fig. 5) observed in the 
different glioma cell lines, as well as the low levels of phosphorylated Smad2 in U-178 MG cells in 
the absence of TGF-P 1 addition (Fig. 4). Thus, irrespective of the growth response, all cell lines 
showed TGF-P 1-induced PAI-1 protein synthesis, indicating that the signaling pathways triggered 
by TGF-P 1 in the different glioma cell lines overlapped at least in part and were functional in all the 
cell lines tested.
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Figure 7 Analysis of TGF-P 1-induced PAI-1 protein synthesis in glioma cells. Cells at sparse, sub-confluent or high
cell densities were treated for 4 hr without or with 10 ng/ml TGF-P1, and during the last 2 hr
35 35[ S]methionine/[ S]cysteine was added. Extracellular matrix proteins were extracted and analyzed by SDS-gel 
electrophoresis, followed by autoradiography.
DISCUSSION
Here, we describe several aspects of TGF-P 1 signaling in six human malignant glioma cell lines. 
Whereas TGF-P 1 stimulated the growth of certain of these gliomas and inhibited the growth of 
others, pathways leading to gene expression, as well as phosphorylation of Smad2, were present in 
all cell lines upon TGF-P 1 stimulation. All cell lines expressed TGF-P 1 receptors, though the types 
of receptors and their relative expression levels differed. The mRNA levels for TfiR-I and TfiR-II in 
the glioma cell lines were differently modulated upon TGF-P 1 treatment, suggesting an 
autoregulatory function for the receptors in TGF-P 1 signaling.
In several tumour types, inactivation of TPR-I or TPR-II has been associated with loss of 
sensitivity to TGF-P, thereby contributing to escape from negative growth regulation (Wang et al., 
1996a; Izumoto et al., 1997). This did not appear to be the case in the glioma cell lines investigated. 
Several studies have shown that, in cells impaired in TGF-P-mediated growth inhibition, TGF-P- 
induced extracellular matrix production as well as transcriptional regulation of other genes remained 
intact, suggesting that distinct signal transduction pathways are involved (Laiho et al., 1991; Chen 
et al., 1993). Similar results have been reported for glioma cells (Isoe et al., 1998), and are 
confirmed and extended by the data presented here. Differential responsiveness to TGF-P has been
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related to the ratio of type I and type II receptors (Centrella et al., 1993; Takeuchi et al., 1995): low 
expression levels of type II receptors compared with type I receptors led to loss of growth inhibition 
but maintenance of extracellular matrix production and transcriptional responses (Centrella et al., 
1993; Chen et al., 1993; Takeuchi et al., 1995). This may also reflect the fact that differing 
activation thresholds control the different TGF-P pathways. However, for the glioma cell lines 
studied here, we did not find evidence to support a correlation between receptor ratios and growth 
effects mediated by TGF-P 1.
Table I TGF-P1-induced responses in human glioma cells. Summary of results. DNA synthesis indicates the
3
inhibition (-) or stimulation (+) of [ H]thymidine incorporation in TGF-P1-stimulated vs. control cells at high density; 
±= no significant effect. TPR-I, TPR-II, Smad6 and Smad7 mRNA indicate relative TGF-P1-mediated induction (+) or 
reduction (-) of respective mRNA expression levels, corrected for the amount of RNA per lane, as analyzed from two 
independent Northern blot experiments; ±= no significant effect. PAI-1 indicates induction of PAI-1 protein levels 
following TGF-P 1 stimulation. (CAGA)12 shows relative induction levels of (CAGA)12 luciferase reporter following 
TGF-P 1 stimulation.
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U-178 MG - - ++++ ± + + + +++
U-251 MG AgCll - - - - - - + + + ++
U-343 MGa 31L ++ + + + + + +
U-343 MGa 35L ++ - ----  - + + + ++
U-343 MG ± ----  -  - + + + ++
U-1242 MG + ++ ± + + + ++
A correlation between TGF-P receptor / Smad expression levels and the potency of the biological 
response elicited by TGF-P1 was observed in the induction of the TGF-P-inducible (CAGA)12- 
luciferase reporter, derived from the human PAI-1 promoter (Dennler et al., 1998). U-178 MG, 
which expressed high levels of TGF-P receptors (Fig. 2) and clearly detectable amounts of Smad3 
and Smad4 protein (Fig. 4 and data not shown) potently induced the (CAGA)12-luciferase reporter, 
while U-343 MGa 31L, in which expression of TPR-II, Smad3 and Smad4 was hardly detectable
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(Fig. 2, 4, data not shown), showed only weak activation. It should be noted, however, that the 
absolute amounts of Smad and TGF-P receptor protein in the different cell lines have not been 
assessed, so that it is not possible to draw firm conclusions regarding expression of these proteins 
and observed biological responses.
Stimulation of cell proliferation by TGF-P has been ascribed in some systems to the activation of 
TGF-P-induced autocrine PDGF signaling (reviewed in Jennings and Pietenpol, 1998). U-343 MGa 
31L and U-343 MGa 35L cells express PDGF-A chains and PDGF a-receptors (Nister et al., 1991). 
However, we found that U-343 MGa 31L cells did not respond to any of the PDGF isoforms, and 
TGF-P1 stimulaton of U-343 MGa 31L and U-343 MGa 35L cells did not induce PDGF-A mRNA 
(data not shown). Furthermore, stimulation of U-343 MGa 31L or U-343 MGa 35L cells with TGF- 
P1 in the presence of PDGF-anti-sera did not inhibit the growth stimulatory effect mediated by 
TGF-P 1 (data not shown). Thus, we found no evidence that TGF-P 1 mediates its growth stimulatory 
effects on these cell lines by induction of PDGF.
Table II TGF-P receptor and Smad expression in human glioma cells. Summarized results. TPR-I, TPR-II, TPR-III
125and endoglin indicate relative amounts of I-TGF-P1 cross-linked and immunoprecipitated receptor complexes. 
Smad2 and Smad3 indicate relative amounts of Smad protein per cell line as identified by metabolic labeling and Smad 
immunoprecipitation. PS2 indicates relative amounts of phosphorylated Smad2 to total amount of Smad2.
Cell line TP
R
-I «I
P4CO.H T
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-I
II
En
do
gl
in
Sm
ad
2
Sm
ad
3
PS
2
U-178 MG +++ ++++ + ++ +++ +++ +++
U-251 MG Ag Cl 1 ++ - +++ - ++ +++ +
U-343 MGa 31L +++ + + - ++ + +
U-343 MGa 35L ++ ++ ++++ - ++ ++ ++
U-343 MG +++ +++ +++ + +++ ++ +++
U-1242 MG +++ ++++ +++ ++ ++ + ++
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TGF-P inhibits proliferation by arresting cells late in the G1-phase of the cell-cycle, in part via 
induction of p15/INK4B and p21, which act early in the G1 phase to maintain underphosphorylation 
of the retinoblastoma gene product pRB (reviewed in Jennings and Pietenpol, 1998). A frequently 
occuring feature in glioma carcinogenesis is deletion of the cyclin-dependent kinase inhibitors 
p15/INK4B and p16/INK4A, and the tumour suppressor p53, as well as amplification of the cyclin- 
dependent protein kinase CDK4 (reviewed in Jennings and Pietenpol, 1998). Northern blot analysis 
showed that p16 expression was lost in all glioma cell lines studied, while p15, p21 and p27 were 
normally expressed (data not shown). There was no correlation with the TGF-P 1-mediated growth 
effects in the different glioma cells, although we can not exclude that the p15, p21 or p27 mRNA 
products encode non-functional proteins. Alternatively, mutations of other proteins in the TGF-P 
signaling pathway leading to growth arrest in G1 may be involved.
In view of the complexity of the TGF-P signaling pathways and the heterogeneity of the 
different glioma cell lines used in this study, it is difficult to pin-point the key-molecule(s) 
determining growth inhibition vs. growth stimulation. Our data suggest that a complex balance 
between TGF-P 1-activated TGF-P receptors, Smad proteins, transcription factors and cell-cycle 
regulators, as well as the possible intervention of other growth modulating factors, together 
determine the outcome of TGF-P 1 responsiveness, leading to, for example, growth inhibition or 
growth stimulation.
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ABSTRACT
The capacities of different members of the transforming growth factor-P (TGF-P) superfamily to 
drive epithelial to mesenchymal transdifferentiation of the murine mammary epithelial cell line 
NmuMG were investigated. TGF-P1, in contrast to activin A and osteogenic protein-1 (OP-1)/bone 
morphogenetic protein-7 (BMP-7), was able to induce morphological transformation of NMuMG 
cells as shown by reorganization of the actin cytoskeleton and downregulation of E-cadherin 
expression, an effect that was abrogated by the serine/threonine kinase-inhibitor staurosporin. TGF- 
P1 bound to TGF-P type I receptor (TpR-I)/ALK-5 and TPR-II, but not to activin receptor (ActR)- 
I/ALK-2. Activin A bound to ActR-IB/ALK-4 and ActR-II, and BMP-7 bound to ALK-2, BMPR- 
I/ALK-3, ActR-II and BMPR-II. In contrast to activin A and BMP-7, TGF-P 1 strongly induced 
Smad2 phosphorylation, which correlated with specific Smad-dependent transcriptional activation. 
TGF-P 1 and BMP-7 were equally potent in activation of the Smad-binding element (SBE)4-Lux 
reporter, whereas activin A had no effect. Transfection of constitutively active (CA)-ALK-4 
activated the 3 TP-Lux and (SBE)4-Lux reporters, indicating that activin signaling downstream of 
type I receptors was functional in NMuMG cells. In conclusion, TGF-P 1 signals potently in 
NMuMG cells and passes the activation threshold to evoke NMuMG cell transdifferentiation. 
Activin A does not induce mesenchymal transformation, presumably because the number of activin 
receptors is limited, while BMP-7-initiated signaling cannot mediate transdifferentiation.
INTRODUCTION
Transforming growth factor (TGF)-P, which is the prototypic member of the TGF-P superfamily, 
exerts a broad range of biological activities. It has an antiproliferative effect on cells of mainly 
epithelial origin, whereas it promotes growth of mesenchymal cell types. It plays pivotal roles 
during embryonic development where it is involved in patterning the embryo and inducing 
differentiation of cells to form tissues and organs (reviewed in Roberts and Sporn, 1990; Whitman, 
1998b). Several members of the TGF-P superfamily can modulate mesenchymal cell fates, 
including development of myoblasts, chondrocytes, or osteoblasts (Roberts and Sporn, 1990; 
Kingsley, 1994). Furthermore, TGF-P superfamily members might be involved in epithelial­
mesenchymal differentiation processes such as branching morphogenesis of the lungs, kidney and 
mammary glands (Silberstein and Daniel, 1987; Heine et al., 1990; Robinson et al., 1991; Rogers et 
al., 1993; Hogan and Yingling, 1998). Processes that are benificial and required for proper 
embryonic development, frequently form the basis for pathological conditions in adults. Improper 
TGF-P signaling is often correlated with pathogenesis, like tumorigenesis (reviewed in Hata et al., 
1998b). Whereas TGF-P acts as a tumor suppressor during early benign stages of skin 
tumorigenesis, it potently aggravates the malignancy at later stages. This is accompanied by an 
epithelial to mesenchymal cell transition, which occurs during transformation of squamous 
carcinoma to invasive spindle cell carcinoma (Cui et al., 1996; Portella et al., 1998).
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Members of the transforming growth factor (TGF)-P superfamily, including TGF-Ps, activins, 
inhibins and bone morphogenetic proteins (BMPs), mediate their pleiotropic effects by signaling 
through transmembrane serine/threonine kinase type I and type II receptors. Upon ligand-induced 
heteromeric complex formation between type II receptors and type I receptors, type I receptors 
become phosphorylated by the type II receptors (Wrana et al., 1994) and activate downstream 
signaling in which Smad proteins play a pivotal role (reviewed in Heldin et al., 1997; Massague, 
1998). The Smad family can be subdivided into (i) receptor-activated Smads (R-Smads) which 
include Smad2 and Smad3 for TGF-P and activin signaling, and Smad1, Smad5 and Smad8 for 
BMP signaling, (ii) common mediator Smads (Co-Smads) like Smad4, and (iii) inhibitory Smads 
(Anti-Smads), including Smad6 and Smad7 (reviewed in Heldin et al., 1997; Massague, 1998). R- 
Smads contain a conserved SSXS phosphorylation motif in their very C-terminus, of which the last 
two serine residues become phosphorylated following interaction with activated type I receptors 
(reviewed in Heldin et al., 1997; Massague, 1998). Phosphorylation of R-Smads results in their 
heteromerization with Smad4, followed by nuclear translocation and regulation of gene 
transcription in association with other transcription factors (reviewed in Heldin et al., 1997; 
Massague, 1998).
The mammary epithelial cell line NMuMG has been shown to undergo mesenchymal 
transdifferentiation following TGF-P stimulation (Miettinen et al., 1994). Here, we investigated 
whether other TGF-P family members, including activin A and BMP-7, share this property with 
TGF-P, and we further addressed signaling by these growth factors in NMuMG cells at the 
molecular level. We observed that TGF-P 1-induced transdifferentiation correlated with Smad2 
activation and specific Smad-sensitive transcriptional activation. Activin A failed to induce 
morphological transformation, presumably due to low activin receptor numbers. BMP-7 did not 
induce transdifferentiation but induced a transcriptional response in these cells. This suggests that 
receptor-activated downstream effectors of the TGF-P but not BMP pathway are involved in the 
transdifferentiation process.
MATERIALS AND METHODS
Reagents and constructs
TGF-P 1 was obtained from Dr. N. Ferrara at Genentech (San Francisco, CA), activin A was a 
gift from Dr. Y. Eto at Ajinomoto Company (Kawasaki, Japan), and osteogenic protein 1 (OP-
1)/bone morphogenetic protein 7 (BMP-7) was provided by Dr. K. Sampath at Creative 
Biomolecules (Hopkinton, MA). Smad2-Gal4 fusion construct, Gal4 construct, and p3TP-Lux 
promoter-reporter construct containing three sets of tetradecanoyl phorbol acetate-responsive 
elements together with part of the human plasminogen activator inhibitor (PAI)-1 promoter were 
obtained from J. Massague (Memorial Sloan-Kettering Cancer Center, NY). Smad3-Gal4 fusion 
construct and (SBE)4-Lux reporter which contains 4 repeats of the CAGACA sequence identified as 
a Smad binding element in the JunB promoter (Jonk et al., 1998) was obtained from Dr. S. Itoh 
(Ludwig Institute for Cancer Research, Uppsala, Sweden). Gal4-dependent luciferase reporter was 
provided by Dr. J. Ericsson (Ludwig Institute for Cancer Research, Uppsala, Sweden).
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Constitutively active (CA) type I receptor constructs (CA-ALK-1, CA-ALK-2, CA-ALK-3, CA- 
ALK-4, CA-ALK-5, CA-ALK-6) were previously described in Nakao et al. (1997b).
Cell culture
Mouse NMuMG breast tumor cells, obtained from American Type Culture Collection (Manassas, VA), were 
routinely cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
10 |J.g/ml insulin, 100 units/ml penicillin and 50 |J.g/ml streptomycin. Cells were grown in 5% CO2-atmosphere at 37°C.
Polyclonal antisera
Preparation of antisera against ALK-1 (RRQ), ALK-2 (RRN), ALK-3 (KSI), ALK-4 (RVY), ALK-5 (VPN), ALK-6 
(DET), ActR-II (ARC), ActR-IIB (RKP), BMPR-II (SMN and NRR), TPR-II (DRL), Smad2 (SED), and 
phosphorylated Smad2 (PS2) have been described previously (Franzen et al., 1993b; ten Dijke et al., 1994b; 
Rosenzweig et al., 1995; Nakao et al., 1997b; Persson et al., 1998; Piek et al., 1999b).
Transdifferentiation o f  NMuMG cells and staining o f  the cytoskeleton
NMuMG cells were seeded at a density of 2x104 cells/cm2 on 22 x 22 mm glass coverslips coated with 0.1% gelatin. 
The next day, cells were stimulated with activin A, BMP-7, or TGF-P 1 in the presence of 10% FBS. Inhibition of TGF- 
P1-mediated transdifferentiation of NMuMG cells was tested with the general serine/threonine kinase inhibitor 
staurosporin (Sigma, St. Louis, MO), the protein kinase C (PKC)-a, -P1, -P2, -y isoforms -inhibitor bisindolyl- 
maleimide I (Calbiochem-Novabiochem Corp., La Jolla, CA), the MEK inhibitor PD98059 (Biomol, Research 
Laboratories, Inc., Plymouth Meeting, PA), the specific PI3-kinase inhibitor, 2-(4-morpholinyl)-8-phenyl-4H-1- 
benzopyran-4-one (LY294002; Biomol, Plymouth Meeting, PA), or the Src-specific inhibitor PP1 (Calbiochem- 
Novabiochem Corp., La Jolla, CA).
After 36 h of stimulation, cells were fixed with 3.7% formaldehyde followed by washing with phosphate-buffered 
saline (PBS) and immersion in -20 oC acetone (direct fluorescence). For indirect immunofluorescence, cells were fixed 
in 3% paraformaldehyde, washed with PBS and permeabilized with 0.5% Triton-X-100 in buffer 1 (137 mM NaCl, 5 
mM KCl, 1.1 mM Na2HPO4, 0.4 mM KH2PO4, 5.5 mM glucose, 4 mM NaHCO3, 2 mM MgCl2, 2mM EDTA, 2 mM 
EGTA, 20mM 2-[N-Morpholino]ethanesulfonic acid, pH 6.0-6.5). For direct fluorescence, specimen were blocked with 
PBS containing 1.5% FBS and incubated with 0.25 |xM tetramethylrhodamine B isothiocyanate (TRITC)-conjugated- 
phalloidin (Sigma, St. Louis, MO) in a humid chamber for 40 min at room temperature. Alternatively, for indirect 
immunofluorescence specimen were incubated with 50-fold diluted mouse monoclonal anti-E-cadherin antibody 
(Transduction Laboratories, Lexington, KY) at 4oC for 30 min. After three washes with PBS, cells for indirect 
immunofluorescence were incubated with 15 times diluted fluorescein isothiocyanate (FITC)-conjugated goat anti­
mouse IgG antibody (Dako-PattsA/S, Glostrup, Denmark) at 4oC for 30 min. At the end of the final four washes with 
PBS, specimen were mounted on glass slides with fluoromount-G (Southern Biotechnology Associates, Birmingham, 
AL) and were observed on an Olympus BH-2 microscope equipped with epifluorescent illumination. Photomicrographs 
were obtained with a 35 mm Olympus (C-35AD-4) camera on Kodak P3200 black and white film.
Receptor affinity cross-linking studies
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Activin A, BMP-7, and TGF-P1 were iodinated to comparable specific activity by the chloramine-T method as 
described by Frolik et al., (1984). Affinity binding and cross-linking of iodinated growth factors to receptors on 
NMuMG cells, followed by immunoprecipitation with receptor-specific antisera, was performed as previously described 
(Piek et al., 1997).
PAI-1 assays
NMuMG cells, grown to 90% confluency, were rinsed in PBS and medium was changed to methionine- and
cysteine-free MCDB 104 (SVA, Uppsala, Sweden) containing 0.1 % BSA. Subsequently, activin A, BMP-7 or TGF-P1
35 35were added for two hours, followed by labeling for 2 h with 1 ^Ci/ml [ S]methionine/[ S]cysteine (Amersham, 
Buckinghamshire, United Kingdom). Thereafter, PAI-1 production was assayed as previously described (Yamashita et 
al., 1995b).
Smad detection by Western blotting
NMuMG cells were grown to 90% confluence. Cells were rinsed in PBS and serum-starved for 3 h in DMEM 
containing 0.1% BSA, followed by addition of 2 nM activin A, 5.7 nM BMP-7, or 400 pM TGF-P1. After 60 min 
stimulation, cells were put on ice, rinsed with PBS and lysed in solubilisation buffer (125 mM NaCl, 10 mM Tris-HCl 
pH 7.5, 1 mM EDTA, 1 mM PMSF, 1.5% Trasylol, and 1% Triton X-100) for 40 min. Cell lysates were separated by 
SDS-gel electrophoresis using an 8.5 % polyacrylamide gel, followed by wet-transfer of the proteins to Hybond-C extra 
nitrocellulose membranes (Amersham, Buckinghamshire, United Kingdom). Nonspecific binding of proteins to the 
membranes was blocked in TBS-T (0.01 M Tris-HCl, pH 7.4, 0,15 M NaCl; 0.1% Tween 20) containing 3% BSA. 
Primary Smad antibodies were diluted 1,000 fold in TBS-T, and secondary horseradish peroxidase-conjugated goat anti­
rabbit IgG antibody (Amersham, Buckinghamshire, United Kingdom) was used in a 10,000 fold dilution in TBS-T. 
Detection was performed by ECL.
Transient transfection studies
NMuMG cells were seeded at a density of 2x104 cells/cm2 in 6-well tissue culture plates. The next day transient 
transfections were performed using Fugene6 transfection reagent, following the manufacturer’s protocol (Boehringer 
Mannheim, Indianapolis, IN). Cells were transfected with 1 |j.g 3TP-Lux reporter construct or 0.5 |j.g (SBE)4-Lux 
reporter construct. For ligand-induced reporter assays, 1 |J.g pcDNA3 empty vector DNA was added, while for analysis 
of reporter activity induced by CA type I receptors, 1 |j.g cDNA plasmid of the respective receptors was cotransfected. 
For Gal4 reporter assay experiments, 0.5 |j.g Gal4 luciferase reporter was cotransfected with 0.2 |j.g Gal4-Smad fusion 
construct. After 24 h, cells were stimulated for 20 h with activin A, BMP-7 and TGF-P1. In all transfections the P- 
galactosidase expression plasmid pCH110 (Pharmacia, Uppsala, Sweden) served as an internal control to correct for 
transfection efficiency. P-Galactosidase activity was measured in 100 mM Na2HPO4/NaH2PO4 (pH 7.3), 1 mM MgCl2, 
100 mM 2-mercapto-ethanol and 0.67 mg/ml o-nitrophenyl-galactopyranoside (Sigma, St Louis, MO).
RESULTS
TGF-P1, but not activin A or BMP-7, induces morphological transdifferentiation o f NMuMG cells
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The potencies of different members of the TGF-P superfamily to induce phenotypic 
transformation of the epithelial breast tumor cell line NMuMG was investigated. Staining of the 
actin cytoskeleton with TRITC-phalloidin revealed the characteristic epithelial architecture in 
control cuboidal cells with strong cortical and diffuse or punctate cytoplasmic actin staining (Fig. 
1A). Treatment with TGF-^1 clearly resulted in transdifferentiation from epithelial to fibroblastic 
morphology, which was evident by simple phase contrast microscopy (data not shown). In line with 
the observations by Miettinen et al., (1994), transdifferentiation was observed from 16 h after 
stimulation with concentrations as low as 20 pM TGF-^1 (data not shown). TRITC-phalloidin 
fluorescence showed that the epithelial architecture was completely shifted into a prominent 
fibroblastic organization of the actin cytoskeleton, with distinct stress fibers emanating from well- 
formed focal adhesions (Fig. 1B). The fibroblastic cells were usually arranged in parallel arrays, in 
line with the arrangement of their stress fibers. Previous studies (Miettinen et al., 1994) showed that 
TGF-^2 also induced phenotypic transformation of NMUMG cells, while 800 pM activin A was 
unable to do so. In the present study, a panel of TGF-P superfamily members was tested. In contrast 
to TGF-^1, none of the other members tested in excessive amounts, including 20 nM activin A, 5.7 
nM BMP-2, 28.5 nM BMP-7, 5.7 nM cartilage-derived morphogenetic protein-1 (CDMP-1) or 5.7 
nM CDMP-2, induced transdifferentiation of NMuMG cells (Fig. 1C, D, and data not shown). Thus, 
only TGF-P is able to induce transdifferentiation of NMumG cells as illustrated by reorganization of 
the actin cytoskeleton.
Figure 1 Organization of the 
actin cytoskeleton in normal and 
transdifferentiated NMuMG 
cells. Cells were stimulated for 
36 h without or with ligand, 
followed by direct staining of the 
actin cytoskeleton using TRITC- 
phalloidin as described in 
‘Materials and Methods’. 
Control cells (panel A), 200 nM 
TGF-P1-treated cells (panel B), 
20 nM activin A-treated cells 
(panel C), 28.5 nM BMP-7- 
treated cells (panel D). Bar, 10 
|jm.
TGF-^1-mediated transdifferentiation o f NMuMG cells is accompanied by downregulation and 
relocalization o f E-cadherin
E-cadherin was used as an additional marker to follow epithelial cell differentiation. Control 
epithelial cells exhibited the characteristic cuboidal E-cadherin staining, which was fully 
overlapping with the actin staining on the cortical rings, but not in the cytoplasmic diffuse or 
punctate material (compare Fig. 2A with Fig. 1A). This is in agreement with the well-established
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association of E-cadherin with the cortical actin cytoskeleton. In the transdifferentiated cells, E- 
cadherin staining was decreased and localized in areas of cell-cell adhesion between fibroblastic 
cells, whereas it was completely absent from areas of the plasma membrane that made no contacts 
with adjacent cells (Fig. 2B). We did not observe co-localization of E-cadherin with the actin stress 
fibers in the fibroblast-like cells, but weak E-cadherin staining was observed in some but not all 
focal adhesions (compare Fig. 2B with Fig. 1B). Staining of the cells for P-catenin showed an 
overlapping distribution of this protein with E-cadherin in both cortical and transdifferentiated cells 
as expected (data not shown). Thus, transdifferentiation of NMuMG cells is characterized by the 
stress-fiber architecture of the actin cytoskeleton, and by relocation and reduced expression of E- 
cadherin.
Figure 2 Localization of E- 
cadherin in normal and 
transdifferentiated NMuMG 
cells. Cells were stimulated for 
36 h with solvent or TGF-P1, 
followed by indirect immuno­
fluorescence against E-cadherin 
as described in ‘Materials and 
Methods’. Control (panel A), 
200 nM TGF-P1 (panel B). Bar, 
10 |jm.
Effects o f protein kinase inhibitors on morphological transdifferentiation induced by TGF-fi1 in 
NMuMG cells.
To explore the possible signaling cascades involved in TGF-^1 -mediated epithelial to 
mesenchymal transdifferentiation of NMuMG cells, a series of protein kinase inhibitors were used 
and morphological analysis of the cells by actin staining followed (Fig. 3A-J). In addition to the 
serine/threonine kinase inhibitor staurosporin and the protein kinase C a, P1, P2, y isoform-inhibitor 
bisindolyl-maleimide I, which were previously analyzed (Miettinen et al., 1994), we also tested the 
MEK1 inhibitor PD98059, the PI-3 kinase inhibitor LY294002, and the Src family tyrosine kinase 
inhibitor PP1. However, with the exception of staurosporin and bisindolyl-maleimide I, none of the 
inhibitors exhibited a major effect on the cell morphology and actin architecture of control or 200 
pM TGF-^1 -stimulated NMuMG cells (Fig. 3A-J). Interestingly, bisindolyl-maleimide I did not 
interfere with morphological transdifferentiation, but it had a reproducible effect on the actin 
cytoskeleton of the fibroblastic cells as stress fibers appeared extremely thin or punctate, while 
strong actin staining was evident in the perinuclear space in a strongly punctate or vesiculated form 
(Fig. 3D). In contrast, addition of staurosporin, a general serine/threonine kinase inhibitor, resulted 
in a relative disruption of cell-cell adhesion and a slight disorganization of the cortical actin 
cytoskeleton in both control and TGF-^1-treated cells, and no evidence of morphological 
transdifferentiation could be observed in the presence of TGF-^1 (Fig. 3 A, B). Thus, our data 
exclude a role for signal transduction pathways involving MEK1, PI3-kinase or Src-tyrosine kinases
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in TGF-ß1-mediated phenotypic transformation of NMuMG cells, and in the organization of the 
actin stress fibers of the fibroblastic cells (Fig. 3E-J).
Figure 3 Effect of protein kinase inhibitors on 
TGF-ß1-induced transdifferentiation of NMuMG 
cells. NMuMG cells were stimulated for 36 h 
with kinase inhibitors in the absence or presence 
of TGF-ß1, followed by direct staining of the 
actin cytoskeleton using TRITC-phalloidin as 
described in ‘Materials and Methods’. Control 
(panels A, C, E, G, I), 200 nM TGF-ß1 (panel B, 
D, F, H, J), 10 nM staurosporine (panels A, B), 5 
|jM bisindolyl-maleimide (panels C, D), 10 |JM 
PD 98059 (panels E, F), 2.8 |JM LY 294002 
(panels G, H), 50 nM PP1 (panels I, J). Bar, 10 
|j.m.
Identification o f receptors for TGF-fi1, activin A and BMP-7 in NMuMG cells
In view of the absence of an effect of activin A or BMP-7 on transdifferentiation of NMuMG 
cells, we investigated whether the cells expressed receptors for activin A, BMP-7, and TGF-^1. 
Affinity cross-linking studies using 200 pM 125I-TGF-^1, 500 pM 125I-activin A, or 850 pM 125I- 
BMP-7, followed by receptor-immunoprecipitation revealed that 125I-TGF-^1 bound to ALK-5 and 
T^R-II, but not to ALK-2, ActR-II or ActR-IIB (Fig. 4A). 125I-Activin A formed heteromeric 
complexes only between ALK-4 and ActR-II (Fig. 4B) and it did not bind to ALK-2 or ActR-IIB, 
while 125I-BMP-7 interacted with ALK-2, ALK-3, ActR-II and BMPR-II but not with ALK-6 or 
ActR-IIB (Fig. 4C) in the NMuMG cells used for our studies. Thus, the specificities of binding of 
ligands to type II and type I receptors on the cell surface of NMuMG cells is consistent with
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previous analyses of these receptors in other cell types (Franzen et al., 1993b; Yamashita et al.,
1995b; Macias-Silva et al., 1998); TGF-^1 associates with ALK-5 to propagate downstream
signaling, activin A interacts with ALK-4, and BMP-7 signals through ALK-2 and ALK-3 in NMuMG cells. It must be 
125 125 125
noted that I-activin A and I-BMP-7, with comparable specific activity as I-TGF-^1, were not only used at
125 125higher concentrations than TGF-^1, but visualization of I-activin A and I-BMP-7 cross-linked receptors also
125
required significantly longer exposure of the autoradiographs compared to the detection of I-TGF-^1-bound 
receptors. Therefore, the expression of activin A and BMP-7 receptors compared to TGF-^1 receptors appeared to be 
very low.
A B
C
Figure 4 Receptors for TGF-ß1, activin A, and BMP-7 on 
NMuMG cells. Cells were affinity-labeled with 125I-labelled 
TGF-ß1 200 pM, activin A 500 pM, and BMP-7 850 pM. 
Cross-linked complexes were subjected to specific receptor- 
immunoprecipitation (shown on each lane) as previously 
described (Piek et al., 1997). Ligand-bound receptor 
complexes were visualized by autoradiography or Fuji-X 
BioImager analysis. A) TGF-ß affinity cross-linking, B) 
activin A affinity cross-linking, C) BMP-7 affinity cross­
linking.
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TGF-fil efficiently induces Smad2 phosphorylation
Using our previously characterized PS2 antiserum which specifically recognizes the 
phosphorylated SSVS motif of Smad2 (Piek et al., 1999b), we investigated the levels to which 
activin A, TGF-^1 and BMP-7 were able to induce phosphorylation of Smad2, a downstream 
effector molecule of ALK-4 and ALK-5. As observed in the Western blot analysis presented in Fig. 
5, TGF-P1, in contrast to excess activin A or BMP-7, potently induced phosphorylation of Smad2. 
Apparently, the potencies of activin A and TGF-^1 to induce transdifferentiation (Fig. 1) and gene 
expression (see below, Fig. 6) correlated to their capacities to activate Smad2 and reflect the relative 
receptor levels on the cell surface (Fig. 5).
Figure 5 Phosphorylation of Smad2 by 
activin A and TGF-P1 in NMuMG cells. 
Cells were serum-starved for 3 h, followed by 
stimulation for 60 min with 2 nM activin A, 
5.7 nM BMP-7, or 200 pM TGF-P1. Western 
blotting was performed as described in 
‘Materials and Methods’, using Smad2 
Sm ad2— ► m  mm  -*"* ^ — Smad2-P antibody (SED) and phosphorylated Smad2
(Smad2-P) antibody (PS2).
TGF-fil is more potent than activin A in inducing PAI-1 production and activation o f Smad- 
responsive luciferase reporters in NmuMG cells
In a broad range of cell types, TGF-P and activin are potent inducers of endogenous plasminogen 
activator inhibitor (PAI)-1 production, as well as of the 3TP-Lux reporter which is driven by three 
TPA-responsive elements and part of the PAI-1 promoter. In addition, the (SBE)4-Lux reporter 
which contains 4 repeats of the CAGACA sequence which was identified as a Smad binding 
element in the JunB promoter, is a suitable read-out system for TGF-P, activin, as well as BMP 
signaling (Jonk et al., 1998). An additional direct system to address Smad-mediated transcriptional 
activity in response to growth factor stimulation, is the induction of a heterologous luciferase 
reporter by Smad-Gal4 fusion proteins in which the Gal4 domain is required for DNA binding. 
Thus, these systems were used to address the signaling capacities of activin A, BMP-7 and TGF-P 1 
in NMuMG cells. Compared to the slight induction mediated by activin A, TGF-P 1 potently 
induced PAI-1 protein expression, while BMP-7 had no effect (Fig. 6A). While only TGF-P 1 was 
potent enough to induce the 3TP-Lux reporter, over-expression of constitutively active (CA)-ALK-4 
or CA-ALK-5 also resulted in 3TP-Lux reporter activation (Fig. 6B). In contrast, all other tested 
constitutive active type I receptors, CA-ALK-1, CA-ALK-2, CA-ALK-3, CA-ALK-6, failed to 
support 3TP-Lux reporter activation. On the other hand, the (SBE)4-Lux reporter was clearly 
induced by both TGF-P 1 and BMP-7, as well as by all constitutively active receptors, whereas 
activin A had no effect (Fig. 6C). These results indicate that the activin A signal transduction 
pathway is not impeded downstream of activated type I receptors. The Smad-Gal4 reporter assays 
(Fig. 6D) further confirmed the finding that TGF-P 1 is most potent in activation of Smad2, and 
Smad3, while activin A only weakly activated these Smads. As expected, BMP-7 could not activate
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the TGF-p/activin pathway-restricted Smads. The finding that activin A is less potent than TGF-P 1 
may be explained by the lower expression level of receptors for activin A compared to TGF-P 1.
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Figure 6 Analysis of transcriptional activation potencies of activin A, BMP-7 and TGF-P 1 in NMuMG cells. A)
Induction of PAI-1 protein synthesis. NMuMG cells were stimulated for 2 h with 2 nM activin A, 5.7 nM BMP-7, or
35 35400 pM TGF-P1, followed by metabolic labeling for 2 h with [ S]methionine/[ S]cysteine. Extracellular matrix 
proteins were extracted and separated on an 8% SDS polyacrylamide gel. B) 3TP-Lux reporter activation. NMuMG 
cells seeded in 6-well dishes were transiently transfected with 1 ^g 3TP-Lux reporter construct, 100 ng P-galactosidase 
expression plasmid pCH110, and 1 ^g pcDNA3 vector or 1 ^g constitutively active type I receptor plasmids, as 
described in ‘Materials and Methods’. After 24 h, cells were stimulated without or with 2 nM activin A, 5.7 nM BMP-7, 
or 400 pM TGF-P 1. Luciferase activity was measured after 20 h, and values are corrected for transfection efficiency as 
measured by P-galactosidase activity. C) (SBE)4-Lux reporter activation. Transient transfections were performed as 
described in (B), with the exception of using 0.5 |lg (SBE)4-Lux reporter instead of 3TP-Lux reporter. D) Smad-Gal4- 
dependent luciferase reporter activation. NMuMG cells were transfected with 0.5 ^g Gal4-dependent luciferase reporter, 
0.25 ^g Gal4 construct, and 100 ng P-galactosidase expression plasmid pCH110. Transfection studies were further 
performed as described in (B).
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DISCUSSION
The breast tumor cell line NMuMG is a suitable model system to study epithelial to 
mesenchymal transdifferentiation mediated by TGF-P 1. We observed that, of all the TGF-P 
superfamily members tested, only TGF-P 1 was capable of inducing transdifferentiation and 
reorganize the actin cytoskeleton from a cortical arrangement to the formation of stress fibers. This 
mesenchymal transition was characterized by decreased expression and relocalization of E-cadherin 
and P-catenin expression and was fully blocked by staurosporin. TGF-P 1 was found to bind 
primarily to TPR-II and ALK-5, but not to ALK-2. Induction levels of PAI-1 protein synthesis, 3TP- 
Lux and (SBE)4-Lux reporter activity, as well as Smad-Gal4-dependent luciferase reporter activity 
by TGF-P 1 and activin A correlated with Smad2 phosphorylation levels, most probably reflecting 
the relative cell surface receptor levels for these two polypeptide factors.
During carcinogenesis, epithelial cell types undergo mesenchymal transformation to a fibroblast­
like phenotype, thereby gaining the possibility to migrate and metastasize. TGF-P has been shown 
to play an important role in the mesenchymal transition of epithelial cells (Miettinen et al., 1994; 
Oft et al., 1996, 1998) and in the malignant progression of fibroblast-like squamous carcinoma cells 
to highly invasive spindle cell carcinomas during in vivo skin carcinogenesis (Caulin et al, 1995; 
Cui et al., 1996; Portella et al., 1998). The fact that TGF-P1 potently induces PAI-1 protein 
expression along with mesenchymal transdifferentiation in NMuMG cells supports this idea. The 
present analysis corroborates the previous findings and further emphasizes that mesenchymal 
transition is not a general property of all TGF-P superfamily members, rather it is a highly specific 
function of TGF-P (Fig. 1).
Malignant progression of epithelial cells is often accompanied by reduced E-cadherin expression 
levels (Miettinen et al., 1994; Caulin et al., 1995; Portella et al., 1998). Interestingly, although the 
overall E-cadherin levels are reduced upon transdifferentiation of NMuMG cells, E-cadherin 
exhibits a distinct redistribution to plasma membrane areas that preserve extensive cell-cell 
adhesion (Fig. 2B). One can speculate that these remnants of the epithelial cell architecture in the 
fibroblast-like phenotype could be the reason for the reversible nature of the transdifferentiation 
phenomenon in epithelial cells (Miettinen et al., 1994; Oft et al., 1996; Portella et al., 1998). In 
other words, the remaining E-cadherin and associated molecules may be part of the signaling 
network that will revert the morphological phenotype back to the epithelial state after prolonged 
(more than 48 hours) incubation post-TGF-P1-treatment (Miettinen et al., 1994).
It is of interest that only the general serine/threonine kinase inhibitor staurosporin could 
significantly interfere with the transdifferentiation process (Fig. 3A, B), as previously reported 
(Miettinen et al., 1994). It should be noted that the general morphology of the epithelial cell 
population changes upon staurosporin addition, since cells lose their tight contacts. Possibly, 
appropriate cell-cell and cell-matrix interactions are required to assure cellular transformation. The 
effect of bisindolyl-maleimide I on the actin cytoskeleton of the transdifferentiated cells (Fig. 3C,D) 
might suggest that proper stress-fiber formation is no prerequisite for mesenchymal transformation, 
and the observed actin cytoskeleton redistribution could be one of the facets of the 
transdifferentiated phenotype. Miettinen et al., 1994 reported that staurosporin does not impede the
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kinase activity of the serine/threonine kinase type I and type II receptors. The results suggest a role 
for protein kinase C isoforms in the proper organization of the stress fibers in the fibroblastic cells. 
In addition, the specific inhibitors against MEK1, PI3-kinase, and Src family kinases also failed to 
interfere with the transdifferentiation process or with organized stress fiber formation (Fig. 3E-J), 
although the latter kinases are known to participate in cytoskeleton-associated signaling or 
organization of the actin cytoskeleton per se (Seidel-Dugan et al., 1992; Wennstrom et al., 1994). 
The present data favor a distinct mechanism which is initiated by TGF-P and does not involve any 
of these kinases.
Miettinen et al., (1994) have proposed the involvement of ALK-2 in the transdifferentiation 
induced by TGF-P 1, based on the observations that ALK-2 expression was high while ALK-5 could 
not be detected by Northern blot analysis or PCR, and that antisense ALK-2 oligonucleotides or 
overexpression of dominant negative ALK-2 abrogated TGF-P 1-mediated transdifferentiation of 
NMuMG cells. ALK-2 has been characterized as a type I receptor for BMP-7, signaling through 
Smad1 and Smad5 (Yamashita et al., 1995b; Macias-Silva et al., 1998), while ALK-5 is the 
established type I receptor for TGF-P signaling (Franzen et al., 1993b; Wrana et al., 1994). We 
detected ALK-2, ALK-3, ActR-II and BMPR-II expression in NMuMG cells following 125I-BMP-7- 
affinity cross-linking and receptor immunoprecipitation studies (Fig. 4C). Comparable studies using 
125I-TGF-P1 revealed abundant expression of ALK-5 and TPR-II, but there were no indications for 
interaction of TGF-P1 with ALK-2 (Fig. 4A). We could also not detect 125I-TGF-P1-cross-linked 
proteins corresponding to the size of ALK-1, which is a TGF-P type I receptor in endothelial cells, 
slightly larger in size than ALK-5, and which mediates signaling through Smad1 and Smad5 
(Macias-Silva et al., 1998). A clonal variation in the NMuMG cell lines that were used may underly
125the discrepancies in our findings and those by Miettinen et al., (1994). Finally, I-activin A 
associated with ALK-4 and ActR-II on the cell surface of NMuMG cells (Fig. 4B). Thus, for the 
cells used in our studies, TGF-P 1 triggers transdifferentiation most likely by signaling through 
ALK-5, and the levels of this receptor are significantly higher then those of the activin A and BMP- 
7 receptors on the NMuMG cell surface.
Activin and TGF-P exert many overlapping activities in vitro. The kinase domains of ALK-4 and 
ALK-5 share high sequence homology and the L45 loop, which is a major determinant of Smad- 
binding specificity, is identical in ALK-4 and ALK-5 (Feng and Derynck, 1997; Chen et al., 1998b; 
Persson et al., 1998), resulting in common signaling propagation that involves Smad2, Smad3 and 
Smad4. In a few cell systems, however, differential effects exerted by TGF-P and activin have been 
observed (Nishihara et al., 1993; Torii et al., 1996; Link and Nishi, 1997), although the mechanisms 
underlying differential signaling are not clear. In human epidermal keratinocyte HaCaT cells, activin 
weakly inhibited cellular proliferation and predominantly signaled through Smad3, while TGF-P 
potently inhibited HaCaT cell growth and signaled via Smad2 and Smad3 (Shimizu et al., 1998). 
Recently, it was shown that Smad2 and Smad3 exert differential effects on the Xenopus goosecoid 
promoter in the presence of co-expressed Fast2, the human homologue of Xenopus forkhead 
transcription factor Fast1 (Labbe et al., 1998). Thus, there is accumulating evidence in the literature 
showing that Smad2 and Smad3 are not merely redundant in their actions. In NMuMG cells, 
differential signaling by activin A and TGF-P 1 seems to be regulated at the respective
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receptor cell surface levels, resulting in differential activation levels of the signal transduction 
pathways induced by these two ligands.
An issue of interest is whether Smads are directly involved in the transdifferentiation process. 
We observed that TGF-P 1, in contrast to activin A and BMP-7, potently induced phosphorylation of 
Smad2 (Fig. 5B). TGF-P 1 also potently induced the persistent nuclear accumulation of Smad2 
and/or Smad3, but not of Smad1 (data not shown). The failure to demonstrate Smad1 activation by 
TGF-P1 in the transdifferentiated cells strongly suggests that ALK-1 and/or ALK-2 receptor 
signaling cannot explain the observed phenotypic changes since these two receptors are known to 
signal via Smad1 (Macias-Silva et al., 1998; Chen et al., 1999). The Smad-activation results 
directly correlated to the differential transcriptional activation potencies by the three growth factors 
as observed for PAI-1 protein induction and activation of Smad-sensitive reporters (Fig. 6). 
Whereas both 3TP-Lux and (SBE)4-Lux reporters were activated by TGF-P 1, they remained 
insensitive to activin A (Fig. 6B,C), and only the (SBE)4-Lux reporter was activated by BMP-7. 
Induction of Smad-Gal4-dependent luciferase reporter activity was also differentially affected by the 
three growth factors. In addition, all CA-type I receptors were able to induce (SBE)4-Lux reporter, 
whereas the 3TP-Lux reporter was only induced by CA-ALK4 and CA-ALK5. These results 
emphasize that responsiveness of a target gene to TGF-P family members is dependent on the type 
of Smads (and/or other signal transduction components) that become activated and that can 
specifically interact with binding elements in the promoter of the target gene, whereby different 
genes are controlled by different activation thresholds. Thus, in terms of the transdifferentiation 
process, the present analysis suggests that the differential effects observed for activin A, BMP-7 and 
TGF-P1 are due to the fact that only the signal transduction cascade activated by TGF-P1 is both 
potent and specific enough to drive mesenchymal transformation of NMuMG cells. Although the 
Smad2-activation levels correspond to the potencies of activin A and TGF-P 1 to mediate signaling 
in NMuMG cells, generation of NMuMG clones stably transfected with inducible Smad-expression 
constructs will further reveal whether Smads mediate the transdifferentiation process. In addition, 
the role of other signal transduction molecules that have been reported to be involved in 
transdifferentiation and actin reorganization processes, like Rho- family members and Ras (Qui et 
al., 1995, 1997; Oft et al., 1996, 1998), is subject for further studies.
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ABSTRACT
Thyroid growth and function is intricately regulated by both positive and negative factors. In the 
present study we have investigated the expression of transforming growth factor-P (TGF-P) 
superfamily members and their receptors in normal porcine thyroid follicle cells. In tissue sections 
of porcine thyroids we observed the expression of TGF-P 1, activin A and bone morphogenetic 
protein-7 (BMP-7) proteins. The staining was localized to the follicular epithelium. In affinity 
crosslinking experiments TGF-P1 was found to bind to heteromeric complexes of TGF-P type I and 
type II receptors, and activin A bound most efficiently to heteromeric complexes of activin type IB 
and activin type II receptors. We were unable to detect any bone morphogenetic protein receptors 
(BMPRs) by affinity cross-linking using BMP-7. However, expression of BMPR-IA and BMPR-II 
mRNA was detected by Northern blot analysis. Both TGF-P 1 and activin A, but not BMP-7, 
increased the phosphorylation of Smad2, induced nuclear translocation of Smad2, Smad3 and 
Smad4, and inhibited thyrocyte cell growth as well as the TSH-stimulated cAMP response. TGF-P 1 
was more potent compared to activin A to induce these cellular responses. Taken together, our 
findings indicate a role for several members of the TGF-P superfamily in regulation of thyroid 
growth and function.
INTRODUCTION
The transforming growth factor-P (TGF-P) superfamily, which includes TGF-P, activins, 
inhibins and bone morphogenetic proteins (BMPs) are multifunctional dimeric proteins that regulate 
growth, differentiation, extracellular matrix production in many different cell types (Heldin et al., 
1997; Massague, 1998). They exert their cellular actions through distinct complexes of type I and 
type II serine/threonine kinase receptors. Both receptor types are essential for signaling; the type I 
receptor acts downstream of the type II receptor and determines signaling specificity. Other TGF-P 
binding transmembrane proteins, i.e. TGF-P type III receptor (TPR-III) and endoglin, which are 
structurally related, have a more indirect role in signaling; TPR-III presents the ligand to the TGF-P 
type II receptors (TPR-II; Lopez-Casillas et al., 1993).
During recent years, Smad proteins have been identified with pivotal roles in the intracellular 
signal transduction of the TGF-P superfamily members (Heldin et al., 1997; Massague, 1998). The 
Smads can be divided into three groups according to their function, the pathway-restricted Smads 
(Smad1, Smad2, Smad3, Smad5 and Smad8), a common-mediator Smad (Smad4) and inhibitory 
Smads (Smad6 and Smad7). TGF-P and activin signal via Smad2 and Smad3, and BMPs through 
Smad1, Smad5, and Smad8. The pathway-restricted Smads are phosphorylated by the type I 
receptor upon ligand binding, and form complexes with Smad4. Subsequently, these complexes 
translocate to the nucleus where they bind to regulatory regions of responsive genes, by themselves 
and/or in combination with DNA-binding proteins (Heldin et al., 1997; Massague, 1998).
The importance of TGF-P superfamily members in the regulation of thyroid growth and function 
is not fully understood. TGF-P has been shown to inhibit thyrocyte growth and function (Morris III
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et al., 1988; Taton et al., 1993; Tsushima et al., 1988). The functional inhibition could in part be 
explained by a downregulation of thyroid specific gene expression, e.g. decreased synthesis of 
sodium iodide symporter (NIS) and thyroglobulin (Tg) have been observed after treatment with 
TGF-P1 (Pekary et al., 1998; Toda et al., 1997). Normal thyrocytes have also been demonstrated to 
produce and secrete TGF-P (Morris III et al., 1988; Cowin et al., 1992; Cowin and Bidey, 1994; 
Yuasa et al., 1992). Interestingly, increased production of TGF-P has been implicated in the 
development of nodular goiter (Grubeck-Loebenstein et al., 1989). Activin A has been reported to 
be expressed in thyroid epithelial cells (Wada et al., 1996), and to have an inhibitory effect on 
thyrocyte function and a stimulatory effect on thyroid cell growth (Kotajima et al., 1995). Recently, 
Huang et al. (1998) showed that Tg could induce TGF-P-like responses in mink lung epithelial 
(Mv1Lu) and rat thyroid follicle (FRTL-5) cells.
In the present study we have examined the expression of TGF-P superfamily members in vivo in 
porcine thyroids. In addition, their role and mechanism of action in porcine thyroid follicle cells in 
suspension cultures was investigated. TGF-P1 and activin A, but not BMP-7, were found to have an 
inhibitory effect on thyrocyte growth and function. Our results suggest an important role for 
members of the TGF-P superfamily in negative regulation of the thyroid.
MATERIALS AND METHODS
Immunohistochemistry
Porcine thyroids were embedded in paraffine after fixation in buffered formaldehyde. The tissue was sectioned into 
3-4 ^m thick slices and placed on microscope slides. The paraffine was removed by subsequent washes: twice with 
xylene for 5 min, twice with 99.5% ethanol for 2 min, twice with 95% ethanol for 2 min and twice with PBS for 2 min. 
The sections were three times microwave-treated in 0.1 M sodium citrate pH 6.0 for 3 min. Endogenous peroxidase 
activity was blocked using 0.3% H2 O2 in PBS for 15 min. The unspecific binding was blocked with 1% goat serum for 
20 min. Primary antibodies directed against TGF-P1 (sc-146 rabbit polyclonal, diluted 1: 50; Santa Cruz 
Biotechnologies, Santa Cruz, CA), activin A (mouse monoclonal (Nagamine et al., 1998), diluted 1: 1,000; kindly 
provided by Dr. Y. Eto, Ajinomoto Company, Kawasaki, Japan) and BMP-7 (mouse monoclonal 1B12-95000 
(Vukicevic et al., 1994); diluted 1 : 100; kindly provided by Dr. T.K. Sampath, Creative Biomolecules, Inc., Hopkinton, 
MA) were added and incubated in a humidified chamber at 4 °C overnight. The sections were incubated for 45 min at 
room temperature with secondary antibody (biotinylated goat anti-rabbit or rabbit anti-mouse, diluted 1: 200; Dako A/S, 
Denmark). The slides were stained using an ABC Elite Complex kit (Dako A/S, Denmark) for 45 min, DAB (Sigma, St. 
Louis, MO) with 0.6% H2O2 for 5 min and counterstained with haematoxiline for 30 sec. Photographs were taken using 
a Vanox microscope.
In the blocking experiments, the TGF-P antibody was incubated at room temperature for 2 h with an excess of the 
immunizing peptide (according to protocol from the manufacturer; Santa Cruz Biotechnology, Santa Cruz, CA). The 
activin A antibody was incubated with 100-fold excess of activin A for 2 h at room temperature. A control omitting the 
primary antibody was also performed.
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Cell cultures
Porcine thyroids were collected from the local slaughterhouse. The thyroids were cleaned from surrounding tissue 
and minced using a scalpel, then digested for 1 h at 37 °C in a solution containing 1 mg/ml collagenase A, 1.5 mg/ml 
dispase (both from Boehringer Mannheim, Germany), 3 mM CaCl2, 50 ^g/ml deoxyribonuclease I (DNase I; Sigma, St. 
Louis, MO), 0.1 M Tris-HCl, pH 7.4, 0.1 M maleic acid, 0.78 M NaCl, 27 mM KCl, 1 mg/ml glucose and 1x non­
essential amino acids (Gibco BRL, Paisely, Scotland). Follicle cells were enriched by passing the digest over a 5% 
Percoll gradient (Amersham Pharmacia Biotech, Uppsala, Sweden), and then washed several times in phosphate- 
buffered saline (PBS) to remove single cells and red blood cells. The follicle cells were seeded in Ham’s F-10 medium 
(Sigma, St. Louis, MO), supplemented with 1% foetal calf serum (FCS) and antibiotics (100 U penicillin and 50 ^g 
streptomycin per ml), and grown in suspension cultures on agarose coated cell culture dishes, or grown on coverslips for 
the immunofluorescence experiments.
Cell proliferation assay
Follicle cells in thymidine-free Ham’s F-10 were grown in 12-well plates and treated with different concentrations of 
TGF-P 1, activin A or BMP-7 in the absence or presence of 10 ng/ml hepatocyte growth factor (HGF) or 10 ng/ml
3
epidermal growth factor (EGF) for 46 h. During the last 4 h, [methyl- H]thymidine (0.25 ^Ci/ml; Amersham Pharmacia 
Biotech, Uppsala, Sweden) was added. The cells were harvested on glass microfiber filters GF/C (Whatman 
International Ltd., Maidstone, England), fixed with 10% trichloroacetic acid (TCA) and rinsed with PBS. The filters 
were treated with NaOH/SDS (0.3M/1%) for 15 min and the amount of radioactivity incorporated was determined by 
liquid scintillation counting.
cAMP assay
Porcine thyroid follicle cells grown in 12-well plates were stimulated with TGF-P1 or activin A for 2 or 24 h. During 
the last 30 min the cells received 1 mU/ml of bovine TSH (Intergen Company, NY) in the presence of 1 mM 3-isobutyl- 
1-methylxantine (IBMX). The cells were treated with 5% TCA for 15 min, followed by extraction with water-saturated 
diethylether to remove the TCA and cell debris. The amount of cAMP was determined using a cyclic AMP assay system 
(TRK.432; Amersham Pharmacia Biotech, Uppsala, Sweden). Protein content was measured in parallel samples, and 
data are expressed as pmol/mg protein.
Northern blot analysis
Total RNA was extracted by a LiCl/urea method (Auffray and Rougeon, 1980) from cells stimulated with 10 ng/ml 
TGF-P 1 or 50 ng/ml activin A for different time periodes. RNA samples (15 ^g/lane) were size-fractionated by 
electrophoresis on a 0.8% agarose gel under denaturating conditions, and transferred to a nylon filter (Duralon UV; 
Stratagene, La Jolla , CA). Hybridization was performed using QuickHyb solution (Stratagene, La Jolla, CA) according 
to the protocol supplied by the manufacturers. Quantification was done using a PhosphorImager (Fuji, Tokyo, Japan). 
To analyze expression of activin and BMP receptors in thyroid follicle cells, 5 ^g/lane of poly (A)+ enriched RNA was 
electrophoresed, transferred to a nitrocellulose filter (Hybond-C; Amersham Pharmacia Biotech., Uppsala, Sweden) and 
hybridized as described previously (Heldin and Westermark, 1988). The cDNA probes used included a 0.6 kb Eco 
RI/Ava I fragment of human ActR-I (ten Dijke et al., 1993), a 0.8 kb Eco RI/Pvu II fragment of human BMPR-IA (ten 
Dijke et al., 1993), a 0.8 kb Pst I fragment of BMPR-II (Rosenzweig et al., 1995), and the 2.6 kb coding part of human 
TSHR (Heldin et al., 1991).
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Radiolabeling o f  ligands and affinity cross-linking studies
Human recombinant TGF-P1 was obtained from Dr. N. Ferrara at Genentech (San Francisco, CA), activin A was a 
gift from Dr Y. Eto at Ajinomoto Company (Kawasaki, Japan) and BMP-7 was provided by Dr. K. Sampath at Creative 
Biomolecules, Inc. (Hopkinton, MA). The growth factors were iodinated using the chloramine-T method (Frolik et al., 
1984). Affinity-binding of TGF-P1, activin A and BMP-7 to cell surface binding proteins on thyroid follicle cells, 
followed by immunoprecipitation of cell lysates with receptor-specific antisera, was basically performed as previously 
described (Piek et al., 1997).
Western blot analysis
Suspension cultures of porcine thyroid follicle cells were stimulated with TGF-P1 (10 ng/ml), activin A (100 ng/ml) 
or BMP-7 (500 ng/ml) for 1 h at 37 °C, centrifuged and lysed in a buffer containing 1% Triton X-100, 150 mM NaCl, 
10 mM TrisHCl pH 7.4, 1 mM EGTA, 1 mM EDTA and 0.5% NP-40 supplemented with protease and phosphatase 
inhibitors (35 ng/ml phenylmethylsulfonyl fluoride (PMSF), 1.4 ^g/ml aprotinin, 1 mM Na3VO4 , 10 mM NaF, 1 mM 
ZnCl2, 50 mM Na2MoO4, 10 mM Na2P2O7) on ice for 40 min. Cell debris was removed by centrifugation at 14,000 x 
g  for 10 min. Protein content was determined using a commercial kit (Pierce Chemical Company, Rockford, IL). 
Samples (18 ^g/lane) were separated on a 4-12% Bis-Tris NuPAGE gel (NOVEX, San Diego, CA) and transferred to a 
Hybond-ECL filter (Amersham Pharmacia Biotech., Uppsala, Sweden). The filters were blocked for 1 h with 5% BSA 
in 10 mM Tris-HCl, pH 7.7, 150 mM NaCl, and 0.1% Tween-20 (TBS-T) and incubated overnight at 4 °C with 
antibodies against Smad2 or phosphorylated Smad2 (Persson et al., 1998). After several washes in TBS-T, the filters 
were incubated for 2 h with a secondary horseradish peroxidase (HRP) conjugated anti-rabbit IgG (Amersham 
Pharmacia Biotech., Uppsala, Sweden) diluted 1 : 5,000. Enhanced chemiluminiscence (ECL) was performed using 
SuperSignal Chemiluminescence Substrate (Pierce Chemical Company, Rockford, IL). The filters were stripped for 30 
min at 50°C in a solution containing 100 mM P-mercaptoethanol, 2% SDS and 62.5 mM Tris-HCl, pH 6.7, and rinsed 
thoroughly before reusing.
Immunofluorescence staining
Cells were grown on coverslips in Ham’s F-10 medium containing 10% FCS. Cells were serum-starved for 24 h in 
medium containing 1% FCS. TGF-P1 (10 ng/ml) or activin A (50 ng/ml) were added for 1h at 37 °C. Cells were fixed in 
1.5% paraformaldehyde (PFA) for 5 min and permealized with 0.1% Triton X-100 for 3 min. Nonspecific binding was 
blocked with 0.1% BSA in PBS for 20 min and incubated with antisera to Smad 2, Smad3 and Smad4 (Smad2, DQQ- 
antiserum; Smad3, DHQ-antiserum; or Smad4, HPP-antiserum (Nakao et al., 1997b). The coverslips were washed three 
times in PBS and incubated with a fluoresceine isothiocyanate (FITC) swine anti-rabbit antiserum (diluted 1: 20; Dako 
A/S, Denmark) for 1 h. The slides were mounted (Vectashield; Vector Laboratories Inc., Burlingame, CA) and 
photographed using a Leitz UV-microscope.
RESULTS
Expression o f TGF-^1, activin A and BMP-7 in normal porcine thyroid tissue
To examine the role of TGF-P superfamily members in the thyroid, we first examined their 
expression in porcine thyroid tissue. Immunohistochemical stainings showed an expression of TGF-
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P1, activin A and BMP-7 proteins. The staining for TGF-P1 (Fig. 1A) and activin A (Fig. 1C) was 
strong and localized to the cytoplasm of the epithelial cells of the thyroid. There appeared to be a 
variation in the intensity of expression between different follicles. Stromal and endothelial cells 
between the follicles did not stain for the ligands. Preincubation of the TGF-P1 antibody with the 
immunizing peptide, and the activin A antibody with a 100-fold excess of ligand, abolished nearly 
completely the staining, thus demonstrating the specificity of the antibodies (Fig. 1B and 1D, 
respectively). We also observed a weak positive staining for BMP-7 in the thyroid (Fig. 1E) which, 
similar to staining for activin A and TGF-P1, was localized to the follicle cells. There appeared to 
be a higher degree of heterogeneity between different cells within the same follicle in the case of 
BMP-7 stainings compared to those of TGF-P1 and activin A.
Figure 1 Expression of TGF- 
pi, activin A and BMP-7 
proteins in sections from normal 
porcine thyroid tissue. 
Immunohistochemical stainings 
of porcine thyroids were 
performed with antibodies to 
TGF-P1 (panel A), activin A 
(panel C) and BMP-7 (panel E) 
as described in ‘Materials and 
Methods’. In panel B, the TGF- 
P1 antibody was blocked with 
the immunizing peptide prior to 
the staining, and in panel D, the 
activin A antibody was 
incubated with a 100-fold 
excess of ligand in order to 
block the antibody. Panel E 
shows a negative control with 
the primary antibody omitted.
Effect ofTGF-p1, activin A and BMP-7 on thyrocyte growth
In the present study we observed an inhibitory effect of TGF-P1 on proliferation of porcine 
thyroid follicle cells grown in suspension cultures. A maximal inhibitory effect was obtained at 1 
ng/ml of TGF-P1 (Fig. 2A). Addition of TGF-P1 also inhibited the growth stimulation of 10 ng/ml 
of epidermal growth factor (EGF) or hepatocyte growth factor (HGF). Activin A also inhibited
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DNA synthesis of thyrocyte cells as measured by thymidine incorporation (Fig. 2B). The growth 
inhibitory effect of activin A was not as pronounced as that of TGF-ß1; an effect comparable to the 
maximal effect of TGF-ß1 was observed at 100 ng/ml of activin A. Activin A also inhibited EGF- 
and HGF-induced growth stimulation of the thyrocytes, however not as potently as TGF-ß1. Taken 
together, both activin A and TGF-ß1 have an inhibitory effect on thyrocyte growth, albeit TGF-ß1 
is more potent compared to activin A.
Addition of BMP-7 in concentrations up to 500 ng/ml did not inhibit cell growth (Fig. 2C). A 
small increase in thymidine incorporation was observed using 100 ng/ml of BMP-7.
Figure 2 Effect of TGF-ß1, activin A and BMP-7 on 
porcine thyroid follicle cell growth. Cells grown in 
suspension cultures in 12-well plates were stimulated with 
TGF-ß1 (panel A), activin A (panel B) or BMP-7 (panel 
C) with or without 10 ng/ml of EGF or HGF, as indicated
3
in the figure. After 2 days, [H]-thymidine was added for 
4 h to monitor DNA-synthesis. The samples were 
harvested and counted using scintillation liquid. Data are 
presented as mean ± SD.
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Effect o f TGF-fii, activin A and BMP-7 on thyrocyte function
In order to analyze the effect of the different members of the TGF-P superfamily on thyroid 
function we measured their effect on TSH-stimulated cAMP formation. Thyroid follicle cells were 
incubated with or without ligand (TGF-^1, activin A or BMP-7) at different concentrations for 2 or 
24 h. TSH and a phosphodiesterase inhibitor (IBMX) was included during the last 30 min of ligand 
treatment, and the intracellular level of cAMP was determined. As seen in Fig. 3, addition of TGF- 
P1 (Fig. 3 A) and activin A (Fig. 3B) inhibited the TSH-induced cAMP production after 24 h 
preincubation. The maximal inhibitory effect of about 50% was similar for the two ligands. 
Preincubation with TGF-^1 or activin A for 2 h did not have any influence on the TSH-stimulated 
intracellular level of cAMP. Interestingly, addition of BMP-7 slightly inhibited the TSH-mediated 
increase in cAMP level after 2 h preincubation, but this effect was lost after 24 h preincubation 
(Fie. 3C).
Figure 3 Effect of TGF-01, activin A and BMP-7 on 
TSH-induced cAMP production in porcine thyroid follicle 
cells. Cells in 12-well plates were stimulated with TGF- 
P1 (A), activin A (B) or BMP-7 (C) in different 
concentrations as indicated in the figure. After incubation 
for 2 or 24 h, and 30 min stimulation with 1 mU/ml of 
TSH in the presence of 1 mM IBMX, cells were harvested 
and analyzed for intracellular cAMP levels. Data are 
expressed as mean ± SD.
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To further elucidate the mechanisms behind the inhibitory effect of TGF-P1 and activin A on 
thyroid function, we performed Northern blot analysis on thyroid follicle cells to study the 
expression of thyroid specific proteins. Total RNA extracted from porcine thyroid follicle cells that 
were treated with TGF-P1 or activin A for various time periods, ranging from 2 to 96 h, were 
hybridized with a TSH-receptor (TSHR) cDNA fragment. As seen in Fig. 4, TGF-P1 induced a 
decrease (60-70%) in TSHR mRNA level, observed already after 2 h with TGF-P 1 (10 ng/ml). 
Treatment of cells with 50 ng/ml of activin A did not have any effect on the TSHR mRNA level 
(data not shown).
Figure 4 Effect of TGF-P1 on the expression of TSHR 
mRNA in thyroid follicle cells. Total RNA from porcine 
thyroid follicle cells was extracted after stimulation with 
10 ng/ml of TGF-p1 for different times ranging from 2 to 
96 h. Northern blot analysis was performed using a human 
TSHR cDNA fragment. The filter was also hybridized 
with a GAPDH probe (pGAP3; kindly provided by Dr 
Ray Wu, Cornell University, Itacha, NY (Tso et al., 1985) 
to correct for loading differences. The two hybridizations 
were analyzed on a PhosphorImager (Fuji, Tokyo, Japan) 
and expressed in the figure as the ratio between the 
expression of TSHR and GAPDH mRNAs.
Expression o f receptors for TGF-p1, activin A and BMP-7 on porcine thyrocytes in culture
125Affinity crosslinking of I- labeled TGF-P 1, activin A or BMP-7 to binding proteins on normal 
porcine thyroid follicle cells cultured in suspension, followed by immunoprecipitation of cell lysates 
with receptor-specific antisera, showed the expression of type I and type II receptors for TGF-P 1 
and activin A (Fig. 5). As seen in Fig. 5A, we could detect labeled protein complexes in samples 
precipitated with specific antisera to TGF-P type I (TPR-I) and type II (TPR-II), but not with
antisera to TPR-III or endoglin. In a Northern blot analysis of RNA from porcine thyrocytes we
125could not detect TPR-III mRNA (data not shown). In the affinity crosslinking with I-activin A,
the cells were found to express activin type IB receptors (ActR-IB), ActR-II and a lower level of
ActR-I receptors, but not ActR-IIB (Fig 5B). By Northern blot analysis we readily detected the
mRNA expression of ActR-I in thyroid follicle cells (Fig. 6). The exposure time needed to visualize
125I-activin A-crosslinked complexes was much longer compared to 125I-TGF-P1-crosslinked
proteins, which may indicate that activin receptors are present at a much lower number. The
observed co-precipitation of type I and type II receptors in the cross-linking by the receptor specific
antisera indicate that they form complexes upon ligand binding. The high molecular band observed 
125after cross-linking of I-TGF-P1 was not recognized by the TPR-III antiserum; its identity remains
125to be established. One possibility, since a similar band was also seen after crosslinking of I- 
activin A (Fig. 5B), is that it represents iodinated thyroglobulin. The 80 kDa band observed after
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cross-linking of I-TGF-P1 is also of unknown origin. Finally, in an affinity-crosslink experiment
125using I-BMP-7, followed by immunoprecipitations with receptor specific antisera, we were 
unable to detect any receptor complexes (data not shown). However, we found an expression of 
mRNA for BMP type IA (BMPR-IA) and BMPR-II (Fig. 6), but not for BMPR-IB (data not 
shown), in both primary cultures of porcine thyroid follicle cells or human toxic goiter tissue (Fig. 
6).
Figure 5 Affinity-crosslinking of 125I-TGF-P1 or 125I-activin A to proteins on porcine follicle cells in culture. Cells 
were grown in suspension overnight before incubation with the different iodinated ligands as described in Materials and
Methods, followed by crosslinking and immunoprecipitations with specific receptor antisera. Panel A shows the results
125 125from affinity labeling with I-TGF-P1, and panel B with I-activin A. Fractions of the total cell lysate after affinity
cross-linking were electrophoresed in the first lanes (denoted Total). The sizes of the type I and type II receptors are
indicated in the figure.
Figure 6 Northern blot analysis of @foQ//and AL OQ, 
and AL OQ, ///mRNA expression in thyroid follicle 
cells. Poly (A)+ RNA extracted from porcine thyroid 
follicle cells in culture and from human toxic goiter tissue 
were electrophoresed (5 ^g/lane), transferred and 
hybridized as described in the Materials and Methods. 
Equal loading of the gel was checked by ethidium 
bromide staining (lower panel).
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Ligand-induced Smad signaling
Stimulation of thyroid follicle cells with 10 ng/ml of TGF-P 1 for 60 min resulted in a rapid 
phosphorylation of the Smad2 proteins, detected in a Western blot analysis of total cell lysates using 
an antiserum against phosphorylated Smad2 (Fig. 7). As seen in Fig. 7, stimulation of cells with 100 
ng/ml of activin A resulted in weak phosphorylation of Smad2. Activin A might be less potent 
because of lower activin receptor expression levels compared to TGF-P receptor levels on these 
cells. Smad2 expression was not altered by the different treatments (Fig. 7). Stimulation with BMP- 
7 (500 ng/ml) did not induce phosphorylation of Smad2 in the thyrocytes (Fig. 7).
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Figure 7 TGF-P1- and activin A-induced phosphorylation of Smad2 in porcine thyrocytes. Cells were stimulated with 
10 ng/ml of TGF-P1, 100 ng/ml of activin A or 500 ng/ml of BMP-7 for 60 min before lysis. Samples (18 ^g/lane) were 
electrophoresed on a 4-12 % SDS-PAGE, transferred and incubated with an antiserum against phosphorylated Smad2 
(Smad2-P; shown in the right panel). The filter was then stripped and incubated with a Smad2 antiserum to determine 
the total amount of Smad2 (left panel).
Nuclear translocation of the Smad2, Smad3 and Smad4 proteins is rapidly induced by TGF-P1 in 
many cell systems. In the present study, porcine thyroid follicle cells grown in monolayer cultures 
and treated with 10 ng/ml of TGF-P1 for 60 min, showed an increased nuclear immunofluorescence 
staining of Smad2, Smad3, and Smad4 proteins compared to unstimulated cells (Fig. 8). The 
nuclear staining of the Smad proteins was almost absent in unstimulated cells but increased several 
fold after TGF-P 1 stimulation. The nuclear staining of Smad3 was already high in unstimulated 
cells, but increased further after TGF-P 1 stimulation. An increased nuclear staining of Smad2, 
Smad3, and Smad4 was also observed after addition of 50 ng/ml of activin A to the thyroid follicle 
cells (Fig. 8). The nuclear staining of Smad2 and Smad3 was stronger in TGF-P 1 stimulated cells 
compared to activin A stimulated cells, but there was no obvious difference in the nuclear 
translocation of Smad4 between TGF-P1 or activin A stimulated cells (Fig. 8).
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Figure 8 TGF-ß1 and activin A induced nuclear translocation of Smad2, Smad3, and Smad4 proteins in thyroid 
follicle cells. Cells were grown in monolayer on coverslips, stimulated for 1 h with 10 ng/ml of TGF-ß1 or 50 ng/ml of 
activin A. Cells were fixed and permealized and subjected to an immunofluorescence staining as described in ‘Materials 
and Methods’.
DISCUSSION
Fine-tuning of thyroid growth and function is achieved through both positive and negative 
regulation (Duh and Grossman, 1995; Gärtner, 1997; Lewinski et al., 1993). TGF-ß has been shown 
to be a potent negative regulator of thyrocytes (Morris III et al., 1988; Taton et al., 1993; Tsushima 
et al., 1988). TGF-ß is part of a large group of structurally and functionally related proteins, which 
also includes activins and BMPs (Roberts and Sporn, 1990). Here we report that TGF-ß1 and 
activin A, but not BMP-7, are important negative regulators for porcine thyroid follicle cells. In 
these cells, TGF-ß 1 and activin A were found to bind to different complexes of type I and type II 
receptors. However, TGF-ß 1 and activin A activated identical Smad proteins. TGF-ß 1 was found to 
be more efficient than activin A in Smad activation; this correlated with their difference in potency 
with regard to negative regulation of thyroid follicle cell proliferation and function.
We examined the localization of TGF-ß1, activin A and BMP-7 in porcine thyroid tissue by 
immunohistochemistry. A specific immunostaining of all three ligands was found; both TGF-ß 1 and 
activin A were widely expressed and localized to the epithelial cells. The staining for the two 
ligands was localized to the cytoplasm of the follicle cells, indicating an active synthesis. 
Furthermore, there was a heterogeneity in the expression level mainly between different follicles, 
but also among different cells in the same follicle. The staining for BMP-7 was weak, and showed a 
pronounced heterogeneity in expression levels between cells within the follicle compared to the 
TGF-ß 1 and activin A stainings. However, comparison of relative amounts between the ligands is
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difficult as the affinity of the antibodies may differ. The BMP-7 staining was localized to the 
cytoplasm, but in contrast to TGF-ß1 and activin A, it was also localized to the nuclei of the cells.
There is still some controversy regarding the production of TGF-ß 1 in normal thyroid follicular 
epithelium. Several previous reports have failed to demonstrate TGF-ß 1 in normal thyroid follicle 
cells in vivo (Jasani et al., 1990; Logan et al., 1994; Morosini et al., 1996). However, as mentioned 
previously, TGF-ß 1 production has been demonstrated in many in vitro cell systems of normal 
thyrocytes (Morris III et al., 1988, Cowin et al., 1992; Cowin and Bidey, 1994) and in diseased 
(Grubeck-Loebenstein et al., 1989; Jasani et al., 1990) and hyperplastic thyroid tissue (Logan et al., 
1994; Morosini et al., 1996). Our in vitro results regarding the production of TGF-ß1 in thyrocytes 
are consistent with previous studies, however, we find a high in vivo expression of TGF-ß 1 in the 
porcine thyroids. The explanation for the discrepancy between the results might be that different 
antibodies were used. In addition, our activin A staining results are in agreement with Wada et al. 
(1996), who also found activin A in thyroid follicular cells.
Previous reports have demonstrated the TGF-ß-mediated inhibition of thyroid cell growth in the 
absence or presence of growth factors, as mentioned above. We have extended these studies by 
comparing effects of multiple TGF-ß superfamily members that were found to be localized within 
the thyroid. TGF-ß1 and activin A, but not BMP-7, were found to inhibit, in part, the basal 
proliferation as well as EGF- or HGF-mediated increase in proliferation of thyrocytes. Our 
observations regarding the effects of activin A contrast with a previous report of Kotajima et al. 
(1995) in which activin was found to stimulate thyroid cell growth. An activin A-induced growth 
inhibition has been reported using mink lung epithelial cells (Yamashita et al., 1995b), human 
keratinocytes (Shimizu et al., 1998), and B cells (Ishisaki et al., 1998b).
TGF-ß1 was found to inhibit the TSH-stimulated cAMP response in thyrocytes when cells were 
pretreated for 24 h but not after 2 h. These results are in contrast to previous reports that described 
no effect of TGF-ß in this assay (Taton et al., 1993; Tsushima et al., 1988), however, they are in 
agreement with another study (Morris III et al., 1988). Differences in assay and cell culture 
conditions are likely reasons for these discrepancies; in contrast to other reports, our cells are kept in 
the three dimensional structure of a follicle, and may thus reflect a more physiological situation. As 
previously reported by Kotajima et al. (1995), addition of activin A to our thyroid follicle cells for 
24 h inhibited the TSH-induced cAMP production. When comparing TGF-ß 1 and activin A, also in 
this assay, we found TGF-ß1 to be more potent than activin A. Interestingly, BMP-7, in contrast to 
TGF-ß 1 and activin A, had a slight inhibitory effect when pretreated for 2 h, but not 24 h. A 
possible mechanistic explanation for TGF-ß-mediated inhibition was provided by the observed 
downregulation of TSH receptor mRNA level detectable after 2 h treatment with TGF-ß 1. A 
reduced binding of 125I-TSH was observed in FRTL-5 cells 12 h after addition of TGF-ß 1 (Morris 
III et al., 1988). The lack of effect of activin in this assay may suggest mechanisms, other than 
TSHR downregulation, that contribute to the inhibition by TGF-ß 1 on the TSH-stimulated cAMP 
response. The potent negative effects of TGF-ß 1 and activin A and the production of these ligands 
by thyroid follicular cells, taken together, indicate an important autocrine/paracrine regulatory 
function for these factors in thyroid tissue. The physiological significance of BMP-7 in the thyroid, 
if any, is presently unclear.
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To obtain insight into the mechanism of action of TGF-ß superfamily members in thyroid follicle 
cells, we examined ligand-induced receptor binding and Smad activation in these cells. Whereas 
TGF-ß 1 was found to induce a heteromeric complex of TßR-I and TßR-II, activin induced a 
heteromeric complex predominantly consisting of ActR-IB and ActR-II. Whereas ActR-I expression 
was readily detected by mRNA analysis, a weak binding of activin A to ActR-I was observed. This 
is also apparent from other studies; activin A binds much more efficiently to ActR-IB than to ActR-I 
(Yamashita et al., 1995b). Furthermore, ActR-I has recently been shown to bind BMP-7 rather than 
activin A (Marcías-Silva et al., 1998). Moreover, Cárcamo et al. (1994), showed that TßR-I and 
ActR-IB, which are structurally related, mediate growth inhibition of Mv1Lu epithelial cells 
whereas TSR-1 (ALK1) or ActR-I did not. We did not observe any expression of TßR-III in the 
porcine which differs from results from studies on rat and human thyrocytes (Huang et al., 1998; 
Heldin et al., unpublished results) that showed a high level of TßR-III. We were unable to detect 
BMP-7 receptor binding on these cells as assessed by affinity crosslinking. However, Northern blot 
analysis of BMPR-IA and BMPR-II showed expression of these receptors in RNA from porcine 
thyrocytes grown in vitro, as well as in human thyroid tissue from a patient with toxic goiter. The 
lack of efficient binding of BMP-7 may be explained by an inefficient translation of BMPR 
mRNAs, or by a low affinity binding of BMP-7 to the BMP-receptors.
Recently, Shimizu et al. (1998) reported that TGF-ß 1 signaling through TßR-I activated Smad2 
and Smad3, but signaling by activin through ActR-IB activated predominantly Smad3 in human 
keratinocytes. In the present study, examination of the subcellular distribution of Smad2, Smad3 
and Smad4 in the absence or presence of TGF-ß 1 and activin A revealed that both ligands were able 
to induce nuclear translocation of these Smads. The nuclear translocation of Smad2 and Smad3 was 
more intense after stimulation with TGF-ß 1 compared to activin A. In agreement with this finding, 
TGF-ß 1 was found to induce the phosphorylation of Smad2 more efficiently than activin A. Thus, 
in porcine thyrocytes there was no obvious difference in the activation of Smads by TGF-ß 1 or 
activin A, although TGF-ß 1 was more potent than activin A. As expected, we neither observed a 
nuclear translocation of Smad2 or Smad3 nor Smad2 phosphorylation upon BMP-7 challenge of 
thyroid cells.
In summary, our results indicate an important role of the TGF-ß superfamily members on thyroid 
regulation of normal thyrocytes in vivo. The simultaneous expression of TGF-ß 1 and activin A and 
their receptors and downstream Smad effectors in normal follicular epithelium suggests an 
interesting autocrine role for these factors.
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ABSTRACT
Cartilage-derived morphogenetic proteins-1 and -2 (CDMP-1 and -2) are members of the bone 
morphogenetic protein (BMP) family, which play important roles in embryonic skeletal 
development. We studied the biological activities of recombinant CDMP-1 and -2 in chondrogenic 
and osteogenic differentiation and investigated their binding properties to type I and type II 
serine/threonine kinase receptors. In vivo, CDMP-1 and CDMP-2 were capable of inducing dose- 
dependently de novo cartilage and bone formation in an ectopic implantation assay. In vitro studies 
using primary chondrocyte cultures showed that both CDMP-1 and CDMP-2 stimulated de novo 
synthesis of proteoglycan aggrecan in a concentration-dependent manner equally. This activity was 
equipotent when compared with osteogenic protein-1 (OP-1). In contrast, CDMPs were less 
stimulatory than OP-1 in osteogenic differentiation as evaluated by alkaline phosphatase activity 
and expression levels of bone markers in ATDC5, ROB-C26 and MC3T3-E1 cells. CDMP-2 was 
the least osteogenic in these assays. Receptor binding studies of CDMP-1 and -2 revealed that both 
have affinity for the BMP receptor type IB (BMPR-IB) and BMP receptor type II (BMPR-II), and 
weakly for BMP receptor type IA. Moreover, using a promoter/reporter construct, transcriptional 
activation signal was transduced by BMPR-IB in the presence of BMPR-II upon CDMP-1 and 
CDMP-2 binding. Our data show that distinct members of the BMP family differentially regulate 
the progression in the osteogenic lineage and this may be due to their selective affinity for specific 
receptor complexes.
INTRODUCTION
Cartilage-derived morphogenetic proteins-1 and -2 (CDMP-1 and -2) are two members of the 
transforming growth factor-B (TGF-P) superfamily. During development they are expressed 
predominantly in and around skeletal elements and in the joint interzones (Chang et al., 1994; 
Storm et al., 1994). CDMP-1 and -2 are 82% identical in their biologically active carboxyl-terminal 
domains. They are most closely related to the bone morphogenetic protein (BMP) subgroups BMP- 
5/ BMP-6/osteogenic protein-1 (OP-1) and BMP-2/BMP-4 (Chang et al., 1994).
The physiological role of CDMP-1, the human homologue of mouse growth differentiation 
factor-5 (Gdf-5), has been established by its linkage to mouse and human skeletal disorders, 
brachypodism (bp) and Hunter-Thompson chondrodysplasia respectively (Chang et al., 1994; Storm 
et al., 1994; Thomas et al., 1996). Both phenotypes are characterized by skeletal abnormalities 
restricted to the limbs and synovial joints and are associated with null mutations in the cdmp1/gdf5 
gene. These genetic studies provide direct evidence for the involvement of CDMP-1 in the 
patterning and tissue specification of the appendicular skeletal structures. The primary role of 
CDMP-2, the human homologue of mouse Gdf-6, is so far unknown. Besides its involvement in 
skeletal morphogenesis, its high levels of expression in postnatal cartilaginous tissues suggest a 
possible role in the promotion and maintenance of the cartilaginous phenotype (Chang et al., 1994; 
Luyten et al., 1995).
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TGF-P superfamily members elicit their biological response through binding to a heteromeric 
complex of two types of serine/threonine kinase receptors (i.e. type I and type II). Various type I and 
type II receptors for BMPs have been identified (ten Dijke et al., 1996). Receptor binding studies 
have revealed that BMPs have affinity for several distinct receptor complexes (ten Dijke et al., 
1994c). Interestingly, as shown for OP-1, BMPs appear to utilize different heteromeric receptor 
complexes to elicit their diverse biological functions (Yamashita et al., 1995b).
The expression pattern of the CDMPs is restricted to skeletal structures during embryonic 
development and therefore suggests a more defined role in the regulation of chondrogenic and 
osteogenic differentiation. Therefore we have investigated skeletal lineage progression using 
recombinant CDMP-1 and CDMP-2 and compared their activities with OP-1 (Asashina et al., 
1996). Our data show that both CDMPs and OP-1 promote chondrogenesis, however CDMPs are 
significantly less osteogenic than OP-1. Furthermore, receptor binding studies indicate that the 
distinct biological profile of the CDMPs when compared with OP-1 may be explained by their 
selective affinity for specific heteromeric receptor complexes.
MATERIALS AND METHODS
xpression o f  CDMP-1 and CDMP-2 in E. coliE
A cDNA encoding the mature cdmp-1 was tailored for insertion into an E. coli expression vector by site directed 
mutagenesis using the Kunkel method (Kunkel, 1985). Following the pro-domain and in close vicinity of the RXXR 
processing site, a leucine residue was converted to a methionine translational initiation codon with a corresponding NcoI 
restriction site, while a 3' XhoI site was similarly introduced immediately after the translational stop codon. The NcoI to 
XhoI fragment containing the open reading frame for mature cdmp-1 was ligated with a tetracycline resistant pBR322 
derived expression vector. Fermentation was done in shaker flasks using 2YT medium with addition of indol acrylic acid 
at the appropriate time for the induction of the tryptophan promoter and led to accumulation of large inclusion bodies. A 
cDNA for cdmp-2 was similarly tailored for expression. Since the yield of expression was quite low, we used part of the 
N-terminal region of the highly expressed cdmp-1 and spliced it with the 7-cysteine domain of cdmp-2 at the first 
cysteine, where both genes share a PstI site. Induced cell cultures (250 ml) were centrifuged (11,000 x g, 10 min., 4°C), 
followed by resuspension of the cell pellets in 50 ml 25 mM Tris, 10 mM EDTA, pH 8.0 (1 X TE) plus 100 ^g/ml 
lysozyme. The cell suspensions were incubated overnight at 37°C, then chilled on ice and disrupted by sonication. 
Inclusion bodies were isolated by centrifugation (11,000 x g, 20 min., 4°C) and resuspension in 1 X TE. The final 
washed inclusion body pellets were resuspended in 40 ml 1 X TE, 15% glycerol and stored at -20°C.
Protein folding and protein purification
Reduced and denatured inclusion body protein solutions were prepared by dissolving aliquots of pelleted inclusion 
bodies in 100 mM Tris, 10 mM EDTA, 6 M guanidine HCl, 10 mM dithiothreitol (DTT), pH 8.0 (final protein 
concentration of 4-6 mg/ml). The inclusion body protein solutions were incubated at 37°C for 30 min., then diluted 40­
fold with refolding buffer (100 mM Tris, 10 mM EDTA, 1 M NaCl, 2% 3-[(3-cholamidopropyl) dimethylammonio]-2- 
hydroxy-1-propanesulfonic acid (CHAPS), 5 mM reduced glutathione, 2.5 mM oxidized glutathione, pH 8.7). The 
refolding reactions were incubated for 72 hours at 4°C. The folding reactions were dialyzed extensively against 10 mM 
HCl, then clarified by centrifugation (11,000 x g, 20 min., 4°C). The solutions were concentrated using a stirred cell
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concentrator and YM10 MWCO membranes (Amicon, MA). The concentrated proteins were then lyophilized. The 
lyophilized proteins were resuspended in 0.8 ml 0.1% trifluoracetic acid (TFA), 70% acetonitrile, then diluted to 2 ml 
with 0.1% TFA (final acetonitrile concentration: 30%). The protein solutions were fractionated by semi-preparative C4 
Reverse Phase-High Pressure Liquid Chromatography using a linear acetonitrile gradient (30-70% in 0.1% TFA). 
Aliquots of each fraction were analyzed on SDS-PAGE (15% gels) in non reduced conditions and after reduction and 
alkylation. Peak dimer fractions were pooled and UV absorbance spectra obtained. Concentrations were estimated from 
absorbance at 280 nm. Protein pools were stored at -20°C. The average yield of properly folded protein per liter 
bacterial fermentation were approximately 50-60 mg for CDMP-1 and 40-50 mg for CDMP-2.
In vivo subcutaneous implantation assay
To evaluate the potential of CDMP-1 and -2 to induce cartilage and bone at non-skeletal sites in vivo, increasing 
doses of recombinant growth factors were reconstituted with 25 mg of rat collagen carrier, lyophilized and implanted 
subcutaneously in the thoracic region of 28-35 day old male Long-Evans rats as described (Luyten et al., 1989). 
Implants without the addition of CDMPs served as negative controls. The animals were sacrificed 10 and 21 days after 
implantation and their implants were fixed, plastic embedded and sectioned. Sections were subsequently stained with 
toluidine blue, von Kossa or Masson trichrome. Cartilage and bone forming activity was further quantified by 
determining the specific activity of alkaline phosphatase (Luyten et al., 1989).
Cell culture
The mouse embryonic teratocarcinoma cell line ATDC5, the mouse calvarial osteoblastic clonal cell line MC3T3- 
E1, the mouse myoblast cell line C2C12 and R mutant Mv1Lu cells were cultured in a 1:1 mixture of Dulbecco's 
Modified Eagle's medium (DMEM) and Ham's F-12 containing 5% fetal bovine serum (FBS) and antibiotics (100 
units/ml penicillin G, 100 mg/ml streptomycin and 0.25 ^g/ml amphotericin B)(Life Technologies, Gaithersburg, MD). 
The rat osteoprogenitor-like cell line ROB-C26 was grown in alpha-minimal essential medium (Life Technologies) 
containing 10% FBS and antibiotics. All experiments were performed under serum-free conditions using a chemically 
defined basal medium. The serum-free basal medium (BM) consisted of Ham's F-12/DMEM (1/1) with ITS™+ culture 
supplement (Collaborative Biomedical Products, Bedford, MA), alpha-ketoglutarate (1 x 10-4 M), ceruloplasmin (0.25 
U/ml), cholesterol (5 ^g/ml), phosphatidylethanolamine (2 ^g/ml), alpha-tocopherol acid succinate (9 x 10-7 M), 
reduced glutathione (10 ^g/ml), taurine (1.25 ^g/ml), triiodothyronine (1.6 x 10-9M), hydrocortisone (1 x 10-9 M), and 
parathyroid hormone (5 x 10-10 M), B-glycerophosphate (10 mM final concentration), and L-ascorbic acid 2-sulphate (50 
^g/ml) (Sigma).
For proteoglycan biosynthesis and alkaline phosphatase activity assays, cells were plated at a density of 4 x 104 cells in 
BM in 24-multiwell plates (Costar, Cambridge, MA). Growth factors were added the next day and the culture media 
were replaced every other day. Cultures were maintained at 37 °C in humidified air and 5% CO2. To determine DNA- 
synthesis, 1 x 106 cells were plated out in BM in 100 mm tissue culture dishes (Falcon, Becton Dickinson Labware, NJ) 
and cultured similarly.
Human fetal limbs from 52 to 79 day old fetuses were kindly provided by the Central Laboratory for Human 
Embryology, University of Washington, Seattle, WA. This was approved by the Office of Human Subjects Research of 
the National Institutes of Health. The cartilaginous cores were carefully dissected from the surrounding fetal tissue and 
the chondrocytes were released by a 6 hour digestion in 0.2 % collagenase B (Boehringer Mannheim, Indianapolis, IN) 
in BM at 37 °C. Postnatal bovine articular chondrocytes were prepared as described (Luyten et al., 1994). For the
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evaluation of newly synthesized proteoglycans and for DNA-content measurement, chondrocytes were plated out in BM 
in the same density as described above for the cell lines.
DNA determination
DNA content from chondrocytes and ATDC5 cells was determined after 1, 2 and 10 days of culture using 
bisbenzimide (Hoechst 33258, Sigma, St. Louis, MO) (Labarca and Paigen, 1980).
Alkaline phosphatase activity
Alkaline phosphatase activity was determined in sonicated cell homogenates after 4, 6 and/or 10 days of treatment 
(Reddi and Huggins, 1972). Briefly, after extensive washing with phosphate buffered saline (PBS), cell layers were 
sonicated in 500 ^l of PBS containing Triton-X100 (0.05 % final concentration). 50-100 ^l aliquots were assayed for 
enzyme activity in assay buffer (0.1 M sodium barbital buffer, pH 9.3) and p-nitrophenyl phosphate (Sigma) as 
substrate. Absorbance was measured at 400 nm. Activity was normalized to protein content measured by the Bradford 
protein assay using bovine serum albumin as standard (Bio-Rad, Richmond, CA).
Proteoglycan biosynthesis
35
Rates of [ S]sulfate incorporation into macromolecules were evaluated as described (Luyten et al., 1994). Briefly,
35 35
cell cultures were labeled with 50 ^Ci/ml of [ S]sulfate for 6 h at 37 °C. Newly synthesized [ S]sulfate-labeled 
macromolecules of both cell extracts (4 M guanidine-HCl in 50 mM Tris, pH 7.2) and media were determined after 
removal of unincorporated isotope using Sephadex G-25 (PD-10, Pharmacia Biotech, Piscataway, NJ) gel 
chromatography. The values were normalized to DNA content. To determine the size of the newly synthesized material, 
500 ^l aliquots of the radiolabeled fraction were analyzed on a Sephacryl S-500 HR column (1 x 30 cm, Pharmacia 
Biotech), previously equilibrated with 4 M guanidine HCl, 0.5% Triton X-100 in 50 mM sodium acetate buffer, pH 6.0, 
at a flow rate of 0.4 ml/min. Each fraction was measured for radioactivity. A small quantity of [3H]glucosamine was 
added as internal elution position marker.
RNA isolation and Northern blot analysis
Total RNA was extracted using the acidic guanidine-phenol-chloroform method (Chomczynski and Sacchi, 1987). 
For Northern blot analysis, equal amounts (5 ^g) of total RNA were electrophoresed on 1.2 % agarose-formaldehyde 
gels and transferred to Nytran membranes (Schleicher and Schuell, NH). The blots were prehybridized for 30 min. at 
68° C in hybridization buffer (Express HybTMClontech, Palo Alto, CA) and hybridization was performed for 1 hour at 
68 °C in the same buffer with [32P]-labeled cDNA probes. Probes included mouse cDNAs encoding biglycan, decorin, 
bone sialoprotein (BSP), osteocalcin (Fisher et al., 1995) and human alkaline phosphatase (AP). A probe for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as control cDNA probe. After hybridization, the filters 
were washed four times in 2 X sodium chloride / sodium citrate (SSC), 0.5% SDS and twice in 0.2 X SSC, 1% SDS at 
room temperature for 10 min. The blots were then exposed to Kodak XAR-5 films at -70 °C for up to 24 hours and 
quantified using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). The amounts of detected transcripts were 
normalized to GAPDH.
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Radiolabeling o f  CDMP-1 and CDMP-2
CDMP-1 and -2 were iodinated with chloramine-T (Frolik et al., 1984). Both ligands were radiolabeled to an equal 
specific activity.
Affinity cross-linking and immunoprecipitation
Cells were incubated 3 hours on ice in binding buffer (PBS containing 0.9 mM CaCl2, 0.49 mM MgCl2 and 0.1% 
bovine serum albumin) in the presence of 200 to 400 pM of iodinated ligand. After incubation, the cells were washed 
and cross-linking was performed using 1 mM bis(sulfosuccinimidyl)suberate (Pierce) and 0.28 mM disuccinimidyl 
suberate for 15 min. The cells were washed, scraped off the plates, centrifuged, and resuspended in solubilization buffer, 
and incubated for 20 minutes on ice. Immunoprecipitation of the cross-linked materials was performed as described 
(Nishitoh et al., 1996). Two T 75 flasks of subconfluent cells were used for each immunoprecipitation (ten Dijke et al., 
1994b). The immune complexes were eluted by boiling 3 min. in SDS sample buffer containing 10 mM dithiotreitol and 
separated by SDS gel electrophoresis. These gels were then dried and followed by Bio-Imaging analysis (Fuji) or 
autoradiography.
Transcriptional activation response assay
Chemically mutagenized Mv1Lu cells were cotransfected with a p3TP-Lux promoter/reporter construct, BMP- 
receptor type II (BMPR-II) and plasmids containing various type I receptor cDNAs. One day after transfection, cells 
were treated for 20 hours with CDMP-1 or CDMP-2 under serum-free conditions. Luciferase activity in the cell lysate 
was analyzed using the luciferase assay system (Promega, Madison, WI) according to the manufacturer’s protocol and a 
luminometer (MGM Instruments, Hamden, CT).
Statistical analysis
Statistical significance was defined as a P value < 0.05, in the Mann-Whitney U-test.
RESULTS
Production o f recombinant CDMP-1 and CDMP-2
The mature domains of cdmp-1 and cdmp-2 were expressed in E. coli , refolded and purified 
using reverse phase high pressure liquid chromatography (data not shown). Aliquots (5 |ig) of the 
purified protein preparations were analyzed by SDS-PAGE before and after reduction and alkylation 
(Fig. 1). The non-reduced proteins migrated as a major band around 28 kDa, while the reduced 
fractions showed a band at 16 kDa. These findings are consistent with appropriate homodimer 
formation.
CDMP-1 and CDMP-2 induce cartilage and bone formation in vivo
Histological evaluation of the in vivo bio-assay showed that implantation of the carrier without 
the addition of CDMPs did not initiate cartilage or bone formation (Fig. 2 A). CDMP-1, CDMP-2 
and OP-1 induced islands of chondrocytes 10 days after implantation (Fig. 2 B). Furthermore, Von 
Kossa staining indicated ongoing de novo mineralization (Fig. 2 C). At day 21, bone formation was
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apparent in the implants (Fig. 2 D). A dose response experiment was performed for CDMP-1 and -2 
and biochemical analysis of day 10 implants produced comparable, dose-dependent increases in 
alkaline phosphatase activity (Fig. 3). However, CDMPs were significantly less active in this in vivo 
assay than OP-1 (p<0.03) (Fig. 3, inset).
kDa
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67
Figure 1 SDS-PAGE analysis of recombinant 
CDMP-1 and CDMP-2. Lane A, 5 ng CDMP-1 after
30 reduction and alkylation; lane B, 5 |ig CDMP-1 non-
„ reduced; lane C, 5 l i e  CDMP-2 after reduction and 
20
alkylation; lane D, 5 ng CDMP-2 non-reduced.
14
Figure 2 In vivo ectopic induction of cartilage and bone by CDMPs. (A) Negative control consisting of guanidine- 
extracted demineralized rat bone matrix (residu used as carrier) (day 10) (Toluidine blue staining). (B) 1 ^g CDMP-1 
treated tissue showing newly formed cartilage islands between the rat carrier matrix particles (day 10) (toluidine blue 
staining). (C) 1 ^g CDMP-1 treated tissue showing Von Kossa staining of implants after 10 days. (D) 1 ^g CDMP-1 
treated tissue showing Masson trichrome staining of newly formed woven bone and bone marrow in implants after 21 
days. A,B,C, Magnification 400 X, D, 200 X
CDMP-1, CDMP-2 and OP-1 equally stimulate proteoglycan synthesis in primary chondrocytes 
CDMP-1, -2 and OP-1 increased [ S] sulfate incorporation into proteoglycans equally. This 
effect was apparent in both fetal chondrocytes (Fig. 4A) and postnatal articular chondrocytes (data 
not shown) and was concentration- and time-dependent. Analysis of the hydrodynamic size of the 
newly synthesized macromolecules demonstrated the presence of the large proteoglycan species, 
which eluted in the void volume of a Sephacryl S-500 HR column, consistent with a cartilage
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phenotype (Fig 4B). Cell proliferation, as measured by DNA content, was not affected by growth 
factor treatment (data not shown).
Figure 3 Alkaline phosphatase activity in CDMP-1 and 
CDMP-2 containing in vivo implants. Alkaline 
phosphatase activity was measured to determine the extent 
of chondro/osteogenesis induced by increasing
concentrations of purified refolded bacterial expressed 
CDMP-1 and CDMP-2. Values represent the means and 
standard deviations of the means of four to eight 
observations. Comparison of alkaline phosphatase activity 
between equal amounts (1 ^g) of CDMP-1, CDMP-2 and 
OP-1 is depicted in the inset. Experiments were repeated 
three times.
Figure 4 [35S]sulfate incorporation and analysis of the hydrodynamic size of newly synthesized macromolecules in 
primary fetal chondrocyte cultures. (A) Quadruplicate cultures of chondrocytes were treated for 24 and 72 hours with 
CDMP-1 (100 ng/ml), CDMP-2 (100 ng/ml) or OP-1 (100 ng/ml). Cell cultures were labeled with [35S]sulfate for 6 h, 
and the incorporated radiolabel was calculated per ^g DNA content. Dose-response data were performed with four 
doses of CDMP-1, CDMP-2 and OP-1 and are shown in insets. The bars represent the means and standard deviations of 
the means. Experiments were repeated three times. (B) For the analysis of the hydrodynamic size of newly synthesized
35
macromolecules, [ S]-labeled materials were applied to a Sephacryl S-500 HR column. *p<0.03 versus BM. **p<0.03 
versus BM and p<0.04 versus day 1.
Amount of Protein
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CDMPs are less osteogenic than OP-1 in osteoblast-like cell lines
We analyzed the expression of osteogenic markers in the mouse osteo/chondroprogenitor cell 
line ATDC5, the osteoblastic mouse clonal cell line MC3T3-E1 and the rat osteoprogenitor-like cell 
line ROB-C26 to determine whether CDMPs promote osteogenic differentiation. Treatment with 
both CDMP-1 and CDMP-2 resulted in an increase of alkaline phosphatase activity when compared 
to basal medium in all the cell lines (p< 0.03) (Fig. 5). This effect was significantly less with 
CDMP-2 than CDMP-1 (p< 0.03). In contrast, OP-1 was two- to three-fold more stimulatory than 
CDMP-1 (p< 0.03). Interestingly, in human fetal chondrocytes (52-79 days) , OP-1 increased 
alkaline phosphatase values more than a tenfold, whereas CDMP-1 and CDMP-2 only slightly 
enhanced this activity (Fig. 6 A). In the myoblast cell line C2C12 osteogenic differentiation was 
promoted by OP-1 but not by the CDMPs (Fig. 6B).
Figure 5 Effect of CDMP-1, CDMP-2 and OP-1 on alkaline phosphatase activity of ATDC5, MC3T3-E1 and ROB- 
C26 cells. Quadruplicate cultures of ATDC5 (A), MC3T3-E1 (B) and ROB-C26 cells (C) were grown in the presence or 
absence of CDMP-1 (100 ng/ml), CDMP-2 (100 ng/ml) or OP-1 (100 ng/ml). Dose-response data with four doses of 
CDMP-1, CDMP-2 and OP-1 are shown in insets. The error bars indicate the standard deviations of the mean of four 
observations: *** p<0.03 versus CDMP-1, CDMP-2 and BM, ** p<0.03 versus CDMP-2 and BM and * p<0.03 versus 
BM
Further analysis of osteogenic differentiation was performed using Northern blot analysis of 
osteogenic markers. In ATDC5 cells, cultured in the presence of the indicated morphogens, OP-1 
and CDMP-1 increased alkaline phosphatase mRNA levels (Fig. 7). In addition, transcripts for BSP 
were strongly upregulated after OP-1 treatment, while CDMP-1 was less potent in this regard (Fig. 
7). CDMP-2 only slightly enhanced BSP expression (Fig. 7). The expression of osteocalcin mRNA 
was not detected (data not shown). Northern blot analysis for the small proteoglycan species
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biglycan and decorin showed that OP-1 upregulated decorin expression (Fig. 7). These data support 
differential regulation of osteogenic differentiation by OP-1, CDMP-1, and CDMP-2.
Figure 6 Alkaline phosphatase activity in primary fetal chondrocytes and C2C12 cells treated with CDMP-1, CDMP-2 
and OP-1. Quadruplicate cultures of primary fetal chondrocytes (A) and C2C12 cells (B) were cultured in the presence 
or absence of CDMP-1 (100 ng/ml), CDMP-2 (100 ng/ml) or OP-1 (100 ng/ml) under serum-free conditions. The 
specific activity of alkaline phosphatase was quantitated after 4 days of treatment. Dose-response data with four doses of 
CDMP-1, CDMP-2 and OP-1 are depicted in insets. The bars represent the means and standard deviations of the means. 
Experiments were repeated three times. (A) * p<0.03 versus BM and ** p<0.03 versus CDMP-1, CDMP-2 and BM, (B) 
* p<0.03 versus CDMP-1, CDMP-2 and BM.
Figure 7 Northern analysis of CDMP-1, 
CDMP-2 and OP-1 treated samples on the 
expression of osteogenic markers in 
ATDC5 cells. Cells were cultured with or 
without CDMP-1 (100 ng/ml), CDMP-2 
(100 ng/ml), OP-1 (100 ng/ml) or 5 % 
fetal bovine serum (FBS) for 4 and 10 
days. Total RNA from each culture (5 ^g) 
was separated on 1.2 % agarose 
formaldehyde-agarose gels, blotted and 
subsequently hybridized with the 
respective cDNA probes as described in 
Materials and Methods. GAPDH 
expression levels are shown to verify 
equal loading of mRNA (bottom).
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CDMP-1 and CDMP-2 bind to BMPR-IB and BMPR-II in non transfected cells
To identify which type I and type II receptors have affinity for CDMP-1 and CDMP-2, binding
125studies were performed using I-labeled CDMPs in various cell lines and in primary chondrocytes. 
ROB-C26 cells were affinity-labeled with iodinated-CDMP-1 and -2 and the cross-linked 
complexes were immunoprecipitated using antisera to a panel of type I and type II receptors and 
analyzed by SDS-gel electrophoresis under reducing conditions. Cross-linked complexes of 80-90 
kDa could be immunoprecipitated by antisera to BMP receptor type IB (BMPR-IB) and BMPR-II 
for both CDMP-1 and CDMP-2. Their binding characteristics were similar and one representative 
autoradiograph is shown in Fig. 8. A high molecular weight complex of 150-200 kDa which may 
represent a type II receptor complex, was co-immunoprecipitated by the BMPR-IB (Fig. 8). Co- 
immunoprecipitation of the type I receptor complex was also detected by the BMPR-II antiserum 
(Fig. 8). A weak band could be seen after immunoprecipitation with the antiserum against BMP 
receptor type IA(BMPR-IA), whereas antisera against ActR (activin receptor)-I, ActR-II and ActR- 
IIB did not immunoprecipitate any appreciable amounts of CDMP cross-linked complexes (Fig. 8).
Figure 8 Binding of CDMP-2 to type I and type 
II receptors in ROB-C26 cells. Binding and 
affinity cross-linking of 125I-radiolabeled CDMP-2 
were performed using ROB-C26 cells, followed by 
immunoprecipitation using antisera against type I 
and type II receptors. Samples were analyzed by 
SDS-gel electrophoresis and autoradiography 
using Bio-Imaging Analyzer.
■° "2rt
CDMPs transduce a transcriptional activation signal by BMPR-IB and BMPR-II in transfected 
cells
To investigate whether CDMP-1 and CDMP-2 are able to transduce a signal upon binding to 
their respective type I and type II receptor complexes, the signaling activity of CDMPs was analyzed 
in R mutant Mv1Lu cells using the p3TP-Lux promoter/reporter construct. The BMPR-IB/BMPR-II 
complex mediated an efficient signal for both CDMPs which was in agreement with our binding 
data (Fig. 9). Furthermore, CDMP-2 but not CDMP-1 transduced a weak signal through the BMPR- 
IA/BMPR-II complex (Fig. 9). No activation was observed with other type I receptors in the 
complex. Cells transfected with either type I or type II receptors only did not respond to the CDMPs 
(data not shown).
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Figure 9 Signal transduction by CDMP-1 and CDMP-2 in transfected R mutant Mv1Lu cells. A p3TP-Lux 
promoter/reporter construct was cotransfected with a cDNA for BMPR-II and plasmids containing activin receptor-like 
kinase (ALK)-I (negative control) , BMPR-IA or BMPR-IB into R mutant Mv1Lu cells. One day after transfection, cells 
were treated for 20 hours with CDMP-1 (300 ng/ml) or CDMP-2 (300 ng/ml) followed by the measurement of the 
luciferase activity in the cell lysates. The bars represent the means and standard deviations of the means of three 
independent experiments.
DISCUSSION
Our study compared for the first time the activity of recombinant CDMP-1, CDMP -2 and OP-1 
in the initiation and progression of chondrogenic and osteogenic differentiation both in vivo and in 
vitro. Our findings suggest that the the CDMPs are equipotent in stimulating cartilage matrix 
synthesis when compared to OP-1, but have markedly reduced activity in the promotion of 
osteogenesis. Furthermore, CDMP-2 appeared to be less osteogenic than CDMP-1 in vitro. In 
addition, our data indicate that the underlying molecular basis for the differential biological 
responses between CDMP-1, CDMP-2 and OP-1 might be due to their relative affinities for specific 
receptor complexes.
The in vivo assay for ectopic induction of cartilage and bone formation, using rat bone residue as 
the delivery system, confirmed that CDMP-1 and -2 are not only structurally but also functionally 
related to BMPs 2, 4 and BMPs 5, 6 ,7 (Sampath et al., 1992; Hotten et al., 1996). Ectopic bone 
induction for Gdf-5/CDMP-1 has previously been reported (Hotten et al., 1996). Our data showed 
that CDMP-1 and CDMP-2 equally induce cartilage and bone formation. Interestingly, CDMPs 
appear to be significantly less active in this in vivo assay than OP-1. It is conceivable that the use of
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other carriers might affect the outcome of the cartilage and bone inducing properties of the 
morphogens.
We studied the promotion of cartilage differentiation by CDMP-1 and -2 in vitro using primary 
cell cultures. The enhanced de novo proteoglycan aggrecan synthesis in primary chondroblasts 
originating from fetal limbs, as well as in postnatal articular chondrocyte cultures, supports the 
stimulatory role of the CDMPs in chondrogenic differentiation. No differences in the stimulation of 
cartilage matrix synthesis were observed between CDMP-1, CDMP-2 and OP-1 treatments. 
Enhancement of matrix synthesis in chondrocyte cultures has been reported for other BMPs 
previously (Vukicevic et al., 1989; Carrington et al., 1991; Luyten et al., 1994). These and our data 
suggest that in these cell cultures BMPs/CDMPs may use the same signaling pathways regulating 
matrix synthesis. In contrast, using alkaline phosphatase activity as a marker for chondrocyte 
maturation/bone formation, the CDMPs are not, or only to a limited extent, affecting this marker 
when compared to OP-1. To further explore a difference in the promotion of the progression in the 
osteogenic lineage, we found that CDMPs were significantly less osteogenic than OP-1 in various 
osteoblast-like cell lines. It is noteworthy that the osteogenic differentiation induced by OP-1 as 
observed in ATDC5 cells, is associated with an increase of BSP and decorin, reflecting a full 
commitment in the osteogenic lineage with bone matrix deposition. The modest osteogenic activity 
of CDMP-1 is in contrast to previously published data, reporting no effect of Gdf-5, the mouse 
homologue of CDMP-1, on osteoblastic cells cultured in serum containing media (Hotten et al., 
1996; Nishitoh et al., 1996). This difference may be due to the fact that we used a chemically 
defined serum-free medium. Indeed, we have demonstrated that biological responses to BMPs in in 
vitro models are diminished in the presence of fetal bovine serum (Vukicevic et al., 1990). In 
addition, this low osteogenic activity of the CDMPs was most pronounced in C2C12 cells, where no 
increase in alkaline phosphatase activity by CDMPs was observed, whereas OP-1 and as previously 
described BMP-2 convert these cells into the osteoblastic lineage in low serum conditions (Katagiri 
et al., 1994). Therefore, the combined data suggest that the signaling cascade(s) with regard to 
osteogenesis may be distinct from these involved in cartilage differentiation, and that different 
members of the BMP family signal through specific pathways.
In a first attempt to identify the molecular basis for specific biological activities elicited by 
various BMPs/CDMPs, in particular chondrogenesis and osteogenesis, we set out to characterize the 
receptor complexes for the CDMPs. We demonstrated in this manuscript that CDMP-1 and CDMP- 
2 bind predominantly to the BMPR-IB and BMPR-II receptors. In addition, our transcriptional 
response data showed that CDMPs signal through this BMPR-IB/BMPR-II complex. This is in 
agreement with the findings that Gdf-5 binds and signals through this complex (Nishitoh et al.,
1996). Recently, using the in vivo developing chick limb model and in vitro micromass cultures, 
Kawakami et al. (1996) found that BMPR-IB and BMPR-II are the critical receptor complexes in 
chondrogenesis of limb mesenchymal cells. These authors demonstrated intense expression of 
BMPR-IB in the developing limb, and showed that a dominant negative BMPR-IB receptor 
markedly inhibited chondrogenesis as measured by cartilage nodule formation and de novo 
proteoglycan synthesis. Taken together, the preferential binding of the CDMPs to the BMPR- 
IB/BMP-RII complex and the evidence of the direct association of this complex with
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chondrogenesis, provides a molecular cascade for the stimulation of chondrogenic differentiation by 
the CDMPs. In contrast, OP-1 binds and signals through other receptor complexes besides BMPR- 
IB/BMPR-II (ten Dijke et al., 1994c; Yamashita et al., 1995b). Therefore, our data further support 
the possibility of the existence of distinct molecular pathways associated with osteogenesis and 
chondrogenesis.
A potential limitation in the interpretation of the data relates to the preparation method of the 
recombinant proteins as the CDMPs are bacterially refolded proteins while OP-1 was produced in 
mammalian cells (Sampath et al., 1992). Contaminants or the presence of inappropriately folded 
proteins in the CDMP preparations may affect their biological responses. However, we have 
consistently found the same results using at least three different batches of HPLC purified proteins. 
In addition our data show that the CDMPs and OP-1 have identical effects in dose response 
experiments on the proteoglycan synthesis in human fetal chondrocyte cultures, while only OP-1 
stimulates alkaline phosphatase levels in the same cultures. Finally, the differential responses for 
CDMP-1 when compared with CDMP-2, most strikingly observed in ATDC-5 cells (Fig. 7), makes 
it unlikely that the distinct biological responses are due to different protein preparation methods.
In conclusion, we reported the expression of functional recombinant CDMP-1 and CDMP-2, and 
their biological activities in chondrogenic and osteogenic models, in vivo and in vitro. The data 
show a weak osteogenic potential of the CDMPs when compared with OP-1. This differential 
response may be due to specific ligand-receptor interactions. Our studies suggest that the 
BMPs/CDMPs may provide powerful experimental tools to further unravel the mechanisms leading 
to cartilage or bone formation.
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ABSTRACT
Mast cells are known to accumulate at sites of inflammation, however, the chemotaxins involved 
remain largely undefined. Transforming growth factor-P (TGF-P) isoforms regulate numerous 
cellular functions, including cell growth and differentiation, formation of extracellular matrix, and 
the immune response. In our current study we have compared the potency of different members of 
the TGF-P superfamily as human mast cell chemotaxins, and analyzed the expression of TGF-P 
binding proteins on human mast cells. We could demonstrate that the maximal chemotactic 
response was attained at approximately 40 fM for the three TGF-P isoforms, with TGF-P3 being 
more effective than TGF-P 1 and TGF-P2 at this concentration. This effect was observed in both the 
HMC-1 human mast cell line and in cultured primary mast cells. In addition, TGF-P1, TGF-P2 and 
less efficiently TGF-P3 inhibited the proliferation of HMC-1 cells. The migratory response is 
probably mediated through interaction with the TGF-P serine/threonine type I and II receptors that 
were found to be expressed on the cells. No expression of TGF-P type III receptor, endoglin, or the 
endothelial TGF-P type I receptor ALK-1 could be detected. These results provide evidence that 
TGF-P isoforms are highly potent chemotaxins for human mast cells and can play an important role 
in the recruitment of mast cells in inflammatory reactions.
INTRODUCTION
Mast cells frequently accumulate at sites of inflammation (Metcalfe et al., 1997). The factors that 
stimulate mast cell migration remain largely undefined, although recent reports have implicated 
stem cell factor, C3a and C5a, and RANTES to be involved (Nilsson et al., 1994b, 1996b; Mattoli 
et al., 1995; Hartmann et al., 1997). Other potential candidates for acting as mast cell chemotaxins 
are members of the TGF-P superfamily, which include TGF-P1, -P2, -P3, activins, and bone 
morphogenetic proteins (reviewed in Roberts and Sporn, 1990). TGF-P has been shown to be a 
potent chemotaxin for several different cell types, including neutrophils, monocytes, and fibroblasts 
(Postlewhaite et al., 1987; Wahl et al., 1987; Brandes et al., 1991; Reibman et al., 1991). 
Pathological processes mediated by TGF-P, such as fibrosis and wound healing, are often associated 
with mast cell accumulation (Meininger and Zetter, 1992; Gruber, 1995). Intra-articular injection of 
TGF-P leads to an inflammatory synovitis, with large numbers of mast cells, indicating that TGF- 
P mediates mast cell migration (Allen, et al., 1990). Furthermore, a murine mast cell line has been 
shown to respond chemotactically to TGF-P1 (Gruber et al., 1994).
TGF-Ps are prototypic secreted multifunctional proteins; activities include inhibition of 
proliferation of many different cell types, regulation of immune responses, and stimulation of 
extracellular matrix formation. They also function as chemotaxins for inflammatory cells. Although 
the three TGF-P isoforms mainly exert overlapping biological activities, some isoform-specific 
activities have been described. TGF-P1 but not TGF-P3 induces scar formation after wounding 
(Shah et al., 1995). TGF-P1 and TGF-P3 are more potent than TGF-P2 in inhibiting proliferation of 
hematopoietic progenitor cells and endothelial cells (Cheifetz et al., 1990). They also show some
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quantitative differences which may depend on target cell and assay used (Ohta et al., 1987; Graycar 
et al., 1989; ten Dijke et al., 1990; Jacobsen et al., 1991). All three isoforms have been implicated 
in several diseases, including cancer and fibrosis (Roberts and Sporn, 1990).
TGF-P superfamily members mediate their biological activities by binding to cell surface 
receptors. Two types of TGF-P membrane receptors (type I and II; T^R-I and T^R-II) with intrinsic 
serine/threonine kinase activities are directly involved in the signal transduction (Heldin et al.,
1997). TGF-^1 and TGF-^3 bind more efficiently than TGF-^2 to T^R-II T^R-III, also referred to 
as betaglycan, and endoglin (CD 105) are structurally related transmembrane proteins that have a 
more indirect role in signaling. T^R-III binds the three TGF-P isoforms with approximately equal 
affinities and functions in presenting TGF-P to T^R-II T^R-I, which is a substrate for the 
constitutively active T^R-II kinase, is directly responsible for downstream signal transduction that 
leads to Smad activation (Massague et al., 1997).
In the present study we determined whether TGF-P superfamily members could act as 
chemotaxins for the human mast cell line HMC-1, and human in vitro cultured primary mast cells. 
In addition, we analyzed the growth inhibitory response elicited by the three TGF-P isoforms TGF- 
P1, -^2 and -^3, as well as their binding to TGF-P receptors in HMC-1 mast cells. We observed that 
all three TGF-P isoforms could induce chemotaxis, reaching optimal effects at approximately 40 
fM. These data indicate that TGF-P isoforms are potent chemotactic agents and elicit their effect at 
much lower molar concentrations than other known mast cell chemotaxins.
MATERIALS AND METHODS
Cell cultures
The human mast cell line HMC-1 (Butterfield et al., 1988; Nilsson et al., 1994a) was cultured in Iscove’s modified 
Dulbecco’s medium supplemented with 10% bovine calf serum (BCS), 2 mM L-glutamine, 100 IU/ml penicillin, 50 
|J.g/ml streptomycin, and 1.2 mM a-thioglycerol (complete medium). The cells were passaged every 3 to 4 days.
Primary human mast cells were developed from umbilical cord blood cultured in the presence of stem cell factor as 
described (Nilsson et al., 1996a). Briefly, mononuclear cells were separated by Ficoll-Plaque (Pharmacia Biotech, 
Uppsala, Sweden) gradient centrifugation, washed in phosphate buffered saline (PBS) and suspended in RPMI 1640 
medium, supplemented with 10% BCS, 2 mM L-glutamine, 100 IU/ml penicillin, 50 |J.g/ml streptomycin, 1.2 mM a- 
thioglycerol, 50 |xM 2-mercaptoethanol, and 0.1 mM nonessential amino acids. The cell suspension was seeded at a 
density of 106 cells/ml in 10-ml flasks. Recombinant human stem cell factor (SCF, provided by Immunex Inc., Seattle, 
WA) was added at 50 ng/ml. The medium was changed weekly.
Chemotaxis assay
Mast cell migration was examined using a 48-well microchemotaxis assay as described (Nilsson et al., 1994b). 
Micropore filters (150 |J.m thick nitrocellulose, Millipore/Continental Water Systems, Bedford, MA) with a pore size of 
8 |j.m, were coated with human plasma fibronectin (Life Technologies, Gaithersburg, MD) at a concentration of 10 
|j.g/ml in room temperature overnight. TGF-P superfamily members to be tested, TGF-P1 (purified from human 
platelets, Genzyme, Cambridge, MA), TGF-P2 (recombinant, Genzyme), TGF-P3 (recombinant, R&D Systems,
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Abingdon, UK), activin A (kind gift from Dr. Y. Eto, Ajinomoto Company, Kawasaki, Japan) and BMP-7 (kind gift 
from Dr. K. Sampath, Creative Biomolecules, Hopkinton, MA), were diluted in medium. The migration of mast cells 
suspended in medium with 10% BCS served as control and was referred to as 100% migration. Cell chemotaxis was 
assayed after 150 min as the migration of the two furthest migrating cells visible in focus of one high power field 
(10x20). The migration distance on each filter was calculated as the mean of the readings of three different areas of the 
filter. The assay was always done with at least triplicate measurements. A checkerboard analysis of mast cell motility 
was conducted according to the method of Zigmond and Hirsch (1973). The specificity of the TGF-P induced migration 
was tested by the addition of pan-specific TGF-P neutralizing antibody (R&D systems) and isotype control.
Measurement o f  cell proliferation
HMC-1 cells (105) were plated in 200 |jl complete medium in 96-well plates. TGF-P1, TGF-P2, TGF-P3, activin A 
or BMP-7 (20 fM - 0.4 nM) were added in triplicate. The cultures were incubated for 54 hr, followed by addition of 
[3H]thymidine (1 mCi/well; Du Pont, Boston, MA) for 18 h. Cultures were harvested and incorporation of 
[3H]thymidine was measured using scintillation fluid in a scintillation counter.
Affinity cross-linking studies and immunoprecipitation
Human recombinant TGF-P1 (provided by Dr. N. Ferrara, Genentech, San Francisco, CA), TGF-P2 (provided by
Dr. B. Pratt, Genzyme Corporation, Framingham, MA), and TGF-P3 (R&D Systems) were iodinated according to the
125
chloramine-T method (Frolik et al., 1984). Affinity-binding and cross-linking of I-TGF-P binding proteins on HMC- 
1 cells, followed by immunoprecipitations with TGF-P receptor-specific antisera was performed as previously described 
(Piek et al., 1997).
Statistical analysis
The data in the text and figures were expressed as mean ± SEM, unless otherwise stated. For statistical analysis we 
used an analysis of variance (ANOVA), followed by multiple comparison by Fisher's method. Differences were 
considered significant at p<0.05.
RESULTS
Mast cell chemotaxis to TGF-P isoforms
Since TGF-P has been shown to be a very potent chemotaxin for several different cell types 
(Postlewhaite et al., 1987; Wahl et al., 1987; Brandes et al., 1991; Reibman et al., 1991), mast cell 
migration in response to TGF-P isoforms was measured in a low concentration interval between 1 
fM - 0.1 nM TGF-P. As shown, both HMC-1 cells (Fig. 1A) and cord blood cultured mast cells 
(Fig. 1B) showed maximal migratory response to the different TGF-P isoforms at approximately 40 
fM (Fig. 1A insert), with an ED50 of approximately 10 fM, under the conditions of this study. Of 
the three TGF-P isoforms, TGF-P3 gave rise to a significantly higher migration than TGF-P1 or 
TGF-P2 at a concentration of 40 fM, whereas TGF-P1 and TGF-P2 were not significantly different 
in efficacy with respect to their migratory response (P1:P2, p<0.19; P1:P3, p<0.007; P2:P3, p< 
0.05). The response at 40 fM was for TGF-P3 185%, TGF-P2 163%, and TGF-P1 151%. No
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migration to activin A or BMP-7 at the concentrations tested (4 fM-0.4 nM) could be observed (data 
not shown).
TGF-p (M) TGF-P (M)
Figure 1 Chemotactic response of HMC-1 cells (A) and primary human mast cells (B) to TGF-P1 (squares), TGF-P2 
(triangles), and TGF-P3 (circles). Cell migration towards chemoattractant was calculated as percentage of the migration 
towards cell culture medium alone. The insert in A shows the dose response within the fM range. Results are expressed 
as mean ± SEM of at least three independent experiments done in triplicate. A significant response was obtained as 
indicated (p<0.05, *; p<0.01, **; p<0.001, ***).
To determine the specificity of the chemotactic response, TGF-P1 was incubated with varying 
concentrations of a neutralizing antibody to TGF-P. Chemotaxis was inhibited in a dose-dependent 
manner by the specific antibody, with a total extinction at 10 |ig/ml (Fig. 2A). As expected, isotype 
control antibody did not affect the migratory response (Fig. 2B).
The ability of TGF-P1 to stimulate directional migration (chemotaxis) versus random migration 
(chemokinesis) was analyzed by employing a checkerboard assay. Chemotaxis should only be 
observed when the concentration of the attractant in the lower chamber is higher than that in the 
upper chamber. As shown in Table 1, the presence of TGF-P1 in only the upper wells did not induce 
any increase in migration. However, at 40 and 80 fM of TGF-P1 in both the upper and lower wells, 
there was a significant increase in the migratory response.
TGF-P isoform-induced inhibition o f mast cell proliferation
We also determined the growth inhibitory effects of TGF-P isoforms on HMC-1 cells assessed as 
[3H]thymidine incorporation. TGF-P1 and TGF-P2 showed a similar dose-dependent inhibitory 
effect on mast cell proliferation, whereas TGF-P3 was less potent under the conditions of this assay 
(Fig. 3). The highest concentration tested was 0.4 nM (= 10 ng/ml). Activin A or BMP-7 did not 
have any growth inhibitory effects on HMC-1 cells (data not shown).
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Figure 2 Neutralizing antibody against TGF-P inhibits chemotaxis to TGF-P1. A) HMC-1 cells were incubated in 
TGF-P1 (40 fM) and different concentrations of TGF-P antibodies. B) As a control, 10 |J.g/ml of species-matched 
rabbit-IgG was shown not to affect TGF-P1-induced migration. Results are expressed as mean ± SEM of three 
independent experiments done in triplicate.
Figure 3 TGF-P-induced inhibition of mast cell 
proliferation. HMC-1 cells were treated with 
different concentrations of TGF-P1, TGF-P2, or 
TGF-P3 for 72 h. [3H]thymidine was added to 
the cultures 18 h before harvest. Results are 
given as mean cpm ± SEM (n = 6).
Expression o f TGF-P type I  and type II receptors in HMC-1 cells
To reveal which TGF-P binding pro^ns are expressed on HMC-1 cells, we performed affinity 
cross-linking studies using 200 pM I-TGF-P1 (Fig. 4). Immunoprecipitations with TGF-P 
receptor-specific antisera revealed that the 66 kDa and 90 kDa I-TGF-P1-cross-linked protein
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complexes corresponded to the TGF-P type I (T^R-I) and type II receptors (T^R-II), respectively. 
Binding of I-TGF-^1 to T^R-III, endoglin, or ALK-1, which is a putative TGF-P type I 
serine/threonine kinase receptor in endothelial cells (T. Imamura, P. ten Dijke, K. Miyazono, 
personal communication) could not be detected in HMC-1 cells. These data suggest that TGF-P 
signaling in HMC-1 cells is mediated by T^R-I and T^R-II.
Table 1 Checkerboard analysis of mast cell chemotaxis to TGF-P 1. Columns represent increasing concentrations of 
TGF-P1 in lower wells, and lines indicate the concentration in upper wells. Mean ± SEM (n=3).
TGF-P 1 
fM 0 4 40 80
0 100 ± 0 107 ±1 97 + 0 100.5 ±0.5
4 124.5 ±4.5 115.5 ±6 .5 103.5 ±0 .5 99.5 ±9.5
40 164.5±0.5 156 + 4 157.5 ±0 .5 132 ±1
80 131 ± 0 126 ± 3 120.5 ±3 .5 126.5 ±3.5
Figure 4 Identification of TGF-P cell surface binding
proteins on HMC-1 mast cells. HMC-1 cells were affinity 
125
labeled with 200 pM I-TGF-P1, followed by cross­
linking with 0.28 mM disuccinimidyl suberate (DSS). 
Aliquots of cell lysates were analyzed directly by SDS-gel 
electrophoresis followed by autoradiography, or first 
subjected to immunoprecipitation (IP) using antisera 
against activin receptor like-kinase 1 (ALK-1), 
transforming growth factor receptor type I (TPR-I), TPR- 
II, TPR-III, and endoglin.
To compare the binding characterist^ of the thre^TGF-P isoforms1 ^  TPR-I and TPR-II on 
HMC-1 cells, affinity cross-linking of I-TGF-P1, I-TGF-P2, and I-TGF-P3 (with similar 
specific activities), was carried out (Fig. 5). Immunoprecipitations of I-TGF-P-cross-linked
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protein complexes with TpR-I and TPR-II antisera revealed that the three TGF-P isoforms all bound
. However, the125
affinity with wh5ch I-TGF-P2 bound to the TGF-P receptors was lower compared to that of I- 
TGF-Pl and I-TGF-P3. Thus, while the three TGF-P isoforms bound to the same TGF-P 
receptors on HMC-1 cells, their binding-affinities for the TGF-P receptors differed.
Figure 5 Analysis of binding characteristics
of the three TGF-p isoforms TGF-p1, TGF-
p2 and TGF-p3 to TGF-p interacting proteins
on HMC-1 mast cells. HMC-1 cells were
affinity cross-linked with approximately 200 
125 125 125
pM I-TGF-pl, I-TGF-P2, and I-
TGF-p3, at similar specific activities.
Aliquots of the cell lysates were analyzed
directly by SDS-gel electrophoresis followed
by autoradiography, or first subjected to
immunoprecipitation (IP) using antisera
against Tp R-I and TpR-II.
Table 2 ED50 values of human mast cell chemotaxins
Ligand 125l-TGF-pi 125l-TGF-ß2 125 l-TQF-ß3
IP - TßR-I  TßR-I  I - TßR-I TßR-ll - TßR-I  TßR-ll
to TßR-I and TßR-IL Binding to TßR-IU and endoglin was absent (data not shown)
Chemotaxin ED50 
. (pM)
TGF-p 0.01
Stem cell factor 500
Complement factor C3a 500
Complement factor C5a 10
Platelet-activating factor 1000
DISCUSSION
In this study we have shown that TGF-P isoforms are potent mast cell chemotaxins, reaching 
optimal induction at approximately 40 fM. Cell migration induced by TGF-P is mainly through 
chemotaxis compared to chemokinesis. In contrast to the potent chemotactic effect of TGF-P3, this 
isoform was less efficient than TGF-P 1 and TGF-P2 to inhibit HMC-1 proliferation. All three TGF- 
P isoforms associate with type I and type II receptors on the cell surface of human mast cells, 
suggesting that TGF-P responses are triggered via signaling through TPR-I/TPR-II complexes.
In analogy to other chemotaxins, the TGF-P isoforms display a bell-shaped dose-dependent 
chemotactic effect with a peak at approximately 40 fM, indicating that the activation threshold to 
trigger cell migration is sharply defined. At this concentration, TGF-P3 induced a statistically 
significant higher migratory response compared to TGF-Pl and TGF-P2. In monocytes (Wahl et al.,
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1987), T cells (Adams et al., 1991) and neutrophils (Parekh et al., 1994), optimal migration has also 
been reported at 40 fM TGF-P, whereas rat aortic smooth muscle cells require 10 times higher 
concentration for maximal response (Koyama et al., 1990). TGF-P2 is the most potent isoform in 
neutrophils (Parekh et al., 1994). When comparing the half-maximal effective concentration (a 
measure of agonist potency) and the efficacy (response at the optimal concentration) with previously 
reported chemotaxins (Nilsson et al., 1994b, 1996b; Mattoli et al., 1995; Hartmann et al., 1997), it 
is found that TGF-P isoforms are the most potent mast cell chemoattractants so far described, 
eliciting chemotaxis of HMC-1 cells at 1,000 times lower molar concentrations than e.g., stem cell 
factor or anaphylatoxins (Table 2; (Nilsson et al., 1994b, 1996b). The efficacy is comparable with 
that of SCF, but much lower than that of C3a (Nilsson et al., 1994b, 1996b).
The mast cell migratory response to TGF-Pl was largely due to chemotaxis and not 
chemokinesis (Table 1). No chemokinesis was observed when TGF-Pl was present in the upper 
well only. However, the cells migrated at higher concentrations of TGF-Pl in both the upper and 
lower wells (no gradient of TGF-Pl). This indicates that the cell movement under these conditions 
is partly chemokinetic. A similar response to TGF-P 1 was reported for murine mast cells (Gruber et 
al., 1994). In contrast, mast cell migration to stem cell factor is solely chemotactic with significant 
migration only when there is an increasing gradient of stem cell factor towards the lower 
compartment (Meininger et al., 1992; Nilsson et al., 1994b).
Comparison of the three TGF-P isoforms in inhibition of cellular proliferation of HMC-1 cells 
revealed that TGF-Pl and TGF-P2 were equally potent, reaching half maximal growth arrest at 
approximately 1 ng/ml (40 pM). In contrast, TGF-P3 could not significantly inhibit cellular 
proliferation at any of the concentrations tested. Since the same TGF-P preparations were used to 
study cell migration and growth arrest, these data indicate that HMC-1 cells respond differently to 
the various TGF-P isoforms in different biological assays. The three TGF-P isoforms were equally 
potent in inhibiting proliferation of Mv1Lu cells (data not shown). Whereas the three TGF-P 
isoforms exert many overlapping activities in vitro, differences between the isoforms have been 
described in certain cell types, like hematopoietic cells (Ohta et al., 1987; Jacobsen et al., 1991) and 
vascular endothelial cells (Jennings et al., 1988). Differences in activity between TGF-Pl and TGF- 
P3 have been observed in scar formation, which is specifically induced by TGF-Pl (Shah et al., 
1995). Several binding proteins are known that selectively interact with the different TGF-P 
isoforms, thereby modulating their biological activity (Cheifetz and Massague, 1991; MacKay and 
Danielpour, 1991; Piek et al., 1997).
Receptors for TGF-P have not been previously described for human mast cells. This study 
indicates that TPR-I and TPR-II, but not TPR-III are expressed on human mast cells (Fig. 4). In 
contrast, the murine mast cell line C57 has been shown to express TPR-I and TPR-III, but not TPR- 
II (Gruber et al., 1994). Providing a possible explanation for the inability of BMP-7 to function as a
mast cell chemotaxin or to induce growth inhibition, no BMP-7 receptors could be detected in the
125affinity cross-linking studies using I-BMP-7 (data not shown).
Whereas TGF-P1 and TGF-P3 had comparable affinity for the TGF-P receptors, TGF-P2 
interacted poorly with TPR-II and TPR-I (Fig. 5), which is in agreement with its weak intrinsic 
affinity for the type II TGF-P receptors in the absence of TPR-III (Cheifetz et al., 1987; Lin et al.,
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1995). Despite of this, TGF-P2 was found to be as potent as TGF-Pl in inducing mast cell 
migration and inhibition of mast cell growth. It must be noted that the affinity cross-linking data 
illustrate receptor occupancy at saturation levels, representing the conditions under which growth 
inhibition was mediated; the receptor binding data cannot be extrapolated to chemotactic conditions 
which are performed with 40 fM TGF-Pl. Affinity labeling studies cannot be performed at these 
low concentrations.
Cells which respond comparably to TGF-Pl, TGF-P2 and TGF-P3 usually express TPR-III. The 
affinity of TGF-P2 for TPR-II is dramatically increased by TPR-III, and enables TGF-P2 to signal 
as potent as the other TGF-P isoforms (Cheifetz et al., 1987, 1990; Lopez-Casillas, et al., 1993). 
However, since TPR-III is not detectable in HMC-1 cells, other mechanisms might contribute to 
effective TGF-P2 signaling. Growth inhibition by TGF-P2 can occur in the absence of TPR-III 
expression (Lopez-Casillas et al., 1993). It has been described that TGF-P2 can bind with high 
affinity to a, presumably pre-existing, receptor complex consisting of TPR-I and TPR-II, which 
enables TGF-P2 to signal effectively (Rodriguez et al., 1995). Possibly, the downstream activation 
triggered by these low abundant TGF-P2 receptor complexes in HMC-1 cells is sufficient to induce 
growth inhibition.
As might be anticipated based on the multifunctional effects of TGF-P on many different cell 
types, TGF-P has been proposed to be involved in a wide variety of disorders (Border and 
Ruoslahti, 1992). In many of these disorders, such as rheumatoid arthritis, mast cells accumulate 
and likewise have been implicated in the pathogenesis of the disease (Malone et al., 1986; 
Wasserman, 1987). An enhanced expression of the TGF-P isoforms in the synovial tissue of 
patients with arthritis has been described (Taketazu et al., 1994). Furthermore, synovial fluids 
contain mast cell chemoattractant activity which in part is due to TGF-P (Olsson, Ulfgren and 
Nilsson, manuscript in preparation). The extremely low concentrations of TGF-P necessary to 
induce chemotactic response of mast cells provide evidence for the role for TGF-P in the initial 
phase of the inflammatory response. At higher concentrations other cellular functions might be 
induced, e.g., cell growth arrest. TGF-P does not induce degranulation of mast cells, but can prime 
mast cells to potentiate cytokine expression in the presence of IgE and antigen (Rumsang et al.,
1997). Our data suggest an important link between TGF-P isoforms and mast cells by the finding 
that TGF-Pl, TGF-P2 and TGF-P3 all serve as extremely potent chemoattractants for mast cells. 
Mast cell migration towards TGF-P appears thus to represent an important mechanism in the 
recruitment of mast cells to sites of tissue inflammation.
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ABSTRACT
Transforming growth factor-P (TGF-P) isoforms regulate numerous cellular functions through 
binding to receptors with intrinsic serine/threonine kinase activity that transduce their intracellular 
signals via activation of Smad proteins. In this study, we examined the signaling pathways involved 
in TGF-P 1-mediated growth inhibition and migration in a human mast cell line, HMC-1. TGF-P1 
evoked optimal migration at 40 fM, whereas maximal growth inhibition was obtained at 400 pM. 
TGF-P 1-induced chemotaxis was found to be partially dependent on functional protein kinase C 
and phosphatidylinositol 3-kinase. The protein-tyrosine kinase inhibitors genistein, herbimycin A, 
and erbstatin analog completely inhibited TGF-P 1-mediated migration, while they did not affect the 
anti-mitogenic response. Pathway-restricted Smad2 was found to be phosphorylated upon TGF-P 1 
challenge in the absence or presence of genistein. The mitogen-activated protein kinase kinase 
(MEK) inhibitor PD98059 blocked the migratory response, with no effect on the growth inhibition 
induced by TGF-P 1. In contrast, the p38 mitogen-activated protein kinase (MAPK) inhibitor 
SB203580 had no significant effect on either migration or growth inhibition. Treatment with 
cycloheximide revealed that TGF-P 1-induced migration is dependent on protein synthesis. These 
results indicate that different signaling pathways mediate TGF-P 1-induced migration and growth 
inhibition in HMC-1 cells, where TGF-P1 elicits migration through activation of MEK.
INTRODUCTION
Transforming growth factor-P (TGF-P) is a multifunctional cytokine belonging to a family of 
structurally and functionally related polypeptides involved in cellular growth, differentiation, 
migration, immune regulation, and tissue repair (Roberts and Sporn, 1990). TGF-P signals through 
a heteromeric complex of type I (TPR-I) and type II (TPR-II) transmembrane serine/threonine 
receptor kinases (Massague, 1996; ten Dijke et al., 1996). Both receptors have been shown to be 
essential for signaling. TPR-I kinase becomes activated upon phosphorylation by the constitutively 
active TPR-II kinase and propagates the signal downstream to Smad proteins that have been shown 
to play a pivotal role in the intracellular signaling of TGF-P. Upon TPR-I activation, Smad2 and/or 
Smad3 become phosphorylated within a conserved SSXS motif at the C-terminus, and then form 
heteromeric complexes with the common mediator Smad4. This complex translocates to the nucleus 
where it directs the transcription of target genes (Heldin et al., 1997; Massague, 1998).
Mast cells are important inflammatory cells of the immune system (Galli and Wershil, 1996; 
Metcalfe et al., 1997). They are widely distributed throughout vascularized tissues and certain 
epithelia, where they function as major effector cells through their release of inflammatory 
mediators, such as histamine, heparin, proteases, and cytokines. Mast cells accumulate at sites of 
certain inflammatory responses including immediate hypersensitivity and autoimmune reactions, 
parasite infections, interstitial cystitis and in transplanted tissues undergoing rejection (Godfrey et 
al., 1984; Aldenborg et al., 1986; Enerback et al., 1986; Li et al., 1992; Gibson et al., 1993; 
Laitinen et al., 1993; Nilsson et al., 1998). A direct migration of mast cells within the tissue is
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probably an important mechanism for this increase in mast cell number. TGF-P is the most potent 
mast cell chemoattractant so far described, inducing optimal migration at fM concentrations (Gruber 
et al., 1994; Olsson et al., 1999a).
In the present study we compared the intracellular signal transducing pathways for TGF-P 1- 
induced migration and growth inhibition in a mast cell model. TGF-P 1-induced migration of the 
human mast cell line HMC-1 at 40 fM whereas growth inhibition was obtained at 400 pM. TGF-P 1- 
induced migration, but not growth inhibition, was found to be dependent on protein tyrosine 
phosphorylation and on functional MEK. Thus, in this study we show that the signals induced by 
TGF-P 1 that lead to cell migration and to growth inhibition differ in mast cells.
MATERIALS AND METHODS
Cell culture
The human mast cell line HMC-1 (Butterfield et al., 1988; Nilsson et al., 1994a) obtained from Dr. J.H. Butterfield 
(Mayo Clinic, Rochester, MN) was cultured in Iscove's modified Dulbecco's medium supplemented with 10% bovine 
calf serum (BCS), 2 mM L-glutamine, 100 IU/ml penicillin, 50 |J.g/ml streptomycin, and 1.2 mM a-thioglycerol. The 
cells were passaged every 3 to 4 days.
Migration assay
Migration was measured in a 48-well micro-Boyden chemotaxis chamber (Neuroprobe Inc., Cabin John, MD) by 
means of the leading front technique (Wilkinson, 1982). Micropore filters (150 |J.m thick nitrocellulose from 
Millipore/Continental Water Systems, Bedford, MA) with a pore size of 8 |j.m were coated overnight with human 
plasma fibronectin (Life Technologies, Gaithersburg, MD) at a concentration of 10 Mg/ml at room temperature. The 
filters were air-dried for at least 60 min before use. The assay was performed as previously described (Nilsson et al., 
1994b). Briefly, TGF-P 1 (Genzyme, Cambridge, MA) concentrations to be tested were diluted in medium. Thirty 
microliters of chemotactic stimuli were added to each well below the filter, and 50 |jl of the cell suspension (1.5 x 106 
cells/ml) above the filter. Cells were allowed to migrate for 150 min at 37°C in 5% CO2. The filter was fixed, stained 
with Mayer's-Hemalum solution, and mounted. The migration of HMC-1 cells suspended in medium with 10% BCS, 
and with the same medium below the filter, served as a control and was referred to as 100% migration. Cell chemotaxis 
was assayed as the migration of the two furthest migrating cells visible in focus of one high power field (10x20). The 
migration distance on each filter was calculated as the mean of the readings of three different areas of the filter and three 
readings on each area. The assay was always done in triplicate.
Treatment with inhibitors
HMC-1 cells were treated with pertussis toxin (Sigma Chemical Co., St. Louis, MO), bisindolylmaleimide I, 
genistein, erbstatin analog, herbimycin A , SB203580, PD98059, wortmannin, and cycloheximide (all from Calbiochem- 
Novabiochem, La Jolla, CA). Treatment with inhibitors, at concentrations as indicated in the text and figures, was 
performed by incubating 2.5 x 106 cells/ml for 90 min at 37°C in 5% CO2 in complete medium, and were then washed 
and resuspended at 1.5 x 106 cells/ml in complete medium before the chemotaxis assay.
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Thymidine incorporation assay
HMC-1 cells (10x104) were plated in 200 M complete medium. TGF-P 1 at 400 pM was added in triplicate. 
Inhibitors were either added at the beginning of the experiments (0 h), or at 0 h followed by extra addition of half of the 
concentration at 24 and 48 h. The cultures were incubated for 72 hr. Eighteen h before harvest [3H]thymidine (1 
MCi/well; Du Pont, Boston, MA) was added to each well. Incorporation of [3H]thymidine was measured in a scintillation 
counter.
Western blot analysis o f  Smad2 phosphorylation
TGF-P 1 was obtained from Dr. N. Ferrara at Genentech (San Francisco, CA). Preparation and characterization of 
antisera against Smad2 (SED) and phosphorylated Smad2 (PS2) have been described previously (Nakao et al., 1997b; 
Piek et al., 1999).
HMC-1 cells were rinsed in phosphate-buffered saline (PBS) and serum-starved in medium containing 0.1% bovine 
serum albumin (BSA). After 90 min, 100 nM genistein was added, followed by stimulation of the cells with 40 fM or 
200 pM TGF-P 1 for 60 min. Cells were put on ice, rinsed with PBS and lysed in solubilisation buffer (125 mM NaCl,
10 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM PMSF, 1.5% Trasylol, and 1% Triton X-100) for 40 min. Cell lysates 
were separated on an 8.5 % sodium dodecyl sulphate (SDS)-polyacrylamide gel, followed by wet-transfer of the proteins 
to Hybond-C extra nitrocellulose membranes (Amersham, Buckinghamshire, United Kingdom). Nonspecific binding of 
proteins to the membranes was blocked in TBS-T (10 mM Tris-HCl, pH 7.4, 150 mM NaCl; 0.1% Tween 20) 
containing 3% BSA. Primary Smad antibodies were 1,000 times diluted in TBS-T, and secondary horseradish 
peroxidase-conjugated goat anti-rabbit IgG antibody (Amersham Sweden AB, Solna, Sweden) was used in a 10,000 
times dilution in TBS-T. Detection was performed by enhanced chemiluminescence (ECL).
Statistical analysis
The data in the text and figures were expressed as mean ± SEM, unless otherwise stated. For statistical analysis we 
used an analysis of variance (ANOVA), followed by multiple comparison by Fisher's method. Differences were 
considered significant at p<0.05.
RESULTS
Effects o f TGF-P 1-induced mast cell migration and growth inhibition
We first compared the dose-dependent effect of TGF-P 1 on mast cell migration and proliferation. 
TGF-P 1 induced mast cell migration in a bell-shaped curve with higher concentrations resulting in a 
loss of directed migration (Fig. 1). The optimal chemotactic response was obtained at approximately 
40 fM. In contrast, mast cell proliferation, assessed as 3[H]thymidine incorporation, was inhibited at 
approximately 10,000 times higher concentration, 400 pM (Fig. 1). TGF-P1 had no effect on cell 
proliferation at 40 fM.
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Figure 1 TGF-p1-induced 
migration and growth inhibition of 
HMC-1 cells. The dose-response 
of TGF-p1-induced migration 
(stars) and growth inhibition (filled 
squares) was performed on HMC-1 
cells as described in Materials and 
Methods. Migration was measured 
after 150 min and growth 
inhibition after 72 h. The results 
shown are from three experiments 
done in triplicate.
TGF-p1-induced migration is partially dependent on protein kinase C and phosphatidylinositol 3- 
kinase
To evaluate the signal transduction pathways possibly involved in TGF-p1-induced mast cell 
migration and proliferation, we used pertussis toxin (PTx) to inhibit signals mediated by G proteins, 
bisindolylmaleimide I to inhibit protein kinase C (PKC), and wortmannin to inhibit 
phosphatidylinositol 3-kinase (PI3-K). Pretreatment with PTx did not affect either TGF-p1- 
mediated mast cell migration or growth inhibition (Fig. 2). Migration induced by zymosan activated 
serum (ZAS; a source of C3a, C4a and C5a) that mediates its effect through a PTx sensitive 
pathway, was completely blocked (Fig. 2). TGF-p1-induced growth inhibition was not affected by 
PTx-treatment. Chemotaxis to TGF-p1 was found to be dependent on functional PKC and PI3-K 
since pre-treatment with bisindolylmaleimide I (100 nM) and wortmannin (100 nM) significantly 
attenuated the migratory response (Fig. 2). Bisindolylmaleimide I and wortmannin both increased 
the spontaneous proliferation of HMC-1 cells as observed in the growth inhibition assays (Fig. 2). 
However, none of them had any significant effect on the relative TGF-p1-induced growth inhibition 
(Fig. 2), suggesting that neither PKC nor PI3-K are involved in TGF-p1-induced growth inhibition 
of HMC-1 cells.
Protein-tyrosine kinase inhibitors block TGF-p1-induced mast cell migration
We next investigated whether inhibitors of protein tyrosine kinases (PTK) have any effect on 
mast cell migration or growth inhibition induced by TGF-p1. Three different PTK inhibitors that 
exhibit rather broad specificity were used; genistein, erbstatin analog and herbimycin A (Levitzki 
and Gazit, 1995). They all completely inhibited TGF-p1-mediated mast cell migration at 1 |aM (Fig.
3). Genistein significantly affected the migration at 10 nM. No effect of the PTK inhibitors was 
observed on TGF-p1-induced growth inhibition. Similar results were achieved when genistein was 
repeatedly added during the assay, indicating that the lack of effect by genistein on TGF-p1-induced 
growth retardation was not due to instability of the inhibitor (data not shown).
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TGF-P1 - - + + ZAS + + TGF-P1 - - + +
Wn - + - + - + Wn - + - +
Figure 2 Effect of inhibitors on TGF-pi-induced chemotaxis. HMC-1 cells were treated with 0.5 |J.g/ml pertussis toxin 
(PTx), 100 nM bisindolylmaleimide I (Bis), or 100 nM wortmannin (Wn). The migratory and growth inhibitory 
response of treated cells to TGF-pi at 40 fM and 400 pM respectively, was compared to untreated cells. Results are 
given as mean ± SEM (n = 3). A significant effect was obtained as indicated (p<0.01, **: p<0.001, ***). ns = not 
significant.
To rule out the possibility that the effect of PTK inhibitors was on mast cell migration in general, 
treated HMC-1 cells were tested for migration against stem cell factor (SCF), ZAS, and mast cell 
chemotactic activity (MCCA) from bronchoalveolar lavage fluid from an asthmatic patient and 
synovial fluid from a patient with rheumatoid arthritis. As shown in figure 4, genistein inhibited 
mast cell migration to TGF-^1 and SCF. In contrast, ZAS-induced migration that is mediated via
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receptors coupled to G-proteins was not affected. Similarly, the migration to MCCA was 
unaffected, or partially affected, by treatment with genistein.
Figure 3 Inhibition of TGF-P 1-induced migration by protein-tyrosine kinase inhibitors. HMC-1 cells were treated with 
the indicated concentrations of the protein-tyrosine kinase inhibitors genistein (Gen), erbstatin analog (Erb) or 
herbimycin A (Herb) at concentrations indicated. TGF-P 1-induced migratory response and growth inhibition were 
analyzed after 150 min and 72 h, respectively. Results are given as mean ± SEM (n = 3). A significant effect was 
obtained as indicated (p<0.05, *; p<0.01, **: p<0.001, ***).
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Genistein does not inhibit TGF-p1-mediated Smad2 phosphorylation
TGF-P signals through activation of the pathway-specific Smad2 and/or Smad3 (Heldin et al., 
1997; Massagué, 1998). Western blot analysis of Smad expression revealed that HMC-1 cells 
expressed Smad2 (Fig. 5), whereas Smad3 was below detection levels. In addition to the 61 kDa 
band that corresponds to Smad2, three additional bands in the 55 kDa range could be detected that 
were specifically competed with an excess of cognate peptide (Fig. 5). Stimulation of the cells for 1 
h with 40 fM TGF-^1 induced phosphorylation of Smad2. The Smad2 phosphorylation was more 
pronounced at 200 pM TGF-^1. Remarkably, the upper of the three proteins in the 55 kDa range 
was most potently detected by the PS2 antibody, and its phosphorylation was also induced at 
concentrations as low as 40 fM TGF-^1. The differential effect of genistein on TGF-^1-mediated 
chemotaxis versus growth inhibition (Fig. 3) was further explored at the level of Smad2 
phosphorylation. Cells were pretreated with genistein followed by stimulation with TGF-^1. As 
shown in figure 5, genistein did not affect phosphorylation of Smad2, or the 55 kDa proteins.
Figure 4 Effect of genistein on mast cell 
migration. The effect of genistein on mast 
cell chemotaxis to 40 fM TGF-p1, 50 ng/ml 
stem cell factor (SCF), 10% zymosan 
activated serum (ZAS) and mast cell 
chemotactic activity (MCCA) from 
broncheolar lavage fluid from asthmatic 
patient (1) or synovial fluid from patient with 
rheumatoid arthritis (2) was tested. Mast cells 
were pre-treated with 1 jiM genistein. Results 
are given as mean ± SEM (n = 3). A 
significant effect was obtained as indicated 
(p<0.05, *; p<0.01, **: p<0.001, ***). ns = 
not significant.
Since Smads, which function as transcriptional activators (Heldin et al., 1997; Massague, 1998) 
are phosphorylated at chemotactic TGF-P concentrations, and TGF-^1-induced migration occurs 
within 150 min, we were interested if de novo protein synthesis is required for mast cell migration. 
Pretreatment of HMC-1 cells with cycloheximide abrogated the chemotaxis induced by TGF-^1 
(Fig. 6). In addition, mast cell migration to other chemoattractants such as SCF, ZAS (Fig. 6) and 
serum amyloid A protein (Olsson et al., 1999b) was also inhibited, indicating that protein synthesis 
appears to be a general requirement for mast cell migration.
TGF-ß1 SCF MCCA1 MCCA2 ZAS
Mast cell migration depends on protein synthesis
TGF-p-mediated chemotaxis through tyrosine kinase signaling 161
Figure 5 Effect of genistein on TGF-p1-mediated phosphorylation of Smad2. Cells were pretreated for 90 min without 
or with 100 nM genistein in medium containing 3% BSA, followed by stimulation with control solvent, 40 fM or 200 
pM TGF-p1 for 60 min. Cell lysates were subjected to Western blot analysis using the Smad2 antibody SED, in the 
absence or the presence of blocking peptide to which the antibody was raised, as well as the PS2 antibody that 
specifically recognizes phosphorylated Smad2. The Smad2-like proteins that are recognized by both SED and PS2, are 
indicated (*).
Figure 6 Effect of cycloheximide on mast cell migration. 
HMC-1 cells were pre-treated with cycloheximide (20 
ig/ml) for 90 min before migration assay. Cell migration 
was tested against TGF-p1 (40 fM), stem cell factor (50 
ng/ml) and 10% zymosan activated serum (ZAS). Results 
are given as mean ± SEM (n = 3). A significant effect was 
obtained as indicated (p<0.05, *; p<0.01, **: p<0.001, 
***)
TGF-p1-induced mast cell migration is mediated through MEK but not p38 MAP kinase
To further define differential regulation of TGF-p1-mediated cellular functions, we determined if 
SB203580, a p38 MAP kinase inhibitor, and PD98059, an inhibitor of MAPK kinase (MEK), had 
any effect on migration and growth inhibition. As shown in figure 7 (upper panels), SB203580 
treatment of HMC-1 cells did not affect either the migration or the growth inhibition in response to 
TGF-P1. This indicates that p38 is not involved in these TGF-p1-induced cellular responses in 
HMC-1 cells. The migration to ZAS was found to be inhibited, thus showing that the inhibitor used 
is effective (Fig. 7). The MEK inhibitor PD98059 significantly inhibited TGF-p1-induced
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migration, without affecting the growth inhibitory effect (Fig. 7 lower panel). In contrast, migration 
to ZAS was only partially attenuated. Successive addition of PD98059 or SB203580 during the 
growth assays neither affected TGF-P1-induced growth inhibition (data not shown). Thus, our data 
implicate activation of MEK in TGF-P1-induced mast cell migration.
Figure 7 Involvement of MAP kinase in TGF-p1-induced migration. Mast cells were treated with either the p38 MAK 
inhibitor SB203580 (upper panel) or the MEK inhibitor PD98059 (lower panel) at concentrations as indicated. TGF-p1- 
induced migratory response and growth inhibition were analyzed after 150 min and 72 h, respectively. Results are given 
as mean ± SEM (n = 3). A significant effect was obtained as indicated (p<0.05, *; p<0.01, **: p<0.001, ***).
DISCUSSION
In the present study, we have shown that TGF-p1-induced mast cell migration, but not growth 
inhibition, depends on functional PTK activity (Fig. 3). Furthermore, Smad2 becomes 
phosphorylated by TGF-p1 at both chemotactic (40 fM) as well as growth inhibitory (200 pM) 
concentrations (Fig. 5). Our data also indicate that functional MEK is necessary for mast cell 
migration to TGF-p1 (Fig. 7). These observations indicate the involvement of differential signal 
transduction pathways required for TGF-p1-mediated growth inhibition versus migration, in which 
the latter requires functional tyrosine kinases and MAPK-kinase signals.
Although none of the TGF-p receptors have a G-protein-linked cytoplasmic domain, treatment of 
cells with TGF-p has been reported to trigger some G-protein-mediated signals (Howe et al., 1989; 
Mulder and Morris, 1992). TGF-p-induced migration of neutrophils is dependent on functional Gi- 
proteins, an effect that is completely abolished by pertussis-toxin pretreatment (Haines et al., 1993).
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As shown in this study, mast cell chemotaxis to TGF-p1 is mediated through a pertussis-toxin 
insensitive pathway, indicating that Gi-proteins are not involved. It is therefore likely that TGF-p1- 
induced chemotaxis can involve either G-protein-dependent or -independent signaling depending on 
the target cell. Another difference between TGF-p1-induced migration of neutrophils and mast cells 
is that while neutrophils are inhibited by the p38 kinase inhibitor SB203580 (Hannigan et al., 1998), 
the mast cells are not (this study). Thus, TGF-p1-induced migration uses apparently different signal 
transduction pathways in different cell systems.
Protein kinases, including PKC and PI3-K, are central components in transmitting intracellular 
signals from a variety of receptors (Duronio et al., 1998). We have found that several mast cell 
chemotaxins depend on functional PKC and PI3-K to mediate a complete migratory response 
(Nilsson, unpublished observation). Similarly, TGF-p-induced mast cell migration was attenuated 
by bisindolylmaleimide I and wortmannin.
Protein-tyrosine kinases are critical components of signaling pathways that control several 
cellular functions (Ullrich and Schlessinger, 1990). We examined the effect of three different PTK 
inhibitors with rather broad specificity, genistein, herbimycin A and erbstatin analog, on TGF-p- 
induced migration and growth inhibition (Levitzki and Gazit, 1995). All three inhibitors completely 
inhibited the TGF-p1-induced migration, without affecting the growth inhibition. Recently, 
Thannickal et al. (1998) showed that TGF-p1 induced tyrosine phosphorylation of two proteins of 
115 and 103 kDa in fibroblasts. We are currently investigating which tyrosine kinases and their 
substrates are involved in TGF-p-mediated migration of mast cells.
Importantly, mast cell migration to ZAS and two other sources of MCCA were not affected by 
genistein. Although tyrosine kinase signaling through focal adhesion kinase (FAK) is generally 
important for integrin-mediated cell migration in fibroblasts (Chrzanowska-Wodnicka and 
Burridge, 1994; Hanks and Polte, 1997). ZAS and MCCA might contain components that elicit 
mast cell migration independent of FAK-activity, or mast cell migration might be controlled by 
mechanisms different from those in fibroblasts.
Recently, Smad proteins have been identified as pivotal signal transduction molecules, acting 
downstream of serine/threonine kinase type I receptors (reviewed in Heldin et al., 1997; Massague, 
1998). Smad2 and Smad3 are specifically involved in TGF-p signaling, and they have been shown 
to transcriptionally activate several TGF-p responsive genes (Massague, 1998). In HMC-1 cells, we 
observed by Western blot analysis the expression of Smad2 (Fig. 5) but not Smad3. Furthermore, 
additional proteins were detected by the Smad2 antibody, as well as by the PS2 antibody 
recognizing phosphorylated Smad2. These proteins may represent Smad2-like proteins. 
Alternatively-spliced Smad variants have been described for Smad5 (Gemma et al., 1998) as well as 
for Smad2 (Yagi et al., 1999). The Smad2 variant lacks exon 3 and thereby is capable to interact 
with DNA, whereas wild-type Smad2 is not (Yagi et al., 1999). Whether the proteins identified in 
HMC-1 cells exert a comparable function is unclear and is subject for further investigation.
Phosphorylation of Smad2 and the Smad2-like proteins could be detected at concentrations as 
low as 40 fM TGF-p 1, suggesting that they might be involved in TGF-p 1-mediated chemotaxis. 
Furthermore, protein synthesis was required for TGF-p 1-mediated chemotaxis (Fig. 6), which could 
refer to a role of Smads as transcriptional activators in this process. The tyrosine kinase inhibitor
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genistein efficiently abrogated TGF-P 1-mediated chemotaxis, whereas it had no effect on TGF-P1- 
induced growth arrest of HMC-1 cells. Whether tyrosine kinases are directly activated by TGF-P 
receptors independent of Smads, or whether their activity is an indirect result of gene expression 
induced by Smads, is under current investigation.
Recent reports suggest that TGF-P can signal through activation of members of the mitogen- 
activated protein (MAP) kinase family (Reimann et al., 1997). The MAPKs can be grouped into 
three families: the ERKs, c-Jun N-terminal kinase (JNK), and p38 (Derijard et al., 1995). Several 
isoforms of ERK have been described and at least two of them, ERK-1 (p44MAPK) and ERK-2 
(p42MAPK), have been shown to be activated by TGF-P 1 (Hartsough and Mulder, 1995; Reimann 
et al., 1997). TGF-P1 also activates JNK (Atfi et al., 1997b; Frey and Mulder, 1997) and p38 
(Hannigan et al., 1998). MEK consists of a family of dual specificity kinases that are capable of 
phosphorylating MAPK on both tyrosine and threonine residues (Zheng and Guan, 1993). MEK 
constitute the principal route for ERK activation (Gallego et al., 1992; Cowley et al., 1994; 
Mansour et al., 1994). The specific MEK inhibitor PD98059 blocks the activation and 
phosphorylation of MEK (Alessi et al., 1995; Dudley et al., 1995), and as a consequence inhibits 
the MAPKs ERK-1 and ERK-2. Treatment of the HMC-1 cells with PD98059, under conditions 
shown previously to inhibit MEK as well as ERK (Downey et al., 1998), diminished the migratory 
response to TGF-P 1. Anand-Apte et al. (1997) have reported that fibronectin-induced migration of 
fibroblasts involves signaling through ERKs. In view of the fact that the TGF-P-induced migration 
of HMC-1 cells is assayed on fibronectin-coated filters, while TGF-P is furthermore known to 
induce fibronectin synthesis in many cell types, integrin signaling triggered through fibronectin 
might be part of TGF-P-induced cellular migration. The migratory response to ZAS was only 
partially attenuated showing that active ERK is not a prerequisite for mast cell migration. TGF-P1- 
induced growth inhibition was not affected by PD98059. Inhibition of the MAPK p38 by treatment 
with SB203580 did not affect either the TGF-P 1-induced migration or growth inhibition. These data 
strongly suggest that MEK and ERK are involved in the intracellular signaling pathway mediating 
TGF-P 1-induced mast cell migration. The tyrosine kinase inhibitor genistein has been reported to 
abrogate MEK and ERK activity (Crepel et al., 1998; McLeish et al., 1998). We are currently 
investigating whether the tyrosine kinase inhibitors genistein, herbimycin A and erbstatin possibly 
abrogate TGF-P1-mediated chemotaxis of HMC-1 cells via inactivation of the dual specificity 
kinases MEK and their ERK substrates.
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GENERAL DISCUSSION
Members of the transforming growth factor (TGF)-P superfamily mediate a broad range of, 
largely cell type- and cellular context-dependent, biological activities (Roberts and Sporn, 1990). 
They regulate cell growth, differentiation and extracellular matrix production, and play important 
roles in pattern formation and tissue specification during embryonic development. In adults, they are 
mainly involved in tissue homeostasis and modulation of the immune response. Uncontrolled TGF- 
P signaling, due to exacerbate cytokine action or an impaired signal transduction machinery, is often 
correlated with pathogenesis, including fibrosis and tumorigenesis.
The mechanisms that contribute to multifunctionality in the biological responses mediated by 
members of the TGF-P superfamily, are only partly understood, and are subject for the studies 
described in this thesis.
Extracellular binding proteins modulate signaling by members o f the TGF-P superfamily
Besides the serine/threonine kinase type I and type II receptors through which members of the 
TGF-P superfamily propagate their downstream signaling, several extracellular proteins are known 
to associate with TGF-P superfamily members. These include transmembrane proteins, proteins 
associated with the cell membrane or extracellular matrix, as well as soluble proteins. Their 
association with TGF-P superfamily members serves various purposes, including facilitating 
bioactive processing of TGF-P by fibronectin and thrombospondin (Fava and McClure, 1990; 
Crawford et al., 1998), clearance of cytokines from serum by a2-macroglobulin (Niemuller et 
al., 1995), and storage of TGF-P in bone matrix by binding to the proteoglycans decorin and 
biglycan to control bone remodeling (Takeuchi et al.,1994; Xu et al., 1998). A number of soluble 
TGF-P superfamily binding factors has been described to play important roles in the control of cell 
fate during embryogenesis, like noggin, chordin, follistatin and the recently identified proteins 
Cerberus, DAN, and Gremlin, which directly interact with BMP-2 or BMP-4 and thereby prevent 
their interaction with the BMP receptors (Hemmati-Brivanlou et al.,1994; Piccolo et al.,1996; 
Zimmerman et al.,1996; Hsu et al., 1998). Follistatin has high affinity for activin and counteracts 
many of its activities by preventing interaction with the receptors (reviewed in Michel et al., 1993; 
de Winter et al., 1996). Mutations in the gene encoding the TGF-P binding protein endoglin, whose 
exact function is not clear yet, form the basis for the vascular disorder hereditary haemorrhagic 
telangiectasia type 1 (McAllister et al., 1994, 1995). Thus, extracellular TGF-P superfamily binding 
proteins may play important roles in cytokine-mediated control of tissue homeostasis and 
development.
As observed for several other TGF-P superfamily binding proteins, such as betaglycan and 
follistatin, the 60 kDa TGF-P binding protein characterized in chapter 2 can exist in a cell 
membrane-bound form as well as in a soluble configuration. Its physical characteristics highly 
resemble those of a previously described 60 kDa protein (Bützow et al., 1993) and the TGF-P type 
IV receptor (Cheifetz et al., 1988; Yamashita et al., 1995a). These three proteins represent highly 
similar, if not identical, heparin sulfate proteoglycan binding proteins (Bützow et al., 1993; chapter
2). Whereas TGF-P can bind its receptors and induce signaling in cells that express cell membrane-
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associated 60 kDa protein (chapter 2; Yamashita et al., 1995a), addition of soluble 60 kDa protein to 
mink lung epithelial cells prevented binding of all three TGF-P isoforms to the TGF-P type I and 
type II receptors (chapter 2), suggesting differential modes of action depending on the configuration 
of the protein. This has also been observed for betaglycan which in its transmembrane configuration 
facilitates association of TGF-P with the signaling receptors (Lopez-Casillas et al., 1993), while 
soluble betaglycan prevents TGF-P receptor binding (Lopez-Casillas et al., 1994). Another 
interesting feature of the cell membrane-associated 60 kDa protein, in contrast to its soluble form, is 
that it displays specific affinity for the TGF-P 1 isoform. This property might be explained by a 
conformational change of the 60 kDa protein, or by occlusion of the TGF-P2- and TGF-P3- 
interacting epitopes on the 60 kDa protein, following its interaction with heparin sulfate 
proteoglycans. Several TGF-P binding proteins, among which TPR-II, endoglin, and various 
glycosyl-phosphatidylinositol (GPI)-anchored proteins, are endowed with specific affinity for 
certain TGF-P isoforms (Cheifetz et al., 1990; MacKay et al., 1990; Cheifetz and Massague, 1991; 
MacKay and Danielpour, 1991; Cheifetz et al.,1992; Dumont et al.,1995). Thereby, they offer a 
mechanism by which the different TGF-P subfamily members are able to mediate differential 
activities, for example with respect to inhibition of cellular proliferation (Ohta et al., 1987; Cheifetz 
et al., 1990, 1992; Jacobson et al.,1991; Shah et al., 1995).
In the osteogenic protein-1 (OP-1) affinity-binding studies performed in chapter 4 using the 
embryonal carcinoma cell line T2Cl13, we observed an OP-1 binding protein with approximate size 
of 250-300 kDa, which was clearly co-immunoprecipitated with ActR-I and ActR-II antibodies, 
indicating that this protein can make a complex with the signaling receptors. In the competition 
binding studies, unlabeled OP-1 could compete the binding of 125I-OP-1 to this OP-1 binding 
protein, whereas activin A was inefficient (chapter 4 and data not shown). We did not further 
characterize this protein.
A prerequisite for proper characterization of the function of a protein like the 60 kDa TGF-P 
binding protein, or the OP-1 binding protein, is its purification to homogeneity. A suitable approach 
for these proteins would be to perform an affinity purification, using cytokine bound to a solid 
support. Purified proteins can be subjected to mass spectrophotometric analysis and/or protein 
sequencing to reveal their identity. In addition, these purified proteins can be functionally analyzed 
by testing their effect on cytokine-induced biological responses, for example TGF-P-induced growth 
inhibition, PAI-1 production, or Smad activation. The in vivo significance of the protein can 
possibly be elucidated by generating mice that lack expression of this gene, as has been performed 
for noggin, thrombospondin and biglycan (Brunet et al., 1998; Crawford et al., 1998; Xu et al., 1998).
The TGF-P superfamily signaling enigma: how can multiple family members mediate their 
pleiotropic effects with access to a limited scala o f receptors?
Signaling by TGF-P superfamily members is initiated by distinct, ligand-induced, heteromeric 
complexes of type I and type II serine/threonine kinase receptors, in which the type I receptors 
specify downstream signaling. Intensive searches for TGF-P superfamily receptors in mammals so 
far only resulted in the identification of 5 different type II receptor genes, the activin type II 
receptors ActR-II and ActR-IIB, bone morphogenetic protein type II receptor BMPR-II, anti-
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Mullerian hormone (AMH) type II receptor, and TPR-II (Mathews and Vale, 1991; Attisano et al., 
1992; Lin et al., 1992; Mathews et al., 1992; Grootegoed et al., 1994; Rosenzweig et al., 1995), and 7 
different type I receptor genes, activin receptor-like kinase-1 (ALK-1), ActR-I, BMPR-IA, ActR-IB, 
TPR-I, BMPR-IB, ALK-7 (ten Dijke et al., 1994b; Lorentzon et al., 1996; Ryden et al., 1996). Two 
other type I receptors have been reported in zebrafish, including TARAM-A which is a type I 
receptor involved in induction of anterior dorsal mesoderm (Renucci et al., 1996), and zALK-8 
which is widely expressed throughout early zebrafish development (Yelick et al., 1998). One can not 
exclude that novel receptors exist in ‘exotic’ tissues, for example intermediate tissue stages during 
embryonic development, such as the node or the Mullerian duct. The Southern blot PCR technique 
described in chapter 3 revealed the presence of a putative novel serine/threonine kinase type I 
receptor in fetal kidney tissue. Whereas the corresponding gene has not been cloned yet, this method 
illustrates its potential to identify putative novel receptor members in cell lines and tissues, 
independent of species origin.
In contrast to the serine/threonine kinase receptor family, the TGF-P superfamily is still growing 
and with every new member identified, the enigma regarding how diversity in signaling with a 
limited scala of receptors is achieved, grows. It seems inevitable that the answers to this question 
must emanate from the assumption that the existing receptors are sufficient to guarantee specificity 
and diversity in signaling triggered by the different ligands. The question remains then by what 
mechanisms?
Multiple ligands sharing the same receptors: extension or limitation o f the signaling spectrum?
Diversity in signaling can first of all be achieved by the fact that a single growth factor can 
interact with different type I receptors via which it activates downstream signaling (Table I). TGF-P 
can signal through TPR-I and thereby activate Smad2 and Smad3 or, in endothelial cells, signal 
through ALK-1 and mediate phosphorylation of Smad1, Smad5 and/or Smad8 (Macias-Silva et al.,
1998). BMP-2, BMP-4 and BMP-7 have access to three different type II receptors, ActR-II, ActR- 
IIB and BMPR-II and signal through ActR-I, BMPR-IA or BMPR-IB, via which Smad1, Smad5 and 
Smad8 can become activated (reviewed in Heldin et al., 1997). This offers the possibility of a 
broader signaling spectrum and allows the generation of multiple heteromeric receptor variants.
Although certain type II receptors are shared among different TGF-P subfamilies, like ActR-II 
and ActR-IIB to which activins and BMPs bind, the type I receptor that is recruited into the complex 
is dependent on the ligand and results in subfamily-specific receptor combinations (Table 1), which 
allows activins and BMPs to signal diverse responses (chapter 4, chapter 6). The only receptor 
combinations known so far that are shared by different subfamilies consist of ActR-I in combination 
with ActR-II, ActR-IIB or AMHR-II, which can be formed by activins, BMPs and/or AMH, 
although a functional role of this receptor complex in activin signaling is debated. The receptor 
binding studies presented in chapter 2, chapter 4, and chapter 6 further illustrate the specificity and 
diversity in receptor complexes that can be generated by the different growth factors, depending on 
the receptor species expressed by the different cell lines. It is tempting to speculate that in view of 
the heteromeric nature of the type I/type II receptor complexes and the possibility of ligands to 
interact with diverse receptor types, receptor complexes could be generated that consist of multiple
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receptor types which could further extend diversity in signaling. For many members of the TGF-P 
superfamily, receptor binding properties have not been addressed yet.
Table 1 TGF-P family members, their receptors and signaling molecules
Subfamily TGF-p Activin BMP
Examples of ligands TGF-P 1 Activin A BMP-2
TGF-P2 BMP-4
TGF-p3 BMP-7
Type n receptors TpR-E ActR-H BMPR-II
ActR-HB ActR-H
ActR-HB
Type I receptors - TpR-I ActR-I? BMPR-IA
ActR-IB BMPR-IB
ActR-I
Receptor-activated Smads Smad2 Smad2 Smadl
Smad3 Smad3 Smad5
Smad8
Common-mediator Smad Smad4 Smad4 Smad4
Inhibitory Smads Smad6 Smad6 Smad6
Smad7 Smad7 Smad7
Responses Inhibition of mitogenicity Induction of dorsal mesoderm Induction o f ventral mesoderm
Induction of extracellular matrix Induction o f erythroid differentiation Induction of cartilage and bone
Induction of follicle stimulating hormone release Induction of apoptosis
Whereas sharing receptors among multiple ligands on the one hand increases the signaling 
spectrum, it might also offer the possibility for different growth factors to compete for a common 
receptor, as described in chapter 4. In the embryonal carcinoma cell line T2Cl13, ActR-II appears to 
be the only type II receptor detectable with which activin A and OP-1 can interact to form distinct 
heteromeric receptor complexes. As illustrated by the affinity binding studies, both activin A and 
OP-1 compete with each other for interaction with ActR-II, which might be one of the mechanisms 
that explains the functional antagonism observed between these two growth factors (chapter 4). In 
analogy to this mechanism, inhibin is known to antagonize activin signaling by competition for 
ActR-II (reviewed in Mathews, 1994). At present it is not fully understood whether the levels of 
ActR-II are functionally limiting the response in T2Cl13 cells. We addressed this issue by over­
expression of ActR-II, by which we expected that in case of ActR-II limitations, competition by OP- 
1 on activin A-mediated 3TP-Lux reporter activation would be abolished. We could, however, not 
confirm this since over-expression of ActR-II enabled OP-1 to activate the 3TP-Lux reporter already 
by itself (Chapter 4). The role of the activin type II receptor in this process is not clear. Follow-up 
studies using constitutive active (CA)-ActR-I or CA-BMPR-IA, revealed that both receptors were 
unable to activate 3TP-Lux, whereas co-expression with ActR-II resulted in potent activation of this 
reporter read-out system. It should be noted that over-expression of ActR-II in the absence of ligand 
or CA-receptor also resulted in 3TP-Lux activation, probably by activation of endogenous ActR-IB, 
but stimulation with OP-1 or co-expression with CA-ActR-I or CA-BMPR-IA further enhanced the 
induction of 3TP-Lux reporter (chapter 4 and data not shown), suggesting that upon over-expression 
of ActR-II additional OP-1 receptors become activated whose signaling is potent enough to drive
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the 3TP-Lux reporter. The activin response element (ARE)-reporter, which contains Smad-binding 
elements derived from the Mix2 promoter and which is supposed to be specific for activin and TGF- 
P signaling (Chen et al., 1997a), could be induced by OP-1 in the presence of the transcriptional 
activator FAST-1. Whether OP-1 is able to activate TGF-P and activin pathway-restricted Smads in 
T2Cl13 cells or whether T2Cl13 cells express novel OP-1 inducible Smads that mimic, to a certain 
extent, TGF-P and activin pathway-restricted Smads is not clear. Additional options that have to be 
further explored are whether ActR-II possibly enhances OP-1-induced Smad-activation to levels 
which can pass the activation threshold for 3TP-Lux induction, or whether ActR-II exerts additional 
roles other than activating type I receptors. Answers to these questions could be obtained by 
studying OP-1-induced Smad-phosphorylation or by performing Smad-GAL4 reporter assays in 
which the fusion protein consisting of full-length Smad coupled to the GAL-4 DNA binding 
domain, transcriptionally activates the GAL-4 reporter upon Smad phosphorylation by the proper 
cytokine. Furthermore, the role of the type II receptor could be addressed by generating chimeric 
receptors that contain the extracellulair domain of ActR-II and the intracellular domain of TPR-II; in 
contrast to over-expression of ActR-II, TPR-II failed to enhance the OP-1 effect on 3 TP-Lux 
reporter activation (data not shown). It has been reported that TPR-II contains basal phosphorylation 
on several serine residues, some of which are located in the C-terminus (Wrana et al., 1994, Attisano 
et al., 1996), and, furthermore, TPR-II becomes phosphorylated on additional serine residues 
following ligand-induced dimerization, which differentially contribute to regulate TPR-II activity 
(Luo and Lodish, 1997). A tempting idea is therefore that the type II receptors could perform 
additional roles in signaling, for example in serving as docking sites for proteins which 
subsequently become activated by the type I receptors, but direct indications in this direction are 
still lacking (Wieser et al., 1993).
Receptor expression levels as a mechanism to control the magnitude o f signaling.
The current model in TGF-P superfamily receptor signaling is that both type I and type II 
receptors are required for signal transduction (Wrana et al., 1994); type I receptors propagate 
downstream signaling following their activation by type II receptors. In several cell systems, 
differential responsiveness to TGF-P has been related to the ratio of type I and type II receptors 
(Geiser et al.,1992; Centrella et al., 1993; Ebner et al., 1993): low expression levels of type II 
receptors compared with type I receptors led to loss of growth inhibition but maintenance of 
extracellular matrix production and transcriptional responses (Laiho et al., 1991; Geiser et al., 1992; 
Centrella et al., 1993; Chen et al., 1993; Takeuchi et al., 1995; Zhao and Buick, 1995). An 
explanation for the observed differential modes of signaling by TGF-P depending on TPR-II/TPR-I 
ratios could be that different activation thresholds control the signaling pathways leading to growth 
inhibition versus gene transcription. This issue was addressed in chapter 5, where we observed that 
different receptor ratios were detected in a panel of glioma cell lines that showed differential growth 
responses upon TGF-P stimulation. However, no correlation could be found. Although all cell lines 
studies were glioma cell lines they may be too diverse to draw conclusions on receptor-ratios and 
biological effects. On the other hand, the cell lines shared certain biological responses, including 
induction of Smad6 and Smad7 mRNA, and endogenous PAI-1 production, suggesting that TGF-P
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signaling could pass the activation threshold for these responses in all cell lines, even though their 
receptor levels were variable. A better approach to study the relevance of receptor ratios would be to 
over-express TPR-II in the U-343 MGa 31L cell line. These cells have very low endogenous TPR-II 
levels but clearly detectable TPR-I levels, and are stimulated in growth by TGF-P. According to the 
hypothesis, over-expression of TPR-II would render the cells growth inhibited upon TGF-P 
stimulation.
Although the significance of type I and type II receptor ratios for the outcome of the biological 
effect is debated, the importance of overall receptor expression levels as a mechanism to control 
signaling by the different growth factors was observed in NMuMG cells (chapter 6) and in thyroid 
follicle cells (chapter 7). The type I receptors through which activin and TGF-P mediate signaling, 
share highly conserved kinase domains and have identical L45 loops which are important for 
activation of Smad2 and Smad3 (Feng and Derynck, 1997; Chen et al., 1998b; Persson et al., 1998). 
In both cell systems, activin receptors are weakly expressed relative to TGF-P receptors, and in 
NMuMG cells this correlates with strongly impaired transcriptional activity by activin compared to 
TGF-P and the inability of activin to mediate transdifferentiation (chapter 6). In thyroid follicle 
cells, TGF-P and activin both inhibit follicle cell growth and thyroid stimulating hormone (TSH)- 
induced cAMP production, and the extent to which activin and TGF-P mediate these effects 
correlates to Smad activation levels, as assessed by their phosphorylation and nuclear translocation 
(chapter 7). Thus, receptor expression levels can influence the magnitude of downstream activation, 
contributing to differential biological responses. The significance of this regulatory mechanism 
could be further substantiated by generating stable NMuMG cell lines that over-express the activin 
receptors, by which potent Smad activation levels could be achieved following activin stimulation, 
leading to potent PAI-1 induction and, presumably, transdifferentiation.
Growth factors as determinants o f downstream activation levels.
Accumulating evidence suggests that specificity and diversity in TGF-P signaling is controlled 
by different activation thresholds of the biological responses. This is observed for example during 
embryonic development, where TGF-P superfamily members can act as morphogens and trigger 
differential biological effects along their concentration gradient (reviewed in Whitman, 1998b). 
Furthermore, as mentioned above, different activation thresholds have been suggested for several 
activities induced by members of the TGF-P superfamily, like growth inhibition and extracellular 
matrix production (chapter 5), transdifferentiation of NMuMG cells (chapter 6), and chemotaxis of 
mast cells (chapter 9), which can be controlled by different expression levels of the signal 
transduction components or by different concentrations of the growth factor. The mechanism that 
underlies the different chemotactic potencies of the three TGF-P isoforms is not clear, but could 
possibly be due to small differences in their affinities for the TGF-P receptors, which become 
apparent at effective concentrations as low as 40 fM (chapter 9). In chapter 8 we observed that three 
different members of the BMP subfamily, OP-1, cartilage-derived morphogenetic protein-1 
(CDMP-1) and CDMP-2, exerted differential effects on cartilage and bone formation in the same 
bone mesenchymal cells. Selective affinity of the ligands for specific receptor complexes might 
explain their differences in signaling. Alternatively, differential affinities of different ligands for the
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same receptor types might result in different downstream activation levels, controlling different 
responses. An attractive speculation would be that the multiplicity of ligands that interact with 
different affinities to the same receptor complexes could be a fine-tuning mechanism to specify 
signaling, without the need of a large family of signal transducing type I and type II serine/threonine 
kinase receptors. Together with the postulation that the existence of multiple growth factor genes, 
controlled by differentially regulated promoters, might offer a mechanism to ensure spatio-temporal 
control of appropriate growth factor activity (Schmid et al., 1991; Roberts and Sporn, 1992), an 
important mechanism of control in diversity of signaling could be achieved by the extensiveness of 
the TGF-P superfamily, in which several members can initiate different responses at different times 
and places while using the same primary signal transduction machinery.
Smads as contributors to specificity and diversity in TGF-P superfamily signal transduction.
Following activation of the type I receptors, Smad proteins are pivotal downstream effector 
molecules in TGF-P superfamily signaling (reviewed in Heldin et al., 1997; Massague, 1998). As 
indicated in Table 1, every TGF-P subfamily has access to unique combinations of receptors and 
Smads that, theoretically, would allow the formation of many different signaling combinations. 
Receptor-mediated phosphorylation of the pathway-restricted Smads (R-Smads) in their C-terminal 
SSXS motif results in formation of hetero- and homomeric complexes, consisting of R-Smad 
homomers, R-Smad heteromers, or heteromers that include Smad4 (Nakao et al., 1997b; Wu et 
al., 1997; Kawabata, 1998), of which the stoichiometry is unclear. In spite of these different possible 
Smad complexes, Smad4 is required for TGF-P signaling in vitro (Lagna et al., 1996) while optimal 
induction of the TGF-P-sensitive 3TP-Lux reporter is achieved by the synergistic action of Smad2, 
Smad3 and Smad4 (Nakao et al., 1997b), illustrating the apparent limitation of functional Smad 
complexes in vitro. In addition, TGF-P and activin signal via the same Smads, and as a consequence 
mediate many overlapping activities in vitro. However, a recent report by Shimizu et al. (1998) 
shows that in keratinocytes, activin mediates signaling via Smad3, while TGF-P activates both 
Smad2 and Smad3, and is thereby more potent to arrest cellular proliferation. Differential activation 
of Smad2 and Smad3 by activin was also observed in thyroid follicle cells (chapter 7). Furthermore, 
Smad2 and Smad3 exert opposite effects in transcriptional activation of the goosecoid promoter, 
which requires transcriptional cooperation of the forkhead activin signal transducer (FAST)-2. 
Interaction of Smad2 and Smad4 with FAST-2 results in potent activation of the goosecoid reporter, 
while Smad3 through its competition with Smad4 for DNA binding interferes with transcriptional 
activation (Labbe et al., 1998).
Using Smad-GAL4 reporter assays, we observed that in certain cell-types OP-1 could induce 
transcriptional activation of the Smad2-GAL4 and/or Smad3-GAL4 fusion proteins (S. Itoh, 
personal communication; data not shown). Whether this is a consequence of the over-expression of 
these Smad proteins by which they can interact with and become activated by BMP receptors, or 
whether the pathway-restrictedness of the different Smads is not as rigid as supposed, is subject for 
further investigation. Furthermore, as a consequence of ectopic expression studies, the importance 
of putatively subtle differences in affinity of different Smads for different receptors might be 
overlooked. Moreover, the phenotypes of the different Smad knockout mice illustrate that Smads
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functioning in the same cytokine-pathway are not merely redundant in their actions (Nomura et 
al., 1998; Waldrip et al., 1998; Zhu et al, 1998).
Studies in Xenopus and Drosophila have shown that manipulations of Smad levels directly affect 
cell fate, and thereby indicate that the effectiveness of the signal transduction pathway is highly 
dependent on Smad protein levels (Graff et al.,1996; Wiersdorff et al.,1996; Wilson et al., 1997). 
The significance of Smad expression levels and the outcome of the biological effect was addressed 
in the glioma cell lines (chapter 5). Whereas these cell lines shared a number of responses, such as 
PAI-1 induction and Smad6 and Smad7 mRNA induction, growth inhibition and CAGA reporter 
activation were differentially affected. Analysis of Smad expression levels revealed that there were 
profound differences among the cell lines in relative Smad2/Smad3 ratios, as well as in the Smad2 
phosphorylation levels. In view of the weak Smad expression and phosphorylation levels in U-343 
MGa 31L, endogenous PAI-1 production and Smad 6 and Smad7 mRNA expression appeared to be 
controlled by low activation thresholds. In contrast, for the more complicated mechanisms 
underlying cellular proliferation no correlation could be found with respect to Smad expression 
levels. More insight could be obtained by looking at relative phosphorylation of Smad2 and Smad3, 
either by using antibodies that specifically recognize the phosphorylated Smad-types, or by 
orthophosphate labeling followed by immunoprecipitation with Smad-specific antibodies. In 
addition, a very suitable read-out system could be the FAST-goosecoid reporter assay, in which the 
activation levels of the goosecoid promoter within the different glioma cell lines would be expected 
to reflect Smad2/Smad3 activation ratios.
As described above, a direct correlation between receptor expression levels, Smad activation 
levels and the potency of the biological response was observed in NMuMG cells (chapter 6) and 
follicular thyroid cells (chapter 7). The assumption that evolves from the work described in chapter 
8, namely that TGF-P superfamily members with different affinities for the same receptor complex 
can elicit different biological effects within a particular cell system due to differential downstream 
activation levels, could be further addressed at the Smad activation level by studying Smad- 
phosphorylation analogous to the work described in this thesis. In addition, Gal4-Smad fusions used 
in combination with Gal4-reporter will allow the analysis of the transcriptional activation potencies 
brought about by the different ligands.
A mechanism which could play important roles in specification of signaling via Smads is the 
existence of alternative splice variants, as described for Smad2 (Yagi et al.,1999) and Smad5 
(Gemma et al., 1998). In HMC-1 mast cells we detected several proteins that were recognized by 
both the Smad2-antibody as well as the phosphorylated Smad2 antibody (chapter 10), suggesting 
that these proteins could represent alternative Smad2 variants. A Smad2 splice variant lacking exon 
3 has been described by Yagi et al. (1999). This exon is unique for Smad2 and encodes sequences 
that impair Smad2 binding to DNA (Dennler et al., 1998; Jonk et al., 1998; Zawel et al., 1998; Yagi 
et al., 1999). The proteins that we detect in HMC-1 cells are much smaller (chapter 10). At 
concentrations as low as 40 fM TGF-P, efficient phosphorylation of one of these Smad2-like 
proteins is observed and, moreover, its phosphorylation is more pronounced than that of Smad2 
itself, suggesting that these proteins could play an important role in Smad signaling. Both Western 
blot analysis and immunoprecipitation of metabolically labeled cells failed to detect Smad3 in
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HMC-1 cells. Possibly, the Smad2-like proteins are involved in TGF-P-induced transcriptional 
activation in HMC-1 cells. Furthermore, alternative Smad variants might contribute to diversity in 
signaling and provide cells with cell type-dependent responses following stimulation by TGF-P 
superfamily members.
Are Smads involved in all biological effects mediated by members o f the TGF-P superfamily?
An important issue is whether Smads are involved in and required for all biological responses 
elicited by TGF-P superfamily members. Other kinases that have been implicated in TGF-P 
superfamily signaling include the MAPK kinase kinase homologue TGF-P-activated kinase 1 
(TAK1), which signals through the stress-activated protein kinase (SAPK)/Jun-N-terminal kinase 
(JNK) and becomes activated by TAB1 (Shibuya et al., 1996). Furthermore, small GTP-binding 
proteins like Ras and Rac have been implicated in TGF-P superfamily signaling (Hartsough et 
al., 1996; Xu et al., 1996).
In this thesis we have made use of two model systems in which TGF-P mediates clearly defined 
and physiologically relevant effects, which differ from the commonly addressed issues of 
modulation of cellular proliferation, PAI-1 protein synthesis and induction of ‘artificial’ reporter 
systems. In NMuMG cells (chapter 6) we observed that TGF-P-induced transdifferentiation is not 
affected by inhibitors of MEK kinase, PI3 kinase, or Src kinases, which have been implied in 
reorganization of the actin cytoskeleton by members of other growth factor families. Thus, TGF-P- 
mediated reorganization of the cytoskeleton may use an alternative pathway. Recently, a Smad 
anchor for receptor activation (SARA) has been identified which contains a potential 
phosphatidylinositol-3-phosphate binding module through which it is targeted to specific regions in 
the cell membrane. SARA associates with Smad2 and Smad3 and presents them to activated 
receptors with which SARA interacts (Tsukazaki et al., 1998). The absence of an effect of PI3 
kinase inhibitor would suggest that Smads are not involved in the transdifferentiation process of 
NMuMG cells. In HMC-1 mast cells (chapter 9) which undergo chemotaxis following exposure to 
low concentrations of TGF-P, we find that cyclohexamide blocks chemotaxis, indicating that 
protein synthesis is required to mediate this biological effect, which might implicate Smads in the 
process of transdifferentiation. Secondly, tyrosine kinase inhibitors like herbimycin, erbstatin, 
genistein, and the MEK inhibitor PD98059, do affect chemotaxis. The fact that these tyrosine kinase 
inhibitors do not impede TGF-P-mediated growth arrest of HMC-1 mast cells or TGF-P-induced 
phosphorylation of Smad proteins, furthermore indicates that several signal transduction pathways 
are involved in TGF-P-mediated signaling. At present we do not know whether receptor activation 
directly triggers tyrosine kinase signaling parallel to Smad activation, or that Smad activation leads 
to transcriptional activation of genes which indirectly evoke chemotaxis through activation of 
tyrosine kinases.
Itoh et al. (1998) have shown that over-expression of inhibitory Smad7, which interacts with type 
I receptors and prevents activation of pathway-restricted Smads, inhibits TGF-P-mediated growth 
arrest and PAI-1 induction. By analogy, a way to address whether Smad signaling is required for 
physiological processes, such as transdifferentiation and chemotaxis, is to generate cell lines that are
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stably transfected with dominant negative Smads or the inhibitory Smad7 under control of an 
inducible promoter, which might selectively abrogate Smad-dependent signaling.
In conclusion, this thesis presents several mechanisms that contribute to diversity and specificity 
in signaling by members of the TGF-P superfamily. An important level of control which is under 
full investigation in the field, is the cooperation of Smads with transcriptional regulators to fine-tune 
signaling. Their cell type, tissue or developmental stage-restricted expression may provide a 
mechanism downstream of Smads to control specificity and diversity in cellular responses to signals 
initiated by TGF-P superfamily members.
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206 Summary
SUMMARY
The development of a fertilized egg cell to a full-grown multicellular organism features one of 
the most fascinating aspects in biology. Several growth factors, including members of the 
transforming growth factor-P (TGF-P) superfamily, play critical roles in the timely and spatially 
controlled patterning of the embryo, as well as in proper organogenesis. The biological effects 
mediated by the different TGF-P superfamily members are highly diverse, and are brought about by 
signaling through heteromeric complexes of transmembrane serine/threonine kinase type I and type 
II receptors. The TGF-P-, activin-, and bone morphogenetic protein (BMP)-subfamilies each signal 
through restricted combinations of type I and type II receptors. Smads are the cytoplasmic molecules 
that transduce these signals from the receptors to the nucleus. Three different types of Smads have 
been classified, namely receptor-activated Smads (R-Smads), the common mediator Smad4 (Co- 
Smad) and inhibitory Smads (Anti-Smads). Following activation of type I receptors by their type II 
receptors, R-Smads get phosphorylated at serine residues in their carboxy-terminus. As a 
consequence, they form homomers with each other or heteromers with Smad4. The Smad- 
complexes translocate to the nucleus where they regulate transcriptional activation of target genes, 
often in collaboration with other transcription factors. In view of the small variety in receptors and 
Smads, it is not clear at present how diversity in the biological effects caused by different TGF-P 
superfamily members is achieved.
This thesis addresses several mechanisms by which the large panel of TGF-P related growth 
factors can mediate their pleiotropic effects. In chapter 2 we describe the characterization of a 
TGF-P binding protein. This 60 kDa cell membrane-associated protein identified on LNCaP 
prostate tumor cells has preferential affinity for the TGF-P 1 isoform. The fact that treatment of the 
cells with NaCl, heparin, or glycerol results in the release of the 60 kDa protein from the cell 
surface, suggests that this protein associates with heparin sulphate proteoglycans. In its soluble 
configuration, the 60 kDa protein prevents the binding of the three isoforms to the TGF-P receptors 
on CCL64 cells. Thus, in addition to the signal transducing serine/threonine kinase receptors, 
additional binding proteins can affect signaling efficiency, for example by preferential affinity for 
certain TGF-P superfamily members, or by storage or neutralization of the growth factors at the cell 
surface.
In view of the extensiveness of the TGF-P superfamily, one would expect a larger variety of type 
I and type II serine/threonine kinase receptors. In an attempt to identify novel type I receptors, we 
developed the Southern blot PCR technique described in chapter3. PCR-amplification using 
oligonucleotide primers based on conserved regions in the type I receptor kinase domain results in 
PCR fragments of equal size for all currently known type I receptors. Hybridization of these 
fragments on Southern blots that contain four lanes of genomic DNA digested with different 
restriction enzymes, results in the generation of gene-specific fingerprints, in which each type I 
receptor is characterized by its own specific pattern. Application of the technique in the analysis of 
type I receptor expression in different cell lines and tissues revealed that a putative novel type I 
receptor is expressed in fetal embryonic kidney tissue.
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The affinity of different members of the TGF-P superfamily for the same receptors can, by 
accessibility to a limited variety of receptors, contribute to a greater diversity in heteromeric 
receptor complexes and signaling capacities. On the other hand, the fact that different TGF-P 
superfamily members share affinity for the same receptors can also result in competition in 
signaling, as is illustrated for activin A and osteogenic protein-1 (OP-1) in chapter 4. Both activin 
A and OP-1 bind to the activin type II receptor (ActR-II) on T2Cl13 teratocarcinoma cells, while 
each subsequently recruits a different type I receptor (ActR-IB and ActR-I, respectively), resulting 
in ligand-specific activation of second messengers. Activin A-mediated activation of the 3TP-Lux 
reporter is competed by OP-1, while the alkaline phosphatase activity induced by OP-1 in 
combination with retinoic acid is inhibited by activin A. This functional competition can be 
explained in part by the observed competition between activin A and OP-1 for binding to ActR-II. 
Overexpression of constitutively active type I receptors ActR-I and ActR-IB reveals an additional 
level for competition downstream of ligand binding to the receptors. This competition does not 
appear to be due to limited expression of the shared signal transduction partner Smad4; this 
secondary level of competition has yet to be elucidated.
The seemingly contradicting activity of TGF-P as inhibitor versus stimulator of cell growth was 
explored using a panel of six different glioma cell lines (chapter 5). Whereas their TGF-P-mediated 
growth responses and TGF-P receptor binding profiles are substantially different among the six cell 
lines, they show several common TGF-P responses including induction of Smad6, Smad7 and PAI-
1 expression. Differential activation of the Smad-binding (CAGA)12-luciferase reporter was 
observed. The relative balance in expression of the different signal transduction components might 
explain the differences in TGF-P responses among the cell lines.
Whereas TGF-P and activin mediate several overlapping biological activities in vitro, we observe 
that only TGF-P is able to induce epithelial to mesenchymal transdifferentiation of NMuMG cells 
(chapter 6). Analysis of receptor expression levels by affinity crosslinking studies reveals that, in 
contrast to TGF-P receptor levels, the activin receptor expression levels are hardly detectable in 
NMuMG cells. Signal transduction downstream of activin receptors is functional in NMuMG cells 
as observed by the induction of several Smad-responsive luciferase reporters following 
overexpression of constitutively active ActR-IB. OP-1 is able to induce transcriptional activation of 
a Smad-sensitive reporter. However, in contrast to TGF-P, OP-1 signaling does not trigger 
transdifferentiation of NmuMG cells, suggesting that BMP-Smads do not have the potency to elicit 
this response. In chapter 7 we also see that the effect of activin A and TGF-P on regulation of 
thyroid follicle cells seems to correlate to receptor expression levels. TGF-P is more potent than 
activin A in induction of thyroid follicle cell growth arrest, Smad2 phosphorylation, Smad nuclear 
translocation, and TSH receptor expression.
Chapter 8 shows that different growth factors belonging to the BMP-subfamily exert differential 
effects on bone morphogenesis both in vivo and in vitro. Cartilage-derived morphogenetic protein-1 
(CDMP-1) and CDMP-2 only induce cartilage formation, but are not similarly potent as OP-1 in 
inducing osteogenesis. CDMP-1 and CDMP-2 mainly interact with BMPR-IB and BMPR-II on 
several cell lines. While CDMP-1 is more potent than CDMP-2 in induction of alkaline phosphatase 
activity, CDMP-2 in contrast to CDMP-1 appears to be able to trigger a transcriptional response
208 Summary
following overexpression of BMPR-IA or BMPR-IB. It is conceivable that the different bone- 
morphogenetic responses induced by OP-1, CDMP-1 and CDMP-2 in the same tissue and cell lines 
results from preferential receptor affinities.
At present it is not clear whether Smads are critical for all responses elicited by TGF-P 
superfamily members. In chapter 9 we show that TGF-P subfamily members induce chemotaxis of 
mast cells, in which the TGF-P3 isoform is more potent than TGF-P 1 and TGF-P2. Using a panel of 
different inhibitors of signal transduction molecules (chapter 10), we revealed that TGF-P- 
mediated chemotaxis of mast cells involves the action of tyrosine kinases and mitogen-activated 
protein kinase kinases (MEK1). These studies furthermore suggest that Smad2, and possibly novel 
Smads, are also involved in the chemotactic response.
In conclusion, this thesis presents a variety of biological responses in which members of the 
TGF-P superfamily are involved, and gives insight into different levels at which control in the 
specificity and diversity in signaling by the different family members is achieved. The 
characterization of additional binding proteins, novel Smad molecules, different levels of 
competition between family members, and various levels to control activation thresholds and 
biological responses, might be anticipated in future research. Novel fields that are subject of current 
investigation and which will provide us with additional insights into regulation of fine-tuning of 
TGF-P superfamily signaling, cover the cross-talk between different signal transduction cascades, 
and the interaction of Smad molecules with various other transcription factors.
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De ontwikkeling van een bevruchte eicel tot een uitgegroeid multicellulair organisme vormt één 
van de meest fascinerende aspecten in de biologie. Diverse groeifactoren, zoals leden van de 
‘transforming growth factor-ß’ (TGF-ß) superfamilie, spelen een belangrijke rol in het op de juiste 
tijd en plaats controleren van de patroonvorming van het embryo, alsmede in de juiste ontwikkeling 
van de organen. De biologische effecten die gemedieerd worden door de verschillende leden van de 
TGF-ß superfamilie zijn zeer divers en worden tot stand gebracht via signalering door heteromere 
complexen van transmembraan serine/threonine kinase type I en type II receptoren. De TGF-ß, 
activine en ‘bone morphogenetic protein’ (BMP) subfamilies signaleren ieder via beperkte 
combinaties van type I en type II receptoren. Smads zijn de cytoplasmatische eiwitten die de 
signalen van de receptoren doorgeven naar de celkern. Drie verschillende typen Smads worden 
onderscheiden, te weten de receptor-geactiveerde Smads (R-Smads), de algemene partner Smad4 
(Co-Smad), en de inhiberende Smads (Anti-Smads). Na activatie van de type I receptoren door hun 
type II receptoren worden R-Smads gefosforileerd op serine-residuen in hun carboxy-terminus. Als 
gevolg hiervan kunnen ze homomeren met elkaar vormen, of heteromeren met Smad4. De Smad- 
complexen verplaatsen zich naar de celkern waar ze de transcriptionele activatie van doelwitgenen 
reguleren, vaak in samenwerking met andere transcriptiefactoren. Gezien de kleine variëteit in 
receptoren en Smads is het nog onduidelijk hoe diversiteit in de biologische effecten van de 
verschillende TGF-ß superfamilieleden wordt bewerkstelligd.
Dit proefschrift behandelt verschillende mechanismen waarmee het grote panel aan TGF-ß 
verwante groeifactoren hun diversiteit aan effecten kunnen medieëren. In hoofdstuk 2 beschrijven 
we de karakterisering van een TGF-ß bindend eiwit. Dit 60 kDa celmembraan-geassocieerde eiwit, 
geidentificeerd op LNCaP prostaat-tumorcellen, heeft preferentiële affiniteit voor de TGF-ß 1 
isovorm. Het feit dat behandeling van de cellen met NaCl, heparine of glycerol resulteert in het 
vrijkomen van het 60 kDa eiwit van de celoppervlakte, suggereert dat het 60 kDa eiwit associeert 
met heparaan-sulfaat proteoglycanen. In zijn vrije configuratie voorkomt het 60 kDa eiwit de 
binding van de drie isovormen aan de TGF-ß receptoren op CCL64 cellen. Dus, naast de signaal- 
doorgevende serine/threonine kinase receptoren kunnen additionele eiwitten de signalering 
beïnvloeden via, bijvoorbeeld, preferentiële affiniteit voor bepaalde TGF-ß superfamilie leden, of 
door opslag of neutralisatie van de groeifactoren aan de celoppervlakte.
Gezien de uitgebreidheid van de TGF-ß superfamilie en hun biologische activiteiten zou men een 
grotere variëteit in type I en type II serine/threonine kinase receptoren mogen verwachten. In een 
poging nieuwe type I receptoren te identificeren, hebben wij de ‘Southern blot PCR’ techniek 
ontwikkeld (hoofdstuk 3). PCR-amplificatie met behulp van oligonucleotiden-primers die 
gebaseerd zijn op geconserveerde regio’s in het type I receptor kinase domein, resulteert voor alle 
bestaande type I receptoren in PCR fragmenten van gelijke lengte. Hybridisatie van deze fragmenten 
op Southern blots die vier lanen genomisch DNA bevatten dat geknipt is met verschillende 
restrictie-enzymen, resulteert in gen-specifieke vingerafdrukken waarbij elke type I receptor wordt 
gekarakteriseerd door zijn eigen patroon. Toepassing van deze techniek in de analyse van type I
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receptor-expressie in verschillende cellijnen en weefsels gaf aan dat een mogelijk nieuwe type I 
receptor tot expressie komt in foetaal nier-weefsel.
De affiniteit van verschillende leden van de TGF-ß superfamilie voor dezelfde receptoren kan, 
bij beschikbaarheid over een beperkte variëteit in receptoren, bijdragen tot een grotere diversiteit in 
heteromere receptorcomplexen en signaleringsmogelijkheden. Anderzijds kan gedeelde receptor- 
affiniteit ook resulteren in competitie tussen verschillende TGF-ß superfamilie leden, zoals 
geïllustreerd is voor activine A en ‘osteogenic protein-1’ (OP-1) in hoofdstuk 4. Zowel activine A 
als OP-1 bindt aan de activine type II receptor (ActR-II) op T2Cl13 teratocarcinoma cellen, waarna 
elk van beide verschillende type I receptoren recruteert (ActR-IB en ActR-I, respectievelijk), wat 
resulteert in ligand-specifieke activatie van secundaire boodschappers. Activine A-gemedieerde 
activatie van de 3TP-Lux reporter wordt gecompeteerd door OP-1, terwijl de alkalische fosfatase 
activiteit geïnduceerd door OP-1 in combinatie met retinolzuur door activine A geremd wordt. De 
functionele competitie kan gedeeltelijk worden verklaard door de waargenomen competitie tussen 
activine A en OP-1 voor binding aan ActR-II. Overexpressie van de constitutief actieve type I 
receptoren ActR-I en ActR-IB brengt een additioneel niveau voor competitie aan het licht 
‘downstream’ van de ligandbinding aan de receptoren. Deze competitie is niet te verklaren door een 
limiterende expressie van de gedeelde signaaltransductiepartner Smad4; het secundaire niveau voor 
competitie moet nog uitgezocht worden.
De ogenschijnlijk tegenstrijdige activiteit van TGF-ß als remmer versus stimulator van celgroei 
is bestudeerd aan de hand van een panel van 6 verschillende glioma cellijnen (hoofdstuk 5). Terwijl 
de TGF-ß gemedieerde groeiresponsen en TGF-ß receptor bindingsprofielen substantieel 
verschillen tussen de 6 cellijnen, vertonen zij diverse gemeenschappelijke TGF-ß responsen, zoals 
inductie van Smad6, Smad7, en PAI-1 expressie. Differentiële activatie van de Smad-bindende 
(CAGA)12-luciferase reporter wordt geobserveerd onder de 6 cellijnen. De relatieve balans in 
expressie van de verschillende signaaltransductiemoleculen zou de verschillen in responsen tussen 
de cellijnen kunnen verklaren.
Hoewel TGF-ß en activine in vitro vaak dezelfde responsen mediëren, nemen wij waar dat in 
NMuMG borsttumorcellen alleen TGF-ß in staat is de transdifferentiatie van een epitheliaal naar 
mesenchymaal celtype te sturen (hoofdstuk 6). Analyse van receptor-expressieniveaus aan de hand 
van affiniteits-crosslinkingstudies geeft aan dat, in tegenstelling tot de TGF-ß receptoren, de 
activine receptoren moeilijk detecteerbaar zijn in NMuMG cellen. Signaaldoorgifte ‘downstream’ 
van activine receptoren is functioneel in NMuMG cellen, zoals waargenomen aan de hand van 
inductie van verschillende Smad-gevoelige luciferase reporters, volgend op overexpressie van de 
constitutief actieve ActR-IB. BMP-7/OP-1 is in staat transcriptionele activatie van een Smad- 
gevoelige reporter te induceren. In tegenstelling tot TGF-ß veroorzaakt BMP-7 signalering echter 
geen transdifferentiatie van NMuMG cellen, wat suggereert dat BMP-geactiveerde Smads deze 
respons niet kunnen opwekken. In hoofdstuk 7 tonen wij aan dat ook het effect van activine A en 
TGF-ß op de regulatie van schildklier follikelcellen lijkt te correleren met hun receptor- 
expressieniveaus. TGF-ß is potenter dan activine A in het induceren van thyroid groeiremming, 
Smad2 fosforilatie, nucleaire translocatie van Smads, en TSH-receptor expressie.
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Hoofdstuk 8 laat zien dat diverse groeifactoren behorende tot de BMP-subfamilie verschillende 
effecten hebben op de vorming van been zowel in vivo als in vitro. ‘Cartilage-derived 
morphogenetic protein-1’ (CDMP-1) en CDMP-2 induceren alleen vorming van kraakbeen, en zijn 
niet potent genoeg om osteogenese aan te zetten zoals OP-1 dat kan. CDMP-1 en CDMP-2 binden 
met name aan BMPR-IB en BMPR-II op diverse cellijnen. Terwijl CDMP-1 potenter is dan CDMP-
2 in het induceren van alkalische fosfatase activiteit, blijkt CDMP-2 in tegenstelling tot CDMP-1 
een transcriptionele respons op te kunnen wekken via overexpressie van BMPR-IA of BMPR-IB. 
Het is aannemelijk dat de verschillende botvormende responsen die OP-1, CDMP-1 en CDMP-2 in 
hetzelfde weefsel of cellijn opwekken, het gevolg zijn van hun preferentiële receptoraffiniteiten.
Op dit moment is het nog niet duidelijk of Smads van belang zijn voor alle responsen die 
opgewekt worden door TGF-ß superfamilieleden. In hoofdstuk 9 laten wij zien dat leden van de 
TGF-ß subfamilie chemotaxis kunnen induceren van mastcellen, waarbij de TGF-ß3 isovorm 
potenter is dan TGF-ß 1 of TGF-ß2. Door gebruik te maken van een panel van verschillende 
remmers van signaaltransductiemoleculen konden wij aantonen dat in TGF-ß gemedieerde 
chemotaxis van mastcellen, tyrosine kinases en ‘mitogen-activated protein kinase kinases’ (MEK1) 
betrokken zijn (hoofdstuk 10). Deze studies suggereren verder dat ook Smad2, en mogelijk nieuwe 
Smads, betrokken kunnen zijn in de chemotactische respons.
Concluderend presenteert dit proefschrift een variëteit aan fysiologische responsen waarbij leden 
van de TGF-ß superfamilie betrokken zijn, en geeft inzicht in verschillende niveaus waarop controle 
van specificiteit en diversiteit in signalering door de verschillende familieleden wordt verworven. 
De karakterisering van additionele bindingseiwitten, nieuwe Smad moleculen, verschillende niveaus 
van competitie tussen familieleden, en verschillende niveaus waarop activatie-drempels 
gecontroleerd kunnen worden en daarmee de biologische responsen, kunnen verwacht worden in 
toekomstig onderzoek. Nieuwe invalshoeken die momenteel in het middelpunt van de belangstelling 
staan en welke additioneel inzicht zullen verschaffen in de fine-tuning in TGF-ß superfamilie 
signalering, zijn de communicatie tussen verschillende signaaltransductiepaden en de interactie van 
Smad moleculen met verschillende andere transcriptiefactoren.
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STELLINGEN
1) De driedimensionale structuur van TGF-P kan voorgesteld worden als twee handen die 
antiparallel ten opzichte van elkaar zijn georiënteerd.
2) Het mysterie rondom de specificiteit en diversiteit in de signaaltransductie van TGF-P 
superfamilieleden wordt met de regelmatige ontdekking van nieuwe leden als maar groter (dit 
proefschrift).
3) Gezien de uitgebreidheid van de TGF-P superfamilie en hun biologische activiteiten zou men een 
groter aantal type I en type II serine/threonine kinase receptoren mogen verwachten (dit 
proefschrift).
4) Verschillende groeifactoren die van essentieel belang zijn voor correcte embryonale 
ontwikkeling hebben vaak een negatief effect in volwassen organismen (dit proefschrift).
5) De gevoeligheid in detectie van eiwitten door middel van ‘Western blotting’ kan drastisch 
worden verhoogd door het ‘Western blot’-filter eerst te strippen in denaturerende buffer bij 55°C 
alvorens te incuberen met antilichaam (ervaring opgedaan uit het onderzoek beschreven in dit 
proefschrift).
6) De complexiteit van het functioneren van één enkele cel is door geen enkel multicellulair 
organisme te doorgronden.
7) Om de mechanismen van tumor-ontwikkeling te bestuderen komt een onderzoeker met heel wat 
kankerverwekkende stoffen in aanraking.
8) ‘Standaardprotocol’ is een contradictio in terminis.
9) Eppen, fiepen, vortexen en huffen; het is veeleer het taalgebruik dan de gedachtengang die 
wetenschap voor leken onbegrijpelijk maakt.
10) Onderzoek doen is als 400 meter hordenlopen; je komt op je weg veel hindernissen tegen terwijl 
je je winst moet boeken op de tussensprints.
11) Het aanhouden van de eigen kweek stimuleert de gez/celligheid op de afdeling.
12) Aan een promotie heeft een AIO een flinke kluif, zeker als daar BMP’s bij betrokken zijn.
13) Val anderen niet onnodig lastig met wat je zelf kunt doen.
14) Discrepanties tussen PhosphorImager resultaten en autoradiogrammen illustreren Science 
Fiction.
15) Het doorlopen van een AIO-baan vergt meer blaren en doorzettingsvermogen dan het lopen van 
een Vierdaagse.
16) Je bent mobieler zonder mobiele telefoon.
17) Gezien de aard van de lading van veel vliegtuigen kan Schiphol beter niet uitbreiden op zee.
18) Het feit dat een vliegretour Amsterdam-Stockholm de helft kost van een retour Stockholm­
Amsterdam, geeft aan dat er nog geen eenheid is in de Europese Unie.
19) De overgang naar het nieuwe millennium wordt vooral een duizendklapper voor de 
zakenwereld.
20) Computers maken het leven er niet altijd gemakkelijker op.
21) Of het promoten van beursalen ook tot een toename in het aantal promoties leidt, is nog maar 
zeer de vraag.
22) Hoewel Viagra aanvankelijk was ontwikkeld als medicijn voor hartpatiënten moet de verhoging 
van de hartslag als bijwerking gezien worden.
23) Hoe meer kanalen op tv ontvangen kunnen worden, hoe minder er te zien is, al helemaal als 
men ook nog eens aan het ‘zap-syndroom’ leidt.
24) Het is onjuist te veronderstellen dat een proefschrift met dubbele omvang in de helft van de 
promotietijd ook een normaal proefschrift had kunnen opleveren.
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